Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-14-405601.txt : 20141110 0001193125-14-405601.hdr.sgml : 20141110 20141110143659 ACCESSION NUMBER: 0001193125-14-405601 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141110 DATE AS OF CHANGE: 20141110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 141208083 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 10-Q 1 d798670d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-09585

ABIOMED, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

04-2743260

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

22 CHERRY HILL DRIVE

DANVERS, MASSACHUSETTS 01923

(Address of principal executive offices, including zip code)

(978) 646-1400

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is, a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of October 31, 2014, 40,894,675 shares of the registrant’s common stock, $.01 par value, were outstanding.

ABIOMED, INC. AND SUBSIDIARIES

TABLE OF CONTENTS


		Page
PART I - FINANCIAL INFORMATION:

Item 1.	Financial Statements (unaudited)		3

	Condensed Consolidated Balance Sheets as of September 30, 2014 (unaudited) and March 31, 2014		3

	Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2014 and 2013 (unaudited)		4

	Condensed Consolidated Statements of Comprehensive (Loss) Income for the three and six months ended September 30, 2014 and 2013 (unaudited)		5

	Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2014 and 2013 (unaudited)		6

	Notes to Condensed Consolidated Financial Statements (unaudited)		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		28

Item 4.	Controls and Procedures		28

PART II - OTHER INFORMATION:

Item 1.	Legal Proceedings		29

Item 1A.	Risk Factors		29

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		29

Item 3.	Defaults Upon Senior Securities		29

Item 4.	Mine Safety Disclosures		29

Item 5.	Other Information		29

Item 6.	Exhibits		30

SIGNATURES			31

NOTE REGARDING COMPANY REFERENCES

Throughout this report on Form 10-Q (the “Report”), “Abiomed, Inc.,” the “Company,” “we,” “us” and “our” refer to Abiomed, Inc. and its consolidated subsidiaries.

NOTE REGARDING TRADEMARKS

ABIOMED, ABIOCOR, IMPELLA, IMPELLA CP and Symphony are trademarks of ABIOMED, Inc., and are registered in the U.S. and certain foreign countries. BVS is a trademark of ABIOMED, Inc. and is registered in the U.S. AB5000 is a trademark of ABIOMED, Inc. IMPELLA and RECOVER are trademarks of Abiomed Europe GmbH, a subsidiary of ABIOMED, Inc., and are registered in the U.S. and certain foreign countries.

PART 1. FINANCIAL INFORMATION

ITEM 1:

FINANCIAL STATEMENTS

ABIOMED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share data)


	September 30, 2014			March 31, 2014

ASSETS
Current assets:
Cash and cash equivalents	$	17,483		$	20,916
Short-term marketable securities		77,981			55,663
Accounts receivable, net		23,072			24,357
Inventories		13,445			13,948
Prepaid expenses and other current assets		3,310			3,082

Total current assets		135,291			117,966
Long-term marketable securities		16,473			41,761
Property and equipment, net		7,351			6,889
Goodwill		36,867			37,990
In-process research and development		17,198			—
Long-term deferred tax assets		813			—
Other assets		1,551			801

Total assets	$	215,544		$	205,407

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	7,616		$	7,746
Accrued expenses		13,762			17,899
Deferred revenue		5,756			4,766

Total current liabilities		27,134			30,411
Other long-term liabilities		210			228
Contingent consideration		5,797			—
Long-term deferred tax liabilities		6,865			6,415

Total liabilities		40,006			37,054

Commitments and contingencies (Note 10)
Stockholders’ equity:
Class B Preferred Stock, $.01 par value		—			—
Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value		417			411
Authorized - 100,000,000 shares; Issued - 41,831,077 shares at September 30, 2014 and 41,122,695 shares at March 31, 2014;
Outstanding - 40,577,134 shares at September 30, 2014 and 39,916,328 shares at March 31, 2014
Additional paid in capital		447,433			436,136
Accumulated deficit		(248,780	)		(250,910	)
Treasury stock at cost - 1,253,943 shares at September 30, 2014 and 1,206,367 shares at March 31, 2014		(17,567	)		(16,554	)
Accumulated other comprehensive loss		(5,965	)		(730	)

Total stockholders’ equity		175,538			168,353

Total liabilities and stockholders’ equity	$	215,544		$	205,407

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

ABIOMED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)


	Three Months Ended September 30,					Six Months Ended September 30,
	2014			2013		2014			2013
Revenue:
Product revenue	$	51,774		$	44,288	$	100,434		$	86,897
Funded research and development		164			57		315			118

		51,938			44,345		100,749			87,015

Costs and expenses:
Cost of product revenue		9,612			9,027		19,301			17,750
Research and development		8,693			7,721		17,755			15,008
Selling, general and administrative		29,455			26,199		61,053			54,166

		47,760			42,947		98,109			86,924

Income from operations		4,178			1,398		2,640			91

Other income (loss):
Investment income, net		36			25		80			41
Other (loss) income, net		(39	)		6		(28	)		(15	)

		(3	)		31		52			26

Income before income tax provision		4,175			1,429		2,692			117
Income tax provision		336			370		562			781

Net income (loss)	$	3,839		$	1,059	$	2,130		$	(664	)


Basic net income (loss) per share	$	0.09		$	0.03	$	0.05		$	(0.02	)
Basic weighted average shares outstanding		40,448			39,260		40,256			38,971

Diluted net income (loss) per share	$	0.09		$	0.03	$	0.05		$	(0.02	)
Diluted weighted average shares outstanding		42,239			41,337		42,069			38,971

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

ABIOMED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)

(in thousands, except per share data)


	Three Months Ended September 30,					Six Months Ended September 30,
	2014			2013		2014			2013
Net income (loss)	$	3,839		$	1,059	$	2,130		$	(664	)

Other comprehensive (loss) income:
Foreign currency translation (losses) gains		(4,804	)		1,795		(5,240	)		2,321
Net unrealized (losses) gains on marketable securities		(22	)		31		5			10

Other comprehensive (loss) income		(4,826	)		1,826		(5,235	)		2,331

Comprehensive (loss) income	$	(987	)	$	2,885	$	(3,105	)	$	1,667

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

ABIOMED, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Six Months Ended September 30,
	2014			2013
Operating activities:
Net income (loss)	$	2,130		$	(664	)
Adjustments required to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		1,196			1,322
Bad debt expense		27			15
Stock-based compensation		8,314			6,719
Write-down of inventory		559			537
Deferred tax provision		450			453
Change in fair value of contingent consideration		219			—
Changes in assets and liabilities:
Accounts receivable		1,108			1,912
Inventories		(653	)		(876	)
Prepaid expenses and other assets		(139	)		(762	)
Accounts payable		(581	)		(1,494	)
Accrued expenses and other long-term liabilities		(3,732	)		(1,978	)
Deferred revenue		1,004			(62	)

Net cash provided by operating activities		9,902			5,122
Investing activities:
Purchases of marketable securities		(44,920	)		(33,849	)
Proceeds from the sale and maturity of marketable securities		47,890			25,750
Acquisition of ECP and AIS, net of cash assumed		(15,697	)		—
Purchase of other investment		(750	)		(750	)
Purchases of property and equipment		(1,496	)		(1,236	)

Net cash used for investing activities		(14,973	)		(10,085	)
Financing activities:
Proceeds from the exercise of stock options		2,560			5,318
Payments in lieu of issuance of common stock for minimum payroll taxes		(1,013	)		(426	)
Proceeds from the issuance of stock under employee stock purchase plan		397			312

Net cash provided by financing activities		1,944			5,204
Effect of exchange rate changes on cash		(306	)		428

Net (decrease) increase in cash and cash equivalents		(3,433	)		669
Cash and cash equivalents at beginning of period		20,916			9,451

Cash and cash equivalents at end of period	$	17,483		$	10,120


Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	299		$	870
Supplemental disclosure of non-cash investing and financing activities:
Contingent consideration related to acquisition of ECP		6,000			—
Fixed asset expenditures incurred, not yet paid		577			92

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

ABIOMED, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(In thousands, except share data)

Note 1. Nature of Business and Basis of Preparation

Abiomed, Inc. (the “Company” or “Abiomed”), is a leading provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the Securities and Exchange Commission, or SEC.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year or any other subsequent period.

There have been no changes in the Company’s significant accounting policies for the three and six months ended September 30, 2014 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the SEC, except for as noted below.

In-Process Research and Development

In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that the Company acquires, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when the Company has regulatory approval and is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.

Contingent Consideration

As discussed in Note 3. “Acquisitions,” on July 1, 2014, the Company acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock.

Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the various milestones. The material factors that may impact the fair value of the contingent consideration, and therefore this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration, and the associated liability at each reporting date, will be updated by reflecting the changes in fair value reflected in the Company’s statement of operations.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more

estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

Note 2. Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the Company’s employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company’s basic and diluted net income (loss) per share for the three and six months ended September 30, 2014 and 2013 were as follows (in thousands, except per share data):


	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
Basic Net Income (Loss) Per Share
Net income (loss)	$	3,839	$	1,059	$	2,130	$	(664	)


Weighted average shares used in computing basic net income (loss) per share		40,448		39,260		40,256		38,971


Net income (loss) per share - basic	$	0.09	$	0.03	$	0.05	$	(0.02	)


	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
Diluted Net Income (Loss) Per Share
Net income (loss)	$	3,839	$	1,059	$	2,130	$	(664	)


Weighted average shares used in computing basic net income (loss) per share		40,448		39,260		40,256		38,971
Effect of dilutive securities		1,791		2,077		1,813		—

Weighted average shares used in computing diluted net income (loss) per share		42,239		41,337		42,069		38,971

Net income (loss) per share - diluted	$	0.09	$	0.03	$	0.05	$	(0.02	)

For the three months ended September 30, 2014, approximately 47,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 465,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share.

For the six months ended September 30, 2014, approximately 44,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 465,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share.

For the three months ended September 30, 2013, approximately 297,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 354,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share.

For the six months ended September 30, 2013, approximately 3,923,000 shares underlying stock options and approximately 1,198,000 restricted shares were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period.

Note 3. Acquisitions

Acquisition of ECP Entwickslungsgesellschaft mbH

On July 1, 2014, the Company entered into a share purchase agreement with its wholly owned German subsidiary, Abiomed Europe GmbH (“Abiomed Europe”) and Syscore GmbH (“Syscore”), a limited liability company located in Berlin, Germany, providing for the Company’s acquisition of all of the share capital of ECP Entwicklungsgesellschaft mbH (“ECP”), a limited liability company incorporated in Germany. ECP is engaged in research, development, prototyping and the production of a percutaneous expandable catheter pump which increases blood circulation from the heart with an external drive shaft. The Company’s acquisition of ECP closed on July 1, 2014.

The Company acquired ECP for $13.0 million in cash, with additional potential payouts totaling $15.0 million payable to Syscore based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock. With respect to such milestone payments, the share purchase agreement provides:

•

that, upon the earlier of (i) the Company’s receipt of European CE Marking approval relating to the sale of an expandable device based on certain patent rights acquired from ECP, or (ii) the Company’s bringing of a successful claim against a third party competitor (or reaching an economically equivalent settlement) for the infringement of certain patent rights acquired from ECP, it will pay Syscore an additional $7.0 million (provided that if such claim or settlement does not prohibit the third party competitor’s further marketing, production, sale, distribution, lease or use of any violating or infringing products, but only awards monetary damages to the Company or to Abiomed Europe, the amount payable to Syscore shall be limited to the lower of the amount of aggregate damages received and $7.0 million); and

•

that, upon the first to occur of (i) the Company’s successful commercialization of one or more rotatable and expandable devices based on certain patent rights acquired from ECP, where such devices achieve aggregate worldwide revenues of $125.0 million, including the revenues of third party licensees, or (ii) the Company’s sale of (A) ECP, (B) all or substantially all of ECP’s assets, or (C) certain of ECP’s patent rights, the Company will pay to Syscore the lesser of (x) one-half of the profits earned from such sale described in the foregoing item (ii), after accounting for the costs of acquiring and operating ECP, or (y) $15.0 million (less any previous milestone payment).

ECP’s Acquisition of AIS GmbH Aachen Innovative Solutions

In connection with the Company’s acquisition of ECP, ECP acquired all of the share capital of AIS GmbH Aachen Innovative Solutions (“AIS”), a limited liability company incorporated in Germany, pursuant to a share purchase agreement dated as of June 30, 2014, by and among ECP and AIS’s four individual shareholders. AIS, based in Aachen, Germany, holds certain intellectual property useful to ECP’s business, and, prior to being acquired by ECP, had licensed such intellectual property to ECP.

The purchase price for the acquisition of AIS’s share capital was approximately $2.8 million in cash and the acquisition closed immediately prior to Abiomed Europe’s acquisition of ECP. The share purchase agreement contains representations, warranties and closing conditions customary for transactions of its size and nature.

Preliminary Purchase Price Allocation

The acquisition was accounted for as a business combination. The purchase price for the acquisition has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase price allocation presented herein is preliminary. The final purchase price allocation will be determined after completion of an analysis to determine the fair value of all assets acquired and liabilities assumed, but in no event later than one year following completion of the acquisition. Accordingly, the final acquisition accounting adjustments could differ materially from the preliminary amounts presented herein. Any increase or decrease in the fair value of the assets acquired and liabilities assumed, as compared to the information shown herein, could also change the portion of purchase price allocated to goodwill, and could impact the operating results of the Company following the acquisition due to differences in purchase price allocation, depreciation and amortization related to some of these assets and liabilities.

The acquisition-date fair value of the consideration transferred is as follows:


	Total Acquisition Date Fair Value (in thousands)
Cash consideration	$	15,750
Contingent consideration		6,000

Total consideration transferred	$	21,750

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on July 1, 2014, the date of acquisition (in thousands):


Acquired assets:
Cash and cash equivalents	$	53
Accounts receivable		25
Property and equipment		619
In-process research and development		18,500
Goodwill		1,964
Long-term deferred tax assets		874
Other assets acquired		141

Total assets acquired		22,176
Liabilities assumed:
Accounts payable		295
Accrued liabilities		131

Total liabilities assumed		426

Net assets acquired	$	21,750

IPR&D is principally the estimated fair value of the ECP and AIS technology which had not reached commercial technological feasibility nor had alternative future use and therefore considered IPR&D, with assigned values to be allocated among the various IPR&D assets acquired.

Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes.

All legal, consulting and other costs related to the acquisition, aggregating approximately $1.1 million, have been expensed as incurred and are included in selling, general and administrative expenses in our consolidated statements of operations. The results of operations for ECP and AIS are included in the Company’s condensed consolidated statements of operations for the period from the July 1, 2014 acquisition date to September 30, 2014. The Company recorded no material revenues and incurred $1.1 million in net losses for the three months ended September 30, 2014 associated with the operations of ECP after the July 1, 2014 acquisition. This also includes a $0.2 million expense for the change in fair value of the contingent consideration for the three months ended September 30, 2014.

The following unaudited pro forma information presents the combined results of operations for the three and six months ended September 30, 2014 and 2013, as if we had completed the ECP and AIS acquisitions at the beginning of fiscal 2014. The pro forma financial information is provided for comparative purposes only and is not necessarily indicative of what actual results would have been had the acquisition occurred on the date indicated, nor does it give effect to synergies, cost savings, fair market value adjustments, immaterial amortization expense and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of consolidated results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period.

The pro forma consolidated financial information has been calculated after applying the Company’s accounting policies and includes adjustments for transaction-related costs, to eliminate revenues earned by AIS from ECP and expenses paid by ECP to AIS associated with a license agreement between the two parties, interest expense incurred by ECP related to bank loans accounted as if the repayment of ECP debt had occurred on April 1, 2013 and was not outstanding during the periods, and income tax provision of AIS due to the elimination of revenue on the license agreement with ECP.


	Three Months Ended September 30,					Six Months Ended September 30,
	2014		2013			2014		2013
	(in $000’s)					(in $000’s)
Revenue	$	51,938	$	44,359		$	100,761	$	87,042
Income before income tax provision		4,557		329			2,770		(1,850	)
Net income (loss)		4,218		(41	)		2,260		(2,631	)

Note 4. Marketable Securities and Fair Value Measurements

Marketable Securities

The Company’s marketable securities are classified as available-for-sale securities and, accordingly, are recorded at fair value. The difference between amortized cost and fair value is included in stockholders’ equity.

The Company’s marketable securities at September 30, 2014 and March 31, 2014 are invested in the following:


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Market Value
	(in $000’s)
At September 30, 2014:
US Treasury securities	$	19,487	$	—	$	—		$	19,487
Short-term government-backed securities		58,480		17		(3	)		58,494
Long-term government-backed securities		16,498		3		(28	)		16,473

	$	94,465	$	20	$	(31	)	$	94,454


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Market Value
	(in $000’s)
At March 31, 2014:
US Treasury securities	$	31,487	$	—	$	—		$	31,487
Short-term government-backed securities		24,174		6		(4	)		24,176
Long-term government-backed securities		41,779		8		(26	)		41,761

	$	97,440	$	14	$	(30	)	$	97,424

Fair Value Hierarchy

Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows, or similar techniques, and at least one significant model assumption or input is unobservable.

The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:


	Level 1		Level 2		Level 3		Fair Value
	(in $000’s)
At September 30, 2014:
Assets
U.S. Treasury securities	$	—	$	19,487	$	—	$	19,487
Short-term government-backed securities		—		58,494		—		58,494
Long-term government-backed securities		—		16,473		—		16,473
Liabilities
Contingent consideration		—		—		5,797		5,797

	Level 1		Level 2		Level 3		Fair Value
	(in $000’s)
At March 31, 2014:
U.S. Treasury securities	$	—	$	31,487	$	—	$	31,487
Short-term government-backed securities		—		24,176		—		24,176
Long-term government-backed securities		—		41,761		—		41,761

The Company has determined that the estimated fair value of its investments in U.S. Treasury securities, short-term government-backed securities and long-term government-backed securities are reported as Level 2 as they are not exchange-traded instruments.

The Company’s financial liabilities consisted of contingent consideration potentially payable to former ECP shareholders related to the acquisition of ECP in July 2014. This liability is reported as Level 3 as estimated fair value of the contingent consideration related to the acquisition of the ECP requires significant management judgment or estimation and is calculated using the income approach, using various revenue and cost assumptions and applying a probability to each outcome.

The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended September 30, 2014:


	September 30,
	2014
	(in $000’s)
Beginning balance	$	—
Additions		6,000
Payments		—
Change in fair value		219
Foreign currency translation impact		(422	)

Ending balance	$	5,797

The change in fair value of the contingent consideration of $0.2 million for the six months ended September 30, 2014 was primarily due to an increase in fair value due to the effect of the passage of time on the fair value measurement and the impact of foreign currency exchange rates. Adjustments associated with the change in fair value of contingent consideration are included in research and development expenses on the Company’s condensed consolidated statements of operations.

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2014:


	Fair Value at September 30, 2014 ( in $000’s)			Significant Unobservable Input	Weighted Average (range, if applicable)
Contingent consideration	$	5,797	Probability weighted income approach	Milestone dates	2018 to 2021
				Discount rate Probability of occurrence	8% to 12% 0% to 100%

Other Investment

In May 2013, the Company invested $0.8 million in preferred stock of a private technology company. In addition, the Company committed to invest an additional $0.7 million if the private technology company achieves certain milestones or receives shareholder approval requesting the additional funding. In September 2014, the private technology company requested this additional funding and the Company paid the additional $0.7 million. There are no additional outstanding funding commitments associated with this investment.

This other investment is accounted for using the cost method and is measured at fair value on a nonrecurring basis only if there are identified events or change in circumstances that may have a significant adverse effect on the fair value of these investments. The aggregate carrying amount of this other investment was $1.5 million and $0.8 million at September 30, 2014 and March 31, 2014, respectively, and is classified within other assets in the unaudited condensed consolidated balance sheets.

Note 5. Inventories

The components of inventories are as follows:


	September 30, 2014		March 31, 2014
	(in $000’s)
Raw materials and supplies	$	6,052	$	6,414
Work-in-progress		5,718		6,261
Finished goods		1,675		1,273

	$	13,445	$	13,948

The Company’s inventories relate to its circulatory care product lines, primarily the Impella and AB5000 product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During the six months ended September 30, 2014 and 2013, the Company recorded $0.6 million and $0.5 million, respectively, in write-downs of inventory.

Note 6. Goodwill and In-Process Research and Development

Goodwill

Goodwill has been recorded in connection with the Company’s acquisitions of Impella Cardiosystems AG, or Impella, in 2005 and ECP and AIS in July 2014, as discussed in Note 3. “Acquisitions.” The carrying value of goodwill and the change in the balance for the six months ended September 30, 2014 is as follows:


	September 30,
	2014
	(in $000’s)
Beginning balance	$	37,990
Additions		1,964
Foreign currency translation impact		(3,087	)

Ending balance	$	36,867

The Company has no accumulated impairment losses on goodwill.

In-Process Research and Development

As described in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP and AIS and recorded $18.5 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows from the expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses and taking into account the stage of development of the technology at the acquisition date, the time and resources needed to complete development. The Company used a discount rate of 22.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2014 is as follows:


	September 30, 2014
	(in $000’s)
Beginning balance	$	—
Additions		18,500
Foreign currency translation impact		(1,302	)

Ending balance	$	17,198

Note 7. Accrued Expenses

Accrued expenses consist of the following:


	September 30,		March 31,
	2014		2014
	(in $000’s)
Employee compensation	$	9,083	$	11,967
Research and development		1,161		1,587
Professional, legal and accounting fees		1,021		1,304
Sales and income taxes		1,000		1,445
Warranty		775		794
Other		722		802

	$	13,762	$	17,899

Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at September 30, 2014 and March 31, 2014.

Note 8. Stock-Based Compensation

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three and six months ended September 30, 2014 and 2013:


	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
	(in $000’s)				(in $000’s)
Cost of product revenue	$	148	$	139	$	357	$	347
Research and development		773		540		1,626		1,285
Selling, general and administrative		3,103		2,119		6,331		5,087

	$	4,024	$	2,798	$	8,314	$	6,719

The components of stock-based compensation for the three and six months ended September 30, 2014 and 2013 were as follows:


	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
	(in $000’s)				(in $000’s)
Restricted stock units and awards	$	3,334	$	2,162	$	6,754	$	5,098
Stock options		624		598		1,423		1,523
Employee stock purchase plan		66		38		137		98

	$	4,024	$	2,798	$	8,314	$	6,719

Stock Options

The following table summarizes the stock option activity for the six months ended September 30, 2014:


	Shares Underlying Options (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding at April 1, 2014		3,492		$	13.27		4.92
Granted		313			22.26
Exercised		(222	)		11.49
Cancelled and expired		(5	)		15.66

Outstanding at September 30, 2014		3,578		$	14.16		5.04	$	38,287

Exercisable at September 30, 2014		2,787		$	11.94		3.99	$	35,928

Options vested and expected to vest at September 30, 2014		3,502		$	14.00		4.97	$	38,013

The aggregate intrinsic value of options exercised was $3.0 million for the six months ended September 30, 2014. The total fair value of options vested during the six months ended September 30, 2014 was $1.7 million.

The remaining unrecognized stock-based compensation expense for unvested stock option awards at September 30, 2014 was approximately $5.7 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.5 years.

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The weighted average grant-date fair value for options granted during the six months ended September 30, 2014 and 2013 was $9.05 and $9.67 per share, respectively.

The fair value of options granted during the three and six months ended September 30, 2014 and 2013 were calculated using the following weighted average assumptions:


	Three Months Ended September 30,						Six Months Ended September 30,
	2014			2013			2014			2013
Risk-free interest rate		1.75	%		1.39	%		1.60	%		0.85	%
Expected option life (years)		4.19			4.23			4.19			4.26
Expected volatility		48.7	%		50.6	%		49.3	%		51.9	%

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock and adjustments for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise experience and estimates of future exercises of unexercised options. An expected dividend yield of zero is used in the option valuation model because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future. The Company estimates forfeitures based on an analysis of actual historical forfeitures, adjusted to reflect that historical forfeitures may not be indicative of forfeitures in the future.

Restricted Stock and Restricted Stock Units

In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the six months ended September 30, 2014:


	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value (per share)
Outstanding at April 1, 2014		1,174		$	21.37
Granted		664			21.88
Vested		(465	)		20.48
Forfeited		(121	)		23.10

Outstanding at September 30, 2014		1,252		$	21.80

The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of September 30, 2014 was $17.0 million and the weighted-average period over which this cost will be recognized is 2.0 years.

The weighted average grant-date fair value for restricted stock and restricted stock units granted during the six months ended September 30, 2014 and 2013 was $21.88 and $23.18 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the six months ended September 30, 2014 and 2013 was $9.5 million and $6.0 million, respectively.

Performance Based Awards

Included in the restricted stock and restricted stock units activity discussed above are certain awards that vest subject to certain performance-based criteria.

In May 2014, performance-based awards of restricted stock units for the potential issuance of 379,752 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company is recognizing compensation expense based on the probable outcome related to the prescribed performance milestones on the outstanding awards.

In May 2013, performance-based awards of restricted stock units for the potential issuance of 268,988 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed performance milestones for these awards such that 154,991 shares of common stock will vest subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.

In May 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees of the Company, all of which will vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed performance milestones for these awards. These awards are still subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.

In May 2011 and June 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed milestones for 234,000 shares underlying these awards and recorded all related stock compensation expense. In March 2014, the Company modified the performance condition on the remaining 50,000 restricted stock units. As of September 30, 2014, the Company believes that it is probable that the prescribed performance milestones will be met on these restricted stock units and the compensation expense is being recognized accordingly.

During the three and six months ended September 30, 2014, the Company has recorded $2.1 million and $3.7 million, respectively, in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at September 30, 2014 is $8.0 million based on the Company’s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 1.8 years.

Note 9. Income Taxes

Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each fiscal year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized.

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses incurred for most of its existence, expiration of various federal and state attributes, the uncertainty relative to the Marketing and Labelling Investigation and the FCA Investigation (each as defined below in “Note 10. Commitments and Contingencies—Litigation”) of the Company and the Company’s Pre-Market Approval, or PMA, application with the U.S. Food and Drug Administration, or FDA, for its Impella products, the Company’s expansion into new markets, such as Japan, the government reimbursement environment for the Company’s products, the Company’s profitability for recent years and uncertainties around the Company’s future profitability. Based on the review of all available evidence, the Company determined that the objectively verifiable negative evidence outweighed the positive evidence and it recorded a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of September 30, 2014. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on its results of operations.

As of September 30, 2014, the Company has accumulated a long-term deferred tax liability of $6.9 million as the result of a difference in accounting for the Company’s goodwill associated with its Impella acquisition that was completed in May 2005, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net long-term deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period. As of September 30, 2014, the Company has net long-term deferred tax assets of $0.8 million relating to differences between the book and tax basis of assets and liabilities associated with the ECP acquisition completed in July 2014.

The Company is subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. Because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized.

Note 10. Commitments and Contingencies

Commitments

In July 2013, the Company entered into a lease agreement to continue renting its existing space in Aachen, Germany through July 31, 2023. The building serves as the Company’s European headquarters and houses most of the manufacturing operations for its Impella product line. The lease payments are approximately 34,500€ (euro) (approximately U.S. $44,000 at September 30, 2014 exchange rates) per month.

In February 2014, the Company entered into a lease agreement to continue renting its existing space in Danvers, Massachusetts through February 28, 2021. Monthly rent is as follows:

•

The base rent for March 2014 through April 2014 was $66,000 per month; and

•

The base rent for May 2014 through February 2016 is $74,050 per month; and

•

The base rent for March 2016 through February 2018 will be $70,750 per month; and

•

The base rent for March 2018 through February 2021 will be $72,750 per month.

License Agreement

In April 2014, the Company entered into an exclusive license agreement with Opsens, Inc. for the rights to certain optical sensor technologies in the field of cardio-circulatory assist devices. The Company made a $1.5 million upfront payment upon execution of the agreement and agreed to make additional payments of up to $4.5 million upon the achievement of certain development milestones.

Contingent Consideration

As discussed in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP using a combination of cash and potential post-acquisition milestone payments. These milestone payments may be payable at some time over the next 20 years, depending on the achievement of certain technical, regulatory and commercial milestones. The maximum amount of the aggregate milestone payments could be $15.0 million. As of September 30, 2014, the fair value of the contingent consideration was $5.8 million.

Litigation

From time to time, the Company is involved in legal and administrative proceedings and claims of various types. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.

On October 26, 2012, the Company was informed that the Department of Justice, United States Attorney’s Office for the District of Columbia was conducting an investigation (the “Marketing and Labelling Investigation”) focused on the Company’s marketing and labeling of the Impella 2.5. On October 31, 2012, the Company accepted service of a subpoena related to this investigation seeking documents related to the Impella 2.5. The Company believes that is has substantially complied with the subpoena and has submitted the requested documents to the United States Attorney’s Office. On September 13, 2013, the Company entered into a tolling agreement with the United States Attorney’s Office, pursuant to which the Company and the United States Attorney’s Office mutually agreed to toll the applicable statutes of limitations for all criminal, civil and administrative offenses and violations that could be charged or claimed against the Company as of that date until June 2, 2014. On May 27, 2014, the Company executed an extension of the tolling agreement through February 2, 2015. The investigation is ongoing, however, and the Company is unable to predict the ultimate outcome or determine whether a liability has been incurred or make an estimate of the reasonably possible liability, if any, that could result from any unfavorable outcome associated with this investigation. The Company has incurred significant expenses related to this investigation and expects to continue to incur additional expenses in the future.

On November 16 and 19, 2012, two purported class action complaints were filed against the Company and certain of its officers in the U.S. District Court for the District of Massachusetts, or the District Court, by alleged purchasers of its common stock, on behalf of themselves and persons or entities that purchased or acquired common stock of the Company between August 5, 2011 and October 31, 2012. The complaints alleged that the defendants violated the federal securities laws in connection with disclosures related to the Company’s marketing and labeling of the Impella 2.5 product and seek damages in an unspecified amount. The District Court consolidated these complaints and a consolidated amended complaint was filed by the plaintiffs on May 20, 2013. On July 8, 2013, the Company filed a motion to dismiss the consolidated class action. Oral arguments on the Company’s motion to dismiss were conducted before the District Court on September 18, 2013. On April 10, 2014, the District Court entered an order granting the Company’s motion and dismissed the consolidated and amended complaint. On May 9, 2014, the plaintiffs filed a notice of appeal, and subsequently filed their appellate brief with the U.S. Court of Appeals for the First Circuit, or the First Circuit, on July 16, 2014. The appeal process remains ongoing with oral arguments scheduled for January 8, 2015.

On February 4, 2013, an alleged stockholder of the Company filed a derivative action with the District Court on the Company’s behalf against each of the Company’s directors. The complaint alleged that the directors breached their fiduciary duties to the Company and its stockholders in connection with disclosures related to the Company’s marketing and labeling of its Impella 2.5

product and sought damages in an unspecified amount. On March 22, 2013, the Company filed a motion to dismiss the derivative action. On June 21, 2013, the District Court granted the Company’s motion to dismiss. The plaintiff appealed the dismissal to the First Circuit. The First Circuit affirmed the District Court’s Order of Dismissal in a written opinion issued on June 10, 2014.

On April 25, 2014, the Company received a subpoena from the Boston regional office of the United States Department of Health and Human Services, or HHS, Office of Inspector General requesting materials relevant to the Company’s reimbursement of expenses and remuneration to healthcare providers for a six month period from July 2012 through December 2012 in connection with a civil investigation under the False Claims Act (the “FCA Investigation” and, together with the Marketing and Labelling Investigation, the “DOJ Investigations”). The Company submitted the requested documents to HHS and believes that it substantially complied with the subpoena. On November 6, 2014, the Company received notice from the Department of Justice, United States Attorney’s Office for the District of Massachusetts in the form of a Civil Investigative Demand (“CID”) requesting additional document production relating to this matter for the time period of January 1, 2012 through December 31, 2013. The Company intends to respond to the CID and cooperate with the U.S. Attorney’s Office in connection with the FCA investigation.

The Company is unable to estimate a potential liability with respect to the DOJ Investigations and the appeal of the dismissal of the purported class action claim. There are numerous factors that make it difficult to meaningfully estimate possible loss or range of loss at this stage of these investigations and lawsuits, including that: the proceedings are in relatively early stages, there are significant factual and legal issues to be resolved and information obtained or rulings made during any lawsuits or investigations could affect the methodology for calculation. In addition, with respect to claims for which damages are the requested relief, no amount of loss or damages has been specified. Therefore, the Company is unable at this time to estimate its possible losses and accordingly, no adjustment has been made to the financial statements to reflect the outcome of these uncertainties.

Note 11. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 66% and 74% of the Company’s total consolidated assets are located within the U.S. as of September 30, 2014 and March 31, 2014, respectively. The remaining assets are located primarily in Germany and include goodwill and in-process research and development of $54.1 million and $35.4 million at September 30, 2014 and March 31, 2014, respectively, associated with the Impella acquisition in May 2005 and ECP acquisition in July 2014. Total assets outside of the U.S. excluding goodwill and in-process research and development amounted to 9% of total consolidated assets as of September 30, 2014 and March 31, 2014. International sales (primarily in Europe) accounted for 11% of total revenue for each of the three and six months ended September 30, 2014 and 7% and 8% of total revenue for the three and six months ended September 30, 2013, respectively.

ITEM 2:

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

This Report may contain “forward looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. These forward-looking statements address various matters including, among others, future actions related to ongoing investigations and litigation, and expenditures related thereto; plans with respect to clinical trials; our expectations with respect to submissions to and approvals from regulatory bodies, such as the FDA, including, with respect to the PMA submission for the Impella 2.5, our expectation that we no longer need or anticipate the requirement for an FDA panel and expect PMA approval by February or March 2015 and our plans to submit Impella 5.0 and Impella CP as PMA supplements; the development of new and existing products and anticipated costs, including research and development, sales and marketing and training costs associated with product development; expected capital expenditures for the fiscal year ending March 31, 2014; commercial plans for our products, including the launch of Impella CP; demand and expected shipments of our products; anticipated shifts in the revenue mix associated with our products; our ability to increase revenues from our Impella line of products and the sufficiency of revenues to fund future operations. Each forward-looking statement in this Report is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, our inability to predict the outcome of investigations and litigation and associated expenses; possible delays in our research and development programs; our ability to obtain regulatory approvals and market our products, and uncertainties related to regulatory processes; greater government scrutiny and regulation of the medical device industry and our ability to respond to changing laws and regulations affecting our industry, including any reforms to the regulatory approval process administered by the FDA, including the 510(k) process and 515 Program Initiative, and changing enforcement practices related thereto; the inability to manufacture products in commercial quantities at an acceptable costs, the acceptance by physicians and hospitals of our products; the impact of competitive products and pricing; uncertainties associated with future capital needs and the risks identified under Item 1A of Part I of our Annual Report on Form 10-K, for the year ended March 31, 2014 and Item 1A of Part II of this Report on Form 10-Q, as well as the other information we file with the Securities and Exchange Commission. Readers are cautioned not to place considerable reliance on any forward-looking statements contained in this Report, which speak only as of the date of this Report. We undertake no obligation to update or revise these forward-looking statements whether as a result of new information, future events or otherwise, unless otherwise required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Overview

We are a leading provider of mechanical circulatory support devices and we offer a continuum of care to heart failure patients. We develop, manufacture and market proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Our products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. We believe heart recovery is the optimal clinical outcome for patients experiencing heart failure because it restores their quality of life. In addition, we believe that for the care of such patients, heart recovery is the most cost-effective solution for the healthcare system.

Our strategic focus and the driver of the majority of our revenue growth is the market penetration of our Impella family of products. Our Impella 2.5 product received 510(k) clearance in June 2008 from the U.S. Food and Drug Administration, or FDA, for partial circulatory support for up to six hours. We received 510(k) clearance in April 2009 for our Impella 5.0 and Impella LD devices for circulatory support for up to six hours. These devices are larger and provide more blood flow to patients than the Impella 2.5. In September 2012, our Impella CP product received 510(k) clearance from the FDA for partial circulatory support for up to six hours. Our Impella 2.5, Impella 5.0, Impella LD and Impella CP products also have CE Mark approval and Health Canada approval which allow us to market these devices in the European Union, or E.U., and Canada.

Our revenues are primarily generated from our Impella line of products. Revenues from our non-Impella products, largely focused on the heart surgery suite, have been lower over the past several years as we have strategically shifted our sales and marketing efforts towards our Impella products and the cath lab. We expect revenues from our non-Impella products, primarily AB5000, will continue to decrease as we continue to focus on our Impella products.

Our Products

Impella 2.5

The Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors. The device is designed primarily for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 2.5 device received 510(k) clearance from the FDA in June 2008 for partial circulatory support for up to six hours, has CE mark approval in Europe for up to five days of use and is approved for use in over 40 countries.

The Impella 2.5 catheter can be quickly inserted via the femoral artery to reach the left ventricle of the heart where it is directly deployed to draw blood out of the ventricle and deliver it to the circulatory system. This function is intended to reduce ventricular work and provide flow to vital organs. The Impella 2.5 is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute.

In August 2007, we received approval from the FDA to begin a high-risk percutaneous coronary intervention, or PCI, pivotal clinical trial, known as the Protect II study, for the Impella 2.5. This pivotal study was a superiority study to determine the safety and effectiveness of the Impella 2.5 as compared to medical management with an intra-aortic balloon, or IAB, during “high-risk” angioplasty procedures. In December 2010, we announced the termination of the Protect II study based on a futility determination at the planned interim analysis regarding the primary end-point, which we view as likely to have resulted from how rotational atherectomy was performed by investigators in the study.

In November 2011, we announced additional analysis of the results from the Protect II study, including those patients enrolled following the initiation of the interim analysis, which showed a statistically significant 22% relative reduction in major adverse events compared to an IAB at 90 days per protocol (p=0.023), a 52% relative reduction in repeat revascularization (p=0.024) and a 56% relative reduction in material adverse events post hospital discharge (p=0.002). Furthermore, additional data analysis of the clinical data from the Protect II trial revealed that more aggressive revascularization is beneficial for patients with coronary artery disease and reduced left ventricular function.

A November 2011 update to the American College of Cardiology Foundation (ACCF) /American Heart Association (AHA) Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Guidelines for Percutaneous Coronary Intervention, for the first time, included Impella in both the emergent and prophylactic hemodynamic support settings. In addition, a December 2012 update to the AHA’s Recommendations for the Use of Mechanical Circulatory Support: Device Strategies and Patient Selection recommended Impella for use in mechanical circulatory support; a December 2012 update to the ACCF/AHA Guidelines for the Management of ST-Elevation Myocardial Infarction (STEMI) included Impella 2.5 for use in patients requiring urgent coronary artery bypass grafting with STEMI and in treatment of patients with cardiogenic shock complications after STEMI; and a January 2013 update to the International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support included Impella for the first time for patients with multi-organ failure.

We are currently conducting USpella, the first U.S. multicenter observational registry collecting clinical data and outcomes for general use patients supported with the Impella 2.5, CP, and 5.0 during procedures. In December 2012, as part of the FDA’s 515 Program Initiative, an FDA panel voted to recommend continuation of Class III status for temporary ventricular support devices within the non-roller type cardiopulmonary bypass blood pumps category, which includes our Impella products. The panel’s recommendation of Class III for this category of device is consistent with the current Class III designation for these device types. The FDA accepted the panel’s recommendation recently as reflected in its issuance of a Proposed Order reflecting this categorization.

Pursuant to discussions with the FDA, we submitted a modular PMA submission for Impella 2.5. A modular PMA allows for a parallel submission of preclinical and manufacturing data for review while still preparing the clinical module. In July 2013, we received written notification that the FDA has reviewed our proposed PMA shell for modular review of Impella 2.5. The FDA has confirmed that it agrees with our proposed shell. In March 2014, we submitted all of the modules required by the FDA as part of the planned modular PMA submission. The PMA will be treated as a standard PMA and all modules have now been consolidated for final review by the FDA. In October 2014, we announced that we and the FDA have agreed on the indication for use for high-risk PCI for the Impella 2.5 PMA. Based on the information available to us to date, including multiple discussions with the FDA, we no longer anticipate the requirement for an FDA panel and expect PMA approval for the safety and effectiveness of the Impella 2.5 by February or March 2015.

Following approval of the Impella 2.5, we plan to submit the Impella 4.0 and Impella CP as PMA supplements. Until the PMA supplement approval process is completed, the Impella 5.0 and Impella CP will remain on the market under the existing 510(k) clearances.

Impella CP

In September 2012, we announced that the Impella CP received 510(k) clearance from the FDA. The Impella CP provides blood flow of approximately one liter more per minute than the Impella 2.5 and is indicated for up to six hours of partial circulatory support using an extracorporeal bypass control unit. It is also intended to be used to provide partial circulatory support, for up to six hours, during procedures not requiring cardiopulmonary bypass. The Impella CP received CE Mark approval to be marketed in the European Union in April 2012 and Health Canada approval to be marketed in Canada in June 2012. We began selling Impella CP in the U.S. during the second quarter of fiscal 2013.

Impella 5.0 and Impella LD

The Impella 5.0 and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella 5.0 and Impella LD devices received 510(k) clearance in April 2009, for circulatory support for up to six hours and have CE Mark approval in Europe for up to ten days duration and are approved for use in over 40 countries.

The Impella 5.0 can be quickly implanted via a small incision in the femoral artery in the groin using a guide wire to reach the left ventricle of the heart where it can then be directly deployed to draw blood out of the ventricle, deliver it to the arterial system and perfuse the heart muscle. This function is intended to reduce ventricular work. The Impella LD is similar to the Impella 5.0 but is implanted directly through an aortic graft. The Impella 5.0 and Impella LD can pump up to five liters of blood per minute, providing full circulatory support.

Impella RP

The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and is intended to provide the flow and pressure needed to compensate for right side heart failure. In November 2012, we announced that the Impella RP received U.S. investigational device exemption, or IDE, approval from the FDA for use in RECOVER RIGHT, a pivotal clinical study in the U.S. In March 2014, we completed enrollment of 30 patients at sites that present with signs of right side heart failure, require hemodynamic support, and are being treated in the catheterization lab or cardiac surgery suite. The study collected safety and effectiveness data on the percutaneous use of the Impella RP and will be applied towards the submission of a Humanitarian Device Exemption, or HDE. In May 2014, we received approval for implementation of a Continuous Access Protocol, or CAP, from the FDA for the RECOVER RIGHT trial. The CAP will allow us to enroll up to 22 additional patients at the 15 U.S. investigational sites for a six month period, from the date of the CAP approval. In September 2014, we announced clinical trial results on the RECOVER RIGHT study that showed a survival rate of 73% in the overall patient population that participated in the study.

We expect HDE approval for the Impella RP by February or March 2015. An HDE is similar to a PMA application but is intended for patient populations of 4,000 or less per year in the U.S. Approval of an HDE requires demonstration of the safety and probable benefit of the product, which is a lower standard than is applied to a PMA. In order to receive an HDE, there must be no comparable devices approved under PMA that are available to treat the targeted population. An approved HDE authorizes sales of the device to any hospital after Institutional Review Board review and approval by the hospital. In April 2014, the Impella RP received CE Marking approval which allows for commercial sales of Impella RP in the E.U. and other countries that require a CE Marking approval for sales. This product is not currently available for commercial use outside of Europe.

AB5000

We manufacture and sell the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. We believe the AB5000 is the only commercially available cardiac assist device that is approved by the FDA for all indications where heart recovery is the desired outcome, including patients who have undergone successful cardiac surgery and subsequently develop low cardiac output, or patients who suffer from acute cardiac disorders leading to hemodynamic instability.

Symphony

In November 2011, we announced Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics and potentially improving their quality of life. The device is designed with the primary goal of stabilizing the progression of heart failure and recovering or remodeling the heart. To date, we have implanted the device in four patients in first-in-human clinical trials of Symphony outside the U.S. We are evaluating the results of these cases and expect to conduct additional Symphony trials outside of the U.S. in the future. Symphony is not currently approved by the FDA for sale in the U.S.

Acquisition of ECP

On July 1, 2014, we acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. ECP, based in Berlin, Germany, is engaged in research, development, prototyping and the pre-serial production of a percutaneous expandable catheter pump which increases blood circulation from the heart with an external drive shaft. In connection with our acquisition of ECP, ECP acquired all of the issued shares of AIS GmbH Aachen Innovative Solutions, or AIS, a German limited liability company, for $2.8 million in cash. AIS, based in Aachen, Germany, holds certain intellectual property useful to ECP’s business, and, prior to being acquired by ECP, had licensed such intellectual property to ECP.

Legal Proceedings

We are the subject of various pending or threatened legal actions and proceedings that arise in the ordinary course of our business. Such matters are subject to many uncertainties and outcomes that are not predictable with assurance and that may not be known for extended periods of time. Any material legal proceedings are discussed in “Note 10. Commitments and Contingencies—Litigation” in the Notes to Condensed Consolidated Financial Statements and are incorporated herein by reference. Since the outcome of such lawsuits or other proceedings cannot be predicted with certainty, the costs associated with such proceedings could have a material adverse effect on our financial condition, results of operations and cash flows.

Summary of Recent Financial Performance

For the three and six months ended September 30, 2014, we recognized net income of $3.8 million and $2.1 million, respectively. We may incur losses in the future as we continue to invest in research and development related to our products, conduct clinical studies and registries on our products, support our PMA submission, expand our commercial infrastructure, incur additional legal fees to comply with the ongoing DOJ Investigations and defend ourselves from other legal claims, pay additional excise taxes, incur additional expenses for activities related to the ECP business that we acquired in July 2014, enter into collaborations with other parties and invest in new markets such as Japan.

Critical Accounting Policies

There have been no changes in our critical accounting policies during the six months ended September 30, 2014, as compared to the critical accounting policies disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014, except for as noted below.

In-Process Research and Development

In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that we acquire, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if we become aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when we have regulatory approval and are able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, we may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.

Contingent Consideration

Recent Accounting Pronouncements

Information regarding recent accounting pronouncements is included in Note 1. “Recent Accounting Pronouncements” to our Condensed Consolidated Financial Statements in this Report.

Results of Operations

The following table sets forth certain consolidated statements of operations data for the periods indicated as a percentage of total revenue for the three and six months ended September 30, 2014 and 2013, respectively:


	Three Months Ended September 30,						Six Months Ended September 30,
	2014			2013			2014			2013
Revenue:
Product		99.7	%		99.9	%		99.7	%		99.9	%
Funded research and development		0.3			0.1			0.3			0.1

Total revenue		100.0			100.0			100.0			100.0


Costs and expenses:
Cost of product revenue		18.5			20.3			19.2			20.4
Research and development		16.8			17.4			17.6			17.2
Selling, general and administrative		56.7			59.1			60.6			62.3

Total costs and expenses		92.0			96.8			97.4			99.9

Income from operations		8.0			3.2			2.6			0.1
Other income and income tax provision		0.6			0.8			0.5			0.9

Net income (loss)		7.4	%		2.4	%		2.1	%		(0.8	)%

Three and six months ended September 30, 2014 compared with the three and six months ended September 30, 2013

Revenues

Our revenues are comprised of the following:


	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
	(in $000’s)				(in $000’s)
Impella product revenue	$	46,910	$	40,167	$	91,885	$	78,821
Service and other revenue		3,297		2,574		6,577		5,190
Other product revenue		1,567		1,547		1,972		2,886

Total product revenue		51,774		44,288		100,434		86,897
Funded research and development		164		57		315		118

Total revenue	$	51,938	$	44,345	$	100,749	$	87,015

Impella product revenue encompasses Impella 2.5, Impella CP, Impella 5.0, Impella LD and Impella RP product sales. Other product revenue includes AB5000, BVS5000 and cannulae product sales. Service and other revenue represents revenue earned on preventative maintenance service contracts and maintenance calls.

Total revenues for the three months ended September 30, 2014 increased by $7.6 million, or 17%, to $51.9 million from $44.4 million for the three months ended September 30, 2013. Total revenues for the six months ended September 30, 2014 increased by $13.7 million, or 16%, to $100.7 million from $87.0 million for the six months ended September 30, 2013. The increase in total revenue was primarily due to higher Impella product revenue from increased utilization in the U.S., which was attributable in part to the increased use of Impella CP.

Impella product revenue for the three months ended September 30, 2014 increased by $6.7 million, or 17% to $46.9 million from $40.2 million for the three months ended September 30, 2013. Impella product revenue for the six months ended September 30, 2014 increased by $13.1 million, or 17% to $91.9 million from $78.8 million for the six months ended September 30, 2013. Most of the increase in Impella product revenue was from disposable catheter sales in the U.S., as we focus on increasing utilization of our disposable catheter products through continued investment in our field organization and physician training programs. Impella product revenue outside the U.S., primarily in Europe, also increased during the three and six months ended September 30, 2014. We expect Impella product revenue to continue to increase as we add new customer sites, increase utilization at existing customer sites and continue our commercial launch of Impella CP.

Service and other revenue for the three months ended September 30, 2014 increased by $0.7 million, or 27%, to $3.3 million from $2.6 million for the three months ended September 30, 2013. Service and other revenue for the six months ended September 30, 2014 increased by $1.4 million, or 27%, to $6.6 million from $5.2 million for the six months ended September 30, 2013. The increase in service and other revenue was primarily due to an increase in revenue earned under service contracts. The increase in service contract revenue was due to the increased number of Impella consoles at customer sites, many of which have related service contracts for product maintenance.

Other product revenue for the three months ended September 30, 2014 decreased by $0.1 million, or 7%, to $1.6 million from $1.5 million for the three months ended September 30, 2013. Other product revenue for the six months ended September 30, 2014 decreased by $0.9 million, or 31%, to $2.0 million from $2.9 million for the six months ended September 30, 2013. The decrease in other product revenue was due to our discontinuation of sales of our BVS 5000 product and a significant decline in AB5000 disposable sales, particularly in the U.S. We expect that AB5000 revenue will continue to decline as we focus our sales efforts in the surgical suite on Impella 5.0 and LD.

Costs and Expenses

Our costs and expenses are comprised of the following:

Cost of Product Revenue

Cost of product revenue for the three months ended September 30, 2014 and 2013, respectively, was $9.6 million and $9.0 million. Gross margin was 82% for the three months ended September 30, 2014 compared to 80% for the three months ended September 30, 2013. Cost of product revenue for the six months ended September 30, 2014 and 2013, respectively, was $19.3 million and $17.8 million. Gross margin was 81% for the six months ended September 30, 2014 compared to 80% for the six months ended September 30, 2013. The increase in cost of product revenue was related to increased Impella product demand and costs to support the higher demand for Impella products. Gross margin for the three and six months ended September 30, 2014 was impacted favorably by lower shipments of consoles and improved efficiencies in manufacturing production. We expect that the shipments of consoles will continue at approximately the current level for the remainder of fiscal 2015.

Research and Development Expenses

Research and development expenses for the three months ended September 30, 2014 increased by $1.0 million, or 13%, to $8.7 million from $7.7 million for the three months ended September 30, 2013. Research and development expenses for the six months ended September 30, 2014 increased by $2.8 million, or 19%, to $17.8 million from $15.0 million for the six months ended September 30, 2013.

The increase in research and development expenses for the three months ended September 30, 2014 was primarily due to operating expenses associated with the ECP facility in Berlin that we incurred after the ECP acquisition on July 1, 2014. The increase in research and development expense for the six months September 30, 2014 was due primarily to a $1.5 million up-front license payment made to Opsens, Inc. in April 2014 and operating expenses associated with the ECP facility in Berlin that we incurred after the ECP acquisition on July 1, 2014. We expect research and development expenses to increase in the remainder of fiscal 2015 as we continue to pursue our PMA application for our existing Impella products available for sale in the U.S., work on other clinical studies and registries and apply for regulatory approval for our Impella products in Japan. In addition, we expect to incur additional costs as we continue to focus on new product development initiatives associated with Impella RP, Impella CP, Symphony and developing recently acquired ECP technology.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended September 30, 2014 increased by $3.3 million, or 13%, to $29.5 million from $26.2 million for the three months ended September 30, 2013. Selling, general and administrative expenses for the six months ended September 30, 2014 increased by $6.9 million, or 13%, to $61.1 million from $54.2 million for the six months ended September 30, 2013.

The increase in selling, general and administrative expenses was primarily due to the hiring of additional U.S. field sales and clinical personnel, increased spending on marketing initiatives as we continue to educate physicians on the benefits of hemodynamic support and additional legal and professional expenses related to the ECP acquisition. These amounts were offset by lower legal expenses related to the DOJ Investigations and shareholder suits discussed in “Note 10. Commitments and Contingencies—Litigation,” in the Notes to Condensed Consolidated Financial Statements.

We expect to continue to increase our expenditures on sales and marketing activities, with particular investments in field sales and clinical personnel with cath lab expertise. We also plan to increase our marketing, service and training investments to support the efforts of the sales and field clinical teams to drive recovery awareness for acute heart failure patients. For the foreseeable future, we

also expect to continue to incur significant legal expenses related to the DOJ Investigations and our defense of the purported class action for the foreseeable future, each discussed in “Note 10. Commitments and Contingencies—Litigation” in the Notes to Condensed Consolidated Financial Statements.

Provision for Income Taxes

During the three months ended September 30, 2014 and 2013, we recorded a provision for income taxes of $0.3 million and $0.4 million, respectively. During the six months ended September 30, 2014 and 2013, we recorded an income tax provision of $0.6 million and $0.8 million, respectively. The income tax provision for the three and six months ended September 30, 2014 is primarily due to income taxes related to our deferred tax liability associated with tax deductible goodwill that is not amortized for U.S. GAAP purposes.

Net Income (Loss)

During the three months ended September 30, 2014, we recorded net income of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $1.1 million, or $0.03 per basic and diluted share, for the three months ended September 30, 2013. During the six months ended September 30, 2014, we recorded net income of $2.1 million, or $0.05 per basic and diluted share, compared to net loss of $0.7 million, or $0.02 per basic and diluted share, for the six months ended September 30, 2013.

The increase in net income in for the three and six months ended September 30, 2014 was primarily due to higher Impella product revenue due to greater utilization in the U.S. and Europe and lower legal expenses related to the DOJ Investigations and shareholder suits. We may incur losses in the future as we continue to invest in research and development related to our products, conduct clinical studies and registries on our products, support our PMA submission, expand our commercial infrastructure, incur additional legal fees to comply with the ongoing DOJ Investigations and defend ourselves from other legal claims, pay additional excise taxes, incur additional expenses for activities related to the ECP business we acquired in July 2014, enter into collaborations with other parties and invest in new markets, such as Japan.

Liquidity and Capital Resources

At September 30, 2014, our cash, cash equivalents, and short and long-term marketable securities totaled $111.9 million, a decrease of $6.4 million compared to $118.3 million in cash, cash equivalents and short-term and long-term marketable securities at March 31, 2014. The decrease in our cash, cash equivalents, and short and long-term marketable securities was due to the ECP and AIS acquisitions discussed above in “Overview – Acquisition of ECP,” and was offset by positive cash flow from operations in fiscal 2015. We paid approximately $15.7 million in net cash for the initial purchase price of these acquisitions. We also could be required to pay up to an additional $15.0 million, which may be paid, at our discretion, as cash, shares of our common stock or a combination of both, in connection with the acquisition of ECP, if certain technical, regulatory and commercial milestones are met. We also expect to incur additional expenses with the operation of ECP as we do not expect to have revenues from these businesses in the near future.

We believe that our revenue from product sales together with existing resources will be sufficient to fund our operations for at least the next twelve months, exclusive of activities involving any future acquisitions of products or companies that complement or augment our existing line of products.

Our primary liquidity requirements are to fund the expansion of our commercial infrastructure in the U.S., increase our Impella manufacturing capacity, increase our inventory levels in order to meet increasing customer demand for Impella in the U.S., fund new product development, prepare for commercial launches of Impella in new markets in the future, such as Japan, pay for legal fees related to the DOJ Investigations, our defense of the appeal relating to the dismissal of purported class actions against us, our response to information requests and to provide for general working capital needs. Through September 30, 2014, we have funded our operations principally from product sales and through the sale of equity securities. We also receive a small amount of funding from government research and development grants.

Marketable securities at September 30, 2014 consisted of $94.5 million held in funds that invest in U.S. Treasury and government-backed securities. We are not a party to any interest rate swaps, currency hedges or derivative contracts of any type and have no exposure to commercial paper or auction rate securities markets.

During the six months ended September 30, 2014, net cash provided by operating activities was $9.9 million, compared to $5.1 million during the same period in the prior year. The increase in cash provided by operating activities was primarily attributable to the increase in net income of $2.8 million reflected in our net income of $2.1 million for the six months ended September 30, 2014 compared to our net loss of $0.7 million for the same period in the prior year, partially offset by a $0.8 million decrease in cash used for accounts receivable due to timing of receivable collections. In addition, net cash provided by operating activities was impacted by changes in non-cash adjustments, including a $1.6 million increase in stock-based compensation and a $0.2 million change in fair value of contingent consideration due to the effect of the passage of time on the fair value measurement.

During the six months ended September 30, 2014, net cash used for investing activities was $15.0 million, compared to $10.1 million during the same period in the prior year. The increase in net cash used for investing activities was primarily attributable to $15.7 net cash used for our acquisition of ECP and AIS, an $11.1 million decrease in marketable securities in the current year due to the redemption of marketable securities to assist in funding the ECP and AIS acquisitions. Our cash used for capital expenditures increased by $0.3 million during the six months ended September 30, 2014, as compared to the same period in the prior year. We also made an $0.8 million investment in a private medical technology company during each of the six months ended September 30, 2014 and 2013, respectively.

During the six months ended September 30, 2014, net cash provided by financing activities was $1.9 million, compared to $5.2 million during the same period in the prior year. The decrease in net cash provided by financing activities was primarily attributable to a $2.8 million decrease in proceeds from the exercise of stock options and a $0.6 million increase in payments in lieu of issuance of common stock for payroll withholding taxes upon vesting of certain equity awards.

Capital expenditures for fiscal 2015 are estimated to range from $3.0 to $5.0 million, and are expected to be for manufacturing capacity increases for Impella products, leasehold improvements and software development projects.

Cash and cash equivalents held by our foreign subsidiaries totaled $4.9 million and $3.3 million at September 30, 2014 and March 31, 2014, respectively. The increase in cash and cash equivalents held by our foreign subsidiaries was due to the transfer of cash to our German subsidiary to fund the operations of ECP and AIS after we acquired these entities on July 1, 2014.

Our operating income outside the U.S. is deemed to be permanently reinvested in foreign jurisdictions. We do not intend or currently foresee a need to repatriate cash and cash equivalents held by our foreign subsidiaries. If these funds are needed in the U.S., we believe that the potential U.S. tax impact to repatriate these funds would be immaterial.

Our liquidity is influenced by our ability to sell our products in a competitive industry and our customers’ ability to pay for our products. Factors that may affect liquidity include our ability to penetrate the market for our products, maintain or reduce the length of the selling cycle, invest in collaborative arrangements with other partners and collect cash from customers after our products are sold. We also expect to continue to incur legal expenses for the foreseeable future related to the DOJ Investigations, our defense of the appeal of the dismissal of the purported class action and our response to requests for information. We continue to review our long-term cash needs on a regular basis. At September 30, 2014, we had no long-term debt outstanding.

ITEM 3:

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Primary Market Risk Exposures

Our cash, cash equivalents and marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. Marketable securities at September 30, 2014 consist of $94.5 million held in funds that invest in U.S. Treasury and government-backed securities. If market interest rates were to increase immediately and uniformly by 10 percent from levels at September 30, 2014, we believe the decline in fair market value of our investment portfolio would be immaterial.

Currency Exchange Rates

We have foreign currency exposure to exchange rate fluctuations and particularly with respect to the euro, British pound sterling and Japanese yen. Therefore, our investment in our subsidiaries is sensitive to fluctuations in currency exchange rates. The effect of a change in currency exchange rates on our net investment in international subsidiaries is reflected in the accumulated other comprehensive (loss) income component of stockholders’ equity. If rates of exchange for the euro, British pound and Japanese yen were to have depreciated immediately and uniformly by 10% relative to the U.S. dollar from levels at September 30, 2014, the result would have been a reduction of stockholders’ equity of approximately $5.3 million.

Fair Value of Financial Instruments

At September 30, 2014, our financial instruments consist primarily of cash and cash equivalents, short-term and long-term marketable securities, accounts receivable, accounts payable and contingent consideration. The estimated fair values of the financial instruments have been determined by us using available market information and appropriate valuation techniques. Considerable judgment is required, however, to interpret market data to develop the estimates of fair value. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act of 1934, as of September 30, 2014. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2014, these disclosure controls and procedures are effective to provide reasonable assurance that material information required to be disclosed by us, including our consolidated subsidiaries, in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Evaluation of Changes in Internal Control over Financial Reporting

During the second quarter of our fiscal year ending March 31, 2015, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.

Legal Proceedings

We are from time to time involved in various legal actions, the outcomes of which are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. We record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. We review these estimates each accounting period as additional information is known and adjust the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. Material legal proceedings are discussed in “Note 10. Commitments and Contingencies—Litigation” in the Notes to Condensed Consolidated Financial Statements and are incorporated herein by reference.

Item 1A.

Risk Factors

Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part 1, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2014, which could materially affect our business, financial condition or future results. As of the date of this report there has been no material change in any of the risk factors described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014, except as noted below:

We have incurred losses in previous periods and may incur losses in future periods.

For the years ended March 31, 2014 and 2013, we recognized net income of approximately $7.4 million and $15.0 million, respectively. For the year ended March 31, 2012, we were essentially break-even as we recognized a net income of $1.5 million. Prior to fiscal 2012, we had incurred losses and had no history of profitability. The profitability we achieved in recent years may not be indicative of our ability to sustain profitability and we may incur losses from operations in future periods. We historically have incurred net losses from our operations. Any losses incurred in the future may result primarily from, among other things, the expansion of our global distribution network, investments in new markets such as Japan, ongoing product and clinical development, costs related to new business development initiatives and legal and other expenses related to the DOJ Investigations, including our compliance with the subpoena received from the U.S. Department of Justice in October 2012, the subpoena we received from the Boston regional office of the U.S. Department of Health and Human Services, Office of Inspector General in April 2014 and the CID we received from the United States Attorney’s Office for the District of Massachusetts in November 2014 and our defense of other legal claims. Additionally, due to the introduction of the U.S. medical device tax in January 2013 we began incurring a 2.3% excise tax on the sales of certain of our products in the U.S. regardless of whether we are profitable or not. These expenditures may include costs associated with hiring additional personnel, performing clinical trials, continuing our research and development relating to our products under development, seeking regulatory approvals and, if we receive these approvals, commencing commercial manufacturing and marketing activities. The amount of these expenditures is difficult to forecast accurately and cost overruns may occur. We also expect that we will make significant expenditures to market and manufacture in commercial quantities our approved circulatory care products, and any other new products for which we may incur additional expense to obtain regulatory approvals or clearances in the future.

We must comply with healthcare “fraud and abuse” laws, and we could face substantial penalties for non-compliance and be excluded from government healthcare programs, which would adversely affect our business, financial condition and results of operations.

Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights may be applicable to our business. We may be subject to healthcare fraud and abuse regulation and patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:

•

The federal healthcare program Anti-Kickback Statute, which prohibits, among other things, soliciting, receiving or providing remuneration, directly or indirectly, to induce (i) the referral of an individual, for an item or service, or (ii) the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;

•

Federal false claims laws which prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us that promote medical devices, provide medical device management services and may provide coding and billing advice to customers;

•

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and

•

State law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ in significant ways from state to state and often are not preempted by HIPAA, thus complicating compliance efforts.

Additionally, the compliance environment is changing, with more states, such as California and Massachusetts, mandating implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other states, such as Vermont, Maine, and Minnesota, requiring reporting to state governments of gifts, compensation and other remuneration to physicians. The Physician Payments Sunshine Act, or PPSA, which was signed into law on March 23, 2010, requires manufacturers of drug, device, biologics, and medical supplies covered under Medicare, Medicaid, or State Children’s Health Insurance Program, or SCHIP, to report payments made to physicians on an annual basis to the U.S. Department of Health and Human Services, or HHS. Companies were required to start collecting this data on August 1, 2013 and are required to report this information to HHS in 2014. These laws all provide for penalties for non-compliance. The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and reporting requirements, increases the possibility that we may run afoul of one or more laws. On April 25, 2014, we received a subpoena from the Boston regional office of the United States Department of Health and Human Services, Office of Inspector General requesting materials relating to our reimbursement of expenses and remuneration to healthcare providers during the period of July 2012 through December 2012. On November 6, 2014, we received a CID requesting additional document production relating to this matter for the time period of January 1, 2012 through December 31, 2013.

Many of these requirements are new and their application is uncertain, and regulatory guidance is limited. We could face enforcement action, fines and other penalties and could receive adverse publicity, all of which could harm our business, if it is alleged that we have failed to fully comply with such laws and regulations. Similarly, if the physicians or other providers or entities that we do business with are found not to comply with applicable laws, they may be subject to sanctions, which could also have a negative impact on our business.

Our operating results may fluctuate unpredictably.

Historically, our annual and quarterly operating results have fluctuated widely and we expect these fluctuations to continue. Among the factors that may cause our operating results to fluctuate are:

•

the timing of customer orders and deliveries;

•

competitive changes, such as price changes or new product introductions that we or our competitors may make;

•

the timing of regulatory actions, such as product approvals or recalls;

•

costs we incur developing and testing our Impella heart pumps and other products;

•

costs we incur in anticipation of future sales, such as inventory purchases, expansion of manufacturing facilities, or establishment of international sales offices;

•

costs we incur in connection with the class action suits and derivative action that has been filed against us;

•

costs we incur in connection with the DOJ Investigations;

•

additional taxes, such as the Medical Device tax;

•

timing of certain marketing programs and events;

•

economic conditions in the healthcare industry; and

•

efforts by governments, insurance companies and others to contain health care costs, including changes to reimbursement policies.

We believe that period-to-period comparisons of our historical results are not necessarily meaningful, and investors should not rely on them as an indication of our future performance. To the extent we experience the factors described above, our future operating results may not meet the expectations of securities analysts or investors from time to time, which may cause the market price of our common stock to decline.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

(a) Not applicable.

(b) Not applicable.

Item 3.

Defaults Upon Senior Securities

None

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None

Item 6.

Exhibits

Exhibit

No.

Description

Filed with

This

Form 10-Q

Incorporated by Reference

Form

Filing Date

Exhibit
No.

3.1

Restated Certificate of Incorporation.

S-3

September 29, 1997

3.1

3.2

Restated By-Laws, as amended

10-K

May 27, 2004 (File No.
001-09585)

3.2

3.3

Certificate of Designations of Series A Junior Participating Preferred Stock.

S-3

September 29, 1997

3.3

3.4

Amendment to the Company’s Restated Certificate of Incorporation to increase the authorized shares of common stock from 25,000,000 to 100,000,000.

8-K

March 21, 2007 (File
No. 001-09585)

3.4

4.1

Specimen Certificate of common stock.

S-1

June 5, 1987

4.1

31.1

Principal Executive Officer Certification pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Principal Financial Officer Certification pursuant to Securities Exchange Act Rule 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Principal Executive Officer and Principal Financial Officer Certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following financial information from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of September 30, 2014 and March 31, 2014; (ii) Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2014 and September 30, 2013; (iii) Condensed Consolidated Statements of Comprehensive (Loss) Income for the three and six months ended September 30, 2014 and September 30, 2013; (iv) Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2014 and September 30, 2013; and (v) Notes to Condensed Consolidated Financial Statements.

ABIOMED, INC. AND SUBSIDIARIES

PART II. OTHER INFORMATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


				ABIOMED, Inc.

Date: November 10, 2014				/s/ ROBERT L. BOWEN
				Robert L. Bowen
				Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-31.1 2 d798670dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Michael R. Minogue certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ABIOMED, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 10, 2014				/s/ Michael R. Minogue
				Michael R. Minogue
				Chairman, President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 d798670dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

I, Robert L. Bowen certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ABIOMED, Inc.

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 10, 2014				/s/ Robert L. Bowen
				Robert L. Bowen
				Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-32.1 4 d798670dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ABIOMED, Inc., (the “Company”) for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned President and Chief Executive Officer, and Corporate Controller, of the Company, certifies, to the best knowledge and belief of the signatory, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Michael R. Minogue				/s/ Robert L. Bowen
Chairman, President and Chief Executive Officer				Vice President and Chief Financial Officer
Date: November 10, 2014				Date: November 10, 2014

EX-101.INS 5 abmd-20140930.xml XBRL INSTANCE DOCUMENT

18500000

40894675

700000

800000

54100000

426000

295000

1964000

18500000

53000

619000

21750000

25000

22176000

874000

141000

131000

15000000

7000000 125000000

10120000

41831077

40577134

3502000

100000000

14.16

2787000

11.94

1253943

14.00

0.01

1000000

0.01

3578000

775000

27134000

417000

-5965000

7616000

-248780000

1000000

6865000

5797000

13762000

175538000

210000

722000

215544000

447433000

1021000

5756000

40006000

9083000

5797000

17483000

36867000

7351000

38287000

16473000

17198000

3310000

38013000

1675000

35928000

6052000

215544000

813000

13445000

23072000

77981000

1551000

17567000

135291000

5718000

1161000 72750 74050 66000 70750

20000

94454000

31000

94465000

17000

58494000

3000

58480000

3000

16473000

28000

16498000

19487000

5797000

5700000

8000000

21.80

1252000

17000000

0.09 34500 44000 0.66

700000

58494000

16473000

5800000

1500000

19487000

9451000

41122695

39916328

100000000

13.27

1206367

0.01

1000000

0.01

3492000

794000

30411000

411000

-730000

7746000

-250910000

1445000

6415000

17899000

168353000

228000

802000

205407000

436136000

1304000

4766000

37054000

11967000

20916000

37990000

6889000

41761000

3082000

1273000

6414000

205407000

13948000

24357000

55663000

801000

16554000

117966000

6261000

1587000

14000

97424000

30000

97440000

6000

24176000

4000

24174000

8000

41761000

26000

41779000

31487000

21.37

1174000

35400000

0.09 0.74

24176000

41761000

800000

31487000

1500000 4500000

21750000

15750000

6000000

2014-06-30

2800000

With respect to such milestone payments, the share purchase agreement provides: • that, upon the earlier of (i) the Company’s receipt of European CE Marking approval relating to the sale of an expandable device based on certain patent rights acquired from ECP, or (ii) the Company bringing of a successful claim against a third party competitor (or reaching an economically equivalent settlement) for the infringement of certain patent rights acquired from ECP, it will pay Syscore an additional $7.0 million (provided that if such claim or settlement does not prohibit the third party competitor’s further marketing, production, sale, distribution, lease or use of any violating or infringing products, but only awards monetary damages to us or to Abiomed Europe, the amount payable to Syscore shall be limited to the lower of the amount of aggregate damages received and $7.0 million); and • that, upon the first to occur of (i) the Company’s successful commercialization of one or more rotatable and expandable devices based on certain patent rights acquired from ECP, where such devices achieve aggregate worldwide revenues of $125.0 million, including the revenues of third party licensees, or (ii) the Company’s sale of (A) ECP, (B) all or substantially all of ECP’s assets, or (C) certain of ECP’s patent rights, the Company will pay to Syscore the lesser of (y) one-half of the profits earned from such sale described in the foregoing item (ii), after accounting for the costs of acquiring and operating ECP, or (z) $15.0 million (less any previous milestone payment).

13000000

P20Y

-0.02

9.67

5122000

P4Y3M4D

0.0085

38971000

-0.02

0.519

38971000

118000

2321000

86897000

2331000

762000

876000

10000

91000

1667000

26000

870000

117000

-2631000

750000

-15000

87015000

33849000

1236000

-664000

41000

-1912000

426000

92000

87042000

453000

428000

-62000

15008000

54166000

15000

669000

-1978000

781000

17750000

1322000

5204000

312000

537000

-10085000

5318000

86924000

25750000

-1494000

6719000

-1850000

1198000

3923000

98000

1523000

23.18

6000000

5098000

0.08

1285000

347000

5087000

<div> Note 7. Accrued Expenses Accrued expenses consist of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,083</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,967</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,161</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,587</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional, legal and accounting fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,021</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,304</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Sales and income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,445</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Warranty </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">794</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">722</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">802</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,762</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,899</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at September 30, 2014 and March 31, 2014. </div>

<div> Note 10. Commitments and Contingencies  Commitments In July 2013, the Company entered into a lease agreement to continue renting its existing space in Aachen, Germany through July 31, 2023. The building serves as the Company’s European headquarters and houses most of the manufacturing operations for its Impella product line. The lease payments are approximately 34,500€ (euro) (approximately U.S. $44,000 at September 30, 2014 exchange rates) per month.   In February 2014, the Company entered into a lease agreement to continue renting its existing space in Danvers, Massachusetts through February 28, 2021. Monthly rent is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The base rent for March 2014 through April 2014 was $66,000 per month; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The base rent for May 2014 through February 2016 is $74,050 per month; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The base rent for March 2016 through February 2018 will be $70,750 per month; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The base rent for March 2018 through February 2021 will be $72,750 per month.</td> </tr> </table> License Agreement In April 2014, the Company entered into an exclusive license agreement with Opsens, Inc. for the rights to certain optical sensor technologies in the field of cardio-circulatory assist devices. The Company made a $1.5 million upfront payment upon execution of the agreement and agreed to make additional payments of up to $4.5 million upon the achievement of certain development milestones. Contingent Consideration As discussed in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP using a combination of cash and potential post-acquisition milestone payments. These milestone payments may be payable at some time over the next 20 years, depending on the achievement of certain technical, regulatory and commercial milestones. The maximum amount of the aggregate milestone payments could be $15.0 million. As of September 30, 2014, the fair value of the contingent consideration was $5.8 million. Litigation From time to time, the Company is involved in legal and administrative proceedings and claims of various types. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements. On October 26, 2012, the Company was informed that the Department of Justice, United States Attorney’s Office for the District of Columbia was conducting an investigation (the “Marketing and Labelling Investigation”) focused on the Company’s marketing and labeling of the Impella 2.5. On October 31, 2012, the Company accepted service of a subpoena related to this investigation seeking documents related to the Impella 2.5. The Company believes that is has substantially complied with the subpoena and has submitted the requested documents to the United States Attorney’s Office. On September 13, 2013, the Company entered into a tolling agreement with the United States Attorney’s Office, pursuant to which the Company and the United States Attorney’s Office mutually agreed to toll the applicable statutes of limitations for all criminal, civil and administrative offenses and violations that could be charged or claimed against the Company as of that date until June 2, 2014. On May 27, 2014, the Company executed an extension of the tolling agreement through February 2, 2015. The investigation is ongoing, however, and the Company is unable to predict the ultimate outcome or determine whether a liability has been incurred or make an estimate of the reasonably possible liability, if any, that could result from any unfavorable outcome associated with this investigation. The Company has incurred significant expenses related to this investigation and expects to continue to incur additional expenses in the future. On November 16 and 19, 2012, two purported class action complaints were filed against the Company and certain of its officers in the U.S. District Court for the District of Massachusetts, or the District Court, by alleged purchasers of its common stock, on behalf of themselves and persons or entities that purchased or acquired common stock of the Company between August 5, 2011 and October 31, 2012. The complaints alleged that the defendants violated the federal securities laws in connection with disclosures related to the Company’s marketing and labeling of the Impella 2.5 product and seek damages in an unspecified amount. The District Court consolidated these complaints and a consolidated amended complaint was filed by the plaintiffs on May 20, 2013. On July 8, 2013, the Company filed a motion to dismiss the consolidated class action. Oral arguments on the Company’s motion to dismiss were conducted before the District Court on September 18, 2013. On April 10, 2014, the District Court entered an order granting the Company’s motion and dismissed the consolidated and amended complaint. On May 9, 2014, the plaintiffs filed a notice of appeal, and subsequently filed their appellate brief with the U.S. Court of Appeals for the First Circuit, or the First Circuit, on July 16, 2014. The appeal process remains ongoing with oral arguments scheduled for January 8, 2015. On February 4, 2013, an alleged stockholder of the Company filed a derivative action with the District Court on the Company’s behalf against each of the Company’s directors. The complaint alleged that the directors breached their fiduciary duties to the Company and its stockholders in connection with disclosures related to the Company’s marketing and labeling of its Impella 2.5 product and sought damages in an unspecified amount. On March 22, 2013, the Company filed a motion to dismiss the derivative action. On June 21, 2013, the District Court granted the Company’s motion to dismiss. The plaintiff appealed the dismissal to the First Circuit. The First Circuit affirmed the District Court’s Order of Dismissal in a written opinion issued on June 10, 2014. On April 25, 2014, the Company received a subpoena from the Boston regional office of the United States Department of Health and Human Services, or HHS, Office of Inspector General requesting materials relevant to the Company’s reimbursement of expenses and remuneration to healthcare providers for a six month period from July 2012 through December 2012 in connection with a civil investigation under the False Claims Act (the “FCA Investigation” and, together with the Marketing and Labelling Investigation, the “DOJ Investigations”). The Company submitted the requested documents to HHS and believes that it substantially complied with the subpoena. On November 6, 2014, the Company received notice from the Department of Justice, United States Attorney’s Office for the District of Massachusetts in the form of a Civil Investigative Demand (“CID”) requesting additional document production relating to this matter for the time period of January 1, 2012 through December 31, 2013. The Company intends to respond to the CID and cooperate with the U.S. Attorney’s Office in connection with the FCA investigation. The Company is unable to estimate a potential liability with respect to the DOJ Investigations and the appeal of the dismissal of the purported class action claim. There are numerous factors that make it difficult to meaningfully estimate possible loss or range of loss at this stage of these investigations and lawsuits, including that: the proceedings are in relatively early stages, there are significant factual and legal issues to be resolved and information obtained or rulings made during any lawsuits or investigations could affect the methodology for calculation. In addition, with respect to claims for which damages are the requested relief, no amount of loss or damages has been specified. Therefore, the Company is unable at this time to estimate its possible losses and accordingly, no adjustment has been made to the financial statements to reflect the outcome of these uncertainties. </div>

0.05

<div> Note 2. Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the Company’s employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company’s basic and diluted net income (loss) per share for the three and six months ended September 30, 2014 and 2013 were as follows (in thousands, except per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic Net Income (Loss) Per Share </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,839</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,059</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,130</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(664</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average shares used in computing basic net income (loss) per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,448</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,256</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,971</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) per share - basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted Net Income (Loss) Per Share </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,839</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,059</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,130</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(664</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average shares used in computing basic net income (loss) per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,448</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,256</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,971</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Effect of dilutive securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,791</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,077</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,813</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average shares used in computing diluted net income (loss) per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,239</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,069</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,971</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) per share - diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> For the three months ended September 30, 2014, approximately 47,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 465,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share. For the six months ended September 30, 2014, approximately 44,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 465,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share. For the three months ended September 30, 2013, approximately 297,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 354,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share. For the six months ended September 30, 2013, approximately 3,923,000 shares underlying stock options and approximately 1,198,000 restricted shares were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period. </div>

<div> The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Payments </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign currency translation impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(422</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,797</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The fair value of options granted during the three and six months ended September 30, 2014 and 2013 were calculated using the following weighted average assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.75</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.39</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.60</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.85</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected option life (years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.19</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.19</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49.3</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51.9</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

313000

P4Y11M19D

11.49

10-Q ABIOMED INC ABMD

1813000

<div> Note 6. Goodwill and In-Process Research and Development Goodwill Goodwill has been recorded in connection with the Company’s acquisitions of Impella Cardiosystems AG, or Impella, in 2005 and ECP and AIS in July 2014, as discussed in Note 3. “Acquisitions.” The carrying value of goodwill and the change in the balance for the six months ended September 30, 2014 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,990</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,964</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign currency translation impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,087</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,867</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company has no accumulated impairment losses on goodwill. In-Process Research and Development As described in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP and AIS and recorded $18.5 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows from the expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses and taking into account the stage of development of the technology at the acquisition date, the time and resources needed to complete development. The Company used a discount rate of 22.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.   The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2014 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign currency translation impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,302</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,198</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The Company’s marketable securities at September 30, 2014 and March 31, 2014 are invested in the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Market Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At September 30, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> US Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,480</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,494</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,498</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">94,465</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(31</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">94,454</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Market Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At March 31, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> US Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,174</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,176</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,779</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(26</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">97,440</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">97,424</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The carrying value of goodwill and the change in the balance for the six months ended September 30, 2014 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,990</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,964</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign currency translation impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,087</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,867</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The components of inventories are as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Raw materials and supplies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,052</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,414</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Work-in-progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,718</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,261</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,675</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,273</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,445</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,948</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the stock option activity for the six months ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Shares Underlying Options (in thousands)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Remaining Contractual Term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value (in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at April 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13.27</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.92</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22.26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(222</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cancelled and expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,578</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.04</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,287</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Exercisable at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.94</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.99</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,928</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options vested and expected to vest at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,502</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.97</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,013</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 11. Segment and Enterprise Wide Disclosures <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 66% and 74% of the Company’s total consolidated assets are located within the U.S. as of September 30, 2014 and March 31, 2014, respectively. The remaining assets are located primarily in Germany and include goodwill and in-process research and development of $54.1 million and $35.4 million at September 30, 2014 and March 31, 2014, respectively, associated with the Impella acquisition in May 2005 and ECP acquisition in July 2014. Total assets outside of the U.S. excluding goodwill and in-process research and development amounted to 9% of total consolidated assets as of September 30, 2014 and March 31, 2014. International sales (primarily in Europe) accounted for 11% of total revenue for each of the three and six months ended September 30, 2014 and 7% and 8% of total revenue for the three and six months ended September 30, 2013, respectively. </div>

9.05

Large Accelerated Filer

<div> The components of stock-based compensation for the three and six months ended September 30, 2014 and 2013 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Restricted stock units and awards </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,334</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,098</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">598</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,423</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,523</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Employee stock purchase plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,024</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,719</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="25%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td width="26%"></td> <td valign="bottom" width="4%"></td> <td width="20%"></td> <td valign="bottom" width="4%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value at September 30, 2014 ( in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"> Significant Unobservable Input </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Weighted Average (range, if applicable)</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="top">$</td> <td valign="top" align="right">5,797</td> <td valign="top" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="top"> Probability weighted income approach </td> <td valign="bottom">  </td> <td valign="top" align="center">Milestone dates</td> <td valign="bottom">  </td> <td valign="top" align="center">2018 to 2021</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="top" align="center">Discount rate Probability of occurrence</td> <td valign="bottom">  </td> <td valign="top" align="center">8% to 12% 0% to 100%</td> </tr> </table> </div>

<div> Note 5. Inventories The components of inventories are as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Raw materials and supplies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,052</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,414</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Work-in-progress </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,718</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,261</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,675</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,273</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,445</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,948</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company’s inventories relate to its circulatory care product lines, primarily the Impella and AB5000 product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During the six months ended September 30, 2014 and 2013, the Company recorded $0.6 million and $0.5 million, respectively, in write-downs of inventory. </div>

9902000

<div> The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three and six months ended September 30, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">148</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">139</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">357</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">347</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">773</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">540</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,626</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,285</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,103</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,119</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,331</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,087</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,024</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,719</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on July 1, 2014, the date of acquisition (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Property and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">619</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> In-process research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Goodwill </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,964</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Long-term deferred tax assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">874</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other assets acquired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets acquired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,176</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Liabilities assumed: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">295</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">131</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total liabilities assumed </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">426</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.00

P4Y2M9D

5000

<div> The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At September 30, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,494</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,494</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,473</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,797</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,797</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At March 31, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,176</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,176</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> Accrued expenses consist of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employee compensation </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,083</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,967</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,161</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,587</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional, legal and accounting fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,021</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,304</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Sales and income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,445</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Warranty </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">794</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">722</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">802</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,762</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,899</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2014 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign currency translation impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,302</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,198</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.0160

2014-09-30

<div> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,938</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,359</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">100,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">87,042</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Income before income tax provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,557</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">329</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,850</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,218</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,631</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> </div>

P5Y15D

15.66

false --03-31 2014

42069000

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 3. Acquisitions <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Acquisition of ECP Entwickslungsgesellschaft mbH <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On July 1, 2014, the Company entered into a share purchase agreement with its wholly owned German subsidiary, Abiomed Europe GmbH (“Abiomed Europe”) and Syscore GmbH (“Syscore”), a limited liability company located in Berlin, Germany, providing for the Company’s acquisition of all of the share capital of ECP Entwicklungsgesellschaft mbH (“ECP”), a limited liability company incorporated in Germany. ECP is engaged in research, development, prototyping and the production of a percutaneous expandable catheter pump which increases blood circulation from the heart with an external drive shaft. The Company’s acquisition of ECP closed on July 1, 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company acquired ECP for $13.0 million in cash, with additional potential payouts totaling $15.0 million payable to Syscore based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock. With respect to such milestone payments, the share purchase agreement provides: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">that, upon the earlier of (i) the Company’s receipt of European CE Marking approval relating to the sale of an expandable device based on certain patent rights acquired from ECP, or (ii) the Company’s bringing of a successful claim against a third party competitor (or reaching an economically equivalent settlement) for the infringement of certain patent rights acquired from ECP, it will pay Syscore an additional $7.0 million (provided that if such claim or settlement does not prohibit the third party competitor’s further marketing, production, sale, distribution, lease or use of any violating or infringing products, but only awards monetary damages to the Company or to Abiomed Europe, the amount payable to Syscore shall be limited to the lower of the amount of aggregate damages received and $7.0 million); and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">that, upon the first to occur of (i) the Company’s successful commercialization of one or more rotatable and expandable devices based on certain patent rights acquired from ECP, where such devices achieve aggregate worldwide revenues of $125.0 million, including the revenues of third party licensees, or (ii) the Company’s sale of (A) ECP, (B) all or substantially all of ECP’s assets, or (C) certain of ECP’s patent rights, the Company will pay to Syscore the lesser of (x) one-half of the profits earned from such sale described in the foregoing item (ii), after accounting for the costs of acquiring and operating ECP, or (y) $15.0 million (less any previous milestone payment).</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> ECP’s Acquisition of AIS GmbH Aachen Innovative Solutions <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In connection with the Company’s acquisition of ECP, ECP acquired all of the share capital of AIS GmbH Aachen Innovative Solutions (“AIS”), a limited liability company incorporated in Germany, pursuant to a share purchase agreement dated as of June 30, 2014, by and among ECP and AIS’s four individual shareholders. AIS, based in Aachen, Germany, holds certain intellectual property useful to ECP’s business, and, prior to being acquired by ECP, had licensed such intellectual property to ECP. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The purchase price for the acquisition of AIS’s share capital was approximately $2.8 million in cash and the acquisition closed immediately prior to Abiomed Europe’s acquisition of ECP. The share purchase agreement contains representations, warranties and closing conditions customary for transactions of its size and nature. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Preliminary Purchase Price Allocation <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The acquisition was accounted for as a business combination. The purchase price for the acquisition has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase price allocation presented herein is preliminary. The final purchase price allocation will be determined after completion of an analysis to determine the fair value of all assets acquired and liabilities assumed, but in no event later than one year following completion of the acquisition. Accordingly, the final acquisition accounting adjustments could differ materially from the preliminary amounts presented herein. Any increase or decrease in the fair value of the assets acquired and liabilities assumed, as compared to the information shown herein, could also change the portion of purchase price allocated to goodwill, and could impact the operating results of the Company following the acquisition due to differences in purchase price allocation, depreciation and amortization related to some of these assets and liabilities. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The acquisition-date fair value of the consideration transferred is as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="86%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Acquisition Date Fair Value (in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Cash consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total consideration transferred </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on July 1, 2014, the date of acquisition (in thousands): <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Acquired assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Property and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">619</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> In-process research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,500</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Goodwill </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,964</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Long-term deferred tax assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">874</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Other assets acquired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total assets acquired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,176</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Liabilities assumed: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Accounts payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">295</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Accrued liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">131</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total liabilities assumed </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">426</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Net assets acquired </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> IPR&D is principally the estimated fair value of the ECP and AIS technology which had not reached commercial technological feasibility nor had alternative future use and therefore considered IPR&D, with assigned values to be allocated among the various IPR&D assets acquired. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> All legal, consulting and other costs related to the acquisition, aggregating approximately $1.1 million, have been expensed as incurred and are included in selling, general and administrative expenses in our consolidated statements of operations. The results of operations for ECP and AIS are included in the Company’s condensed consolidated statements of operations for the period from the July 1, 2014 acquisition date to September 30, 2014. The Company recorded no material revenues and incurred $1.1 million in net losses for the three months ended September 30, 2014 associated with the operations of ECP after the July 1, 2014 acquisition. This also includes a $0.2 million expense for the change in fair value of the contingent consideration for the three months ended September 30, 2014. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following unaudited pro forma information presents the combined results of operations for the three and six months ended September 30, 2014 and 2013, as if we had completed the ECP and AIS acquisitions at the beginning of fiscal 2014. The pro forma financial information is provided for comparative purposes only and is not necessarily indicative of what actual results would have been had the acquisition occurred on the date indicated, nor does it give effect to synergies, cost savings, fair market value adjustments, immaterial amortization expense and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of consolidated results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The pro forma consolidated financial information has been calculated after applying the Company’s accounting policies and includes adjustments for transaction-related costs, to eliminate revenues earned by AIS from ECP and expenses paid by ECP to AIS associated with a license agreement between the two parties, interest expense incurred by ECP related to bank loans accounted as if the repayment of ECP debt had occurred on April 1, 2013 and was not outstanding during the periods, and income tax provision of AIS due to the elimination of revenue on the license agreement with ECP. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,938</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,359</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">100,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">87,042</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Income before income tax provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,557</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">329</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,850</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,218</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,631</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 1. Nature of Business and Basis of Preparation <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Abiomed, Inc. (the “Company” or “Abiomed”), is a leading provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the Securities and Exchange Commission, or SEC. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year or any other subsequent period. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> There have been no changes in the Company’s significant accounting policies for the three and six months ended September 30, 2014 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the SEC, except for as noted below. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In-Process Research and Development <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that the Company acquires, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when the Company has regulatory approval and is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Contingent Consideration <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As discussed in Note 3. “Acquisitions,” on July 1, 2014, the Company acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the various milestones. The material factors that may impact the fair value of the contingent consideration, and therefore this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration, and the associated liability at each reporting date, will be updated by reflecting the changes in fair value reflected in the Company’s statement of operations. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Recent Accounting Pronouncements <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements. </div>

0.05

<div> Note 9. Income Taxes  Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each fiscal year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses incurred for most of its existence, expiration of various federal and state attributes, the uncertainty relative to the Marketing and Labelling Investigation and the FCA Investigation (each as defined below in “Note 10. Commitments and Contingencies—Litigation”) of the Company and the Company’s Pre-Market Approval, or PMA, application with the U.S. Food and Drug Administration, or FDA, for its Impella products, the Company’s expansion into new markets, such as Japan, the government reimbursement environment for the Company’s products, the Company’s profitability for recent years and uncertainties around the Company’s future profitability. Based on the review of all available evidence, the Company determined that the objectively verifiable negative evidence outweighed the positive evidence and it recorded a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of September 30, 2014. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on its results of operations. As of September 30, 2014, the Company has accumulated a long-term deferred tax liability of $6.9 million as the result of a difference in accounting for the Company’s goodwill associated with its Impella acquisition that was completed in May 2005, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net long-term deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period. As of September 30, 2014, the Company has net long-term deferred tax assets of $0.8 million relating to differences between the book and tax basis of assets and liabilities associated with the ECP acquisition completed in July 2014. The Company is subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. Because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> In-Process Research and Development <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that the Company acquires, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when the Company has regulatory approval and is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value. </div>

<div> The Company’s basic and diluted net income (loss) per share for the three and six months ended September 30, 2014 and 2013 were as follows (in thousands, except per share data):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Basic Net Income (Loss) Per Share </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,839</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,059</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,130</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(664</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average shares used in computing basic net income (loss) per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,448</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,256</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,971</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) per share - basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted Net Income (Loss) Per Share </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,839</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,059</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,130</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(664</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average shares used in computing basic net income (loss) per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,448</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,260</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,256</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,971</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Effect of dilutive securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,791</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,077</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,813</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average shares used in computing diluted net income (loss) per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,239</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,069</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,971</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income (loss) per share - diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.03</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P3Y11M27D

22.26

0000815094

<div> Note 8. Stock-Based Compensation The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three and six months ended September 30, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cost of product revenue </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">148</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">139</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">357</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">347</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">773</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">540</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,626</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,285</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Selling, general and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,103</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,119</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,331</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,087</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,024</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,719</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The components of stock-based compensation for the three and six months ended September 30, 2014 and 2013 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Restricted stock units and awards </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,334</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,098</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">598</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,423</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,523</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Employee stock purchase plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,024</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,798</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,314</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,719</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Stock Options The following table summarizes the stock option activity for the six months ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Shares Underlying Options (in thousands)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted Average Remaining Contractual Term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value (in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at April 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13.27</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.92</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22.26</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(222</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11.49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cancelled and expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15.66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,578</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.04</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,287</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Exercisable at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.94</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.99</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,928</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options vested and expected to vest at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,502</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.97</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38,013</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> The aggregate intrinsic value of options exercised was $3.0 million for the six months ended September 30, 2014. The total fair value of options vested during the six months ended September 30, 2014 was $1.7 million. The remaining unrecognized stock-based compensation expense for unvested stock option awards at September 30, 2014 was approximately $5.7 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.5 years. The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The weighted average grant-date fair value for options granted during the six months ended September 30, 2014 and 2013 was $9.05 and $9.67 per share, respectively.   The fair value of options granted during the three and six months ended September 30, 2014 and 2013 were calculated using the following weighted average assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.75</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.39</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.60</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.85</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected option life (years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.19</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.19</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.26</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50.6</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49.3</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51.9</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock and adjustments for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise experience and estimates of future exercises of unexercised options. An expected dividend yield of zero is used in the option valuation model because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future. The Company estimates forfeitures based on an analysis of actual historical forfeitures, adjusted to reflect that historical forfeitures may not be indicative of forfeitures in the future. Restricted Stock and Restricted Stock Units In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the six months ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares (in thousands)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant Date Fair Value (per share)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at April 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,174</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.37</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">664</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21.88</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(465</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.48</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.10</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.80</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of September 30, 2014 was $17.0 million and the weighted-average period over which this cost will be recognized is 2.0 years. The weighted average grant-date fair value for restricted stock and restricted stock units granted during the six months ended September 30, 2014 and 2013 was $21.88 and $23.18 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the six months ended September 30, 2014 and 2013 was $9.5 million and $6.0 million, respectively. Performance Based Awards Included in the restricted stock and restricted stock units activity discussed above are certain awards that vest subject to certain performance-based criteria. In May 2014, performance-based awards of restricted stock units for the potential issuance of 379,752 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company is recognizing compensation expense based on the probable outcome related to the prescribed performance milestones on the outstanding awards. In May 2013, performance-based awards of restricted stock units for the potential issuance of 268,988 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed performance milestones for these awards such that 154,991 shares of common stock will vest subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.   In May 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees of the Company, all of which will vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed performance milestones for these awards. These awards are still subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly. In May 2011 and June 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed milestones for 234,000 shares underlying these awards and recorded all related stock compensation expense. In March 2014, the Company modified the performance condition on the remaining 50,000 restricted stock units. As of September 30, 2014, the Company believes that it is probable that the prescribed performance milestones will be met on these restricted stock units and the compensation expense is being recognized accordingly. During the three and six months ended September 30, 2014, the Company has recorded $2.1 million and $3.7 million, respectively, in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at September 30, 2014 is $8.0 million based on the Company’s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 1.8 years. </div>

<div> Note 4. Marketable Securities and Fair Value Measurements Marketable Securities The Company’s marketable securities are classified as available-for-sale securities and, accordingly, are recorded at fair value. The difference between amortized cost and fair value is included in stockholders’ equity. The Company’s marketable securities at September 30, 2014 and March 31, 2014 are invested in the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Market Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At September 30, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> US Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,480</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,494</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,498</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(28</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">94,465</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(31</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">94,454</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Market Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At March 31, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> US Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,174</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,176</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,779</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(26</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">97,440</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">97,424</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Fair Value Hierarchy Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.   Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows, or similar techniques, and at least one significant model assumption or input is unobservable. The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At September 30, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,494</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58,494</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,473</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Liabilities </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,797</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,797</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At March 31, 2014: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> U.S. Treasury securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,487</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Short-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,176</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,176</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term government-backed securities </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> The Company has determined that the estimated fair value of its investments in U.S. Treasury securities, short-term government-backed securities and long-term government-backed securities are reported as Level 2 as they are not exchange-traded instruments. The Company’s financial liabilities consisted of contingent consideration potentially payable to former ECP shareholders related to the acquisition of ECP in July 2014. This liability is reported as Level 3 as estimated fair value of the contingent consideration related to the acquisition of the ECP requires significant management judgment or estimation and is calculated using the income approach, using various revenue and cost assumptions and applying a probability to each outcome. The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(in $000’s)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Payments </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in fair value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Foreign currency translation impact </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(422</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,797</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The change in fair value of the contingent consideration of $0.2 million for the six months ended September 30, 2014 was primarily due to an increase in fair value due to the effect of the passage of time on the fair value measurement and the impact of foreign currency exchange rates. Adjustments associated with the change in fair value of contingent consideration are included in research and development expenses on the Company’s condensed consolidated statements of operations.   The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="25%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td width="26%"></td> <td valign="bottom" width="4%"></td> <td width="20%"></td> <td valign="bottom" width="4%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Fair Value at September 30, 2014 ( in $000’s)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"> Significant Unobservable Input </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Weighted Average (range, if applicable)</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="top">$</td> <td valign="top" align="right">5,797</td> <td valign="top" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="top"> Probability weighted income approach </td> <td valign="bottom">  </td> <td valign="top" align="center">Milestone dates</td> <td valign="bottom">  </td> <td valign="top" align="center">2018 to 2021</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="top" align="center">Discount rate Probability of occurrence</td> <td valign="bottom">  </td> <td valign="top" align="center">8% to 12% 0% to 100%</td> </tr> </table> Other Investment In May 2013, the Company invested $0.8 million in preferred stock of a private technology company. In addition, the Company committed to invest an additional $0.7 million if the private technology company achieves certain milestones or receives shareholder approval requesting the additional funding. In September 2014, the private technology company requested this additional funding and the Company paid the additional $0.7 million. There are no additional outstanding funding commitments associated with this investment. This other investment is accounted for using the cost method and is measured at fair value on a nonrecurring basis only if there are identified events or change in circumstances that may have a significant adverse effect on the fair value of these investments. The aggregate carrying amount of this other investment was $1.5 million and $0.8 million at September 30, 2014 and March 31, 2014, respectively, and is classified within other assets in the unaudited condensed consolidated balance sheets. </div>

<div> Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements. </div>

0.493

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Contingent Consideration <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> As discussed in Note 3. “Acquisitions,” on July 1, 2014, the Company acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the various milestones. The material factors that may impact the fair value of the contingent consideration, and therefore this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration, and the associated liability at each reporting date, will be updated by reflecting the changes in fair value reflected in the Company’s statement of operations. </div>

<div> The acquisition-date fair value of the consideration transferred is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="86%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total Acquisition Date Fair Value (in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent consideration </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total consideration transferred </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,750</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes the activity for the six months ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares (in thousands)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Grant Date Fair Value (per share)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at April 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,174</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.37</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">664</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21.88</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(465</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.48</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(121</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.10</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.80</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

222000

40256000

1700000

315000

-5240000

100434000

-5235000

139000

653000

15697000

5000

2640000

-3105000

52000

299000

2692000

2260000

750000

-28000

100749000

44920000

1496000

2130000

80000

-1108000

1013000

577000

100761000

450000

-306000

1004000

18500000

17755000

61053000

219000

27000

-3433000

-3732000

562000

19301000

1196000

-3087000

1964000

1944000

397000

559000

-14973000

2560000

98109000

47890000

-581000

-1302000

8314000

3000000

2770000 P15Y 6000000

465000

44000

0.12

2021 1.00

0.08

2018 0.00

219000

6000000

-422000

137000

P2Y6M

1423000

3700000

234000 50000

154991

121000

P2Y

21.88

465000

664000

20.48

23.10

9500000

6754000

0.11

1626000

357000

6331000

2014-07-01

284000

2023-07-31

0.225

284000

195188

268988

379752

P4Y11M1D

0.03

2077000

P4Y2M23D

0.0139

41337000

0.03

0.506

39260000

57000

1795000

44288000

1826000

31000

1398000

2885000

31000

1429000

-41000

6000

44345000

1059000

25000

44359000

7721000

26199000

370000

9027000

42947000

2798000

329000

354000

297000

38000

598000

2162000

0.07

540000

139000

2119000

0.09

1791000

P4Y2M9D

0.0175

42239000

0.09

0.487

40448000

164000

-4804000

51774000

-4826000

-22000

4178000

-987000

-3000

4175000

4218000

-39000

51938000

3839000

36000

51938000

8693000

29455000

336000

9612000

47760000

4024000

4557000

465000

47000

66000

624000

P1Y9M18D

2100000

3334000

0.11

773000

148000

1100000

3103000

1100000

200000

0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2014-07-01 2014-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-07-01 2014-09-30 0000815094 us-gaap:CostOfSalesMember 2014-07-01 2014-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000815094 abmd:InternationalMember 2014-07-01 2014-09-30 0000815094 abmd:RestrictedStockUnitsAndRestrictedStockAwardsMember 2014-07-01 2014-09-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2014-07-01 2014-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000815094 abmd:EmployeeStockPurchasePlanMember 2014-07-01 2014-09-30 0000815094 us-gaap:StockOptionMember 2014-07-01 2014-09-30 0000815094 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0000815094 2014-07-01 2014-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2013-07-01 2013-09-30 0000815094 us-gaap:CostOfSalesMember 2013-07-01 2013-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2013-07-01 2013-09-30 0000815094 abmd:InternationalMember 2013-07-01 2013-09-30 0000815094 abmd:RestrictedStockUnitsAndRestrictedStockAwardsMember 2013-07-01 2013-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2013-07-01 2013-09-30 0000815094 abmd:EmployeeStockPurchasePlanMember 2013-07-01 2013-09-30 0000815094 us-gaap:StockOptionMember 2013-07-01 2013-09-30 0000815094 us-gaap:RestrictedStockMember 2013-07-01 2013-09-30 0000815094 2013-07-01 2013-09-30 0000815094 2013-04-01 2014-03-31 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember abmd:ShareBasedAwardsMember 2014-05-01 2014-05-31 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember abmd:ShareBasedAwardsMember 2013-05-01 2013-05-31 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember abmd:ShareBasedAwardsMember 2012-05-01 2012-05-31 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2011-05-01 2011-05-31 0000815094 2014-07-01 2014-07-31 0000815094 us-gaap:LeaseAgreementsMember us-gaap:EuropeMember 2013-07-01 2013-07-31 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2011-06-01 2011-06-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2014-04-01 2014-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-04-01 2014-09-30 0000815094 us-gaap:CostOfSalesMember 2014-04-01 2014-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-09-30 0000815094 abmd:InternationalMember 2014-04-01 2014-09-30 0000815094 abmd:RestrictedStockUnitsAndRestrictedStockAwardsMember 2014-04-01 2014-09-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2014-04-01 2014-09-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember abmd:ShareBasedAwardsMember 2014-04-01 2014-09-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2014-04-01 2014-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2014-04-01 2014-09-30 0000815094 abmd:EmployeeStockPurchasePlanMember 2014-04-01 2014-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember us-gaap:FairValueInputsLevel3Member abmd:ContingentConsiderationMember 2014-04-01 2014-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember us-gaap:FairValueInputsLevel3Member abmd:ContingentConsiderationMember us-gaap:MinimumMember us-gaap:IncomeApproachValuationTechniqueMember 2014-04-01 2014-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember us-gaap:FairValueInputsLevel3Member abmd:ContingentConsiderationMember us-gaap:MaximumMember us-gaap:IncomeApproachValuationTechniqueMember 2014-04-01 2014-09-30 0000815094 us-gaap:StockOptionMember 2014-04-01 2014-09-30 0000815094 us-gaap:RestrictedStockMember 2014-04-01 2014-09-30 0000815094 2014-04-01 2014-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2013-04-01 2013-09-30 0000815094 us-gaap:CostOfSalesMember 2013-04-01 2013-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-09-30 0000815094 abmd:InternationalMember 2013-04-01 2013-09-30 0000815094 abmd:RestrictedStockUnitsAndRestrictedStockAwardsMember 2013-04-01 2013-09-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2013-04-01 2013-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2013-04-01 2013-09-30 0000815094 abmd:EmployeeStockPurchasePlanMember 2013-04-01 2013-09-30 0000815094 us-gaap:StockOptionMember 2013-04-01 2013-09-30 0000815094 us-gaap:RestrictedStockMember 2013-04-01 2013-09-30 0000815094 2013-04-01 2013-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2014-07-01 2014-07-01 0000815094 abmd:AachenInnovativeSolutionsGmbhMember 2014-07-01 2014-07-01 0000815094 2014-07-01 2014-07-01 0000815094 2014-04-30 0000815094 us-gaap:USTreasurySecuritiesMember 2014-03-31 0000815094 us-gaap:OtherInvestmentsMember 2014-03-31 0000815094 us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-03-31 0000815094 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-03-31 0000815094 country:US 2014-03-31 0000815094 us-gaap:EuropeMember 2014-03-31 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2014-03-31 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2014-03-31 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-03-31 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-03-31 0000815094 us-gaap:FairValueInputsLevel2Member 2014-03-31 0000815094 2014-03-31 0000815094 2013-03-31 0000815094 us-gaap:USTreasurySecuritiesMember 2014-09-30 0000815094 us-gaap:OtherInvestmentsMember 2014-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2014-09-30 0000815094 us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-09-30 0000815094 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-09-30 0000815094 us-gaap:EquitySecuritiesMember abmd:ScenarioTwoMember 2014-09-30 0000815094 country:US 2014-09-30 0000815094 us-gaap:LeaseAgreementsMember us-gaap:EuropeMember 2014-09-30 0000815094 us-gaap:EuropeMember 2014-09-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2014-09-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2014-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2014-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember us-gaap:FairValueInputsLevel3Member abmd:ContingentConsiderationMember 2014-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember us-gaap:FairValueInputsLevel3Member us-gaap:IncomeApproachValuationTechniqueMember 2014-09-30 0000815094 us-gaap:FairValueInputsLevel3Member 2014-09-30 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2014-09-30 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-09-30 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2014-09-30 0000815094 us-gaap:FairValueInputsLevel2Member 2014-09-30 0000815094 abmd:PeriodThreeMember 2014-09-30 0000815094 abmd:PeriodOneMember 2014-09-30 0000815094 abmd:PeriodTwoMember 2014-09-30 0000815094 abmd:PeriodFourMember 2014-09-30 0000815094 2014-09-30 0000815094 2013-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2014-07-01 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember us-gaap:MaximumMember 2014-07-01 0000815094 2014-07-01 0000815094 us-gaap:EuropeMember 2014-06-30 0000815094 us-gaap:EquitySecuritiesMember 2013-05-31 0000815094 us-gaap:EquitySecuritiesMember abmd:ScenarioOneMember 2013-05-31 0000815094 2014-10-31 0000815094 2014-07-31 iso4217:USD shares iso4217:USD shares pure iso4217:EUR abmd:Segment

EX-101.SCH 6 abmd-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME link:calculationLink link:presentationLink link:definitionLink 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Nature of Business and Basis of Preparation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Net Income (Loss) Per Share link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Acquisitions link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Marketable Securities and Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Goodwill and In-Process Research and Development link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Segment and Enterprise Wide Disclosures link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Nature of Business and Basis of Preparation (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Net Income (Loss) Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Acquisitions (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Goodwill and In-Process Research and Development (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Nature of Business and Basis of Preparation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Acquisitions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Fair Value of the Consideration Transferred (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Preliminary Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Pro Forma Consolidated Financial Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Investable Marketable Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Financial Instruments Recorded at Fair Value (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Components of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Inventories - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Goodwill Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Goodwill and In-Process Research and Development - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - In-Process Research and Development Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Stock-Based Compensation Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Components of Stock-Based Compensation (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Summary of Restricted Stock and Restricted Stock Units Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Segment and Enterprise Wide Disclosures - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 abmd-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 abmd-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 abmd-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Aachen Innovative Solutions Gmbh [Member] Aachen Innovative Solutions Gmbh [Member] AIS GmbH Aachen Innovative Solutions Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable, net Accrued Expenses [Abstract] Accrued Expenses [Abstract] Accrued Expenses [Abstract] Accrued Liabilities, Current Accrued expenses Accrued expenses Accrued Professional Fees, Current Professional, legal and accounting fees Accrued Research and Development Expense, Current Accrued Research and Development Expense, Current Research and development Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Achievement of Certain Performance Milestones Period Achievement of Certain Performance Milestones Period Period of milestone payment Additional License Fees, Upon Achievement of Certain Milestones Additional License Fees, Upon Achievement of Certain Milestones License agreement, maximum agreed additional payments upon achievement of development milestones Additional Paid in Capital Additional paid in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments required to reconcile net income (loss) to net cash provided by operating activities: Aggregate Contingent Milestone Payments to Be Paid Aggregate Contingent Milestone Payments to Be Paid Aggregate worldwide revenues, including revenues of third party licensees, targeted to be met for milestone payments Amendment Flag Amendment Flag Amortization Period For Deferred Charges Amortization Period For Deferred Charges Amortization period of deferred tax liability (years) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares excluded from the calculation of diluted weighted average shares outstanding Antidilutive Securities [Axis] Antidilutive Securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Available-for-sale Securities Available-for-sale securities, fair value disclosure Fair Market Value Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Available-for-sale Securities, Amortized Cost Basis Amortized Cost Available-for-sale Securities, Current Short-term marketable securities Available-for-sale Securities, Noncurrent Long-term marketable securities Award Type [Axis] Award Type Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Date of Acquisition Agreement Business acquisition, date of acquisition agreement Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information [Table Text Block] Pro Forma Consolidated Financial Information Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes Income before income tax provision Business Acquisition, Pro Forma Net Income (Loss) Net income (loss) Business Acquisition, Pro Forma Revenue Revenue Business And Basis Of Presentation [Line Items] Business And Basis Of Presentation [Line Items] Business And Basis Of Presentation [Line Items] Business And Basis Of Presentation [Table] Business And Basis Of Presentation [Table] Business And Basis Of Presentation [Table] Business Combination, Acquisition Related Costs Legal, consulting and other costs related to the acquisition included in consolidated statements of operations Business Combination, Consideration Transferred Total consideration transferred Business Combination, Consideration Transferred, Liabilities Incurred Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Expense for the change in fair value contingent consideration Change in fair value of contingent consideration Change in fair value of the contingent consideration Business Combination, Contingent Consideration Arrangements, Description Business combination, contingent consideration arrangements, descriptions Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Potential payouts payments Business Combination, Contingent Consideration, Liability Contingent consideration Fair value of contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Contingent consideration Business Combination Disclosure [Text Block] Acquisitions Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Accrued Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Accrued Liabilities Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Acquired assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets In-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Other assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Property and equipment Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Net assets acquired Business Combinations [Abstract] Business Combinations [Abstract] Business Combination, Separately Recognized Transactions, Net Gains and Losses Net loss Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized Revenues Business Combinations Policy [Policy Text Block] Contingent Consideration Business Description and Basis of Presentation [Text Block] Nature of Business and Basis of Preparation Capital Expenditures Incurred but Not yet Paid Fixed asset expenditures incurred, not yet paid Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing and financing activities: Commitments and Contingencies Commitments and contingencies (Note 10) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, Authorized Common Stock, Shares, Issued Common stock, Issued Common Stock, Shares, Outstanding Common stock, Outstanding Common Stock, Value, Issued Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 41,831,077 shares at September 30, 2014 and 41,122,695 shares at March 31, 2014; Outstanding - 40,577,134 shares at September 30, 2014 and 39,916,328 shares at March 31, 2014 Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive (loss) income Contingent Consideration [Member] Contingent Consideration [Member] Contingent Consideration Contingent Milestone Payments to Be Paid Contingent Milestone Payments to Be Paid Expense due to infringement of certain patent rights acquired Cost Method Investments, Fair Value Disclosure Cost method investment, fair value Cost of Goods Sold Cost of product revenue Cost of Sales [Member] Cost of product revenue Costs and Expenses Costs and Expenses, Total Costs and Expenses [Abstract] Costs and expenses: Current Fiscal Year End Date Current Fiscal Year End Date Deferred Income Tax Expense (Benefit) Deferred tax provision Deferred Revenue, Current Deferred revenue Deferred Tax Assets, Net, Noncurrent Long-term deferred tax assets Deferred Tax Liabilities, Net, Noncurrent Long-term deferred tax liabilities Long-term deferred tax liability Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Components of Stock-Based Compensation Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic Basic net income (loss) per share Net income (loss) per share - basic Earnings Per Share, Basic [Abstract] Basic Net Income (Loss) Per Share Earnings Per Share, Diluted Diluted net income (loss) per share Net income (loss) per share - diluted Earnings Per Share, Diluted [Abstract] Diluted Net Income (Loss) Per Share Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Line Items] Earnings Per Share Disclosure [Table] Earnings Per Share Disclosure [Table] Earnings Per Share Disclosure [Table] Earnings Per Share [Text Block] Net Income (Loss) Per Share Ecp Entwickslungsgesellschaft Mbh [Member] Ecp Entwickslungsgesellschaft Mbh [Member] ECP Entwicklungsgesellschaft mbH Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash Employee-related Liabilities, Current Employee compensation Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized stock-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized stock-based compensation expense, weighted-average recognition period Employee Stock Option [Member] Stock Options Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity Securities [Member] Equity Securities Europe [Member] Europe Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Financial Instruments Recorded at Fair Value Fair Value, Hierarchy [Axis] Fair Value, Hierarchy Liability Class [Axis] Liability Class [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Marketable Securities and Fair Value Measurements Fair Value Inputs, Discount Rate Discount rate Fair value inputs, discount rate Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Inputs, Level 3 [Member] Level 3 Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 Fair Value Inputs Probability Of Occurrence Fair Value Inputs Probability Of Occurrence Probability of occurrence Fair Value Inputs Year Of Payments Fair Value Inputs Year Of Payments Milestone date Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Foreign currency translation impact Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Payments Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Ending balance Beginning balance Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Goodwill Ending balance Beginning balance Goodwill Goodwill, Acquired During Period Additions Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Line Items] Goodwill and Intangible Assets Disclosure [Line Items] Goodwill and Intangible Assets Disclosure [Line Items] Goodwill and Intangible Assets Disclosure [Table] Goodwill and Intangible Assets Disclosure [Table] Goodwill and Intangible Assets Disclosure [Table] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and In-Process Research and Development Goodwill, Impaired, Accumulated Impairment Loss Accumulated impairment loss, goodwill Goodwill [Line Items] Goodwill [Line Items] Goodwill, Translation Adjustments Foreign currency translation impact Income Approach Valuation Technique [Member] Probability weighted income approach Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income before income tax provision Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes Paid Cash paid for income taxes Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Income Tax Expense (Benefit) Income tax provision Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other long-term liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Indefinite-lived Intangible Assets Acquired Additions Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets (Excluding Goodwill) Ending balance Beginning balance In-Process Research and Development Indefinite-lived Intangible Assets, Translation Adjustments Foreign currency translation impact In Process Research and Development, Policy [Policy Text Block] In-Process Research and Development International [Member] International [Member] International Inventory, Current [Table] Inventory, Current [Table] EX-101.PRE 10 abmd-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT

Inventories - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Inventory [Line Items]
Write-down of inventory	$ 559	$ 537

XML 12 R48.htm IDEA: XBRL DOCUMENT

Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	1.75%	1.39%	1.60%	0.85%
Expected option life (years)	4 years 2 months 9 days	4 years 2 months 23 days	4 years 2 months 9 days	4 years 3 months 4 days
Expected volatility	48.70%	50.60%	49.30%	51.90%

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#,O-#`%P(``-,?```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,V-SW/1]-:&LJ;DU(WTR?8_!MQW^[L/GEW*8\7N1` M2K=:M175KKKO\PF4T030(#EF(#DN0')\!,EQ"9+C"B2'F*($01%5H)`J4$P5**@*%%4%"JL" MQ56!`JM`D56BR"I19)4HLDH4626*K!)%5HDBJT215:+(*E%D52BR*A19%8JL M"D56A2*K0I%5HP"3N'[6-HR1`]_:$`X)*8]O1 M]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL M7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7 M4"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++ M28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`."?2OU'`@``*A\` M`!H`"`%X;"]?0BS,4`*9@:K&:_7:T>'G\=]L6/ M,,1=W]5.9G-7A*[M5[MN4[MO+Y]O[EP14].MFGW?A=J=0G2/RX\?'KZ$?9/R MG^)V=XQ%/J6+M=NF=/Q4EK'=AD,39_TQ=/G*NA\.3F_:UV812Y_-% M.?Q]AEM>G5D\KVHW/*_$7/%R.N9;OW]XOU[OVO#4M]\/H4O_N$?YLQ]>XS:$ ME`]MADU(M1NW8GF^(C;+FEWY'SDY'EPY=TB.+LAR=('DV#U9CMTC.2ID.2I( MCGFR'/-(CE>R'*]0SBU;SBV24V424A.]FD,YU91RXK89PNIK&C+F8S[X#857 MVT@-^U'!)\6V,72QL($L$,C*!K)"(`L;R`*!K&P@*P2RL9ULT,K&SG*#:>[9 M0/80R'Y2((]-Z`7&X]9;7^HK1.1JTC8YY?X]7*20Q/3@(-*P?0QM+.S0"/2-LGVCT#?*KN`* M*[BQB6R0R,8N5P;KE9^T@H_=PZ6*CUM_&@HXZ/+L09>'@RZV&BBF8A?/"A9/ MMG&@;X2-0($(%#8"!2)0VNRV3TO$9M,3L:,!ALXT+?"IMY`IFG;.8I9)ZRF:>0><:V MCD'O>/;;IA]?-\NK+]S+WP```/__`P!02P,$%``&``@````A`'[5@M_9!``` M`A````\```!X;"]W;W)K8F]O:RYX;6R4E]U3ZC@8QN]W9O\'IO=[@)8/==0S M*+C+C`?=A:.7G=@&R-@V;)(*_O?G32KXM!''N%* M"UE64N7,T%*MVGJC.$OUFG.39^VPTQFT M6U'U2YN2I%1E=/HTX4M"\/2=ZK5LJ7K,S,@M+; MJU.]PEX8#NP_;2D>!-_J]TUVV=H]BB*56_M7*NWK8151`%MWZ5&D9DW7.YW. MX;=_N%BMS?Y'DF^#OJL@W<=]M@J7WKXB,74JGA1&F-=X6E35%Y)::*L^IE%@77VG7LBFFA8^Q3'Y,:-J.9<4/M363.XUM)&O=AVFCK3 MXH5.KU2T&S>1U1P:T/7@_%O*="NRS!5L6MPKF=CR_<@<)8DJ M.9V2'5F4KD4PH"/Z'H$'Y-S(Y)E:19NO96YW.]^!6P]JQ\MC\:UE"[:KWY;P M>;^MCY[,@D$&`:$4'8]*A%EM[5>7$21/+AA>9\C7(/'S)3N,;.ZRY.&0FTDJ(E,EG0"?"QM.B M$8\]!C0OVD?$!T<+=(;H,I%'\DUU8U=9;90;]ZS9)U*E/$4=-)G(`_IZS<@J M8U$<:E)5O#)1T+$#V<&$:='(ZX-DX-&'0`\1Z,BSX7]+9L42="H&G1*-#!PT8) MI6;G3QN'0!_O(1D.L2<^#^)B;6HQ7].)SF(-[>!AHT0BDWNNF*NH@Q#T/XGF9Y]8H"!@G M$M]MK'W%50PW(W@;A)R5&C2+DUK'/88?W6L.^=6(WD`9'=.1UF7N M8M+Q3XP'&>YY#$->-`X:)1)K@E6*K%;G6K\\AG$^>TOF8W/O8UZT\/MU?&*+ M(:\3!+GO@?SYR$9[#P"=(,E]1W+;7:3WQ(1E";W`V@_[!NBB;>]?WR]_`0`` M__\#`%!+`P04``8`"````"$`!QL98KT%```1%P``&````'AL+W=O&G$:E)%.',L!_.\/];F_6&NJ)>::LOOZ>^-_JS^TK[]U]?9+?1(0;"`M5>T1'(!/JZEE:4!$RN_CW]=Z.QPVMA>N@LCU&-"M9]$/GVIITK:J MEWYHF_\4B4VFE!$^&8$5DQ'&5SP.6!#>M^(HCT:!>3F43X]=^VI!U<`S^W,I M:Y"MP?)%F?+CJO4MJ:!1&ODHK8RV0$4/^?GV%'F/SC<(:3514D6);$M3`DS) M+A090&DVO_R@US"\I+@P9/9`T546!(O*\B#M/T_8185<1%3X^'GIG,(Q(YLS MHA!3\CF%&"GF#,,($NIAH;<%2C+4GIF#"/N6*HIO4&B6[C+RNXSB%@/)`T?, M/-Z6)\D;&V*G2RPF\A0E'DLT8%%$\IN9N._SF*S/39RYKN\1`X5)B,,XT?%% MNF"K+=HQDNS!1QG0XD)KP/6HD&:N) M7:)&4<(I2XFG'SNZG)FX#SD@3N)4G&FRLF MIU6J*%`BUP(EGF=W&?E=1G&+@>3)ZXEQ]M_>7)),TD9.K5115-J2D!$X0[#+ M:1V:,$L\EP2O0'@4!;IHD*CD/:(DF8BB?4M1E*@X3`B)T;L)PW`0D MWP7"`]?5E8Y$,>A=RU,ULHDL3WX8A+QE-VZ$TS*[E+R^U:*FQ0L4C;SY2)5ZT>Y([%/ MF>*HV'HDLQE".2GJ'*&T918(]=_*FNSFRP6IWH\$D6V0RK<@.$&5H`>/P!F" MB=P<@0^=;-_+!:EFCP01IU*F.-<#@Q16AG#F[DNU>V1+O+<46H+/TN?FD"J`5TCNKW(Q/'86U7[(J>+'/;. M]5J9&F M^C*TYW$(]MP.,(H<_SW`Z%G`0,Y=`7G7ML/EBQR[78?93_\#``#__P,`4$L# M!!0`!@`(````(0!\]3/;M`(``)L'```9````>&PO=V]R:W-H965T;LK\)_?#S?/RT/4CWJFC&#P*'5!:Z-Z19AJ&G-!-&![%@+,Y54 M@A@8JEVH.\5(Z1:))DRB*`L%X2WV#@MUC8>L*D[9O:1[P5KC311KB`%^7?-. MG]P$O<9.$/6X[VZH%!U8;'G#S8LSQ4C0Q;==*Q79-E#W1[.0W!:+4L.%=C8D6)5@>_BQ2;'X6KI\OG+V4&?W2-=R\,7 MQW.@$#(L[L>>&GJ`J=9,,VC-`8YVC)M M'KBUQ(CNM9'BGQ?%1RMODAQ-X'HTB:?!))GFLX^XI$<7N)Y M&+):*GE`L/6`7'?$;N1X`QK4JAX>\CV45#I&1,](9D1'2IF*11KQE`0D;GD._# M63$4@=%97K/>UV6Z]IK)F68Z5&S>4PS8P.1Z-BLN,%3>LR79J%-KKYFY3J?Y M?/Z:B6/?G,_'\VS2@P^PX$6Y'LN*QUA)[^LC\YK,80T>ZZG\-+#UE;TF.@#+ M/@)FQ6.P5U\/YC4>[":-9J.=N/'S5Y#E'R&SXC'9Z,EKKSEV,IMEHWDX@JV' MGQ]$Z@/SYZL_.#JR8S^(VO%6HX95$'(4Y)"Y\J>K'QC9N;=R*PV&PO=V]R:W-H965T7J08:4.:G-2R81E^9AI?;CY_6A^D M>M`58P8!0Z,S7!G3KGQ?TXH)HCW9L@:^%%()8F"J2E^WBI&\"Q*U'P7!W!>$ M-]@QK-1[.&11<,IN)-T+UAA'HEA-#.C7%6]USR;H>^@$40_[]H)*T0+%CM?< M/'>D&`FZNBL;J0 M@;4=*59D^"I<;>?8WZP[?WYS=M"C9Z0K>?BB>/Z--PS,AC+9`NRD?+#0N]R^ M@F#_)/JV*\!WA7)6D'UM?LC#5\;+RD"U$TC(YK7*GV^8IF`HT'A18IFHK$$` MC$APNS/`$/+4W0\\-U6&X[F7+((X!#C:,6UNN:7$B.ZUD>*/`X5'*D<2'4G@ M?B0)$V\6)8OT(RSQD07N/4OD16D2)O/_:_%=7IU--\20S5K)`X*M!\IU2^Q& M#E?`;/V)P667S>#8OPP#IRS)E67)\`(C"-=0Y,?-;+E<^X]0&7K$7#L,C"^8 M-)YBMCW&EA0$#BK!N;'*MZO7B[%@*\96TZJ[=B^F*\]>K7R*B0;$1`J8-);2 M&W9>D@T"8T>Y)T$P\#N5#C,;8Z:([3G$1".0?%RC#BDN"EVWCRNHPR]@YXD61$]BIA.&5P]`++>7;#CNAKM>Y0RR8*MF6U;5& M5.YM'PMAG>'MT&*OHJY+#A^@Q;6D9/=$E;S1J&8%A`;>`GQ2KDFZB9%MUR)V MTD!SZQXK^)&ULE)5= M;]HP%(;O)^T_6+YOOB"$(D)5J+I56J5IVL>U<1QB-8XCVY3VW^_8AHP$5L$- MBM$58P:!0Z-S7!G3SL)0TXH)H@/9L@:>E%()8F"H-J%N%2.% M*Q)UF$31)!2$-]@[S-0E'K(L.64/DFX%:XPW4:PF!OAUQ5M]]'3. MM^%M"$Z+><%A!C9VI%B9X_MXMLIPN)B[?'YSMM-']TA7(;;QB$#6VR M#5A+^6*E3X7]"XK#D^I'UX#O"A6L)-O:_)"[KXQO*@/=3F%"=EZSXOV!:0J! M@DV0I-:)RAH`X!<);E<&!$+>W'7'"U/E>#0)TBP:Q2!':Z;-([>6&-&M-E+\ M\:)X;^5-DKT)7/`27^P2^GFYF!Z((8NYDCL$2P_( M=4OL0HYGX&SS&4'*Y_.!8&S-O2URI:#6T-/711J-YN$K-(+N-D?05JU/%>#KN-#U(R.IZ2%L$^6)TE-L_?Y?M MTFO&QYJ.P"E6'REZC&!RS/AQ3ZTXQY!`QY9,!AU;>LU';%XQ=6LBGJ91U+'W MR&#O7$YFQ4.RI//UJ7G-Y,Q[?6;^^7GR'MGD&C(K'I*E`S*O\60W\2@:D*_\ M\PO(LFO(K'A(-MP/7K/O51;?3OOD<"Q;C__WTA^Z_C1IR88]$[7AC48U*V$- M14$&H2M_Y/J!D:W;HFMIX*ATMQ5\&1D<*5$`XE)*=/JQ-EC[S"6%C`T/*U70G1+5V7YQ5N$'=H MAUN(E)0U2,`K.[B\8Q@5:E)3NX'GQ6Z#2&MKAB6[AH.6)3_["Y2? MN=7+!7U#IESYF8N,&U6!8$,I.T6P^7:OO.7.]^SW#9D_B!$Z21'\4?8`E[%GB. M+%=*<75:RJ5[)-!FQ>C)@JT'PGF'Y$;VET#\NBW@A\3>2;":`AESJ.73)O*B ME?L$_N<]9JLQB6T-F,!$[%Y!I`/$!5V#./!K*D[6+H0=\+Y(.&>'%8CRYABK9^:Z^$21XKFH\S%J5QBQ4!9-D7%6+,J+9&TYE']$D MP7--F6G%5F-Z3<'\AII&4V^,&CY!U_J`40IMJIH40!O58_0)],,D'E?67IF` M),W&M+0TW0;U!=]@=L`[7-?)A=G+[K"O#=D!P* MOJO=#[W_"K*L'%8[Q8!\7+/\>0U68$(1$PU23Q*Z1@/X2Y3TG8$)X4_=_U[F MKLKHR2-&_MKC$&OX=O:/EORAOJ7!I'_? M\@U)7[&Z5$Q>PNIYQ-R=>WS?FQ=C#YRE8C1-^U] M>7%&,?"7,B7Q*V]!<]T5.DVG_5T<1$\X[`Y?DAX\A2$+/:C`E+""NK9$Z)T? MH`29I[=AMI#2.)CA,)DQG6#C==BVPT0ZG MJGNL\",*V+)QA.)":W=<^*8[?987?P$``/__`P!02P,$%``&``@````A`-IX MC(38`@``VP<``!D```!X;"]W;W)K&ULE%7;;J,P M%'Q?:?_!\GNYA4N"0JHF57E+P/9X M,F?&/JROG]L&/5$A&>\R[#L>1K3+><&Z*L-_?M]=+3&2BG0%:7A',_Q");[> M?/VR/G+Q*&M*%0*&3F:X5JI/75?F-6V)='A/.U@IN6B)@J&H7-D+2@JSJ6W< MP/-BMR6LPY8A%9=P\+)D.;WE^:&EG;(D@C9$@7Y9LUZ^LK7Y)70M$8^'_BKG M;0\4>]8P]6)(,6KS]+[JN"#[!NI^]D.2OW*;P1OZEN6"2UXJ!^A<*_1MS2MW MY0+39ETPJ$#;C@0M,WSCI[L$NYNU\>0,"X!>U3)\,,(0\F^>1%:K.\")VHL1;^`!'>RK5'=.4&.4'J7C[SX+\ M$Y4E"4XD\#R1^($3+",_BC_!LCBQP'-DN5"*:\LR+MT2139KP8\(3AX(ESW1 MY]A/@5C;LP"3W[<'?-%[;O0FLQ70$B)]VH2K<.T^00[Y";.UF`2C`1-,$;MW M$,L!XH*^023X]GF1>M-49)`,]*:.K868TV'1:@M_:DH@]$5*R3J*$E M4'I.`OD)VYWM0/'>7-X]5]!5S6L-'U$*[<=S`%QRKEX'NO\/G^7-?P```/__ M`P!02P,$%``&``@````A`"F6[SAG!```#A(``!D```!X;"]W;W)K&ULE)C;CJI(%(;O)YEW(-QO3H(B47>V''I46M,@6OF:.!C\:VO=5#:;?(",J"V*PTZ;M4? MII>8EJKO-IU!_Q3H1AZ^*^2,;W%3Y+\5-0*W89SH"!PP?J/HSYR&H+'^U#KJ M1N"/1LG1,;V6[9_XEJ#B=&YAN!W(B";FY9\!(ADX"C*:Y5"E#)?0`?BO5`4M M#7`D_>@^;T7>GK?J8JDY*V-A`JX<$&FC@DJJ2G8E+:[^99#92S$1JQ>!SU[$ M=#3;=[9K;?1W*(VL9_:OF`7/^(Q9=<-'A0,Q$(J!2`S$0T"Y]\7DGY(,!*U< ML.'N!12(Z,4"2OYUL0ZITT9\ZM:*?]Z>(2MU[)'MVCSC/S."?\&+!_$:H92( MI$0L)9(I@K,3WIA'.Z=MI#"UDX2=_E7=XS!EZA^U(E5*,O)0(I$4J)2$K$ M4B*9(C@WU[R;T\L"A;ASE;J4)IF^'W&W7 M,/C'1]SM)_&8W9[H73)%<,:9L!=YK,-IYSI:L,X5O>NAB>[Y1( M_`*QU\*`)"^A<5_`6TJW@@^OML12MG'DJU'8INU-!JT77;G!N<9RC,>_L2== M]?D]/S$$@1P)Y4@D1^(>N??=$":L1`3,,7O>5[I)G.\KVU+RO@J[M#T<4^E4 M,.&3+T<".1+*D4B.Q#TR6,E/&O3,39/I[XXEP4QDQVEV3*M0V[)5?@?9Y=M/A"UW7E@%LXAW=?S_"["X*MO*$!?,2X'2[H MN>O^2\[N/P```/__`P!02P,$%``&``@````A`*#'44^-!0``1!D``!D```!X M;"]W;W)K&ULG)E;CZLV$,??*_4[(-XW!`.Y* MU;DH-ZX_F;H.+S.QR\O#QOW[KZ>'A>O435KNTI,H^<;]Y+7[;?OS3^MW4;W4 M1\X;!RR4]<8]-LUYY7EU=N1%6D_$F9/3:23_4YWN^:XX;-YA-HODT\$'N//.Z M> M(`Z9UL2HF;M.JV%4D0PH%JW$`[X6$OQV/Z2<1"&9R8B2N8J57%C2NT$`P#-] M`+MWI'CC@JEVY6'4+4QY,$9-V--$[=*5(K$I"!L8Z;/)"(9?;O!+!.4DB'3O M^\-H20EBU-@8;0K""#Q]1KO_I-CPWVQJL*%FH?:>OPP71F23_GC@]\<)UXQR MC?.=G&3R^08?:FR^LRD((Z10WW?C&.6D6_%%C8W1IB",LEOVJH@]OE)L^L^, M+VIF*K[1(ER&U+])?YR%_GS6CA.N)>4:YSLYR>0S:E>,&IOO;`K"Z$.Y[3MO M'*2:=2O"6F3#M$HHI]$J[$'VL;J3*GB5Q5J$8?9GX3QHPXA%D`ADF+L\HVRR M<(_>@#Z6^3X;B\P=J$56WZ&=80GED]6\QS1AVD:!L=S41^8QWQ694D5B+0E5F6/>] MVFUH`D?];BZE,EK(#8\-]0[#(;%_:0WRP>HAZ+:\QJ+#'37E,MKZL]/V, M"*^S%45M)*/.)9J,".8AZP24[:YVX0_UBZ[>JZ^.M:$F:L,15\P#0]2)EF;QS-A):=,ABMBAB)+ M#/L"6PQEZ>ZQC>M:#`L^932>SV,M&DY&'5&T,RRA/C0ZPTA.+._@B]Y[FOD. M)%_/H8T,0VA.FX1RWM4KV%"O,+NK%F&LX4%Y86R&A`CDDW*7593MKG[!AOI% M9UGG*XIT_S1V0*)-X&A7SBG478V"#36*JX2]=`%LKL;SIC:!4`_=@BB5T1YN ME!$LYS0=C"C%#$5M&*_>=XC`\L(CSV[N3UDURRR_5T<6TK0]%;2=X6PA/@R, M]C`N9=6L6R\]6C0,@2EKE5!.6<)[)=`>ZT"J33^:*:M%NCS/PJ7AZ(0((&/G M75&B;+*,CV?#HD_W8;?#,64#%.'^-\`3,MA!4R9P^QU,4FWZR\S8`$4Z)UGW MQ3J6=/B+2@)'S/=P84FGOC)S5IG'7C"3Z?: MR<2K/)!F\%;2WL7#\MA?Q4R>5AKW$SA$5_>]=@#.L,_I@?^>5H>\K)T3WX/) MZ60.*ZOP%!PO&G%6AZ3/HH'3:_7O$7ZMX'`:.IV`>"]$<[F0Y^SM[Q_;_P`` M`/__`P!02P,$%``&``@````A`-G67[?)!```AQ4``!D```!X;"]W;W)K&ULG%A=C^(V%'VOU/\0Y7T)-OD`!*P61M.NU)6JJMU] M#L%`-$F,DC#,_/M>^YH0F^!DYF48DN/#\;GV/8D77]_RS'EE997R8NF2T=AU M6)'P75H/E2'1FK'6`HJJ5[ MK.O3W/.JY,CRN!KQ$RO@SIZ7>5S#U_+@5:>2Q3LY*,\\.AZ'7AZGA8L,\W(( M!]_OTX0]\>23*$+H_+E_/I2\+S$U!LTRRMWR6I MZ^3)_/NAX&6\S6#>;\2/DRNW_')'GZ=)R2N^KT=`YZ'0^SG/O)D'3*O%+H49 M"-N=DNV7[CS8/CYG]3_\\B=+#\<:RAW`C,3$YKOW)U8EX"C0C&@@ MF!*>@0#XZ^2I6!K@2/PF/R_IKCXNW4DX"J+QA`#LDYZKF^2\$ M$46%)%21P*XCE>+DE\<6'H@O#K% M8B&3.1`+>R9@:X1$LE9B8IO6!4T`.&,*\!\NHJM+8A"X MV7+`#TR7$..W,(&N<6-#:!J!I*W17D$!7KHPW:8ZOBD-(5-9WB":&=YM\#;\ M;1ANRC5=X--P70)LZ`INBP*KAICN7Y:(C0VA:0MU;6+U]]=5#.JK*V)L&FT( M32-LH;9_PW:H&&3X&(WUE;5&3"@+3&;^U*QP^_Z$M.]K^D12&AVDWT,QR-`7 M$D,?8FP>VA":QMEG-(I!?75&C$VC#:%I)-!V32,'M&(QRG#RKM*2>NEBJ8.I M/_-UJS<:@/HD"AN`KK$C+OJ+3;#3:]TF--)@K4`V*ZT07:=HY!]>E`3;O[UC M*Y!5)_)T0W2=HKL;.@?4'#-!\_.^Y@A2VSOTHTE34FR2I`T0);_M/UTCS*.M MT1XL1*#U]4@#L_,H4+=!2AWR=$-T?4;`#&OBXAFP=WZ45HGL)-)_0*4;U MUAQ!5ITVB*ZS(WOZ][EXY^^O.8(>Y[=B08`EOZF1._:>+M'Z>J3![[H" M63W$Q.F&Z!X:F3,LOREFAKVG*U"W"+4F!VD^ M?,56][OEHX=X[H4G.CDK#VS#LJQR$GX69UH4WNV:JWC>MB;S-14''L;UC3B' M$]>]Y@8<@YWB`_L1EX>TJ)R,[8%R/(I@899XD(9?:GZ2YRQ;7L,!F/SW"`>> M#`Y4QB,`[SFOKU_$#S1'J*O_`0``__\#`%!+`P04``8`"````"$``_W62JH" M``"%!P``&0```'AL+W=O+O)\<\?#Y,Y1DJ3MB"U:%F.7YG"-ZN/'Y8[ M(9]4Q9A&P-"J'%=:=PO?5[1B#5&>Z%@+;THA&Z+A46Y\U4E&"EO4U'X4!#._ M(;S%CF$A+^$09/FU9(LJXA]TL8$WK@M@]G]`VG4BA1:@_H?&?T/'/F9SXPK98% MAP2F[4BR,L>WX>(NP_YJ:?OSB[.=.KE'JA*[3Y(77WC+H-DP)C.`M1!/!OI8 MF+^@V#^K?K`#^"91P4JRK?5WL?O,^*;2,.T$`IE=[S058ZG,R])@VD(<+1F2C]P0XD1W2HMFM\.%.ZI'$FT M)X'KGB1,O#A*TOD%++YS9`/>$TU62REV"!8-:*J.F"48+H#9),N@/V\G@TBF MYM84V5)`*YC&\RI.PZ7_#"VD>\S=.>:(\$&\=P"J8P?3?SHP14,'43HR\`:D M1PP,3/_'@"G*,6BYP`&HG3IX?_P&/,P>S<;9'69N%\V"#X[!I9`Q[+C@,[S"#P M$3*03J^1-N"Q=-Q'*QZ7$%.U6&"LM# MNG/4/6C1V>V\%AK./WM;P>>.P6D3>``NA="'!W-2]Q_0U1\```#__P,`4$L# M!!0`!@`(````(0"(8UEKV@,``$(.```9````>&PO=V]R:W-H965TZWWS(&&AP$]$T(E<\GKE-E;+;?W_-,>D,527&QDW5%DR54Q#A)B^M._O5O M\,V1)4*C(HDR7*"=_(&(_'W_YQ_;!ZY>R0TA*H%"07;RC=+25542WU`>$067 MJ(!?+KC*(PJWU54E986BI!Z49ZJA:6LUC])"Y@INM40#7RYIC'P0][MN M1G&K7=\\R>=I7&&"+U0!.95/]#GGC;I106F_35+(@-DN5>BRDU]T]^3(ZGY; M^_,[10_2^RZ1&WZ$59K\3`L$9D.96`'.&+\R]$?"0C!8?1H=U`7XNY(2=(GN M&?T'/TXHO=XH5-N"A%A>;O+A(Q*#H2"C&!93BG$&$X!/*4]99X`AT7M]?:0) MO>WDU5JQ;&VE`RZ=$:%!RB1E*;X3BO/_.*0W4ES$:$3@VHCHEF(:ENU\1675 MJ,"U53&^/!6S$8')MR*VXEB6N7;LY0FM&Q6XMBK6UU7L1@6NC6NN\>/:+3?5O@AP8J$@I(R8NM;=T%YO%V@3QC[PN"=#&E` M)Q!H\;>]:9M;]0WZ,FZ8`V?@LV/T(>&U!&M")NN+@:,8"'C`KIN-#0G%P*DW M1(74NOR@%9?GQV"67SNS0QOX3,80DADAG"'B1/^DD!I;!NEMN&8,'EHD!3PSX/-#WP[2%;(X+F&",67&P0-KQ(`G!GP>X`]5UN=',1"(@;`-?':7:=M#%TYCS&># M#3*$9V,_0[:-F!";?BZP0;!A]#K)XRP1S!+A M+'&:(@9NPKXANKF"K7W:339H)\-R[9PR;=%-SCCUT\#0-YJF#>WV.#!AMS]+ M'&>)8)8(9XG3%#$P$_:=OIG3)C)8,-$1/#IP9L(C;Y;P9XGC+!%P8ET7TX%2 MBL4,^X`]`IPF@(&%[+#?V^W9ZI[O1S9(M%+8TP^3'2J$>*"[<)!YCA\,]S#&>X8+6P;P:B<$1_@RNJ*_HNJ:%D3*T`6F MH"GLB%OQEP!^0W%9G_7.F,+AO?YZ@W__?\```#_ M_P,`4$L#!!0`!@`(````(0"9HS[4YP,``-P.```9````>&PO=V]R:W-H965T MMSL(\W7][SS'@C%:>LV)IH89L&*1*6 MTN*\-7_^>'E:F@87N$AQQ@JR-3\(-[_L_OQC28[Y@)2D@+EQ7!:3THSRS'M@,KQ[0PE<*Z>D2#G4XT(1%+ MKCDIA!*I2(8%S)]?:,E;M3QY1"['U>NU?$I87H+$D694?-2BII$GZZ_G@E7X MF('O=^3AI-6N'T;R.4TJQME)+$#.4A,=>UY9*PN4=IN4@@.Y[$9%3EOS&:UC MY)K6;E,OT"]*;KSWV>`7=ONKHNDW6A!8;)?DWE5S#8&HU^J3/P M;V6DY(2OF?C.;G\3>KX(2+MZ08+/[1=!+AQ)%R\4"EI&LF5"Y;_IR#42"D1IQ&!$8T(?V=5?`H19ZE2JT% M+CCDYVWGV^'&>H,U31IFKYC0-#HF]'7DT")R!:5NU'YQ'X/T(7%+R/2!IZE/8*\;K,SIQF"6B62*>(C2?,)%^0J<3*>&M"8O8U1JR5_KL M]XI9UM7JV8ZGAP_]L!.N!JL3]<-+%PU&Q_UP$*+[;VN>($^/>Y*P[FDYJ)J] M0N"W.]O#-VR6B&:)>(K0[`6Z/;FWS)>F'#17FHJ9\CE+1+-$/$5H/F%/>SR- M$M;3."Y-Q7AU:2)O4'H'+>K>2TMMF?VHZP^VKUB+>O>HYD>V+;TS8?I5D[#N M9^GJK])>(5/IFB6B62*>(C1[*]W>8V4I!\V5I6*F?,X2T2P13Q&:3P3GW>-Y MK&D]D>/";"!5F6$X2/1!"_N>K==!U(0#5=>!,S@68ST.K4TW7O@F90?0,_E8E2+5-\"A>C\!1@=[`TVZ53H3 M2#2O$D\BNEO9!O3<3F\YT.H/]YQ/2E5!ZGQWD3VJU7[<0;TCNFD]^_'`=4>- M9S\.W=-P+U67"=5KYZ0ZDP/),FXD["HO"@Z\`]VWZA*S1VMH@*&/'7P?R*X;.B7.*ULJK)I'-.CQF*LUZM3!^1*W'S>JF? M4EK6(''(BYQ_M**V5::KKZ>*-OA0@.]W-,=IK]T^C.3+/&THHT<^`SE'#G3L M>>DL'5#:KK,<'(AIMQIRW-C/:)4@WW:VZW:"?N7DRI3?%CO3ZU]-GGW+*P*S M#7D2&3A0^BK0KYEX!<'.*/JES<"_C961([X4_#N]_DWRTYE#N@-P)(RMLH^8 ML!1F%&1F7B"44EK``."O5>:B-&!&\'O[_YIG_+RQ_7`61*Z/`+<.A/&77$C: M5GIAG);_20AU4E+$ZT0@HA-!WLQ;!"@(S2J.'%%K,,8<;]<-O5I0-=`GJ[&H M0;0"Y=Z9',?-Z^^L@DT3,H-"-^Q?W&*2')#TAT@>6;KY@MH:^?,C[YQGK;8@@W887Z?WM/D%T8C\F MHE!'XC'BZ40R)A01S:@_-CK_;6GV1D40%*&2B\!=Z$/826:N,CJQ-Q*QD4BF M",TG#$1-Z'0B!;RQ81)OM89&]2B915NM<]>;#\RIS5ZT',Q.K#8O?#2(3M3F M,$+W;T'S!'EZW).`=4\^&A363C+0^MY'->F9,*V-GW?'U377FWV4#A8/&*U.8R" M072B-L,R?:]LS9,XNR@;P_3W)F#=DZ_4?+N6[R0SE3,C$1N)9(K0_"UU?X_5 MI@@RU:9DIGP:B=A()%.$YA/!KO=X(EM:S^2X.CMHWI9G.%HYM>9`J:]N3Q<# MVMBRN-'<\_6%-^G"N_9`:==]B9W_X0)%\IR@[@@!=QTTE3HS$IN19!+1 M78J#@.+RL3)%\O@`>^M]'QCM[QTTZ5;J3""Q62691'2WXC2@N)U>=.#$/UQU M/JE5"RLO,3NT@@,PG&,'[V-QN6FO)[<&N%O4^$3^PYP]4`ZWBO;G&6Z1!([6[@S@(Z6\?Q`'Z-N]=/L_ M````__\#`%!+`P04``8`"````"$`?DZ>XH4$``"8$P``&0```'AL+W=O9K[7M%FUR0ZR$BO_0S3^E_7OORU/LGYI]D*T'CA4 MS9?Y:BJI%DUHYB5V;UR^OQ(9?E$2R>BT/1 M?G2FOE?FBV^[2M;9\P'6_<[&67[V[CY8]F61U[*1VS8`NQ!![37/PWD(3NOE MIH`5J+![M=BN_*]LD?*)'ZZ778!^%.+47/WM-7MY^J,N-G\5E8!HPSZI'7B6 M\D5)OVW4OV!R:,U^ZG;@[]K;B&WV>FC_D:<_1;';M[#=,:Q(+6RQ^7@430X1 M!9N`Q\HIEP<`@%>O+%1J0$2R]^[]5&S:_EG+DP>I M!^#-,5.)S!9@K,(309!OAP?BHN9\59.ZJ:!N8$_?UC%CR_`-]B'7FL36$$5J M*V+&>Y<0`'M*"-QP2C7)I)R.>_MN(8DMN0!TBO2&8M:;&(P0O6O&^Q%48HBT M[_41C'C4^R(<:L97FMA4I/<4!AN8N+,I\_91K,H1+B2G7Q-RJ!#7(]<`Y M#=AY^%.PZ1`P):9@="=1H\%(--/SX*=8JEU>E9'[R:_$!&M"=BI!C4XP*)1F M.%-C^#K_C.R:#Z%28I,JIOF3H`:I^'0V)50X[)#V#$KL=;PNL M5_XYTF)%\2K3H]I=CP;TK,7:7J=KLG'2=V@Q> M9)4U+9IWY8-%`:<[K`6W%V#2J>+L3H>EW"BZ5FUC*$(ZS@-.BDRJ!2YTH!E` MI]0D=A'Y\H2A2,>.!>,Y.1U:X$(WJ"VHGW,6'2D8B19INCB8$/Q4"USH!C4' M=J,[6-5.BS3=.&`6';IH@9&89M8-Z@_,;A!VS=.B?E_GI.*D6N`2.=(F',N> MW2]B&J"$H6B&)]="Q%$71-(S'!&Q\IO%C]2.A-UK#[KXW9,8&\U)![E?G#NU M>8!C1H^(%AE!8O00WQ+Q47_23<9!#81C`[DN@78R:I'!R.F#Q2W1+PA)"W'; M;:YFT6B2$YMHD4E*F_$MT2](![43CIW"R$?K^4*+#,+^RS$?[TK,O08;]X;" ME=J,8&0512W"(QW-N/5S2PMN+\"D&]10U),]H;N1B2@Z_\Z:%57C'<06'N]& MP10B4>/-"GYHY;%[[GZ6+=R(='_NX09,P-7!*`#Q5LKV_$'=W?1W:NO_`0`` M__\#`%!+`P04``8`"````"$`U;79%18-```C?P``#0```'AL+W-T>6QE_JK^D,\NW64GD+J6E-FA[PL42)S63RZ@;-Y&:W=$+Y917'@)/`Q?NALUK'K+#>X M4^!W^MWN92=PO-!,)5P%"QDA@1-_W*XO%E&P=A+OWO.]Y)G),HU@0MW'^6D,^F`I)OK MAZ?H*GQ%],0/]U/3MB$?];I=I)4ZK"5EDWD7])U-V>7P;)8-[($]4FH9%XO[ M?D.%`ULEE0*%]JO1Z[/1J5Y9E759&C[7",`!IY9%#X9NS?@>V?@Z1YR<>4)K MQV-,:IKTBP2IVF-<*)Y+(1+R3J#LL^336 M6K."Y<8-)$W/]\O&@(7+7=AR&_N3).LW%JJ0)9R#,2#]MKW9>CR60RAA;5 M>#RQ!CW+8B3?9Q'MA4OWR<6.FS*:]A$,`<%D,)Y<]@%(UQHS56=%,```H^%P M/.Q-^A;\S_)^^PA4:P2!)J\2A!H\JJRXC/+P!/M M7B4(-'F5(#BW5_-EU?SVUF:=Y?W*K+H^9BLY6#O>1_$2CL#GAY5[N'I,M]U< M^^XJ@55B[#T\XM\D6L._]U&2P/'JF^NEYSQ$H>/#VTZ^1_ZW9D\XH@\'[Z=F M\N@M/H*RM-M35+^I-%31EH8B$UE8X5LCJSNRAOW+=!&56G>RZL!=>MM@W[I" M]\%8`1KE#"<\C92':0M)'L(6LC!/NAP94SN8RV<#+)KH-M>]SMLI58XW@Y+)``/Q`QPGWV M^13N^W8*=CA@I6`/61OYN#EH,9=0 M#R#9X9O[^7$P`%2Z8XYG)PEF^:GL%$N'[V%SA>*)U2"AV725V[!#T[X-*I0T ML20')MRGSHG9?`W3_\+U_?P]A MX+)FG9F*^2Z.$G>1L+,)V<''*CR#"CR]3)`,GE/T6Q7Z@2=I/D[1#\V@@TX$ M7K3JA^"2UJ\R'J"-DO,!+J!!78=')0)8\N<(P`DZ$."YF-G`AO#4@0"64CD" M"-`2`<"IB8I3QD&/9#.(@5(EZ&]+)>28W$I.98M65J5?T%]CI;VJG*^-$))T`4/)"*2! M.D;4127)N:"S!%#/R$QA'4*"`E.1;@@`1PL$X@@X*4<_!DTS,(T&35,PA<#- MP6<<$S0:N!E2$P;`HV54E'5"CYLQSD@#@:`K0Y)HZ.M*D12#KAQ9NJ*O*T42 M"+HR)/6$KA1),>C*D<05NE(D@0",:,F0U!.Z4B3%H"M'EJX8Z$J1!(*N#$D\ M,6@Y179HVS1MHI+^Z61X5/_4>%H)&ZF]JD43^#W?/5T]I2M'\`5;2Y&E-%X- MZ^2]4^,QBKV?89&)5\4NH)GJQB9>D9UX"[KE<^RL[]PG6(JFQYV>5M6]7D"2 M]S=V@Y%'6(FIU`_-==-HHEPY/R=@.9T(H>5L42]LS.]$!M_<%D:($`0V=W1C M0*XS#,I#0-$0P9&KFR:8)+5CH*Z""5,N5]C`'"8?0383QBI5CF1D#6_8S!4P M?*)J03DN9;0IE];=1H;NDU[P^6F'ND`;[;AN:Z:\[HAJ33NW_>@]1Q729"SW MJP!A5[6.CEG6S!5FED.30".$).P'NZOG.H0VZWGMM`J;J^*,O#RE32A M0HAU)*LY$6PYH(U((R-&I)V;("1).Q:+DKQ%(TK>8^QV)/L>.T,-1O&R4Z$D M*G,"2S[[':Y/)2?A8U#B?-BT,JN<&D\$($_3>0CIDU6UDK!O-.:JE,/]F]2D M]49H6LY&-').3@@DIN'*W:+NT))%219`6%G-+8!2D07D)AE*Y8FYZCB8Q\Q& MQX`F;I:G-I\=Z\K+4V.]3G;EJ`:E=:60=+%V[*@&"D]?!NZ[451CT0&J!$(C M^ZM*9T!2YPRI"3#O*"H!].74\E64]2#3U7$F'<`TAH[BL&J('>O4)@X$'7F. MKX_FRA!JHNU_N)]0$@5!9(V*:G=]*35(3^?!':W'5_!TO3SKG3U0^UJ5Z_0YGO2A MCW:B7)0@CIGI&E5+#?K[M-_8-F[93@Q)+JO7JPW6J M^KJ4RZ,6T&0X*W'NEQIH.3F*\+6=0H0+Q2\H]36IOFDR:8/#5MPK6E+:7"4L MW?QJBI4<7FA`8\7QA5/GYFR.:\6&?;Z;&R'M!9I!CS1*VSPNG'](=F]CM%'N M6DVP^Q'!+WV/'($MXO__9%I_ODUE_PZ(:[VIBV-!VPI*J_+*BO18V@\,(6%6 MJCRL)`!Q5$[/\I(0%$F52L8N)498S8G0#70>`FE0;-1EY]-[) M=:?T4=SG=ZD(*+VDH;+)N3<@9`HA*:+WI^M\B[" M"54,(GVFGNA>33MSB0(4[)(HN`B*W%**OZ%4<C[<+!:OA<+9<+'=P,T@9^G&[`*D.EF0L-*)$H\,4UF0*YK**GKI M>!H*Y'TIR M;QWR([M4N\2%)LO@HK)*/P)SQ,8!F-Q45NE'[&96/^+YDQ*=22M_! M.\(1UNHR'*522J_Q43Z0C/)42NDO/KXMR?A.I92>`GG$(@N^D+>H\-&`9]>2 M9'?F+/.LRP<,SC,R,."!1(NM#X\@CO`!QNRZ8>P%$(.PRI.2].@N/AISN`UD M(8@?#SB-R@BZ?5K[3N@D4?QLX+7"A3C>Z4-)<;^+HH(C7@*NU60`_1X>]PQ/ MDC:`EY0A/H:QN&PBIA@+/#T]28_E:&#O%`T??WC,N`D:V#L5PR=5K)]DQ+P) MU]O"0WPNQ:E;1L1;+_SH+OG(X1GN`T@92>_<;1([1?SQ0PJ/9TL)P9N'%C+X M%)$^B#"_TVE6?[Z#>X7F).*B@XP=K.1E=/YQFQ`:<2\BI"^9E^Z\!.[QG`]B M3@3"DL%Q%\'U^X6(G8PB*>//3ASB:.&&[DZ,5EA4W@T!JO_E4WDC6<9[@@]$ M9[>8+=8#0-3273E;/[DKOIR:Y?L_L+NG0S!EO_K.^Q0E3,34+-^_Q=O2PRB& M)@&DF[<;N-4Y_#6VL3W]K]BW%W-KZP!N[P8C*$G/)V=/44>[H?0LZXV/CS#/&UL[)W9;AQ)EJ;O!YAW<`BJ229` M,KEHKI]"C MY)/,]Y]C9FZ^!$5E5C>ZT=/H[A3#S6TY=I;_+&;^[3]\N!H7[ZKY8C2=_/[. M[O;.G:*:#*;#T>3B]W=^.'V^]>A.L5B6DV$YGDZJW]^YKA9W_N&[__R?OETL ME@7O3A:_OW.Y7,Y^^\TWB\%E=54NMJ>S:L*3\^G\JESRY_SBF\5L7I7#Q655 M+:_&W^SM[#SXYJH<3>X4@^EJLOS]G?V'NX_O%*O)Z*^KZM!_NO_HT9WOOEV, MOOMV^=W3Z6!U54V6!?,HGDV6H^5U<33Q`9CWM]\LO_OV&S7UY@^*E]/)\G)! MTV$U;#\]J6;;Q?[.9K&WLWNO_?#U8,G#W?Z':1K9V,5_?S&:5,71LKI:_(]V M;U^U?T@]G%[/JO;#KW9WMO[4_O&`=0]M[<_'Y47[Z5?GY7C1Z2B-UH+8K7JZ5)+X1NOW;X^M739Z].H!/_.GG]XNCIP2E_/#EX7U?S]:%$5BUDU M&)V/NL+WLIROEZ](V7*QJ):+W[;'/"P7EZ8!!OI']=?5Z%TY9B]%#AF/RK/1V#:SPR9I-V?EM;:R M/5&>SU?,+FY5^_G3./TYBYVL.N\W=RR;2;LC7R1F,VS>#4T/L5>(*-N$19PL M1D/)>X]E6T/D&WKVV=[00&ICM!2'.-,ROD]E`)L7&Z^FRZK8W>DH@*\^??ST ML;UBTSV7TS'37WQEK+>\[NS/X9B]+9X4B$S@DZ"R[F[O[!8S3!!BO4+OK9;( M\>@GMFJKV-U$'^O_BH4IMM\51XN%=M'DK%9R-)V`4]H3"[IQX;KQQH%\F+ZA MMHI[NYN/``<[#Q^&:13EL@!/8/S/X.<(*FQ2M-W=V]M\\/A^UA;UAR1%?/&[ M7#TS\WL[F_0@S:/!J*,+3P%TB]7\&G"(O1$=!E,0H79J[_[^ MYN-[^]F\UJR!ICLLX4%.S<\L(9M8T*[3*[#E)4IW]*XJQM-%1[N[!-@T6ZS9 M7G9'5FPC;_/F+6WI,3898%HM1\"MK]?9UK4"DF2C/?&U;]0R=.M77*YNW7Q: MRU[G'0C63[[1[(89-]JMF6:CS0W@I\F^FX%7.ROHAT@GIR"EE\]>`8]> M/R]>'S][)I!@>%Z*.!R%,9J3^$0->&6)AK@SFS4I)B>%[.; M9]5`)C=,YZ0:CS&NFP7V%;LZ-JDNAU>CB7D12Q3'^DD^"X!NL[!5M1L>X2M? M5<7Y?'I5"'69U>ZH($<"(V^[(27U=6?1`I<+L\.%-^P%;-Z3=W%3NU?329@. M'E:8Y$98R]&X=B'=R,%"-:L7CAO;9M7U3+VY=-N=_*D7(P& M@MO-9@74=+'L?^%]-;JXE$]4$KTH\9,<&!0W**2GH_%*;WS!6/&57S#:&IO0 M5!Z'KU\>OWGV!_RPHS\_*S9>O#XY^5I^*_[K.FWB+`#;97:OP1`=UGK.?HXN ML/;FB0RN"_G."\P[6UK8J]7BZ^*"@$R'<[5[JPFV?FQ`K-FXX/5;.5B?G7)[ MB\%KZU;7:7H;'7UX4`C;#&M1C^N'(9E:^(9V5> MSI1_@YH'^.8]K+674=MXMJ.?>IV# M)^6P&%9GR^C9M"EU(J2V=58NF(#8!\S4V\]?\)*KK>'T_41*>!2;I.;\1F/Q]]?J`-W"4U[9_Y,A]N3_U=[\VU*'*_W MUOO]SK;/:).8FA-[*_].8G0K#FC/U*V"PF0WL.7Q"J^";24"Q()1BJR)FJS`)#'K+O@X&",+"/`N]\^SPV/HY.#HQ"Z;?;.E0EB#N ML+W".'FUI%Q*MJ-6C\MK][AAZ_&H6NF%$?1A4'L9\50L MS_O0I`56KE97.&[7\^EX++/K?[AN&(@:R9<.Y+!DC,^N^7>M.(`:`6IH9*^<1`2Q:V9'Y-@6?CS[`*:9- MW1X1>X`.4N0&0X8HA^FRN&:SM=CVZZ^DA8QJ3U8+$BQ$C&3^A!5-^$V#]\?( M7A&Q^O1Q=YO^7U7B>+G\Q6`T'RBN0K2_6,`I&'-,]KL1D59;WQ21 MF:L?-X\K)-X8!U)`]4L"L4O9T;%H,X-_%+7;)A)?%6%NZDT1VL4FAF"R.L=J M&-5%/(=J"\UM1@Q[63()_BW';U$L+Y$,PA-TL``KLG<,6$TL/R;%-[I-_] M#\UO0@M%\!E0>Z%WI^.I3V6*8<;QMA8J>**@29+_G+/:[,88H`A M#@_+#XT@_5^ M!)5_V#[9CAXV:^&QXJ*H`$^N:'BX#J.*>H0[6DR;6RCT0PQ2*H[@_IP@29MV9!V$\?8YR:@5`.($SG@G,V*[??+LL,.@1R[%TQGHQI4`2@M?7GQGVW8#^WZ& M2OD^E[7;MHFHCI3,0EC9_A)*8HC'[(FLDOAM8E9#T%7I+^E(V>'2W1<$8,'< MC-/T/G^NQHB(FHB4IF)@9$<54ES6OAJZ3HO->;,.%GG_DZ"?TLNHZVOC6#AF M-!FB,!2HZAOT?`4OYYNH^=*?H^G%ZFP!4F+685:=73@5&V52/IDFB`:7MAE* MUH'4[D#9]URV85K+&$52+"_GX$LQZV+TH0#-JB##V2NE`V"Q4(4%3! MH]:HGQL)2S68C\Y<';6GVF<+DC,3>>MC M>&.(?E^.\`V@7=!.)E5PPQG[,)U(K*+2`YE-%5C@K;6S8;H_@N!!&&E.-`X\ M;>HG=^KI,0&')9!G8K;5U!3:(]L?V,9")UB!((S^>#D"Z4HH,W!IMD=Z&Z5) M>1$K3ST+3YWC(XPL$^S9[M`<[8Y!09(E,>@;K`C:H7R-6N)H`%ZB&LX93&*^E]3N(191BR0%D1L%"!V&<0RCASJ M!"7-/K)7@G_OHTY"=!6&1ZU,27>Y5J*?Z#;)<@A&7JFP0\#1M'-0$H2KQ@,X M"%6+OTYX0GZD47HV1>>CH`MQK]$JEV=6!",">ZT#Z6671+D6.56DZXUWL3/2 MYK1$%2Y9?LY@<(`*@C(_3'UTUX]DF)?!G*&VVDA+H7<0KK2]GF3GE[X^"L/T M-0=UE-EA[23RS_4%"P<+0U(K*GH,GKP2MMK?-N>I%O/%IOE4D^*/J_$U2MK+ M[YHD"DJ#)67(S6L`%E[KQ%H4?'HV6;X?#=Z.5Y.+Q06*=CRF,!$@77Q_=?:' M32SY]^P([#X>4??`K&(L\=JX&<-I4DM/CDWO[NYO[Q!_(8<$3TCXB"W`[\*\ M99919V%H7S:,$(W$8U&L9N+D$D/^P6(WS._N[OVLLYS3T'J7(\0^ZN@!H2T" M\J[OY"UL-L0&KJU%1+.#3:E[6$3@F7ZIIR,>.ZN8S1!Q;6ID<[(\5+4I5T?^ MY]69N#;`,HLEP)3!X;6QH89%CV[BC6BRO".D0>[B?.B,B;<5]918&> MF9,;@\7R_W$#C(^DD6A@TS'W$A^K&ABXV;D:GF M/X+_:BFV1Z^<>2$1"DN&1UN@AS(VT5+.TLXFHB+^4AN33#G(7]#L"@]Q27U- M<"&1^QHIST>+MR:$+I+4R#46(Z6R!-"LO%X-WE&[=R4!JM6BOPESE'8=8N23KBD3,D M$(]_=`C,_?SL>8>A"7.%:IDLPF->$/*BFT^C$&R M?UK4[J\8I?9X.AKC#;X6#"FG'1'2@,=S$M@XQQZ"^+91X#U72?C1!"_UVFJX MW4X\]X@T`I%UJO2U^L)4;!#\X^<'`MZJ>MW8>;\9* M-T;6_Q[S_T;?4&W^DTK5J)K?N<-?`_#NO)A?G/W^SO/G*A_>L9_GS]DH;W<( MFCF;C]3XG+@0[&2O[^D'*YZ7M-,?>&$ZUX_?V%#+[T(IA6=K#NEOCH`#KF2# M#E=H8;#2HF>2_VH3A'\13V4'$@-=K(@I63IC`B=960G_'4SQ'F55"-&<_&#; M!X%YX!Z!6YZ9I),N0W,`8.S`,.@(W:8$MH5*&98H`WMZ0.R3+B;)@6/D4,`N%8,C<#:A%RQT-Q\+_AUM%0Q-P;-4"@'K(LHV10O4.W-)YK`]LHQ3M!"X3_!AX1`,)-%<$FJ7;"%J8 MEEHHWB@;VC_E)A-AL"I+.9G7ARQFZBAJI_/1G-JBOZX`UU+CYS%N@J0_W"Z> ME7.$LAPZ%%)$7ZXG8X,448JNBH."TU-Y9Y"5=RK!Z7I%P03+/%IG+#1G=P%) MY%?$NS'6%Q0EZB8[W:+\V%$H)7JA4J*ZE*RI)Y??"6U_^KA'*N3V[RC%21!R$I<*S7(51?'^C& M&I*F*=:G&_(*J!28C"0\3F"V[\THO(;K8^[:0`RXU$"5/U&L0N<^0#?-!YS@ M6O)[)JVAWB1_SV!06)DKTYA_5@3+5%H+1]R4KC;%ZLL+X0:"NG"BJNS$#0YT MY'#+<8P[:6GO+(%L^!8]KMP`:1"5\YDJ#)ZTU-=9-2BEH/G]NG"*=1\%`.,3 MBCBG=&'ZGE,%+)'B_GA\*,10Z_&`H&6W0K+OQ,&IS>@ED.B&XWY>GF_!YK:& M/"$V?=/;K@V_0'W>;8^P\>#!O?9O7T>L5I]9_,N:W1-/NF7JXIO>7=M5_9V-G>Z1S8>QK4[Q=0HRX!26Q:*ZKVH#__[7_U;?'M M*6-CW,S*[3%OIDWHL/W2\X`M7!P^E]I`\VVMK=_&`-9 M)SHVJ(+B=E5O=L0A<>8LI^"$8>O*G)V)NF3.L]JO&N:U/C7XT#8_;A5I$&D M(\F41=W8<0XCM6^31NK0^M[_I_4OH?6M.'N_3>V]Q_^:K+U_WS?W/P9K=XB] MO_EX;_]6W-W5"AQ->_QHC5XP";X9"67R>QO$F@&G&!V2/9+O1!`U@!MW%]$" MX)Z."CC(4@5M9?S*?!Q2"CF)G`!`3A2=:AH M(H92L)0X>5%N45X`FLR9MWB-'#_*A:SZY[WJK+[W=(3R]/A1%!QLIC#[LY5J M7"UQX7$I+TLK_'?/#X.Q3JZ)/3.D$AS6+OR@!LCH^DP'M,<-MYD73ZHYT=+- M,!TFX0$=(8X(_PX]$F(`TM(Q==5OEI3QY8>3A2UJ]Q+;ILR6?'ZZ0C'SV501 M`3,L3KIK''?R/G+_)Q=4C]@CM(*EV*FF\HHX[8`M:CE=7L^T+,F%3!,+5759 M2'64,D4#8O"32F%WHCZT\UA'*#*SZK40(&)&(7+M-6^QP$^=)2_"*\<\8Z1H M$=RB`K3A7+XEY#KGSHG3ELO3HJ\6J%)2%D?/C3191UJRKCR7+MY4!]K'7Y+. MTI$:7%0J6D6V9@XK'+*6!QO9$(#JTQ1Q__VFM8J_*+P*'RF`K_61;[BL;AY[5"[V)4=:\S^/EO_Z>M9A27Y"3@C"T6[6!@BL,M3+4QPF?0;[D,$A^M M1A2?2*.9IB`C=?A,U5MOC;^%!(E+.8#4+RQ"?2Q4Z\]+2F#5[(V<*#Z7=B]F M(&=(F_):.FY%BLIK-X*/#%=9MG1CU#<_8MU4+C*NQA+YE*Y1"GTP+JES*NW$ MT9)'))L(SBOC[4E8#LB2TBHV^#^K^[#5,%D"9D1[B:`HXD;$F,5I:MP602A6 M`OYUTE44]6GT3C[ULZLANFRY$!@[<32$RE*]=Q]F.=R-L+]2)025*>XP-O$5 M,O]Z;D1_"?=.%%"<3R^I6H&IV(S^M9N./5_-:4$%B5UBP6I,?P5=Q9E55H]Z MTR%&)0U1.9NJ/R9$P;B*5-@6DV2@RM5#D_P>Z"**,@VKJB7ENX*))A`UH'WY M%E8>/"RO4*@6\\Z83_W#2C$9[+SG8A!"Q#U:`0'Q#%/,NP=F]#P:4]4`=82Y MO,!L$I@F;QCF8-RN*B?I[7P/OOZ=?OJ,+'G@ES&M,$6DZ16IG$FS$I3DMT`8 MK=YJ>N9H1$_5:D8=2:):,BK"6XL2\1[LN'&0BZ,$SNH"D)9(D/?3^9A;.\BU MA+2(Y6'O[NYEM06*(N69[KQESG$4[:D,.%3D]HMQ5!<;!^@@D_B-)_S+3#X, M#F[!6*KT00S$'D-;6CE*L)M<7$4<\DXD1-:D(9#-DH\DAVQ;-"[B$I4L!;7X M@4[9DRV8BPQC2A2?"V7)MX1=S`P;26TAG:I!K"+7[T@@*`>Y@BU&`DU>>%TG M)",&TBT'1F]7A'I-NQ^2F_R55.(U4VO:R@VKM5)R:\9^-+/ZT9Q\W3'GD98' M-0C62CE?Y8#O``ZAO.EH,D'96[CZ9*JX-P6>U( M[83R'14$CY5%5S\H7+`E-@[E+#,(6\?-/0NG7."\":%J@C.N8\\JX[!H=,D8 MV(Y<4D$>1)?Z6N&2_H%\A`Y+G;)YR3]A+,Q^Y.\6[HPD:6[U>XC:#&K=W=M^ M)&R4%TD93<4G>9\!Q(ZHC\'9L8!86FS3H*QA1X?*/I^TAMK'@K]5-V5Q?_D` MH5A[06B*PD;I* M$ZNCK&RB/HZC`WAL!#X(.<_N*7KM1DXBHZYK'JDO&$'DQDB'@U"$@F-MEA,C MD6']5J;B?<0W^'SPAFV.J>A,OEE=+!,*($ MM:<=856R*D7,D M0R,A\@)M='2M$V.L-;6V5=>3MJ98K5@N&D5-N]Q#!P=+3)TJ>:O2Y7@1TZ!3 MQA,ZL&,4GNAP]LKG9`2O];B"%LUS*F'Q.3N4M1'*#C+`MSI.,ASIQ%@J!L," M)Z\S(VS`5=EYA+`!3`!K%)U8(9M8?<6//83Z`H9!DRG#W2SISX_:<""&$^;. M""J(T'*XS3`>/K#19SH$Y-O9SP_L/7NK:@MQA6G/T%56!5<;9_C/SFL$I!"< M*61,>2EM5VN#R$*#T&$>(S,78Z(\($S_7)BHH@W0?=V)_2(+Y2^4)_=Y`-4C M]S69KJ-?)!X9;VS)Q.756&%=Z+2Z)#<5RUB("DV2\G"=HY^]5YPF,MA,,) M="55?I)+P^-<1&)M#1HW751@>O\+>!X%T(S-.)ZU79)&JBG93(%V^_DN\61DS;5_*J.R(Y!&;8;^4Y\IM&+^HX^L?<*@]]9 M!NK/[N++%&W_6%F#V%F[H5)YGYE272IOA@>]-YIA6+Q*I8\!@H`*=)G9%\!- M)U"H`K"S9`)CD^R("DHOG%VHVRIHT3BM0H4?%?_2>!8---Q>GU2QP6`\+PE( M/(^V2TN()>CQU(T*D-Q3/T-')"OO"%<\'`N)4P]M:G6T3;P=THIJ.F<*:IU( M:<3RO`4? M2!G;/28KXLN+GK.T!T"$,0$);(R4%%;$@#GS]6-V[A=F^KU%"TQ3<.#MO1F^ M0,H(W]W=WHW@F:/5Z;BM9FUG=%'9S#$D3!A2^05^\&(5[)$..=#M33=<&0GL M9E+:R[_1*E+Q679.%3T5["4-G)J9U:P?&>5RN6A/2@0(!M:@/`/V'3E>-[3U MKSX$U3CFD;PNZ%33<]BK7O.%_I"PG0PP^$4`B`NU=&G$(F8,)$[WQM^3:5% MB%ITF6Z5++TG:8OEV,GSSL@)W8V:AF2U[K7KU%K@:\-*@0OD']S=V=Z+7!1W M.\UQX/=OL(!:M*)R8V/$S(JDBBD(+)%@$>KZL@5VU,>I!#D9X/KL.:ROKJ]* MZ&G_M<&PQ?(-W#`CC[@XR.MZUA.)G/+:K]L4!YA253V205,BM>]UZM4J\N4V M2#O09X.E:UT&A8DW\/PLOSTDG+I5G;AS6+TV>3'8%]1^ODJS.^$:%9&7A5J% MJS)!H$K3/2$4*RYT[16/(JL8I'D4^+UBSI37*KH02965IEE=AI:HB>?HPP\6 MLF)V6<],4V;H/#BFDOT+O`,I0BII5V4.C'#7\98 M'JI6&3O`.7-7B$>"O#!U(@@V"5COEU@E3M4N!E5JO&JI-P(GKK1]<;42R!;3 MXT3U[4(DS]#O`3!B1)BC]!CI9*FGYWY@S.)[EL<. MQYUS&L>&T%?;K[:^Z&#['2K:?1E]B?!3]JI>7&.>_?R6_'[P1SH3Z+%-[JFQ MLB/M?ZZG,W]S%@]U!Y4H@X,@U,?I746H&-]KO+>B`31S"/K%27;O'DWR9BE(_XB<6T,3MTC6) M62Y6!\0MQO$LX[[I'@5VA$:R*PJ[9<[,-5`[81*=K-`]"AI/A`A.J38N4C<\ M#22.8MVECUD>YMQ1UBK)O,N1%9GJCF_VQL]OM!'W!M?RP-R'?.F'`I7FN_G5$BW?_PAW5O9?O*] M(L3M'U_01?=.-;'BIX_.'^TWC$/;/Q[T$J2SO!].BOH.XL0][%`9>;@+22LF:C]VL9^^Y?ZXO@OZF?O4;NCC:XD M''.JP3!Q1>\JFJQ0C&*D9INP$_$4&N`[QB<$T-16AYQUEBA+(B0OV?6&FR8% M(`1Z$7/-*1R!MFHQ08%MOO@18:0-3TMD.XZF^+P.])NBR16%R9HL65,7\6JX MU\@ET++9;M22(#(/%?FK+HR/DC!"9\=>J*"JV/UM\:<5"CC>*^;TE*81(!5F M]'6ZG^3'SQ0$"FV[ZCGG;KDJ/XN=Q MQCM4C&'I`^VA;;EFS/W?%C_T'!Q//4XPX%_>*Q\V2/7-_=2`K#+Z?#4D7!4`=V0S,;,CJG*9(%*W&/G+Q'`WBIWD'WR-C<-HOK445: M`:3WCE*9=U8'PV=#R)+`HQR:5Z8UH3D*O;@252'\\Y+XCIWDYT\[5[.`YW4K M*DZ/G_F+G"2Z,C$H'G.\8-(Z-F#GF1QG]Q(3T\]V$[[1?YUP`%%.$^*,QW*G MJ!6(QIST%5M`;L\@1&(8RS3N/G#E8GB+>^0&T(+[FZ0=T%*(*FC!+C"O94T" MHKW4_H3;ZVB%`&7=,LUJ;*HK'):M_0#G6JY#I9#2&+$]@36\MV^A1GQBKDK@ M/?3NC=+=F!G[2A68)FU1'6%+UT1L6Y\>9661HQC*%0Y'E51+`44Q:>=9'D!T M2!G$R/*R(#7K6RE6]!;2#14P$#-:D!0><[V:Q8[UD3-^%N>@]E6QA54A'W6M0,KDY,Y8E`.4TZA#S-414Q3<%KF+R.K>00MIU/F-=A<^P\[$:\C2?D&;%O:%D)2@"MZJ MI[9-]8E^Z_(3JDNHKTPV`[QN"?K.!:$7_Y;434#044;Z,A26BQL MC_[)M"D)X_G$8O`>A.RQ3KU,W,^G&6AP\363AJ*0$NZ-8L[BD5?@6%:7J,@C M9DK^NQ63!(>(I8R!/H3,0GE$'0*,[CYRH-BL75X@U@'1]0D.%I*L4BW2=`%HD3$,!`VD@YIN%AMR4JUL<1L4? MK,J'`C.JDLW*QR12##2X^4.!U:H*W2_-%L-+U--GM^Q`5;];9[54_[T;GT%1 M=ZZ;2=N^4+:9T4QH,%11H3M01`L[SEU+:87CM/#;1)([JNI)"@H'A=@6\/CM MI8[7>1QNBVJ_<-@3L&^W>4[E(K?H!$C2^JZ#US^T7]FXM]R;S68)"\$9*XDL(3+&6BE7B"<@0\`*RP)9VWD+&J+;/C8A8NG55# MJOR37=BLQG$40P>T9J-JEUYKFR0W,.(7D1D"_ M;4OT%!#O\0-4`PGL#$*7S[U_;U!3-;9@\Z-XPR=L4T_&KR.CLKX!"%"\W`DA M-;O@U@QR.AWI$=NMC9+F-UKE+N2GCT*[YT\<#?`N8M-U@`SQ]`50? MG;>?2+E240"TZX1JCS-E&P_GM5]OZ?;VXY?Q-CE+"W4T%H1Y].GC0&]BE_6TE200,VOAZ;IB176EJ\(L3!5C]3J<& M!*0.@GB'P!D_9&W9@D0&"PZ@_QPRYJWRE$F8,J`I^W)E1_4RHQH5]R@XGKN_ M7;<2&*H3/M)--1ZRN+I',B)N"I;#O+A,:0E8`7@)/BM4X);5OEJ@`S:^SV&) MX4XF1>^48`'',V1M,'IN>=5E4>&>T!SJE4,T"#&`D*7M&CD'/[2H%TLTX50[ MD8Z5I)M!22:L"#_8.WU4DFVF+.)^8EZI^88DX=8F7KHY*6!WR+1NR&/,3-]LOS1??&^R-_[85_1"$:;X:#;!M4? M1%+P58P*-1RQ=B.E+U,&I*W4WI3O4^6)`V;%,CCMUU&W?YG.WVZ-[.YH#@!U MLQS/]1D[W8QL5XZUQ]'T@_19$8[V/ZP4I2!/Q_03-(TG5W4K+ZR@H($=#\.W MX0Y%.Y)`\%0E")+H(SX?-1Z7)@H'3^Z3.$SM"3`MD9TK&*PY-VO,X:6X'.)D M+J-Q0NPB@F*<-^336H-E(A%1.,"%\N4$A>!U3M1R9TYVF_-M4+N][?4?6D)4 M2@SD5Y+"P@_:/)V8O,VHL.3[])TLPR"1M-<=99/JZ#3]7_!I9>?3!]O%K^TH MO9_*`M+B60_DO^W1(%MPY(%#^Y#&XAI3<,4'![ZWB%=XJ,0[UF3GOA%?OJIH MH"0VOR&3&TE925X:?!>[&\G`S2`]K=6I/HK MJH*(.&_%,+('ZZ5[@^L7'CV\0>(LE$,P$IN2/J%N/!O^_U:$I&P_6A7E.4/-6'S!8\CQDMBL^B=4QM0156FLF3LC'N;W M.=*1;JN'?[*FZ30$WA(KMG@"J2W[6`P%5U=5&)^2ZW`'-;NHP(UO`W*&#&%6^&3PW%&: M79WO.[J@N%,9"-TI"2V@EW??\W)K$9 M22T@61>I0O9TA[)7!OFHX7I-6V*Z^#C:%*:4KGPHL6AF?$6$%(3K M^-'/X";[=ISXBOIDV[_V/([GTW/,.U%&54Q;X;1M6X#70L7GG#INOW92(A'(TX0?QJW_+ MQF<7?Z\B+<[XM+`=.KX]].UPY(E]G_-)*1,HR5Q'6]_C1V0#;_F"6#WM9T@) M92=AS-4-:?5\3U-I)M'4.E&4ZK4-&/J9:4Q/6W!$X)0E2N^8HLR*GJ,U_H6% MO!W>/%7M`N4ZY`(NN1"9R&:W?DC4T#)K1+^6`+]R>NU[#SO3?8,!:5RL:?=G MNJ#8%9MM9K8=CQ=SMA\F3K?U9(?42-&UVWI'K_N_3OD9?M%6^Q#AGERK]["L M.A#=GM[BBS\=8IS8O73MB?Z@"T$M@=Y^LF;R%#(2G8J72W;B8S'JUNYM30SN MV0.&3HUVZRX/HG/> M?NN(@@-*,D:#]H/7^6VSW*B.Q4Q%J)UPYO<$&,%+[3[BFCL/-O:ZR8-#I7\Y MX4X4!$")-=$WD=L];MQO_]*:9T^TH/U&F)4AN'XEVWXC,$@1*@[#_%))N7Y6 M`OX68TL@ZD`)",Z)[^A36,T%0:#5V86OY2A(DG\Y).J2VS@>CL[LQJ4\RY$- M%-;$=_]D2F\KUN?$C$D"%6E7X-]35L'N[C\[8X,$V->.&2%H*GB/%NB+YLX(\1%ID_=6W^=TW6B?V3$.($O M91`)B4(DSBF/MX/C?O?Q]H.']1V=S6!(!\B(;DT*W3"M7VCZW;;VIJYKJ-,A M7.;'=>W/Z,-GD,,;OM^RQ9>\%$:E/D/Z0U?1M67H-]W;?87"S34-VSP>G7-) M>K_23VW?I7*U]@@BL'RJGLDHAIU<6+%JLQ8DJX=3!"8$C!%,-34O$B7C["IV MXFHN[%-$RT0._9L3:BS'P99D:^$M_9C#`N)_?TXKR%TQBYIF.]>8+ID$!6)Y MG)?KA>Z#,)IGYD.)7]OG4>('<284G00O%(7$:OO[-G]6@?4S5242^&P>!@IN M?;T93=>YJ1<248QLF;Y.:\SF$(V%D9)*6]51F9$B4:.S4GE4(;:UW[C+)MF9 M(%FZR*'>$KNYIH(TOMW,XZ>*0W>PAGGZ`:X'7LP2M/8QI;/ZGO.D_>JKRZ"3 MQ0+B$.X/I>=.`(O0T%**L]4ZC`US55P[9=;<*;R.K)G:KQF[5/%*N-N#U87: MRXRVV5L8"\O1PP,$0^JP!$S?_P*1A#5?WLQZ%3^)X\/DVQ*:(?L3NVM>&]OY M\0==E]]^]:C.$FK"N4BY9.*7:N1HF>P6]M9V&F)NK<$*;`G(6B0NY2\$7`A>]W(BFCTC>_5MQ> MMICYJ+8VE97_:C?C5?SV1)ONW\MF?_KXM$>C;X`J/+':\2=:0-8`=Q%.O+1' M^#.K[@'']QYTX/%SQSH]C7>[*??6%!*>+>)U5^UYG,(H:T">'.,8=S!]HJ-R ML'WCS%J7#75>18^">$E+=IS:$F'W3O&+0F`,*?Y9YE#3SGF]RZ*\\04 MT<3_*@"XUN/WID=+^[M[^]^V@M1+.D M29]#\25S_H5.AZB08\J44_.)/ZAOT_P,KCRN.:?P,-E!;Y3D*+L:03SR)6M, ML0QE(CP=9=7)#EJ"^@K79!IR$%%T"6);Q779/"F[MCRB\5]B13ZTR5KEAZ79`'GN"E_8>/-Q_>WW/]9?@!(>?>NV!9+.FA M]FX?8]8#A$'MOH[Q3,_YVC/E!;9;,>"IV"B'%NC>G2RC@AV:"G4J=H2)QS/F M'+[2O/`/"=8/W&-+ZE$:32L) M]HENGQF>/CV70)H1T_(:.E#@I:J\/L8T&(CPYVEA:V8:RC!XWXZS:%C?RH[# M5#/`_K\``^P]>+3YAE4'_81E`"(GZ'1>4FBG7[%T0*8Q?D#X[8V4"O\MW M!QX_WEU+3GU(L:T4(NN'0FT_Y:4QU%",48^7),R$0)S6:Y/EYMG=D)&KX4PE M5^:JYAIW:Q!J%MO[%V"QWVC6FU66KLF;`X$R\_C[6;.]1XY,N<,BOL&97E;Y#9RI1 M?,89*5V["C0E(Q\-6(,!_YT8NS5,EQE>Z9N]_08I*00-F18)7<9TYC"&&BD9 M_6@(W3/MTTY636K%;P'49$34D4Z_&D$_9ORA*)/?Q!JK]&L?Y?Y.YVLEYE4' MO_66&"`5%)@>YVH;E*B7+V#F[3>;TF>-0XPCRYRXD8=::[!9]%/ZR&2QNB]1 MXEG!VY>%39M82.PALV$?XN;FWG3YF$DO68M4D-L$Y%;,9;O^N32`'3$F_N-^ MX8A:N53=,?LL>>O:DH`EJ?GSDZAILQ![MWZQA0<0:H9I9"YZ:1^YF$B)LWMS MSFMR%7#,W4>UPU)'I#(.M_!D/":LLI'%(BH37P`?*^<(,FOPVAJKYO'RU9-5;9C'E*&3 M`''LFCU5!T#O=*%J"+):0%R$J:\X$B,[G-\+X>.X?0N\^"[O5;V:P>6XPUAS$LA3FXWY,PEVHFC['Z<0=,-]`J3 M#%7>K@J!QHI\CT=O]84Z?M/]QF!ENT&"`U=C90`[;LMIC=HYG MICJ8FL4C0S?V<\^\Y,E)5*(T>',_.22.Z%G);8\]FCF*A8GJ'YJQ3YRH9H9] M'8O&O00)D^+@35.CAL__"H-C(-.%/WCD^D023K289Z+O6>@/[O[G=)9.X>OG M*-K&.O%1S8>:X]2B"Q;\Y%M'X6UK?QC2DQ(H7=S'#."><#$D;WJ$VY2-^"&4 MWD""4'Q*8]UGX">QKI0DA=8:LOI`(L8G":>.PHV`/(PG0,\I+YPC.5$L6..2 M2#.?$E'AE,1@Q1+GNHP=96?:5FL/W`%%BFNWC0JK$!^'Z%ZFM M;_7T_/``_9,_V3#AQ8ZQ?791(!U,WRLH__/?_EDZJ]C=V9;CP"$<][8T3]5A M,";+0E'PNW]YT]Y7QI2M(^%U?0?/M#2 MG@9;PNUD.L,+=;G0KM)I`E$4TL?;0/Y8TL9WHCZ_S4:,KL[X?H+CVVKR;C2? MVJU"T06-R[?EKI\!3ZAWB^*MF:/JE2!T'2[:U?OO1R4X5=(E:-#\C>ZV0W0O M!%"HJ!VQ0':G*5Q15IJB&.5$GLHL8Y^4=*:$UVF87ZB$;=IP/;3HB7@Y5(CL:R@5O0#'4R'/ M@*Z8C2!C7=T1^;U.`-8K"*J50Q9'^J*10H"*S/50Q!2%SG&$5)@@O5D_1@SW MF#!+7,X/(Q^E-OZ,I6*AP!BK=**FJ>C),D@?D!X09 M;WFO:PT[UNN63H/`,H&55,"O#Q9.+OP*A8;MB!C$E.W=!]N/Z[,DGIOS:1D? M9P!'E%/@9F6JJ5<*X_$`[6#C@'&N+/+"<&-\Y4P&F`>_VI11/,:\'`O[-CPOD8-RD[I7S*FB7JQT``G,MC@8 M6Z@BE6WW4-&+`;45KY.OES$/QY7M_$2:G5!SG%2'J;!*ZZ'8M]\LO_OVF_IC MZ`)P7/SS.037?BT;H_WHJ#YMMM_$"UBU`)NE0SBJ0/U]=J$L/R8;.J>M*"&U M:V9/?RRP/*9`6E^"@MCSZ>KB,MSC[;=@DJ2U3.S9:C0>VMODQ.34N85@`3-J M9@QZI2\ZZJPC5R[,F28-@5"J;>:=B-8EZ80L5RI[0J284FWTUD%*J]WWJ?B" MPXVV#,`F-HLQB1)ROO/G__E_BXV*KTQ^7?P_XLYLMX[K2L.O4C`4B`1(690H MR382`11)R3)DBRU2\470"#C*;%,\!`_IV$:N\AX-^`'Z*?QD_?UKK3W4KCJ# M9*4;R&`?5NW:PQK_->R5_M]-*-S9="QQ!FS2[YJQ*AG+_$G2']`)!_7\].B: M]::`J-87&T-#Y4]T6#N'N!/J_];CU'QF:0KT./AB#0R3.'MG1048D*("(7>< MF2>L#.M^)4$%)/BSTI(%#,W?\%01!7T]V?+Q8\,X\]:,WFHX-K)O5!XWS5W0 MZV--],X3SN81!;IITY<>F9Z:/DJBY7KL+W(^[9TG]XDP_X$/?#$V^0<;U0<> M]#\P()M7T0EZ*UVV/"(`RH;/DP!*HT/J3^6LSNB?_/J*2`&T\_+R^%XVV.)^ M5,F+R!)0?IVP)3TL_9(*#4V`1O:8M2=$82!)3\XGZW41-BH$'Q$'5]>R-@KR M/?T=$5:]*OS;*XH=9:)'!'I/@'RG[_9#Z MUE1U>EQN2=/:+0U12RY)$GAW-^NUV9Q!U[2'ONOP\?`O;)AEC+)/[I21!&+0 MIW490K;8;I.H>0,'NND+#$ MK4>ER.T%E`&&1^M?L:9P&S.#3TQ])X;?[<'L& MKW>FP%HZ/^4&`#/1U+,G97CQD^UR>-2]+H_"@!7SNL4U[%O`#C`PXPQM6V=A M61[L=:FL*Q!W56,GA<.IB&[!Y&0V&$@LSU4=%Z;=CY>Z>HVG-%;`ANP3=;Q8 MZB(SDQ1.1]$H%.1S2C'G$0I0`)T\;\"!@THWN^5HA@Q?3@]A*0EFKSQD M/BMQ4[>1RA,T"66YNVX>V?299W3#]T4)A?.Z8,,J#F/-%EOC:*H`GY!Q`0-& M+M&\43G*]7*-,.P[<];=)\2R4@TE<<;[V&?:0T3,U*X9LB'9<++^O-A;/]B$ M]9C]E65?XA#G<]#Q9!]Y;/NAPIHZ_/6,3,$32U'+@"-?7W:OCV\F!,:Q?A[+ M^MD@9433W`ZP64SM!U:#;#LTTKTVL%7,]YPI8K8`[--()*[;XF3-M#.?D](%@3`_-="E`V ME/=L0EX?,PIT,19E-K=CJ)+/.DI:CL#4LJ===298EH*A>UV]2]'AOMDE2!Z_ ME`^E!`V&T2WH1U<38DO0(F)=^Z>8D0LS45(@WY(V^O0)DW7\NO=\:E=8=+Z3V5?Q9LHO)\4:9 MC\V;\I)%QVM;58&5NGX'DN)_:Y)J#/L;K@VR8TCF7)GJP@^2=');[@=$ MO8GA%PX$>*&+==BP8B9I8C;QP/HE,"5Y%?40G=CEY@8L>`]H@9RD/PIMT,UA MA'`NC+8.^TH*?QTCD2$TN;BO'=',EW"HLI:FH\GU.PY!DD%:C'\<`?4$$@.'!RF`(74#,C0JC\,.!3R0'Y[X+\UQI,[-\!LF#'-3K"'X8'@XK7N0 MO@.?B#3['`NM`Z#JPFWN.IO\0P@D!XDI1/ M3LMD,S+DGP-[M6`4.=M%2*`@'NOB%3=W65SHLK2V2LX6V9UTA:EU_'/M53Z7 MT"G6:$3U+K>79X<_T7!>!+!A:\V;AT1A:(,=2AK3"M^!$"M?"F3FL1W8QI=9.^BJ M'5U?!4J!D:I.C:A\"X0="X)6$%`0(>#"&=F_,^B662?_`5*3]LJYQS$YPQJR MGMBFU0FW'G"DV@PIZ1A=HGNFP.?)CFE'TC96X$5-O4$#R_P3ZTX3^.NW/,`O5E MYM/U0V>:Q0AF25B<]49P*H=:2GD&9%_-(,I39EDX,0)V:E><3+GI5P(*$I)T MO&\'\-#DI5_(9WA0J[Z"J,&TC.;A.?9-'4-LX-Y$:N9@6`NA7[\+)<]W-9,@ M!]_9P9#&1HRI;61%1Z=P`'*R9@'?)$:K%6_,W-:2&@/X^B@[&'D]Z61.Q:XS M<8]&:GG&'"5V8MU!:+V5Z\^#8RB:R(5)3*4ZB[2W&,<8E!+4Z%Z0=E<:LFPL MD^@&/>V/,CN2?_00'>K0%$?45E*GD&P=DR&Q0=RG96.YLM:RGI]?`[ILGU\? M/T:<'O.OS$H4#V(A=U`Y"Q&3:SF>`9L`"R`<^/:9UWZTD MHL38-\"X`)^__^9']6A,"B<([O??V"HWI#B@Q/J6G1?=/QO9DO;QA/@L_4R% M;X6(SEO3,-D(-8803&:'^7;][QC1>OL^+MAH9%2>9Q%1UNB/)SDFC>:$8\E; MT/>Y8.`3@@I(GS`XDZ@4-4E.5RN6TOST`DP?J4S_O@`3PB\SRV"!.2+LM02* M78?UP$VPQOY-AS,N0`9'%O+(+#HO-HSQFA-,568S&+;(*3^GS'5!RL'%P=,0 M;IQ!CQW\U=Y/2FA3DSO7-OTY&7V\UO5(8F7^)C')T!+_UE(1:Y,(!@DRD%_4 M)?%/;KYNA+P:8XR`=UUEAAA)Q()7?.H!X>+JY-9PS\`!^0)(&Y]D)FYT:';: MMKZ;T'=RO_:`GTCQZUMB,(C;:T-K37!\_?7^6A<^+H.]-,V&^]N]H%F4Q$"X M59*H*9/!E&R$W3R9L-8%_>0=QLS&FZ:`O,'&CTPM3HK`$>%(D&4#P90U!I=) MS."%I@8],E[(UO#[7U)(^`$+]]C5#OLFDT^"1O<"#;@++6L^3=_$OU4JN>W> M.)AT(I$^YI_S$4:H2XM4NBTQYQ#T3/`4^EX^RYK=FWI`4F<0U# M7RK`SJ:DB4=MO+XVI%U;A_X4QD5(I2*2XX=9WITK6SP<*2LR]NB`:1.CER.KU_#@@?Y>P\^3(^6LHKNTMEO!4,3:%6^+4FTY M^6GN>J99VK&A_2FCFX,KUY]AH/(\81V[B1=&N0?395^<0(&(M*((`WE<9#N, ME>P,':1HHN!R[(V%']1M-L=_$NB<7LM(2':Q@C*8UC"Z$O@+0(?!%<:S4$4F M!-E%/6+`1M->"NJ/*D1=),WZ_@M?U@*$>0*VGV%,C(8P^%OIU%&`%"=V-$HO MMW3`DONG[^Q[FLZN4@8($/#2]ZA`61P"Z.70MA&G[SSMA%C_1PYPP)DD41"2 MQVQ2W>YUI,"DW(*I3X[T8S]"O]Y#P4%(>W*5)XY19-X.9I2%D2,0+,Z,T+`( M]!2;#:](0ZF=K80N_?$=>@G10+C.P%3L@>N;G@@U6TSW"JB#F5D.@IQQOPWN MDU"X[E8RNF;B%<[1M[;MI=U<).YFSO6JWQJ.,H-E5$4'1>C6)6":F$S:GJFB M!7AG%Z!I.B8-BA,SH3FO-`A/">X?]>3W'?L\>,_V62>;/ZIF:_ME/=/Z`W)22@?47.PN2,V MQ,6A8LW5=#BV$P6X/_L5:IXC6WLE0UC7P-RB9JX3?#8UAJ M3SRF!="G,H#<6]J^YGWDPSN=<:\,VWOGT>:@*.S1OCCJ`1): M0AEU*)X-!(#![*P[AU>IC/P]6:MROBG>[J;,_R9E;VXB[[IP'/]],\W MW<_O+[ZR/+R_?'8%_RBG[K.GJ%8G(775T-R?YW*PK9)OO1\WC4Z[9Q-=.!H> MY^@3;Z\LGB*;>&O_K=G$"J:LWP>Z\K4Q&_UGC_\Y__SIGZ>_JCS@+Y]MW/^, M?SOF"E3SBMZ?\I-^N7ZNA!U[Y(!PSK3[CCJ'-Q-X6'\](TD56\='T`^?V\`W M3]^D(U>&Q#9#Z/)1X'69#]OH6O)0KD.Y51/Z]TQF?._%+'"6?$ZRA[1KW$]Q M>PX4C:XR!\&)5M%JVDM*Y".+]]_*S]1^(@6YI):C-!C7.S":21#=*/F[#V`Y M`!BN;,'E]$P.+I\%4=#WJ+DQ`U7TH!0J38K0KV^/#$H<]C"6S`@.@T,FL66T M6&:$JR/>+('$XPB#5Q$6M*)!_P+R&#BG.XHI/>EV,!NS_4X4!B/MA-"@#2J< MZSUR3\W;-5T"U5Z(EF_P$X.8M6[U:X+GYW9.30P^PIRTW/:*A&#KI M!8X&C^3L%TV@5J<3"@L]"&VF2^R%D=A:,O[TCOY03$WETEC(2V*1H0L*D;_G M7J<=5.".B#K(P;1[:/X8=_@0>V'"+9D-,Z;<)R+<$&]P**S3CZ+89QR3E@!. M!=X;^;4215$0"B'217W7*QI/HE4>`\JT8;L@94\HXB:I?>2BPK>X]BQ6E M`A7`:QN,GVMRAR5D3O=TRIA=')8N7%UG2Y/I_=(+;U=>X92M=GO8;=9.N5LY MT*D,.PO+#+LE;AVVED3NL9W$SOF%7=G[W>Q!6S%^P#:&66=F$L98#'82@ZD^ M`CI0?MR*G!)/`+9^-/E,:F/=>%P']-%XZ(>A"^%;4?A!`B7-WN$:I, MJ0&7PK-W(^9\TI4!S7#0B%MNQ-A\5)5]_(2!@"&X<#;N3F\9MR[KSNK/(*I#Y?Y==^2_X6RE@$^9X.RA@7LS/>% MOTFM!G`ERXCM++;S'9/E&?&C]!M;W>;,=\HUN<3PTI6`=MO>P+G[C_K6 MPFHW*%'&8H2!X`=W8'7"SAG?UC>7=V^E521&J@GVM@68DW2O,V760(0QG7:= M@MG2A4>S"$W<5-K35V^T@[VH+[U9XF:AF:2]G6["R.2=AFX_*6ZWN@^)MI\2 M,TB]6<&AR$9T3#1=F6XA98_BFN@DA)PQ/K;Q6#F]6[) MF+D_^VHWLHZ8Y&QU.F3$.(G,.L*9+X@;O*-V.YG^J<\:H'UKWV['M:)#>Z5[ M[<50@.U6,-X^_SW%5S]@CZU'QWN7*/;.U$D<7;L=&!5&[N]T=QH_Y>;I_"-WNON^^QO,WVC]D]VF(3W3UZ?=:A M4R@M""7^MU>@2]U+7<'UG^WK>W''L"S*2$/)<)2*]2TWGFNI!I-2`>'NYKM MD^*2C[5?#O3+12764`R/RO-NJOZ$DC`@V[->K`X!;I/*QMN MWM'NVZ49LG*J(4W^%I196C198KG91.J7/_4!M.7RA/ETNXR6:=N_]TRGA9LT MBSL*B1=+K)NW\EWESN/3))52%,Z91)9K!0SJ9#S(MLZ.2;N&5[3F4'XFSRC! M$,TF<>69_;HZ8)#[9&RDY@"RW'/##8N/EIPC=A1^A$7-N@OTD4^T7\]KKT8% M#U;N"D=7_>B)J!IQYA#'I>S%UC.Z?/!*B]K8W(0\JT6GJX!VX+O?-T$):R\Q MK"5QB,6H*2?3E>DF,&#Z57?T&?;!X0T7RF/BF*D`+$WPPM(!5LY7[2H]*++=_JDSHKT M`M*^IU."9IZCFS-T::7_PSD`$X@6_5`XIBOZGR@;8(7_6NJ+DUV'?7`)A'$, M&HX;"0P"*6M6JB6^,'):S41/W$I?MU_U_:47`F1BYAK2MMO_94K$1HYXCD6A MVN[4W99!)0W,D6V'%4]UBY&!!:@4`RMS*P$`7OGA_$C8#&I\?.WE?,_(Y%1' M'K!L[PM#%KZ$U&*B9J6UE&AY[#`^'<&FS$/VP=G>.S$D.B[O4J(F2!>:2Z M+YY*^P?QD^T-%&1)X+P6-$AC&J=N;42!3$IE5OJT$;FU+4#XU/N_:A6;(ZSC MZ`7?L7NU10$S.:@FS%Q$=OZK6[&\J!@5FV:PTC78[XUQBL3@@''(U3)#&/Y= MFN``ZB`QHYH4R(KB-S@DE:AQ.>P%;@2@8>![)CCO;#QX5%JN]`9#:L*$F$`FH#<&E'^@NMB2Y/UZOT8Q&T73>'[%2HVB24;:XM MQP7Z$7](*!?\[4F(%..\M]T@%G-&^"&%%L0E696:QF,-+@%=+J$.`5%$W%(AO;"IX2J#]-%'.![@%.[W/'VGO^W[>T?_[CQA,BX4);O*9/H1A(_& M">R.7_2C!/*H;-G%8\+!*E*I)94>?)>&D4,6_8F6>Q[[?\P/+W18D2UT*/7, M=B9:Y!]G@Q$27)$UB/V69E@SPF"*V>3)R'SQ,QS%*`.U+_]_!48J%AOGCHUN M(6":TJ;:-:'[\Z7D&?**"*1A!?@>[3O?4G)`_XS!S^.`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`BPC'B-V"`!:N M23W5VN6VC_FPBYZ*U?0NJ:)EKB!?N5]+OTZ(BU0E$'GOGV81,OE[5RPZKCZ$ M[K(L\2\H7=NC12.?RL?W"7)TL@X>7<\?$3AKM7=O>8DA1W3@)74.)V"FD97U MSH/$0>,Z8OC<@X>CG)8??)@&W!Q][@]F*N5-[5;>%/XQ!35'*!SP\%=EJK$4LM4+(`9A^J"T<:"G.!,CI1I9GG.W*4MS-X"M=! MR4K62$XFF])?"-IJY'$@,34TKM[(#5ZU*S@W)0TQQJ!G&H`-45N*,VG5I7D; M2Y2ZTARY'&SHGKN9/)^?F34U<"BWE]I5]NV`9>'.)6MM/UX&Q0?:VF5(E$([2K\.-=&+VK@*)7#1:WP8'J<%@25 M2^QG%22V^7PZO7GZOP(```#__P,` M4$L#!!0`!@`(````(0!SIR5/``,``&T)```8````>&PO=V]R:W-H965T&ULE)9+;Z,P%(7W(\U_0.P+&`*$*$E5J#I3:2J-1O-8.V""5<#( M=IKVW\\U)@^3-$JR"!`?'SX?/V[F]^]-;;T1+BAK%S9R/-LB;MXSC50WC?D<3G.^\ M^X<3^X;FG`E62@?L7`UZ.N;$35QP6LX+"B-0L5N2 MK3BZMT3%MM\X+7[0ED#:,$]J!E:,O2KI^G?@9^B<@A4;!Q_%`YY:P&`/BV&JJ6!B2"W_OKEA:R6MA! MY(2Q%R"06RLBY!-5EK:5;X1DS3\M0H.5-O$'$[@.)LAW_&F(PN@&EV!P@>O! MY4H45P^K3^D12[R<<[:U8.D!N.BP6LAH!L8JG@!"/A\/Y*+Z/*A.?5=0"YC3 MMV44S-TWF(9\D*2G$M]49&<4T[W$!;P](\1VS'B938D7-GP?V"9[VQX_U9*D M!_<<#YG-V:?-!A2$=3V4$H^@0O.MJ99$/13R^H^IR"XI#+3)+6A*/$*+S!>G M6C+1>9EMV?DV`P?VR?5)*?$()S9?F6K)>9SS;09.=`N.$H]P#HM4KR8M^70U M?=IL0,6W0"GQ""H99:0EQFKR/%.37=88>*H:'IT2EW>@$IMX\>C5J99HO`F: M!LB+1[.&0#WP'!"7C,G=@RK( M^S]*R_\```#__P,`4$L#!!0`!@`(````(0`Y#`BD"@8```49```8````>&PO M=V]R:W-H965T&ULE)EM;Z-(#,??GW3?`?&^"3,\1TU7"ZN] M6^E6.IWNX34E)$$;0@1TN_OMSS.>9K!I4WC3-/$?\QO;8Y/)_8'77^Z?V^Y; M?ZRJP0$/YW[K'H?ALEFO^_)8-46_:B_5&2S[MFN*`=YVAW5_Z:IBIR]J3FOI M>=&Z*>JSBQXVW1P?[7Y?E]6GMGQJJO.`3KKJ5`S`WQ_K2__BK2GGN&N*[MO3 MY:YLFPNX>*Q/]?!3.W6=IMQ\.9S;KG@\P;I_B*`H7WSK-Q/W35UV;=_NAQ6X M6R/H=,WI.EV#IX?[70TK4&%WNFJ_=3^*3>Z'[OKA7@?HW[IZ[D?_._VQ??ZM MJW=_U.<*H@UY4AEX;-MO2OIEISZ"B]>3JS_K#/S9.;MJ7SR=AK_:Y]^K^G`< M(-TAK$@M;+/[^:GJ2X@HN%E)C5&V)P"`OTY3J]*`B!0_].MSO1N.6]>/5F'L M^0+DSF/5#Y]KY=)URJ=^:)O_4"04U-6)-$[@U3@1"NH>< M?G^0T?WZ.Z2A-)(,);'K6`E5Y*\HDJMD#7A71@C;AE%D ML0E6M`1+B1F69%@H02SI>S&SY\0>^*&M0((%VV1^M)288=G58F&C!+&$'P2\ MNJ@]#=[8=VH&+NX-ZB*&%["HH03Q?%^P$LR)V4ML3$G,4@IW>T\J,8-B,>"".(TM65(T50KGH^&C9N@V34;--28=,8B9>RYF-W]Q:+V MK]6TU@*[:@.'#3[0G381DTI[,=L18C<2C=NB$:`>R=@.#5@M949CXA9.:PU] M&'3/7DZY%LT`,1T"@6U()F2DRXLP#%C#RXT7))=>&'BV&BG<`2EAD-I.VJL0G3_/E-"<5C$^&=;3H=!3PRF1@W>^A;K/7EU!X'UD[!%DT# M,1T'?$1F1F.*S8\CEO6<"N(DM=NE:HWS^ZY6LW06$O-C`9[ M@YP\S81L? MLX5\$DC4(!L,4-XVJ#T0UD[!%LT!]768S0'>YS.C0;#`@_,47F;HQ)19#/WV M*J!H;!3,^_(KIR,A9,TA,QJ2-]:9\]L:"KIH+,CI6!A%P!0>:@C@-4A:DALW MKTLH'AL+*HX!Y.#V>)#3\1#:&C*8J,%MRPHT-PZXD:*QP:"/?[SWV:83@K?9 M3*(&;P\/W3Q\U/Q&IU-G+?.WK5;33C?Z2HDA,QJS.X(X\'GA484?"=]N(!(\ M?]&$T&H&9QNI@1M/B#L9)''"LVK<(/^=#.&,P4HH'IL2\\K.5U'340PE5 MGY\].7REIN$;?=LT9*C!\$'T0I_506Z\&$64^*$M4@JG6OD(;F;X<`",QQM_ M?LO@T%DM!$^ZY&M/[53QVE,[GCKC>6I3=8:,.RJ\_8#S\#P``__\#`%!+`P04``8` M"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]O MVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IA MEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.( MH4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ M)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7" M-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9 MVP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51 MK;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P M;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@. M<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$ M'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z M@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6 MG'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J# M[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ M4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_ MJ]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+ M:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&W MUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1 ML;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8> M\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D M-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ M;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF M_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+A MP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[ M.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P M8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965TVU!5BC+,]F%",S)5OTFA_IC]_MOD0O./XD1( MJ8!"5DS54UF>Q[I>1">2AH5&SR2#G`/-T["$U_RH%^>D4O#_./S_!;1]`P2 M[W$2E]^5J*JDT=@_9C0/WQ-H]R^S'T:U=O72DD_C**<%/90:R.F\HNTVC_21 M#DJSR3Z&%K!N5W)RF*H_S?%NI.JS2=4__\3D4MS]5HH3O:SR>!_$&8'.!IN8 M`>^4?C#4W[,D**RW2GN5`7_DRIXUB0^GDIPVX8&L7:-]]\N*2+H M4)#1>C93BF@"%8#_2AJSR(`."7]5STN\+T]3U1IHMF-8)N#*.RE*+V:2JA)] M%B5-_^60>97B(KVK"#RO(J:M]7NV,WQ%Q;JJP+-6,5]7Z5]5X%FK]%YN$#2] MZI7!3<32S+XQ>*%3G*L&/&\5Z0UMTWY%!89I51-X-BI/^S*Z%C;ONO3ISM!Y MI%2!YX9E.)OD]*+`8(98*,XAFQK,,5.N0XX'2!.$_Q>#$'Q,Y2>3J<0@O`H8 M-U\SB)>)_@7!'EV9>9LQ16)1$RRRF:PK)RSE!$].6,D):SG!EQ,V/`&L;2KO MV&+-MC52URRH$VYEI,;L:H(->.CLIL=A7+5ZW(*IXO$@KSN8E1([N.>(=9P_ M0$1BP8G[AO8M0V3<-M.3C%RB'_(>$)+(Z@$BUF3=)NRAU,E^FY%KNWF`B!_: MM@EG(")!&^F)Q*Y-W(D(`0"C3`B`;N,9S8RO(V]>)]PBSW9&8F46G'&:0JZ< ML'R@,I1"P7N"63U@!E)@KI]@_">8S0-F*-FP?8()GF!VW8S@)RQ.@I]L"L4' M-"L%W-VD8P\MT<8Y9^!_,S%)\](")5R46**$AQ(KE%BCA(\2&Y38HD2`$KLN M0C`>-A:"\=T#F=%3%::)FYG#OF0X9_K5`BI-=8LZ[ZZ\6-I%B25*>"BQ0HDU M2O@HL4&)+4H$*+'K(@2K8>_X@M6,EJV61NZ<,Q!KMW`0[5R@A(L22TZ,K"JB M#&T@K6N>E.](`;E"O[!&"1\E-BBQ18D`)79=A&`V;)!>,)O1HMF6M->9L1DMFRWM;>>- MV]S+G>>7;?S.(R7YD2Q(DA1*1#_911K;:C6I_(YO8X[AN`_'+2D]@+N_1^F+ MWAC.6VW>[8WAV,5._XT0W-6=PR/9A?DQS@HE(0>H@J$YL`W)^6T??RGIN3KK MO],2;NFJGR>XE"5P)6)H`!\H+>L7]H'FFG?V'P```/__`P!02P,$%``&``@` M```A`+Y%Q2(P!0``H1L``!D```!X;"]W;W)K&UL ME)E=CZHZ%(;O3W+^`^%^"R@?:M2=4>1#)3DY.1_7#%8E(]8`,[/GW^]5BHXM MA@4WP[CZ\$+7NRBEG?W\E9V5#Y(7*;W,56.@JPJY)'2?7HYS]=]_O!]C52G* M^+*/S_1"YNH7*=2?BS__F'W2_*TX$5(JH'`IYNJI+*]332N2$\GB8D"OY`(M M!YIG<0D_\Z-67',2[ZN3LK,VU'5;R^+THG*%:=Y%@QX.:4)OYZAW[\, M,TYNVM6/AGR6)CDMZ*$<@)S&;[39YXDVT4!I,=NGT`.6=B4GA[GZ8DPC8ZAJ MBUF5H/]2\ED\_*\4)_KIY^E^EUX(9!M\8@Z\4OK&T'#/0G"RUCC;JQSX*U?V MY!"_G\N_Z6=`TN.I!+LMZ!'KV'3_Y9(B@8R"S&!H,:6$GN$&X*^2I:PT("/Q MK^KXF>[+TUP=V0/+T4<&X,HK*4HO99*JDKP7)NF/T[@YTO,H)'&\BHX$YM)QQGZ38M8KS MK6+U3PH\I]P?5AFU0<-!SZP8=Y*]ADU&NM=-DVBH;)N,9=OBE79-1KI2U$9H MX/G=>'C.>QC/:&8\&WQ8)2QY`*YV=]FRI;RL.C#N,T;JT_H9,Q(SXSUC3)'Q MGS&6R`1-QAQ)UPH[,)L.S+;)6+8CWL^N`Q.U,X+K\(3W<)W1@NL\P%\!R9J9P3SX(78PSQ& M"^;QP(-YIF^"\>V&,WJNPF#Z;:8C34N6G&DS'"5<3HRKZ9-MZ[I45.O' M=L?4+:G=$]IU1V[WA?9AHSW@[2U]"%%B@Q);E-AQ@N?!-!MYB'C[Q*P2-3*M MAT0)+L-TM(?+C)9=EB8<2\ZT9&B%$BY*K%'"0PD?)0*4"%%B@Q);3EB55:9E MC.0W(:H0M1&"W6S5H_L7"Z-ENZ7YW)(S;79SPJZZ9T`A-HK51376*.&AA(\2 M`4J$*+%!B2U*[%`B:B,$PR>2X>SU;:.O;W:6;+ST0;#D3)OQG.#&LQ&H:3RJ ML48)#R5\E`A0(D2)#4IL46*'$E$;(1AO@,D]'O4*%RTW1]+WW;*&VCS'$1=' MUCCBX8B/(P&.A#BRJ1%AB),F'EM<9H.(AR,^C@3/$$=:.`J?0>*7R@9'MCBRPY&H%1$+@*UL]"@`OA`B MSN"E!94E+.2S*N'33LN9.(TA?54C+>ZZ.++&$0]'?!P)<"2LD;K3XR?OL0VN MLL61'8ZPG11FP//L_2^0_-B5GLL M]P;8(+G&1Q+%^3&]%,J9'.!4?>#`QV/.MUCXCY)>JU7P5UK"UDCU[PFVP@BL M;ND#@`^4EK&ULG-M;,)*\M4H'OW^>CJT?\24]).?'-NOTVJWXO$OVA_/K8_O?_[+^&K=;:;8][[?'Y!P_ MMG_%:?OOIW_^X^$SN7Q/W^(X:_$*Y_2Q_99E[Y-N-]V]Q:=MVDG>XS/_STMR M.6TS_N?EM9N^7^+M/I_H=.QJO=ZP>]H>SFU987)I4B-Y>3GL8C/9?9SB/]KEYS>>8GGP_&0_7 M[?.1+_=/UM_NRMKY'Y7RI\/NDJ3)2];AY;JRH]5E-KI&EU=Z>M@?^!*(U=ZZ MQ"^/[6]L$K%QN_OTD*^@_QSBS_3F]U;ZEGS:E\/>.YQCOK;Y=A);X#E)O@OJ M[D43G[A;F=K*MT!P:>WCE^W',0N33R<^O+YE?',/^!*)!9OL?YEQNN-KE)?I M:`-1:9<<>0?X]];I(*+!U\CV9_[S\[#/WA[;^K`S&/5TQGGK.4XSZR!*MEN[ MCS1+3O^5B!6E9!&M*,*G*(HPK:.-!VPP_(,JPZ+*Z%I%__,J/-CY`O&?95^& M?U[%**KPGV65_Z,OC&].N7:O=9JOWJ[<5/F6-[?9]NGADGRV^.[$-T;ZOA4[ M)YLP7KGK*$(U)FPD=%3M]Z&@#[M9DA`;T@J1'6=4,*JD["*`Y[.CZWUH153*:&E M#3/:8-*&.6VP9,-MW'1FJ&O&;F"J-L0SY*54Y]XFC2 M_^V0N3P%BJGX4>?F/#/0QNK"3*7A7?DZ%Y%#]PP*$XHY%!84-A0.%"X4"RB6 M4'A0^%"LH%A#$4"Q@2*$(JH32HCYAZ5*B/$I44SUV.;GW6M`-7+VFDI3%V(H M3"G&^0!%[^5?ZJXRAS4L*&PH'"A<*!90+*'PH/"A6$&QAB*`8@-%"$54)Y00 M\\^>2HCKSZ9"D_#J9$@YE:8NO%"84@SS\++1O?#"&A84-A0.%"X4"RB64'A0 M^%"LH%A#$4"Q@2*$(JH32GC%%51Z%08?@<54-,3D4L!4FKH00V%",8?"DD+N M"/R2H/A2C^(VK.'`&BZLL;BM4>R0I"-+6,2#PH=B==N1<;X^2#_64`1P+ALH M0BBB.J&DF%\^K*08#X;%5#3%Y!+#5)JZ%$-A0C&'PH+"AL*Y(W3R*=N]8]2] M97%'Z.32S?*.4:MX4/A0K.X(G7Q46=\Q:D\"*#90A%!$=4*)LKC:7LDR/B+G MD]$PDTL?TP+5I1D3LR!&/K0P.KV!/(84W\E'XSG10_)_"\_0QL3!Q,5D@3$$T+5!ML6:>& MF$450\^334Z*@9II>AFN0#6!G6%B8C+'Q,+$QL3!Q,5D41!Y^M%89TQ6W%(% M>H<1X.&9^)BL,%EC$F"RP23$)*HE:JC%G00:Z@8C$'D#0@TUO2S')*H--20F MKC+'Q,+$QL3!Q,5D41#Y*=60(RIUG+I4R/#>YS8/S\C'9(7)&I,`DPTF(291 M+5&#S6.G!!N,/`0G0^H^&15,F42U@8;$Q%7FF%B8V)@XF+B8+`HB`ST<]GE> M:9[A:O&4(MJX6L2'8H7[NL8D4.:CCXS1@%PHV"A"&XX->EX*%<&,`:,BJNV( M&F5QB^7V&`VB+._(*,?F/KU@)QZXXWFOC3(D)JXRQ\3"Q,;$P<3%9%$0&>7^ M4!R<:93A:O'P?'Q,5IBL,0DPV6`28A(51*XY-N@;QC5S:IS%S9;;.#=[-H;) M>S1JK,F..2U0;:SK[O44CP-",LN(H@O4U\0")VEE7)8,[9%&0FIU\B8F'B8_)JB#%ZF=\ M>>@2K16BW[O9&N`9;3`),1'OJ_Q^."OC+-]'D6\EG.++:SR+C\>TM4L^Q+LF M_#+@T\-7LWP1)F`3_K@Z?X"^U3-N&O+E2]R2;\_81JN\4F_!V$:KO#)OPU@FJ[QR;\30'>WOU: M8/[>S?OV-?:WE]?#.6T=XQ>^KGJ=$1\#7^2;._*/+'G/7_)X3C+^QDW^ZQM_ MPRKF#WOV.AR_)$E6_B%F\/7.UM/_````__\#`%!+`P04``8`"````"$`1=:N M`4$#``"W"0``&0```'AL+W=O")<4%9%R#%M9)`J82FM#A'Z_>O^9HX,(7&5XH)5)$(O1*#; M]>=/JQ/CCR(G1!I`J$2$0^NQ/SQ6-\D MK*P!L:<%E2\-%!EELGPX5(SC?0&^GQT?)RV[N9G@2YIP)E@F3M54Y\_E)Q$[[LAP[(C3T1\IXJ)#*2HY"L_*M% MSAFE(>X9`M+WB M[&3``(-_46/U.CA+(*LJ>]`K79.N[O\K.]1;0>X4)4(S9$"X@%%Y6@>^O[*> MH+_)6;.9:F;!4+)M):J;BANW"Z]<9QBR:Q5JE,!2YPLZUO=U>6K:])58I=\^ M=Z,7@-WY<8?/W4X5LW`HB:>2$60W5?0@`SLP.GT[JDTAM.FZ+14$[>RY"/Q1 MR3=:`[/5.1TIMF\JXC<5NVN*@4](I._SNC\ECA`4L!003A2[@6)N#E.P(<#KDAX4`][']Q=#B4?% M".R.V[Q.&ZV!=+J"!?YH:K>7-+,A)[ZD&7%VES2OS1GX##_B4XG'/D>;PD9K MSDVW37\>#GJX&-K9CN2!'?9GQ![1XY'<7[C7Z'!&JH2[9`)G,:"_SI^NB3X0 M]1Y=$GX@6U(4PDC841UV:HZ[U>X,R?9& M;"]@"*2) MDJR:5+U;Z59:G6YWGQUP$JN`D>TT[;>_&4QH;+(I?4D"_/WWSS/V,%E\>:U* M[X5)Q46]]$D0^1ZKK_T?_SW='?O>TK3NJ"EJ-G2?V/*_[+Z\X_%2^!0JZ5_T+J9AZ'*#ZRB*A`-J^')3LB*:KB4^U`UDM&B'52581Q%65A1 M7OO&82['>(C=CN?L4>3'BM7:F$A64@W\ZL`;=7:K\C%V%97/Q^8N%U4#%EM> ME<^_[FLAZ;:$=;^2"CG]H,?)=>P7;T6.I_Q>EOQO<'#>E.846XL'GQ]LA4#A$%FR!N M,7)1`@!\>A7'K0$1H:_M]XD7^K#TDRQ(IU%"0.YMF=)/'"U]+S\J+:I?1D00 MJC>).Y,$Z+OG<1#?IR3-/G8)#5&[P$>JZ6HAQIG%!0C"H8.V=;F!GCW;+$S[U`QS7J)10(1NB3!:"6PFVX3X:"E#Y/T M`$F:]/X&TF@F%YK45FQN*2Q&,+EDO,V&8EC#Y;QI9,^\-II;;+<4%AOLK/%L M*+;CEJ;.EED;3=9N.4*FDRARZ#=&<9W>8LL^PX9BFRU)G(RMC<:P9=D5-",8 M@08':WS84.R@I>Y9-!J#=C?)TF'8C&($&[[C+@K([>V&8HTH]\"ZQ:03 M78=HZ\WFIL0Z%@2K\N@$MVHWBFZ&.]&L/;4Q"9*I77$VG>#Z`FPZK-WCZ4RE MMTKQX-@2(^KI[N]=.DN0!.1=8+-AR1[/9@J\Q38XM\2(.K8HF+Q/W>75",9$ M#C2?H$.UG==D<'*)$75T$!@W<.8Y?/9OPO>::8?N4R\*;,4+83OW=_N^]"'&3L2YO\9^M>TX^P?0+C9T MS[Y1N>>U\DJV`\LHF`*5-`VGN="B:9NVK=#0*+8_#_#'@$&G$P4@W@FASQ?8 M1_5_-5;_`P``__\#`%!+`P04``8`"````"$`$U=(DL$"```2"```&0```'AL M+W=OV&6;>OLJ)",=QD. MO0`CVA6\9-TRP[]_O3R,,)**="5I>$^+XN:MD1ZO*<=O*FX:(F"I5CZLA>4E":H;?PH"%*_):S#EC`6MS!X5;&" MYKQ8M[13%B)H0Q3XES7KY8[6%K?@6B)6Z_ZAX&T/B`5KF/HP4(S:8ORZ[+@@ MBP;R?@]C4NS89G&&;UDAN.25\@#G6Z/G.3_ZCSZ0II.200:Z[$C0*L//X3A/ ML3^=F/K\870CCWXC6?/-%\'*;ZRC4&QHDV[`@O.5EKZ6^A$$^V?1+Z8!/P0J M:476C?K)-U\I6]8*NIU`0CJO_K6B<(NRD&@+@?L6$B9>'"7#T3V4 MP98"]QTEO)\2;REPWU&B6Q/R;7%,K7.BR'0B^`;!_$+ZLB=Z-X1C`.LB#Z!5 MEXL,U=4QSSK(A():PF"\39,DGOAOT,UBJYF=:T)7,=\I=.LT-C]ZX(.]O4=9#K,1JZ!F87)*YB?JZ(!X&KR<\UT6@O M:PHVLQIHVT'C*N;_5>37%(Y[^)O;W6MQAJ$T!V=)ZGJ;64?A0/7UMQY.SS9W'#L:[R3^C[>FK;'NCUJ>K*DWXE8 MLDZBAE;0S\`;0M["'NIVH7AOMNN"*SB,S<\:OKT4#H;``W'%N=HM]&=C_S6? M_@,``/__`P!02P,$%``&``@````A`+UTF\2+`P``0@P``!@```!X;"]W;W)K MV#C__^3CD4+/Z^%86P2M76L@J(704 MD8!7FP9N=5"4S<*OVH:X59WDSJ"S".(IF8?2DR);7B#//VA1/Z7J#AD&];)L.T_O."9X3FL'`EP1;92 MON#03_`H@B"Z$6`0_=\ES&.,4<(V3/?Z$O*Y6;;/*LCYCAT+\T6>_N1B?S`0 M:0IIP&PL\_[-T(C>'A(QGH^D\&E.0 M!UNNS;-`2Q)D1VUD^=V*Z-G*FL1G$_@_V?J7D*8#M"9RZ9KC9Z1(,;V-6X8!`%H:#H!AV M0&>^D];5DEG%I*.8NHKT1PJ'#$R&DZ$X(3#K=B5F;MR-573)YJXB[2NN[`X9 M[/SA9"AVR1[G5>!F[/&P?.J);VAN<>' MA^_@A:7VJ.X>(=2KP\U9T^6+O9));VCN\>$A/9S/'NE=OMBO"OPRP@YP^/R2 MO:&YQX=']7`^>[`[?'YET/[A'_NE<4-SCP_FV>7#WF8,>_(G7W4[#^!K` M5@FT<7X>/0EV>BB9V:,Q>EA,9O.KQM:)[=!L`U)RM>%H>W3 MMH4\]W;M"VC&:K;G?S.U%Y4."KZ#H=%H#I\$9=LY>V-DW;0W6VF@#6LN#]"K M&PO=V]R:W-H965T,X<^\P9QEG< M/-65]4BXH*Q9(L]VD46:C.6TV2_1[U]WDRFRA,1-CBO6D"5Z)@+=K#Y_6AP9 M?Q`E(=("AD8L42EE.W<8PF/?.^(EA.<=TEUY?BN&SLU MI@W2#'/^$0Y6%#0C*,XUT%NI^\$&<]=_=P15_3C#/!"FD#G:,/>JUYYLP<8%HM M<@H*5-DM3HHENO7FVQ@YJT57GS^4',7@MR5*=OS":?Z--@2*#38I`W:,/2CH M?:Z6(-FYRK[K#/C!K9P4^%#)G^SXE=!]*<'M"`0I7?/\.24B@X("C>U'BBEC M%1P`/JV:JLZ`@N"G[OM((&'L"M'1'RCBI*9&4'(5G]5X.\$Y4F M\4\DD'$B\7S;GT9>%+_/XN@3=0)3+/%JP=G1@J:!/46+50MZESG+6^ M)A4T*I);Q=)Q@0H!]CRNPBA:.(]0T^R$66M,@JPS)AE!-CU$55#QIOW")<J'/6&C/MNC7R9L'4M&`SC(=A$,W,>#J,>ZZ;Q*,-MD/`-''# MB\>&,##KX\(4V!0V&VV[UI"X_Q>.&GBCPV$7#ORQJ&&RGR2NJ7D[#$^\:72) M&Y+B_Y&DP"-)@;GM6D.T5:'OC9T:AB?AJ![I,.K[\>7(W8B!:T-MK[DG?AQ< MTK4D?2GHF5D3OB<;4E7"RMA!#7P?ZGA>U7?1VIO#((-Y-%I/X8[JUIUS`.Z( M%N_)=\SWM!%610J@=.T$RLSU+:,?)&N[L;1C$FZ'[F<)+P,$1J1K`[A@3/8/ M:A">7R]6_P```/__`P!02P,$%``&``@````A`*,4C9)I`@``#P8``!D```!X M;"]W;W)K&ULE%1;;YLP%'Z?M/]@^;T8".2FD*I1 ME*W2)DW3+L^.,<$*QLAV+OWW.[93FBQME;X$3+[S7?/\T.2F]-S;E%P-":`M?6 M=E-"#*NYI"92'6_AGTII22T<]8:83G-:^B+9D#2.AT12T>+`,-6W<*BJ$HPO M%=M)WMI`HGE#+?@WM>C,,YMDM]!)JK>[[HXIV0'%6C3"/GE2C"2;/FY:I>FZ M@=S')*/LF=L?KNBE8%H95=D(Z$@P>IUY0B8$F.:S4D`"UW:D>57@AV2Z&&(R MG_G^_!'\8,[ND:G5X8L6Y3?1$K%YO:PK1S".1R3O37@RAM M7>#!,,I'\2`!.%IS8U?"46+$=L8J^3>`DA-5($E/)'`]D21YE*7Y:'P#"PF. M?,`EM70^T^J`8&E`TW34K6`R!6:7;`#]>3T91'(U#Z[(EP+:P#3V\RP?S,@> M6LA.F,4KF'328PC(]QY`]^,>7-&EAW34TWN;BVM(-HA[S(6%P:6%]^,[,+0) MHY?X6=KS!NV`R8^X4`;(>?CWE1VXP)"K5TXF_S<^8,9^+$D^RM](#(MW MNZX#7^IF+[,,@0-DZ&6'_C","54O;YX+X9 M_:=\_@\``/__`P!02P,$%``&``@````A`(^.M'+?!P``=B$``!D```!X;"]W M;W)K&ULK%I1;]LV$'X?L/]@^+VV)=FR+20I8DG< M"G3`,'3;LR++L1#;,B2E:?_][G0DQ2,5Q^GZ4M6?CL?[[HZ\HYB;C]^.A]'7 MHF[*ZG0[]B:S\:@XY=6V/#W>CO_^(CZLQJ.FS4[;[%"=BMOQ]Z(9?[S[]9>; MEZI^:O9%T8Y`PZFY'>_;]AQ-ITV^+XY9,ZG.Q0G>[*KZF+7PLWZ<-N>ZR+;= MH.-AZL]FX?28E:?'D]5G3T<@/KJ>@Z>YF6P(#=/NH+G:WXWLO$D$PGM[==`[ZIRQ>&N/_ MHV9?O?Q6E]O/Y:D`;T.<,`(/5?6$HI^V",'@J3-:=!'XLQYMBUWV?&C_JEY^ M+\K'?0OA7@`C)!9MOR=%DX-'0,J1ZYZO.VY*_NKA2?B<-.A*O!0(B@$KN4#D>@8\;R)ZO=_YZ M?C/]"A'/I#"XT)L2&AN"BTL8EI$,W.0U$&$B3!RL%1, MHL\J@6PDZO5&\49/*0 M4I"Y1@PL,Q,Y,#0CY7LSOKS37DK-*-B,/%98YJXG0T61D2$HA/U96^Z'3@]! M4CX\M)2;B-Z@U-KF1U+0]V)'$RS7:\L#0NH)S&W0G(U[`(OA]1Z@TLD\0%!H MQLX/?6YUC*4>\_DUFV1KI:54[%(Y$,H#TO76H9450FFK0MYPMUE&#[8^M M32K&S`D$66E@EWZ/I-Y*`RW5.T&J-[WGKY?F"J!O:04%"GGEN.I?A_QY#J.8LA M058B6TZ./3G03'=S<4F.4@JH&DGI+&62DKD=A*O0FDVHV4#0T-,O`>X8+/P7 M'/.E.D,(!PN/&6K48H6:(!9J#0T;)MU`4D'?TJ10OE"]`0D)D7K."%L%@]$; M22H;"[/6$&1UA':#ZVDIM>(2%TI=2#"(6X[MP?66RV;"M)P@WIE;"11[6J@W MW(%25THPB!GN#W4O,Z@Y[SQ\=WIX&DG("H;-J9?2G%PH=2'!(,[I72V+[[8L M$EKU\8E=*'&AU(4$@[B96-F-G,'BY"\FL(>\U_?4(IB;&]8<6';,]\',ZASB M7JKWO1ZHH-25$@SBI+"D6Z2N.A_YLA?H?;Z1D'E"H`X&2R- MUY.A0LK($&1UQO8!"5M&[!QALS%2RN%'4KS!75@%))6Z0A#N=3F=E92R=/4S M"U2"F1<(LGI+^Y#DRX&P"GO+G>\5O92*7RHA6%_=(6FUL'=VH09! MU@ZJ9G2#H1Z`OFE=_P6C4\)7HX2L7+!/25+JC5SHI;07E'K3?<',2C4AI7C@ M7SLE!>_J'#IIBS(U$]3;=JLTEE*8@(.AH+6LI/I5FKJ04)"[HP98MXV4_:$= MM5-B$:)^P,IDZ]P2JX&PKUSB2+JLCP+V>I:Z5'(OO;75OPLUVW7)_7I#TB7W M=:='9;I!%JNKBDF[-C43\6<7$X M-*.\>L9+26@=[FXT3#>FFV4DNK)BX]XJPM,,K"7GS1K>=%EHO_%G$3;=`V-\ MN)B%/G?HC0]O_($WT!S`F^Z@:,V3^,LHA:+E:H/[W_LA71N8?GAVF&)(3Q#= M@WO="38!7#`/X?-(S(=PX-"U>!:%31C!!8*K/UE'\&5Y`/=F$7Z5'7KCP9MA M&ULK)G;CN(X$(;O5]IWB+@?R`$"1#2CAIRU M*ZU6L[O7Z1`@:D)0DNZ>>?LMQX?$+DC#:&Z:YJ-LZK. MR_/3R!CK(RT[I^4N/Q^>1O]\\[\L1EK=).==40].-4]/LK]/D\SMTS?BNS<4"=5=DH:Z']]S"\U]U:D][@KDNKU M[?(E+8L+N'C)3WGSHW4ZTHK4B0[GLDI>3I#W=V.:I-QW^P6Y+_*T*NMRWXS! MW81V%.>\G"PGX&F]VN60`9%=J[+]T^C9<&)3'TW6JU:@?_/LH^[]K]7'\B.H M\MT?^3D#M6&6?`TT$&;-8!J9PWNBK-DS>#SOC@&C!N5D0P@E6HHTH2.0CNH;M(D MZU55?F@P4T#O^I*0>6GF M:O(.A90RFPVV,62++;<@54/2PE=V'$F[F(>(CXB`2(A(A$B,1](N4."^0#N1-K.7=*IO#1RWVJY"Z,1.Z( M>(CXB`2(A(A$B,1](N4.:[Z4.UU"QW-H,%P"I*$L`R536ZP56T1<1#Q$?$0" M1$)$(D3B/I%RAI5>RGDX46(M)\H(W2"0I7Z+B(N(AXB/2(!(B$B$2-PG4J)D MV]I_/@XG2JSE1!GI5O^M(%VI&S.EU%UJ9,%^0,P'8V;+\\$31GP^^,(W)X$@ M?4=*M%`XZHS,Q5*.%@DC[CL6OH%(HD&W)=%Z,Z(YYNGKIH2LX*E[14P+-@]T M2T&J@F0K)DEX12K8NW*M6G-9+(YZ:G5H(`N764FU9QJZ7`U>9\63\3$* M,`HQBC"*&8*C`5*&[-;NGY$&W=S!IH/W<\.0#0\S,;DL7=UD,"L3]D3""M?6 M=2MEZGC,RB+%_;Y>Z@OEJ>YS`WADW`X67`^FE'-XW4KI4L0CTBX9QM*>RR,< M.*)\&BX`VXU&#_LK'C-14K\V0*IS?I\*[ZL-MF#/J`VW;)* M:E.DS`'E`;,E6W58@S^;`\**I^NQAJS@#=U$'7KNK): M^]SSK>IJYTW`K6Z)TEJ%G15/+V*(QY].E<4TYFUNQ9?EAOB/R$W,E6&7J+:I MXYOA9;%A2"2Q?VJO9A`ORAA0I)2\\AC:\H;0Y=O+KMM9<1$\ALPY'0-3N4'Q M>9-;%<'@-R^GA@?6&'E?[Z0I&Y$$O. MEMRJDNJ&3?J0LLQJ*1IZO&&'?(XZ]T&'!MR'W*KS%6$4<]2ZEY4A1XR^,C]7 MG>R@TA>,(KMWTC8HLF##."08M5(>B4I9>]P7VUU9),'N8;T2F+[FVDP=N(T$!RJ?.7!3=X7;#MQF7>&FSM^7*9[`*3R>5O"_+AG\A`<3KW?7_````__\#`%!+`P04``8`"``` M`"$`;SY0X?X>``!?LP``&0```'AL+W=OQ)FX)HE3MF?FG&^_H)H0 M2/SIEI0]Y^$X\R,(H`F238+=ZE_^\Q_?OI[]]?#\\OCT_?WYXN+R_.SA^\>G M3X_??W]__M__E?['S?G9R^O]]T_W7Y^^/[P__^?#R_E_?OCW?_OE[Z?G/UZ^ M/#R\GI&&[R_OS[^\OO[8OGOW\O'+P[?[EXNG'P_?J>3ST_.W^U?ZS^??W[W\ M>'ZX_[2K].WKN^7EY>;=M_O'[^>3ANWS,3J>/G]^_/@0/WW\\]O#]]=)R?/# MU_M7\O_ER^./%];V[>,QZK[=/__QYX__^/CT[0>I^.WQZ^/K/W=*S\^^?=P6 MOW]_>K[_[2M=]S\65_/ST\O3Y]?+TC=N\E1O.;;=[?O2-.' M7SX]TA689C][?OC\_OS7Q7:\O3Q_]^&770/]S^/#WR_.O\]>OCS]G3T_?JH? MOS]0:U.<3`1^>WKZPX@6GPRBRN^@=KJ+0/]\]NGA\_V?7U_'I[_SA\??O[Q2 MN-=T1>;"MI_^&3^\?*06)347R[71]/'I*SE`_W_V[=%T#6J1^W_L_O[]^.GU MR_OSY?IB?7VY6I#XV6\/+Z_IHU%Y?O;QSY?7IV__.PDMK*I)R=(JH;]6R6IS MLI*557*U5[)87BQOUHOUQK@R8YY*=]=`?]G\U<7UXO)V=3U?<6,KTE^^^,7% MXNKRD,%K6X\&D:UWK*NWMB;]95>=EIJYQ@7UC"E0IHO82!WE[&(?8@G/L>XN M."CF'^SP<6V[H#A.#DM`E\O_AE^>GO\]HNJ,&?_EQ;R;/Q79!RGA,3N'=C]*W!BF-3J/E5Z/F M_3E=!XV_%YI9_OJP6BQ^>?<7S08?K@T0'O*/P[&-$8^%?$2.CQL2(6_>.@01MZ8)%C>9V M+VKA90?/:$9Z%QQNU+N)7-$?)UQZQ.R%N%H,)`&2`LF`Y$`*("60"D@-I`'2 M`NF`]$`&(*-+O%C0;?.$6!AI/Q83N:(_3BQ6:ESLA?:Q`)(`28%D0'(@!9`2 M2`6D!M(`:8%T0'H@`Y#1)5XL:.7BQ6):`ER8]>C\$#$5_;!,Y&JSO\=$0&(@ M"9`42`8D!U(`*8%40&H@#9`62`>D!S(`&5WBQ8!63EX,YAO>2/L-;\FT:S)+ MIPA(#"0!D@+)@.1`"B`ED`I(#:0!T@+I@/1`!B"C2[R&IR7O"0UOI/V&G\CJ M1GK\GLC4M%A?^5-3;(5H:^7,7THHV0OQ_)4"R8#D0`H@I27B=;4GXA!X7>\5 MN4+7_J4U>R'VN@72`>F!#$!&2W9>>T&D9O2"Z,Q@KU\>/_YQ]T2M3*OKP*A: MT69EVL(8)7YL)^+&%D@\D2O:Z.X#24D`OTF2O1`W20HD`Y(#*8"4$W%7"R60B``W4RJ:&66"9HSEHLMLE\F86KX4(L":2]',J!(T8ZP67=:8 MNK)&!%AS*YH9=8)FC/6B*WQE@PBPYE$T$_*[B=D6NRF*P"BFI!L/8Y-"4N.8 MD=L?K!3=%YQQJQHEMA57U(7W4LO%I1K=(L57DR+*$.6("D2E190D8O65(/$+ M9VO1)5+@?2-2K+Y%U"'J$0V(1HLF[_VXFMWU"7&=-N.T6V8_[Q83VM`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`'%MN*! M$RB1XM9)$66("V2D4SHTS0C+%<=(5/ M;0H18,VE:&94"9HQ5HLN:TQ=>B,"K+D5S8PZ03/&>M$5OK)!!%CS*)H)^?.X MR9ZXW>3`/75*MKCKFZ5%;G_8HYD+B6W%`^=1(L57DR+*$.6("D2E14YOK@3- M>%^++I%:ZM.T1J38^Q91AZA'-"`:+9J\]^-*V]=3XFK$U80](2^MNEJH^2VB MW:>I:.:A_P8E%]E1J M`SD[KD+ZY[KI,>9SUB4[EL(WO]:-77*56?,52\U>?2U2?/4-F^=CXZ4Z$&FY MSJS]CJ5F[?OB-AZS[W>^T1*`Y8M)SW82<#&QD MI?F*7DR"5!E#*2?6XF:$9]SE*BOD!4,A+UE:`9]35+B?H&4" M9M3W+"7J!T0CH\`VVF3X_O_3RI0G]*:5";GG44LK19/$7+BME#_?JCMY8G71 M_=IL+@+G46SLKI69=&GR7`N=1K.8ME[QI::4SK?JN>-QYU$Z-OS2SB$8. MSZ>1H+G^:Z7<\RA$J>AB]9F@&?4YZBH0E:*+U5>"9M37J*M!U(HN5M\)FE'? MHZX!T2BZ2+T?[].RN2O,YEITX_;2E3X4C42*+S!&E"!*$66(D0#HM%#?GAT4G8^2;.:\JKN;<,B_[APJ9YGBT1*PC/IHHJ,$I1* M$66(D0#HM%#?GAF4JT'(H7I5>UR(*$:4 M($H198AR1`6B$E&%J$;4(&H1=8AZ1`.BT4-^6$Y+;:XPM4(I'1H&XTF;FE(%NQ%5<)^0T?+0"%%NDXJI< M3T2*74]15X8HEXINPZM$4R%2K+Y$716B6BJZZM5FO!$I5M^BK@Y1S\B-ZW*I MO!]$BM6/C`)Q-6DF-Z%Q8`*?LE+>$G1"7EP!Q51L.H2*JSJ62$2*74\M(4JR8(HMHL=LLI\WR,%[7YT;@3]V=9B_SC M"7W@&EFI`Z>[(L57DUA$BW.31UQ=W:H[;LH"M(3;+RE@X9&AYER06U%-G865 MVK])>*%GO_(H!ZJP-34=U2+%#=#X#EQ=Z`9HC[+?B6;W:I7]7J38_H!H])#? MG4Y+_]`3/'JT6^2?N*[4*CCBBK-!CT6*KR:QB(Y6=MU)OUR>%:R95FK54L-7NQM4CQQ3:(6D2=H)E+[D6*U0^(1@_Y M/>.TS-,59IXL4A.-:M+(2AV::";U),57D[!ZMY57^D0PM5)F.R+]8Z.F\TR< M8/4YHD(LFKZX6%Q:L=M\A5OI]\Y0K M>@,=NXWU7N:0G"L**L3BKMNL+_29?/";GG2%;*',KN8PJNQRPE)[L)HI21K%XS M1#DCT54@*AF)KDK0C*NU2'$K-XA:1)V@&?6]2+'Z`='H(3^(U`6]1>A/;1W, MD82.[83\6X9^^3ZR%+6-"O#9=7ZM9)67-)/>VYHREIA]D-K]2 MEEND[F+J]E!8*5Z;7EWHARI+5CWK0,52LPU0BT\M=^Q MU*S]7NR[C:G:9&!==K]PLX37O%GB+9_\KDESZ&S7/.[\F@YAH&].R)MW]LB] M0M6FL=5%F3..0X(HM^/3O$+"4K@,0B^VS- M\EIW\93K4']Z6W/&4I(RR1GY8T.-L8+M3YLH6KC>JCY:LIY9!RJ6FFV`FJ6D M`1K?@=7%K?*PY3JS]CN6FK7?L]1LFPSLTO2\TVI]NU0W@Y'UO.63WS5-]G*N M:QXY[TQ)4*]O3LB9&**K/9KI+K&5\N:=J:*#4M'%8S)#E*.N`E&)%2M!,Z[6 M(L5.-(A:1)V@&?6]2+'Z`='H(3^XH53I^L M]8JE9A<;M95RKK[QK5,B3AV#M*QYUG['4K/V>[$_TR`#Z^+%#OQ8XL@2;_GD M]KRI6 M5^JD-+(528K]C!$EB%)$&:(<48&H1%0AJA$UB%I$':(>T8!H])`?GM/RHVO, MCUJDPJ,&5"12$IY)EQ.Q!*521!FB'%&!J$14(:H1-8A:1!VB'M&`:/20'QZ= MGCPP>C`/N9Z0"H\^V!`I"<^^(J,$I5)$&:(<48&H1%0AJA$UB%I$':(>T8!H M])`?GM/2@&M,`UIT(^^G1XAB1`FB%%&&*$=4("H158AJ1`VB%E&'J$"[@^GW&B,N+K13$@-%7W2L]Y+\;B($26(4D09HAQ1@:A$5"&J$36(6D0= MHA[1@&CTD!\>VG]ZX7$6>0H1S0@&CWDQ\*D-4Z(Q90%<9,L:YL8D9.:2)"LGO%0B:5H M/RQK;/TKA8E(\;!+$66(%\AJAEYKNI?D6Y$BEUM$76(>D0#HI'1 MSE4_B":EX`;1F>>.3[*LI\2$%]L).0^?15;*0;%%YE&9?2#Q"Q@BQ:V3(LH0 MY8@*1*5%CE\5HEHJSKC:B!2[VB+J$/6(!D2C19.K7B`WA[(21SU8N-/B3YB, M)/\="7*;0NVA8BM%#[N8$_C`]S!$@-LJ%ZZ$`%64Z*:"E$M M%<,^-R+`FEM4TR'JI6+8YT$$6//HJ?&C?5J:8H-I"HM4$E1EXR,KI4Y8(=*3 M>B<-F+!ZFX2D[X'Y:8:4:.- MJ05W>Y2M#A7WB`;?UN4%_"+$6-^ISDM>;+!Y(E%_HG=6CUO'7%%VGDXDSIT M&JM>%F*)K6@?.Z2#^MM+]W]*0\IV:"G]MIV,I<1.CJC0II9:Q#S3VBP3>VIH-M?]8>#QGS>XU.2ID5J/DT.W$ M_>C/2)MNHW9[%ODYDK4ZD(M$BJ,7(TH0I8@R1#FB`E&)J$)4(VH0M8@Z1#VB M`='H(3]R)K7D[AWF-^,T["`\$_)_Q6"M^FYD*Y*4A&=?D5&"4BFB#%&.J$!4 M(JH0U8@:1"VB#E&/:$`T>L@/#TW:IX3'B*NE_X34Z%&WX6BSE^)8Q(@21"FB M#%&.J$!4(JH0U8@:1"VB#E&/:$`T>L@/CTYE.3OO`P,)LUIF14;!H1S0@&CWDA^6TK-8&LUJ,9+J*$,6($D0I MH@Q1CJA`5'K(OV:=!#K0_S#;L\%LCZ"9U7G,4E1_OX9?K=5F,1$IGF)21I)] MRQ#EC#SU\&L!(L7J2T:8,:.?`CME6MV)^].J14Z^*4(4,_)=5VOA1*38]921 MTS*(K5&+42*U9>,`BUS6E+B&I,2%GDM,TDY*&8IWW5U6TI$BEU/&;DM M`^ISEO+4ZZ_R%B+%ZDM&@98Y;>=]C3MOBYQFB!#%C.0%B011RLAMALFBHSYG M*;<9EOJ'\PN1DF9P=7GSS+79.+D+1N>6=WRR>:=%C:AI1^:X'UDI!\464;*9 M?4T0I5@Q0Y1+17?>4OO)0J388NGI\EM';X3F9^%KW.U89%;LSF2J>"W(IJ6UE8*5KQ[E*HBPO]WF%Y MR`&_OPNV-!]I[VG*X9QS7$S*+B?WUKN`M7"ME/J:VEX)6B45*VGM2;]-A MFPTTM_6(UM]O*\Y0<8ZHL,C:6BXN;E2W*;G26];\MC5[@A/:=MI">&T[(=67 M59>(KB>I0WUY+R5M:]6[05EM5"8SM>J]?-`"7D@4)UA]CJBPB'OOY87^`'`9 MM.:\D.BW\,SVX82Y%+<2UQ/R.[6^YLA*'>K45KTLA1-;T7\35/_,>\KJ*4K2 MM;43&4N)^AQ1(19WT\;J0JVA2J[C&7NSW4_;'USC_L`B]RE?0<[E.AY,/XW. M4N[=?5)//S;*72]E*??N;J4$Y2PE%0M$):/`BH:6!=X`_[E;N=&B;N43\L?] M1J>$KB>I`P_G6RDW!1;]Y3MN0W."&Q"(_`Z9OQ)%(\=7$B!)$*:(,48ZH0%0BJA#5 MB!I$+:(.48]H0#1ZR`_/:;NB&]P56:3"H[('D4A)>"9=5)%1@E(IH@Q1CJA` M5"*J$-6(&D0MH@Y1CVA`-'K(#X_>KT[:+-[A=M$B-'K6'C41*PC/I M\D8/H!0K9HAR1`6B$E&%J$;4(&H1=8AZ1`.BT4-^>,SFS-T!F5OS3QUKFN&C M%DD6J&_)G+3)M/=UIH?6C0'-=3H^XW-:J-6B9%(2>3V%1DE*)4BRA#EB`I$):(* M48VH0=0BZA#UB`9$HX?\R.D]\8$[%FY^Z8<137AHUN56CA#%B!)$*:(,48ZH M0%0BJA#5B!I$+:(.48]H0#1ZR(^%WB?__/R'6^B;"?FCZ%IE;R*1XF#&B!)$ M*:(,48ZH0%0BJA#5B!I$+:(.48]H0#1ZR(]<:&O_H1#8A&#WF1NPVE`WXJ' MU_C^]?[#+]\>GG]_B!Z^?GTY^_CTYW=:'RSH@^`./WM^^/S^_.YFO37+%VK@ M?0TNV5#)[BTS*+FFDMTC_%!R0R6[!!^4W%+)+D&H2VXOM^9B`AYLR`-ZYB54 M0AY04CE0K*D. MO:H9*J&VIK<$0R5TI?2B6J!D0]HH?QDJ(6V4^@N4+*BM%\&V7E'K4)XS4&=% MK4-?20F5T)72,5V@9$W:Z/7Z4`EIHS>[L82>A=B:8TLL^76Q_354XXZ,!&V0 MB9#\KZOMK^'N9*XC8/B.6CC8P"9:(7G3*T-\09U_$>K\=%B\-:?#>-'TY,G6 M'!)C"3V`LC5GQ5A"SZ%L"WJD)%!R?;DU3UF$2A94$FI&.IJGDE!#TK$TE80\ MH+=QM@F]3Q*P0R7FA1DLH;=AMN:%%RRAMUFVYH45++FC*[T+>A!1B3F5QSKT M$!#Y%FH=>@B&HA"R0P^!4$FH=>@A""H)M0Y]'H.Z4\C.W?IF>T?O5J%O]$+B MUKRXAB4QE9C7`D,E%.U@'7IG<&M>-\,Z].K@UKQUAB7T!N'6O-,7*KFEDE`= M>N&/!D*HA#Y*LC4_FH[:Z-LD6_/;Z5A"WR/9FJ^-A$HV5!(:6?1-!"H)3??T MJ_I4$KH>^IEV*@EY0!]OV9I?DDWBI#]B&X4(1[3$`Q=7TP#,"1? MTBTBQ"NZ0>SXNWT'?_GPRX_[WQ^:^^??'[^_G'U]^$Q[ADMZU_+\[/GQ=Y-P MF?[C]>D'[27.SWY[>GU]^K;[YY>'^T\/]!NZE^8]F\]/3Z_\'S2$W_W]]/S' M;E_RX?\$````__\#`%!+`P04``8`"````"$`K^,P/* MVC8CQ+"*2VH"U?(&OA1*2VIAJTMB6LUIWAV2-8G#<$$D%0WV#)F^A$,5A6#\ M3K&]Y(WU))K7U(+_IA*M.;))=@F=I/IQWUXQ)5N@V(E:V)>.%"/)LH>R49KN M:HC[.9I1=N3N-B?T4C"MC"IL`'3$.WH:\Y(L"3!M5KF`"%S:D>;%&F^C[/8: MD\VJR\]OP0]F](Y,I0Z?M)8 MC[GU&'@.F&A`$!`=E$'MM!L MA)F?EP;(Y1$Z<"<]A-A;QD)).CLO!5TTEO+MF03IFRUZ+*D[.)7M+;`,%4S2 M-R)TM4]7%^6"A`5\'&R?=Q7M'UAV,&A,GP6]O\!0``__\#`%!+`P04``8`"````"$`'E0F M9H`&``!,&@``&0```'AL+W=OZ.9OK6G[)JD-Q>;K7__D6?'%TK6G3RR$] M5Y?\7O^>-_K7[>^_W;U5]7-SRO-6`X5+J M+M,6/M9/1G.M\_30-2K/AC6?KXPR+2XZ57#KCVA4QV.1Y5Z5O93YI:4B=7Y. M6QA_BW/1?N]$=:W,W/CI4M7IXQG\?C?M M-./:W0&!L#E+9WAP(\(&'7ZOQXKS^8;F*N=6-[ MUP7HWR)_:P;_:\VI>@OKXO!'<M$%!%'4M>VG:JOR/V3`EJF$Q#7@RC<5JMES/ M%R81F6BX8`UMT1`ZMZWEVOE12]#MA@U/WN5R9CE+<]D-?*+/%6L)"Z!W^$-] M;EA+>'ZR3Q/22J-,\BO"/-6K0?/4I=U+VW1[5U=O&JPE2$5S3(CH6,Y:\5T8\68>(CXB`2(A(A$B M,2+)D$B^P[;Y"=^)M>P[)38\!KX[BN_"2/B.B(](@$B(2(1(C$@R))+O\`*0 M?*<;Z&P-#::G`&DHAX$2>R6VBCTB'B(^(@$B(2(1(C$BR9!(/L,^+_D\[2BQ MEAUEA!809*??(^(AXB,2(!(B$B$2(Y(,B>0H*6N';\=I1XFU["@E"Z?/J"#] M5#>7MCS5/68$E8%8#U")R$:^,.+K(1#:G(2"#(64WB(AU!M9SD;N+19&7#L1 MVD"DH,&PI:`-5D1[*K+G705>P4MW))@+*!UH04%$Y%A2,HPE(AXE]KRK0*RY MJ;CJB^^Y%P'2"!&)1"M2UV#56'S/59.AAA0;4F))P1D)`E2Y/`J=N1P&COJ" M8M^C/H-X4C&K!8Q-S"K+G,MY]GLK[DR`48A1A%&,4<(0/<+(D2%EV,?7FDFK M-J@F^#AW#*W@-=4[N%$K^5(IY`)N M`"^#VYV%'QI2-&ZE#"GF/;(AV>H22+C!K2')22$EX2>20BM(*2D4K6"+%1&P M-JCR9PUO#8H=!X05S[EO4M0MF=?MZO56/`H^ M0VP=F*NU4K,'W&`ROF&O/)&KJ+?B_<=5C%'#4RX<]FI"/N%4O'V.4<-3)RY&! M^$F1^;GY2524EQI%Z^YRJEOL>W+K1*R&&P=:N!ZW`N/!\E8V19]9L5W"7-@V MFJ"LMUO+M!M3R'N;'%/$K2;'%*MCVMC*UI5PG5MCDE,#5I.I^59=(9JC5=>P MX"`R2FXHDB:S0,.HHXV"6BWZ\XQ/MF&0'Z"`H8%\V*,)^0AKQ1@EO1:L3CEB MI.H?+G,RF:WE#-+VV."^4VYIXY=TD%BK^!._0':X3OR-WZ M&+=&.NQMS8>^X^S'N.2Z<_K".MW'A MA(-YX+APSL$\=%PX[0`W1`[@+O^:/N5_IO53<6FT``"!KP``&0```'AL+W=OKM6V;"O:MAR2NGOF[3=! M("L+^8-%TK$W+?>''XDL)(`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` M_(.O]>V;F]5JN;ZYG@[GC$:.;5:&T&D!-6/=UI2A<%I(9SP6S#_8WQ.'WXS' M@_G'*1U\9:?=?A;O[E_O/[Q[?OK[@I9&"M#+SWNST,XVQAC/7]O1PXP^-*%I M)ALKOQDS[R_I0FBNOM`J]->'^6SU[NHO6CD^.LT=:F:^8LL*LTP8LSL-(@UB M#1(-4@TR#7(-"@U*#2H-:@T:#5H-.@WZ$;BB\`PQHJGP_Q$C8\;$B'OWCL$H M:"H@K.`J.PTB#6(-$@U2#3(-<@T*#4H-*@UJ#1H-6@TZ#?H1\`)""\S_1T", M&9IW]&=BUEC1HO"*9M3[X'"GWEFRI#^C<*W5C!E$7&T')`(2`TF`I$`R(#F0 M`D@)I`)2`VF`M$`Z(/V8>+&@N^89L3!J/Q:6J%A[&P6^,WYB@Q?>LP M%?VP6+)<#WNO+9`=D`A(#"0!D@+)@.1`"B`ED`I(#:0!T@+I@/1CXL6`CJU> M#*8[WJC]CG?$9A[,D6(+9`?Z M'&>>/9C)27\&52"N096R%3E;^P7BKP^SV^6-NJO$W!J=70^WEK!JTJ>45;XM MY5/F5`MO\5DKO_*P+;7J%ZR:]*MDU:1?U4E^U6%;RJ^&57)":06-.UIU3N=4 MAP/6LQW_8L0!?\R2RANS9ALP7[VA_CIR'S$5U<[?H@4=(8:1,E^HV\%V9E7' M5J5!Q?,Z=P/M;5Y/^#BC!VGS=MXJZ9%_JJY4,>XK=G+G+!J#BKN^,A5 MY!FW7MZJ&VW,IFD`#`,?8IJPZE!G[;LT%14[D+$#U_MQI\XL.5>8;+Q@U63C MI:BX\4H:EVN;+Y03-5?TG,!A!YW;61.@XF0]`I$?,>=4ZC:F[M81V[)+Z.URN5;GQI@5DQ,S8=6D3^E)/F5.Y6YC M.L&650]8/_KZ2>-Q&.[K+T9?\0Z-%Z-!$D'XFKD5`L9ZA&B M6&QQ!R:")LRG:"M#E(LM-E\(FC!?HJT*42VVV'R#J,6*':+>J^@'E^+FK4;3 MMY2YD:L@6N0%T:*EG,-WKN((18AB1`FB%%&&*$=4("H158AJ1`VB%E&'J/>0 M'PN=QSP2"TQ8FB6UT,U%QBSDC:;$0--%BR:K)%BM1<8LU(VFQ0=0R\LPOU#VR$Q6;[QGA M5L$<`\Z9G"[3.%RF'(U.U9YKL_522L2%;L>,Q);":*4D6]>[80S M4;'YG)&8+Q"5C";-5Z)B\S4C,=\@:AGYYM6)N1,5F^\9['U' M/>F!Q=QF.\?;>X>\^6]5([1SJO$#"T0QVDH0I5)1IAX^L!`5]TZ.M@I$I50< MFU>3JA(5FZ_15H.HQ8H=HMZKZ`>2-E!>((^LV$:N[IX.C1Y8F"2"4=$)3&_G5F76]JD@#BH.3R05&<6($D$3YE-1L:T,48ZH$#1A MOA05FZ\0U8@:1"VB#E'O(3^N)A\S7E*/S$27OAG?*BTRJ_80,7Q@,7<5:8X. MJL#D#*KTB=K9HL%JDK"+&3ZPX-9HF!QN+6'5I$\IJWQ;RJ?,J8X\L`C;4L?< M@E63?I6LFO2K.LFO.FQ+^=6P2A)UK:!Q1ZO.Z9SJ<,!ZMN-?C#C@CUF3>1N/ MV7T6^80'%B97IU%Y'KJ)[8#%?SJ[EFO8IA9@5D\%. M3G(@%14[D#GD,CUJMHXQ;M'P3LPJR1+'R&*&8GY1-"$^9158CY#E#,2\X6@"?,EJ\1\ MA:AF).8;1"TCL=4AZAGM;7EKAWEXX`7QEPZK>RLJMC9+.'Y>X51'GE77AH:5MD/MILWU=N3G.BXXA`I_<)CSPK/@8.KCDZC MZ@%[VO.*!:97'?)6(ZLR=^/#HV/G*HZ?5R"*T7PB:,)\BK8R1+G8XK6T$#1A MOD1;%:):;+'Y!E&+%3M$O5?17XW.2XG2AE5O61SR/WBGUX:MJ/AJ=H@B1#&B M!%&**$.4(RH0E8@J1#6B!E&+J$/4>\@/C\YL'KGC8PIS89'_^:^EVH9L127A M&2HRBE`5(TH0I8@R1#FB`E&)J$)4(VH0M8@Z1+V'_/#0`NK=RX^$Q\C53=LB M%1[UV&9KWMFBBJ3B6.P018AB1`FB%%&&*$=4("H158AJ1`VB%E&'J/>0'Q[: MPY\3'B-7X;%(A4<]:MG2?0C"`RA"58PH090BRA#EB`I$):(*48VH0=0BZA#U M'O+#8[)ZXWS-D=GCDH"C'*-)J]EY(??;^5)M`[>BDMDS5&04H2I&E"!*$66( M@_YX3%IJS/"8[-F&<7@DVWGF-_689UYZW;-( MK7LJ9[9U%;W;TE"1@QFA*D:4($H198AR1`6B$E&%J$;4(&H1=8AZ#WF1HP?% M?N2FU[V]W+\M.70C2^$6T0Y1A"A&E"!*$66(@_Y ML=#9F".QL#F6\2*WM$A-%97,WHJ*Y\4.480H1I0@2A%EB')$!:(2486H1M0@ M:A%UB'H/^>'1N8+>4:)(+$%#X]2L26J^4H]/LA$Q>9S,<^H$"2VH,52 M;(EJOE)9KTI4;+X6\XP:06(+6FS%EJCF*Y7(Z43%YGLQ3\@?.B:',-[A'UE2 M;H<#;<$N35C@C8C8+X47,(O]M./CX_KX=^HP9;5&&\`2":&V- MWSN1BA(Q4"6BFC"?BHIM98AR1(6@"?.EJ-A\A:A&U`B:,-^*BLUWB'H/^9/S MO.S($K,C#JVI_X<@SE\D-M^5")GQ:1/1;@UE?DMP[:43Y533?=5';:E6FQ.\JL-JY1?';=XL*]Z M5ASJ*V\8KW3:21*&TQN+?44_`>60>D]-[>BV7/&0>_8]-5;)N2]RR.2F95S" MZ)6*(Q6,7E9-.I&*BM>(S"'WLAQ]J83^CH.<*]%F2=S4#A2LFG2@9)7T0N70 M="_44G'"B895DTZTHN)>Z!PZW`L]5SK4"_X@U/FVDP;<&X#<>Y*R8C&PAIB?<+,46.U`Y M--T+M52<,-^Z%GQ:%>\`>A2>V=?D-?V4S@^(;ND-J[Z2=; M7/&04V[]<^;'0P]0++:X5Q)!$YV>BHHK9HAR1(6@"?.EJ-A\A:A&U`B:,-^* MBLUWB'H/^:'6&0WXL*&+>DNX!3L24J3,&*BLWG8IY1(4AL04JB%%NBPA2LJ-A\+>89-8+$ M%K38BBU1S5=J&>E$Q>9[,4_('SHF#WK&3L&F3;V=@D/C,3(@\1.N9K>RJB,I M6%'QU<2($D0IH@Q1CJA`5"*J$-6(&D0MH@Y1[U`@!;LRZ&)$,6($D$38R05%9O/$.6("D$3YDM1L?D*48VH$31AOA45 MF^\0]1[R)^=Y*=@5IF`=\M,8>K7>&/XN9L9]*G@E63/I6L\FTIGRJGFNZK.FQ+]57# MJDF_VK!*^=4YU>&^ZMF.?WWBDS^,3:IVO&*=G!*Q.5[O;N.2PUZB&;YG=655 MQTXKSM;XM&+1]$$A=N:/9)5/#I9 ML\:4L$/FG8KA)CQ?Z;?]1,57LD,4(8H1)8A21!FB'%&!J$14(:H1-8A:1!VB MWD-^>'3:5&Y49[YQOL:,JD,J\A/W(FRSC>8AR96#8I.=Y8K"WRP[/6#_Q$Q;'8(8H0Q8@2 M1"FB#%&.J$!4(JH0U8@:1"VB#E'O(3\\.EDX2E`=B13F#E:))5KL:<",^XL]@# MI'=G<6=*6K;$*?UE&%OC,W7#D2.K4ZF3I]I$1$XU?7Z+P[8D]-Z@O=;'I^EE M>R_WIZ!#_A/EM7I_>,L5:1$9.@L'K*@X@I%#;J>^?OM6W;ICKD/3/FC9O]SS M-NK7N%%WR"R^0W/SM7[YT:F.1-VI*.IRN;;%(R&6BN+$N#?]:]:[WR,AQBWN MM44JQ#*B]B?"K5.9G^H9>F;LE#T7BTJNV9JGK\S;+U,S->QCKG):A/6.\9=6 MX6O<2#JD`J_?G'"J8X&WYDDEG6"1N5D.O3=?JR=KL3/OKQ.C-<0^!F(LK5%7Q(F%P@H%END\ETWFXVQZ[\616-%K586J:&L M'K5MS>\BFXIT+QR"$;A(IZ(_(Y4:O9&SY18P?#T@YL9.&]YF=S/5,:=]I]&U M,:-ZQB(OU@,:7Z":]SMGB[XN06)M*XY0[%36O!]KL^/0EV1_KNO,T_FUV[O( MIXOO'%+'/YU7$15?P@Y1A"A&E"!*$66(@_YD3.[ MJW'DCMQ9W&9L'!Z+QI\'OP:T0Q0ABA$EB%)$&:(<48&H1%0AJA$UB%I$':+> M0WXLSMO/7N-^UB$U5=1RMA653!5K:YS(0E6,*$&4(LH0Y8@*1"6B"E&-J$'4 M(NH0]1[RPG.C]]FC&]KTK-G7])=JA\:9$D0[1!&B&%&"*$64(H]Y(?EO//`#9X'&,D>?HMHARA"%"-*$*6(,D0YH@)1Z2&_9\X[ M-=S@J<$A^B(87BFV@J8V%*RB96785\VOU;DO$A6;CQE)BXD@L04[N514;"L3 M-%$Q9Y7OJCH-%JRB.]MP0>!$Z53F!^,&U7ST]=I^>/0QY\@B@N<9NN>:+:`7 M'D`[5OD7J#Z/'(F*^R]F-(X%F$]1E2'*&N!/4:$?HD#GS#\W!6^LLH@$UB&!"[5@U?3YCEL[1!&B&%&"*$64(H]Y(7G M-G2@_*6LV=Z2'SF'O/5E?B-;*9OP%]40.401HAA1@BA%E"'*$16(2D05HAI1 M@ZA%U"'J/>1'3I\YS=;SUR*'Q]%;BU3D9+?F(C>H)'*`(K'%JAA1@BA%E"'* M$16(2D05HAI1@ZA%U"'J/60C=_7R]>'A=7?_>O_AW?>'YR\/VX=OWUXN/C[] M^8-B-Z.D]HA?/#]\?G]Y=WV[,?D@ZKJAABNY>;LQ*8E0"=6A*1\HN:4Z-*1" M)3,JV>\-=#MK*J&7X@)UUG,JV=\KH,Z"2O8;&RA94LE^*Z9+KJ_I2O?/]*'D MADKV&S-=LJ`2>R""$NH#>BTCX/62^H!.3*$2NE+Z+L90"5VI_=BA;F=)5TK? M1!>J0P4AOMKT^RR/MK2FC@GI3;>$.%UZN$_((_I&??2(-F0;LS?`$MJ$;.EWU"EWP4[9 M4LDV6$);[XW9!:*UB$K,9A!+:".^,7M"+*$D%O5!:$A2XHK"'RJA_!7U3JB$ M9`AR7T MJ<*-^3Q=H&2]WD1TK@N54%_3D]Y0R0V5A/KZCOK@+M@'E+RD*PWUSHY*3#HR MT,[-@DI"XYHR0%02LD993.J#4`E]N=W&?*T;MK-=+3?FL])80A^7WIA//F,) M??AY8S['C"7T469:Z4(E]/G?C?ET+]:AS^ENLF`)?9YV4P5+Z'.O%-.0-?HI M;%H_@A[,J0X]2TH5_6P#IW"[I#V)=YE`=W"[I'V*?A4$)W"?HL!%JCGRG?F!\A#Y4LJ"0T MJNAGDJDDY!O]=OG&_!8R6J.?,-^8GT3&$OHE<^KKD`?T6]A4$O*`?DF92D+6 MZ.?@-^:'H[$=^@GXC?F!]U#)@DI"[=#O35-)R!K]+OS&_*@T6J.?A]^8WY;& MDCLJN0N6;*ED&RS944D4])I^1IU*0E[3+VY32CM&_-2T_/C%W.TM?_S^O233DJ7 M%[\_O;X^?=__\^O#_:<'^G6XMV](_/GIZ97_AR;!U=]/SW_L3UT?_D\````` M__\#`%!+`P04``8`"````"$`\>@-I.<5``#?@P``&````'AL+W=O7Q\VW M=^>3-Y?G9^MO#YN/C]\^OSO_G_]$_UJ>G[V\WG_[>/]U\VW][OSO]B8E?'MY=_[E]?7[[<7%R\.7]=/]RYO-]_4WV?)I\_QT M_RK_^_SYXN7[\_K^XW:GIZ\7T\O+JXNG^\=OY[J$V^=CRMA\^O3XL`XV#W\\ MK;^]ZD*>UU_O7Z7^+U\>O[_TI3T]'%/_@^*?WI\>-Z\;#Z]OI'B+G1%V>:; MBYL+*>G]VX^/T@)UVL^>UY_>G7^8W';+Z_.+]V^W)^A_']<_7JQ_G[U\V?R( MGQ\_%H_?UG*V)4\J`[]M-K^KT/2C(MGY`GM'VPPTSV)=T+:9%JV.W'OX/URX.<42GFS72A2GK8?)4*R'_/GA[5I2%GY/ZO[=\? MCQ]?O\B_)F^6B\7\:GDMQ?RV?GF-'E69YV+*XO9Q,YZ+X=9V;'^6['FZ/VDU*WU9:_(P<\LM97II#K72$W>RLK?69[ M4/EK#GI<9:74[7[RMZ^LG*@]IW,BEX'.BKH>S`F7!"X7D\75@3,ZV654_M$? M[KAD3/HTJG^JN+ZOZBMAUWM_ MUGFEUZI2/JABWIU+"Z1;OL@=Y\_WD^OYVXL_Y2[Q8&+N1F+!DQ"Y MH?P3"5'%2+^3/WMZC0Z:VT$++TN[D%V:("$D@L20!))",D@.*2`EI(+4D`;2 M0CI;G*S)3=W)VOAPI+^CJ>AMJ=%,M'+"A)`0D@$B2$))(5DD!Q20$I( M!:DA#:2%=+8X)UX>HB><>!7MGG@M"WDZ6?W$[P2[H#X[`22$1)`8DD!22`;) M(06DA%20&M)`6DAGBY,+&9Z9"B]T)(`$DA$20&))`4D@&R2$%I(14 MD!K20%I(9XMSXF5L=,*)5]'NB=>RD&&HU0FNO"?!+FC7"2`A)(+$D`220C)( M#BD@):2"U)`&TD(Z6YQKUEZO6:( MVG4;4DB*2#$I(:6DC)23"E))JD@UJ2&UI,XA-W-J^FAG[D`OTK--F0[V9_E. MK7E)QIQ>!`H8%9(B4DQ*2"DI(^6D@E22*E)-:D@MJ7/(S86:%9Z0"SV)='*A MZ6JR2\]*S=PE/18%I)`4D6)20DI)&2DG%:225)%J4D-J29U#;B[41-'.A1H% MS.8R"#C00?0$4PH>.HB9<^YD-3$B8S]K''#CWM$"$S7=[1>.[K>\W.WGMD!- MK^P6'*BXGHTY%=?D]&Q0H%XTJ;F)$73?-=#5Q,C\F=?S]91=L\>VV\Y^4G/5E,7 MNP4'*JYG.D[%[W&`2DD1:28E)!24D;*206I)%6DFM206E+G MD'LUJ?G)";G0TQDG%YK<19.E_R+'9!?5/U<"4DB*2#$I(:6DC)23"E))JD@U MJ2&UI,XA)SW3TR:)VW!WDFC(?@B2`E)(BD@Q*2&EI(R4DPI22:I(-:DAM:3. M(3<7_]@D<&^$6`U10U>-^\=F4TX7#3E=QG^8C(#ML9DA;VSFOZH[1`U=19NJK7E,]E77RI,E[XOBO"YL=):KO M,P$I)$6DF)204E)&RDD%J215I)K4D%I2YY";NM-6`Z9<#3#D=".N!C`J)$6D MF)204E)&RDD%J215I)K4D%I2YY";B]-6`Z9<#3#D=17_)>(A:N@JNBRK]X2, MBD@Q*2&EI(R4DPI22:I(-:DAM:3.(2<]L]-6`[;A[H#`D-U52`$I)$6DF)20 M4E)&RDD%J215I)K4D%I2YY";B['5@,GBC?KPQ/XQ\XRS?T-7PXKJBA200E)$ MBDD)*25EI)Q4D$I21:I)#:DE=0ZY:3EMJJ\^!."-F0U9B^*0`!)"(EO<*OHS M8#564:^]G/CVG!FGQH:<[JVCA*P5_84W6P[,C@LG:NF]1R$I0R'J*%-=O%NF]2TR!]F_DKJ5#G>G5F3DSI0 M,-/DMNEF>`55KVH,44.;[++<-JGIQ3_1)CU-LFX;4CTR9= MED0-;;*+=]LT-ATP-^?7+X\/O]]M5)\;O5//Y),UVT-^F'$F8,C)DHZR*#!1 M"[F.AE?1;KR71,(A:FB179;;HM-&R3..D@W-98M5*7^%V42IM=0ABK<+7;P7 MA:ZEH^1&N/VLTN)ZX5VHD3F:ZH.C1W-/@3\XU3>4[1/WA*1RS#K3)(^"727F M7EM6)N9G%=U>,,$NJ$]HV!<]WYZ"J\M+G`$Y]NZH$^M$.TV?GS;PVX:[MQ=# M\V%!9S70>`UTFTS48IC5AJ1H*$N:[E9]SSCI^*S-.68RY%W/WH-M9:(6^Z]G M$W7@>C91YGJ>3G@]]Q$_NTS<,^,/5?SK^3^;[S^[2;9(:;-C/DOTC834H\1Z#AJR[Z8H4D$)21(I)"2DE M9:2<5)!*4D6J20VI)74.N;F0B_"47*AP[YZAZ6IXY*[FH(`4DB)23$I(*2DC MY:2"5)(J4DUJ2"VI<\C-A1I]G=`O]&#-'DJI=^Y)>B3=_;-E10I((2DBQ:2$ ME)(R4DXJ2"6I(M6DAM22.H?<7*A1XPFYT(-,)Q>:W#6N&_]5E?DNJL]80`I) M$2DF):24E)%R4D$J216I)C6DEM0YY*;''[H?>(1PC#ZW!]';0=D^7`!)"(EN<&LILX80:;J/=H8#NK)F(F209@5 MY$U5P_YP5]LYY\*;X4=JL[7W,&%R&ZUF`D=?8S([0*,UN1F<#$?3-V:SXT_K M9)JMRW(RJ&FA&SGU'KZ1*?>XA06U\G1"6SEIV18@'[*T3^R-_YJ7"3J485WZ MT!'#OG#=TJN)E^Y(;3\BGVK@?GP^]3#?OF>HQ2QUAW![I+="O#)1A_*IRW+R MJ:E?*UHNL%)BBCXRI?:`^W"?Y7A;I4F::Z=TAL;JF$,9U5%V1DW9>E%HWZY]Q; MTHY4N4?T7#5(.C[->DCE]%Q-\K#NGW\K]34?JC/+4W^T`J9%.DJ>C/V.H=G1 MHF@H2Z+<"U0-*HZON1Z".#4WHQ*IQZZ:\C6#WINBU;O;I#&'KE`=Y5RAFOKU M/%G0\P88D2GZN&M4S0>/;^XVVNV/ANR+<7KI730K$W3@8C11UDT'$MGBY$T^ MI'5*0SC@V1;@/2OFWDUN98(.I,U$V6GK=S2/?G_B'9GM1R9-SK:=M%^ZL<@$ MQK^W&G)SZ;T"M#)!AW*I2[=SJ:6_LXZC#V*=--\TK!'5@'11C-6 ML6XL)NK`C<5$67>1D!0-9?DWEBLU6+!N++^6-#WBL.\WVW*]ZW9ZZ0V@5R;J MT(7+,4Z_H[YPYU/_;F.V'WGAJD%$?P[4Y[OVSP*O])C#::T9F-CIV]'X]:.? M"Z8L)WUZ1XLB$Z4?.^Z%IY[\=M5_+7]Z_."T2)-]]4\O<=_108'H@-_:"D(JP"ACJXIX0-5#8=T*.>R7H2H\WG#.BR7[VFZA#753O M:+WL$YH=+8J&LM!%U=C!;M*!RU,/-9RJ:[)7O*]``2DD1:28E)!24D;*206I M)%6DFM206E+GD'MYJ7'.";G0PR(G%YK4B&%W-4\OO4GWZFH7U8\7`U)(BD@Q M*2&EI(R4DPI22:I(-:DAM:3.(2<]U_:X\?"=?!ON#AP-V5V%%)!"4D2*20DI M)66DG%202E)%JDD-J25U#KFYL(>^1^2"8]]K35Y7\1[UJR%JUU5((2DBQ:2$ ME)(R4DXJ2"6I(M6DAM22.H?<]*B![_%WLFL]3K;O9(:2F3LW^[-3MG^)< MZ\FB\S#2Y'0C4&!VM*)"4D2*20DI)66DG%202E)%JDD-J25U#KFY&)M!_]K# MB)/H:TU>+_(6`U9#U-"+=COV%#(J(L6DA)22,E).*D@EJ2+5I(;4DCJ'W,RI M.?T)O4@O`3B]"*L"JVM00`I)$2DF):24E)%R4D$J216I)C6DEM0YY.;BM(6" M:RX4&)*EV_Z*7Y$"4DB*2#$I(:6DC)23"E))JD@UJ2&UI,XA)Q?+TU8%MN'N MJH"AX76#%22`A)`($D,22`K)(#FD@)20"E)#&D@+Z6QQ3[V_"*#7IT_^@-Z2 MJP.&K&?Y:J!A;W@I<.$3UW2\BQ:2$E)(R0U;M#''=%$=)._J4&_WD%?NO8#0E"L!_9F*<*AX)_8Y]TI* MAI+,H;S7*-,AH#]4MBNXEQQ2#+N--Z$<`OI2*I12[V1/$YJAI/$FM$-`?ZAN M5["(VZ?]%8U?O6-SJ6-IECIV.5OM9$_S`A/DW*^G$^^M*^$0U;61_7-L]2VXWA*((>=- M;M.)]XZ)E8F2MYD,9V'D(:R+]Z*\B6!HRC)O*UI,;OPW#D9]Q-[[27Q4G9+Q M**].:7]$_5'<^7RV\"*R/F)OG?+A:/UU4`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`N"N,^=U.UNM&ZRDGBK5IRX3R!;U'K>V):I;!G; M1Q;[;M4Z$?>YFZNDC69M+FF33]Z/[2.)DP]]CVV17B0?01[9(N?@;O0 MO_U^_WE=WC]_?OSVKY?;[R=Z?ORLEB3T_[R:[W7Y;?/ZNGF217MY M[\SZ_N-:?HS]4OU,XZ?-YK7_'VG(Q8_-\^_;'Y5___\"````__\#`%!+`P04 M``8`"````"$`,&G4!V4#``!*"@``&````'AL+W=O36+`VB2.;+/L_GW' M,0FVV>ZE+X'XG#GQF;$]GM\\5J7W0+B@K%[X:!CZ'JES5M!ZO_!__;P;I+XG M)*X+7+*:+/PG(OR;Y<,B)R2"C(#*.Q4LI9"1.`IU=1M3(@(?BQ_3W10AX6?IP,QY,P M1D#WMD3(.ZHD?2\_"LFJ/YJ$SE):)#J+0,19!$7#*!VC1^_U7U;!HQ*Y52JM%K@04)Z'Y32=!P^0TOQ, M66G*Q/=ZRF1L4]8=1250R6;=P"4&V2&;CJ&J!XYZ6Y`LUU8,97^^8)T+%62[ MB";V]U;/4&S&^IHQ26Q*=DV);,;FFF&(6$9CV^C+!A5YX8-X7X-I;']YI2EI M6\,XC:/:N MW87W*B-[E;%YB6'9@UWV_J6I@NS*H=#)[DISDK9T@U$:7M+;[J:UB:/)U$E" M9L*#<31RY#"7'<7_7;V*\T9:7>1LV'6)AH[H9D).JXW M)H8NEBU/<&B9%7MYCRFRZ\69[4IS^DI%S@&Q-G&4NG!FPE"IV/5DXE%LI,-R MI>XFQLG_LBM%=EVY1X?FZ*-C,$V=HW-MPE&:.I/.3'@0P]G2'PYM_:&]JQEH M=90D%W5M2O=NW=HJPO=D3#D[JKXYL!%I9.`3R MCC'9O:B&U=\"EW\!``#__P,`4$L#!!0`!@`(````(0"W%;MX=@8``"X<```8 M````>&PO=V]R:W-H965T&ULG%E=;Z,X%'U?:?\#XCT)MOD( M5=/1P&AV1]J15JO]>*:$)&A"B(!.9_[]VEPG]KT02OK2-O7AYOA^G./$CQ]^ M5$?G>]&T97W:N&SIN4YQRNMM>=IOW'_^_KQ8NT[;9:=M=JQ/Q<;]6;3NAZ=? M?WE\K9MO[:$H.D=&.+4;]]!UYX?5JLT/196UR_IK=KLR+3W7^4A6G#H(TQ3'K)/_V4)[;2[0J MGQ.NRIIO+^=%7E=G&>*Y/);=SSZHZU3YPY?]J6ZRYZ/<]P_F9_DE=O]B$+XJ M\Z9NZUVWE.%60'2XYW@5KV2DI\=M*7>@TNXTQ6[C?F0/J>^YJZ?'/D'_EL5K M:_WMM(?Z];>FW/Y1G@J9;5DG58'GNOZFH%^VZE_RX=7@Z<]]!?YLG&VQRUZ. MW5_UZ^]%N3]TLMR!W)':V,/VYZ>BS65&99@E#U2DO#Y*`O*G4Y6J-61&LA_] M[]=RVQTVK@B70>0))N'.<]%VGTL5TG7RE[:KJ_\`Q'0H",)U$"'9ZW6^Y.N` M!>';45;`J-_@IZS+GAZ;^M6172/?LSUGJ@?9@XQ\V1GPN.[UUE;E'E60CRI* M'TONHI7U^?[$//]Q]5WF-->8!#"1ZQ@,1J07A"J%I'?E*'=..0I9P_'L7RBI MAS`E'N'W2T8@&)$.$5%XA2".,G'EU%Y>A*'I`T1*-KY-2C6>?W.D+D55 M#]'$F8)`X@`C25PW0!,WA4`<0\QQNJ@*C!/'/-IQ@`EA0EA,J*=H67!^32QB M)4?(SMPT*P6FK-;7N)`QP/A03T(YM1>9R21BI'S.$I%I1@I,&<6$$6`@3VO! M3`OUA%-[.8R8>1JQBN]AI<"$%2.-G0`&\A0$YEV!%%H5)HV($Y.Z-3]5/9JR M8B17&@2T_("03LFRF67,:\0'WM98!HIMBP5CIFNANS1(MY=5+$C;=7EL7C%' MI<:SVXR!=B.196;WFAN`IL1"QQF'8'Y*D.?S`_G&N2.-GC``703#(Y.;XO78 MRCUFIB1Y/C.%QETG!HD##!1U$09D/65H?7W+-=4AZ@YB(-PX94:2=$DOZJY. M(0LFZ)CV;RF]IE>[112:=L4INTO[V5#\_4$M`:/?.%B3.4YU#*CU@OFQ"8"9 M$?U7SCEC5$>,@!'_21B`-`41"9,)[BV#,,=.KL]8#=,G=^ET'T:'(@8J8F MP$R#Y$3>/!%-0E`&.3&*::_OT5A*&'6`1(-TU_E^S*F'8800:]],-6:G]-P2 MNGGUY>`"2%,!28@"`!Y$EA-CCL0F9G(@U%XB/RD!<&$`F-M=ML&'ML&XD7T]O@`RW"+"/M5A+@C/6QM3Q.R( M=;Q14Q![V5-7W9#?5Y#3)P?0>$/ILDY!,#]B&S-'8V@?C)OZZ"S:_L&#<#"] M]GH@+!'%#$<,Y.V/K7S$0(;?1M@&L6`>/:RF.HH>']_:(J*HS@+VX,Y+8O\4 M46I.G42#@($8B`M>OG48%<1!9O(;^:C!C0M`D?O0&Q<&@<7T"):B]8!;APB< M0:7DEO3-9`CZCR20?C>2"`#I&@J/M&F*UGVK`)C@NRQ$C%B(H!:B05I+A$]/ M_JD&P`["T)0`,R3N,3.%(RY"SZ")`!`PY%Y,3[$I`L1^8+:(*1(;F4EQQ$YH MCA(!(-V'D;^FBHT!'K-.&Y@CL9.9',$QD'`+:BL"0%/"/0G!/.\R%@&&@">% M&HL&09_QV/09F`I:7D=&SC&O=QF*`"_`^2.3FFC09/X@SC@$\QRQ%:6FTP8M M1FS%^N)):Z)M*Z'GF4SI1,+Z#)+RAN4=LM@_18Q%4&/1(/A*.8CHJ14MQ^98 M"3F$:QNXU:B*9E^DQ?'8.GG]HJYDF/R@?_TO7!0GB+25X5]?= MY86ZQKC>]#W]#P``__\#`%!+`P04``8`"````"$`*][8IL<#``!@#@``&``` M`'AL+W=OJ`HMBR^!RZA\.A:?8I$5`/'(4ZY? M#:CO9?'JVSX7DCZFP/N%S&A<89N+#GS&8RF4V.D)P`4VT2[GZ^`Z`*3M.N'` M`,ON2;;;^+=D=1T/5; M@B8X''1./Y@._)1>PG;TF.I?XO25\?U!0[OGP`B)K9+7>Z9BJ"C`3,(Y(L4B MA03@T\LXC@94A+YL_!`"\T0?-GZTF,R7TXB`N_?(E'[@".E[\5%ID?VS3L0D M9;%,:O=4T^U:BI,'_09O55"<'K("X"HGBU!G.90D9(<@MXBR\9>^!_$55/9Y M2Z+K=?`,U8A+GSOK`Y]O/K5'`-G4*4$:S93ZRU-%1F>,C.7"5.ZLH1DF[`\3 MC0F#SE`B^'K+OL/0.LT:/O/^T.!R.4-T-J%KBM8R,WUM%@ZFH`F+O0P7.$L# M(U;5$,^Y$4H+C/@;W=FTG\S"C?I^N]#9#64M73(P3!TRD;DSSK#!@VZ(TM*< M"3(C_6Q0;!OWP_MLT-D-92U=-M90FJ%FM!`W=+;LOZ M*5J:>BCUZ$`4A1=H6]@5@LKD"L'5`*=10A!VA:`T]7`:)02X,K2$H#*YX_:V MXSE*$(Y2`N/=FH0A)8#]W!$TU.AHNI@LS\];5PH,&`1V>C-OKSEVG[=+<\;D MGGUF::J\6!QQ5P]AVZVM]7O$;8ASUK9'JUL("7\$]3^PWQ=TSWY0N>>Y\E*V M`\RIH2/M&X*]T**`1&'+%QHV>_/S`&]R##9>(X,[(71U@0'J=\/M?P```/__ M`P!02P,$%``&``@````A`/C"5V^Y#P``'E0``!@```!X;"]W;W)K3CP4$3#8(`2/'='W\]/9Y\7VUWZ\WS^]/1 MV<7IR>KY?O.P?O[\_O3??P;_NCX]V>V7SP_+Q\WSZOWIWZO=Z1^W__S'NQ^; M[=?=E]5J?T(.S[OWIU_V^Q?O_'QW_V7UM-R=;5Y6SW3DTV;[M-S3/[>?SWIQN:?X M=U_6+SMV>[K_&;NGY?;KMY=_W6^>7LCBX_IQO?^[-3T]>;KWXL_/F^WRXR.= M]U^CZ?*>O=M_@/W3^GZ[V6T^[<_([EP'BN=\H:U"++O]J_/]8/^R_O3\>SL_'UY>AR1OJ3CZO=/E@K MS].3^V^[_>;IOUHUZKRTR[ASH;^=RV1V=GEU,1F]P632F4P/)J/QV6AZT0;B MJ)S";$^!_@Y4[B@XZPK2M=`5_+D*;[IR]/=M%8XHO;JUI:%^KLH1-X[ZGS=6 M2NVI*Z7S?=-YCJZX)/W/&RNE-M65]AIWXLCFN>Z7;3=?+/?+VW?;S8\3&CNH MX^U>EFHD&GDC,N,.KO-ZZ/+'>CQU=>7R0=F\/Z7SH+Z\H\OT^^WH=YFY`8RKFK%#7D;)=V,"W06"#T`:1#6(;)#9(;9#9(+=!88/2!I4-:ALT M/7!.Z3GDB'KS[\B1LE$YXM:]8R!)&UL)80476=C`MT%@@]`&D0UB&R0V2&V0 MV2"W06&#T@:5#6H;-#U@)(0&B=^1$&5#UQW]<5PU6C3MBRZM+!TDAS0!\8$$ M0$(@$9`82`(D!9(!R8$40$H@%9`:2-,G1M9HH#:R-GP/YQ%-J=OD<*/>:3*E M/[UTV5?,0<3%%D!$`&0$$@$)`:2`$F!9$!R(`60$D@%I`;2](F1"YI,&+E0 MMYW)M9I#=?.@G[[S*"*4V&[XC>GFBIE5S(`L@ M/I``2`@D`A(#28"D0#(@.9`"2`FD`E(#:?K$:'B:#K^AX97:;'A-]/*TG<_. M#Z0_-$W-H6G1B6CYTQN_K'N^?Q#Q^!4`"8%$0&(@24?:174;=7H@_8"LJ+.# M45]T99Y:?A!QU`60$D@%I`;2=*2-VD@B-:.11+W`:4>P_9?U_=>[#;4RS;P' MKJH)+63T\D:9F+G5I)];(`M-IK0J[25R9C:)?Q!QDP1`0B`1D!A(HDDOQ!1( M=BCE"#$_B#C$`D@)I`)2`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`VCUM[,J]KY>$->]48)^?'@>#?2R,AKMYTR/J@6G6HJR$<4(`H118AB1`FB M%%&&*$=4("H158AJ1(V!S%S0M6_DHMULHJGGS\__U2,_:P'0H8DQ<9C9VX&L MHHF'#!EX*6K[<3^+&DW4&N3[[?1B.K7F)`%;D_"X=<@J9P!1I^H%$'-!'<#D M9FP/=`DKG`&DK'(&D&$`.1?D%AA?6DNG@A7.`$I6.0.H,(":"W8M<'US)8-X MNRQL6'$L`+,;T@W!Z(:O#/5*;JU=-#*&A`-R=(+%J%/):.8C"AC)8!D*L+];B8.D0/^8@"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J#&0>8VI M;:!^+GYMD:`WDXR[L4;&(F$T@U5"5Y`R=7Q(7JC'[.K*-D<-:[+I=ZKQ57L# MN#B[L`0!V]"U?;RRD%7.D")6.4.*(23K_!.V<8:4LLH94L8J9T@YA&3MDQ9L MXPRI9)4SI(I5SI!J":F7EYFU+FO8RXCKZ"I![9.YNO6?FQ?J4(.;F/WM#[W= M9O1KC8RAYX!Z\>.41:LF\CC''P$*.M2S#P4Y["/TBA$EXL73YE20PSY#KQQ1 M(5YL7PIRV%?H52-JQ(OLC6%,[489^79/%5JY.57H4*_AYQWJW3\6B'Q$`:(0 M480H1I0@2A%EB')$!:(2486H1M08R,P%759OR8626[G0J+<1/Q\?D*,;+5A% MUU5OA+=&.%]4W$L#1"&B"%&,*&$D\ZI44#\N:X3+6&5&;S\1$A5'7R`J$56( M:D0-(YRVT5K'S.LO315:%RO=>A/02#>@15?PE8=#HN+6"1"%B")$,:*D0[U0 M4T29%.RGVUJ,Y:+B4`M$):(*48VHZ=#`HR(U)S,NT%]+I-X-Z]\;6V/*;>]1 MD:!^4U@]?]&ICC\J$@&W52#.C$)!CLHB\1I^H!*+@)T3<6:4"G)4EHG7D4=% M(F#G0IP9E8(IDA]S"HR*:<`\L[V",&%19:SR_\SK^J(@K,Y81=F\+ M645U'N*&IU?1L,H**>Y4]$==E0./BMC&&5+**F=(V;#*"BGO5/2G'2CP41'; M.$,J6>4,J1I662'5G8I6[[T6MW=0&_8RXCJV"!R3RNC5KRP*E-SJOAH9BX(# MZL5I]Y]%6S4]4)(M,A]1P$AFBJ$@AWW$*K&/$26,Q#X5Y+#/6"7V.:*"D=B7 M@ASV%:O$OD;4,!J8B%(?>4M>E=S*JT9&7C4R%GN`?-4]R:NG"A"%B")$,:($ M48HH0Y0C*A"5B"I$-:+&0.:=0VW-V1LMW7O)KUQNW:9>;UN7\J%:]Y4G1*RB M%>'QL7G1J6@6S+=$GPOR\Q%\0L0*YX`6LLH90(0!Q%SP^!,B5C@#2%GE#"## M`'(NR"V`3XA8X0R@9)4S@`H#J+G@\2=$K#@6@-G[U`::W?NZMZU__EDEC=(P M0&ADS%M&,VL%-^>"-"BX>F)G+Z\3^UU!NINU4X*K&^LY6<#.=+,Y[ARRREE_ MQ"JI/S;K'U]<69L,"9=QUI^RREE_QBJI/S?K'UW;;^L57,99?\DJ9_T5JV3C MM>[0Q"@XLQJAD8+#23"ZHAJTC*[H'OU:N7E3ZA!=`#QBS04-1]`^5%VP2NZG M/J*`D=B'@ASV$:O$/D:4,!+[5)##/F.5V.>("D9B7PIRV%>L$OL:4<.HM3?S M2F.D]A/NE4]$=4,,7L5/T;'!?LAO?Q M&%Z48\6QT;7M4"&KG`%$&$#,!;L`1I.)=4TEK'`&D++*&4"&`>14,H,(`:BYX_`;'BF,!F+W/WG-]I3X)102-KLF%U MW#D7-.Y9."IT]F;OLKS\SHNF]6K^,?"HG"MSWG]#5CE#BECE#"F&D.Q'Y6SC M#"EEE3.DC%7.D'((R=JY+-C&&5+)*F=(%:N<(=424N_6`(_*V MYK6?!OS M/!U+!3GL,_3*$17BQ?:E((=]A5XUHD:\R-XX0.0C"A"%B")$,:($48HH0Y0C*A"5B"I$-:+&0&9ZZ*)]2WJ4 MW$J/1E9ZK!7FG*XD59!4DAY`/JH"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J#&0 MF1X:Q=^2'B6WTJ.1E1[[-6BU-+73`\A'58`H1!0ABA$EB%)$&:(<48&H1%0A MJA$U!C+38V]'OC*XX1XD/2_O&KXW"%]9DY&YJ.3J.11DY*,J0!0BBA#%B!)$ M*:(,48ZH0%0BJA#5B-3GQ:3OZO3HSX7I[R@]K;:?5_/5X^/NY'[S37T*[')& M\]`#UM\IN[OTFG9LLOG,:]J=')M/J``-J]3X<(2*T!4]=.2*CK1O*T"9:SK2 M[@981^:3L:<60NA&:R%/+6OP"*UL/+5(P2.T3J%ZAH[0=]H^#/$[^GY;^ZTS M*ZX[,AK2?YAX'P9/Y&Y"-0^$=#?UFND`IS>#J(:A*NCU#<^GU0N>'KUKX<6# M1^C%""\?/$)O,7CJ105TFX^O//6X!8_0$Q=//3S!(_3\Q%./0O`(/0VA\QDZ M0B_^D5O[F3NKD>G5.RHS=.2.6N=NL'7HU35O/GB$7E>CUAE*)KWL1$>&VIK> M+J/8AH[02V:>>AD)SY1>+*,6':J'WE2B(T-EYJ.IIWX%A6[T0RA/_:8)C]#/ MFCSU"R4\0C]2HEX[=&0^HISJ%X:LMJ:W\*F>H?S0._54S]`1>D.>ZADZDEU[ M]=#EG-UX=;LU:-7>T/4_Q.E7[9[ZX3J>(_T$W5._,LNW11P^(GQ\: MA+[.^++\O,J7V\_KY]W)X^H3#=D7[?<@MOK[COH?^^Z5ZH^;/7V6D28]]&T\ M^@[GBKZ?_Z$J.'S9\_9_````__\#`%!+`P04``8`"````"$` M.*?VX#,$``#*#P``&0```'AL+W=OZ5GC'L#&!JZ-<]]WZYMF^9G7&?4(BUN8.1(NCKKX;4[ MV;3M<%;P275ENXX3VG56-J9@6'=+.,CQ6.8X)?FEQDTO2#I<93WHI^>RI2-; MG2^AJ[/N]=)^SDG=`L6AK,K^@Y.:1IVOOY\:TF6'"N)^1WZ6C]S\Y8Z^+O.. M4'+L+:"SA=#[F&,[MH%IMRE*B(#9;G3XN#6_HG6*0M/>;;A!_Y;X2F?_&_1, MKK]W9?&C;#"X#7EB&3@0\LJ@WPOV"2;;=[-?>`;^[(P"'[-+U?]%KM]P>3KW MD.X`(F*!K8N/%-,<'`4:RPT84TXJ$`!_C;IDI0&.9._\>2V+_KPUO=`*(L=# M`#<.F/8O):,TC?Q">U+_)T!HH!(D[D`"SX$$N9:["E`0/L'B#2SP'%F0Y;M! MM'I&BS^PP'-D<9<&9`MSN-=IUF>[34>N!A0PA$_;C"T'M`9B9K+_2Y/!73;G M*YO$IP*:0F6\[?S`W]AOD,U\P"0"$YG&A'%EQ/X>X7N.C$GO,>YJ@M@0PQ0( M9$@-Q(.:^_]J&0-AD^1`W&BBY[$F`A+QJF#![]4/Z>R#I`BR/5>D5\+`4*$S MNU`<*E($!K(T61K(B/U#1*I#2.KA9Y:K9^"M"49,RM1,)@*B$R\0*UY/@2=' MENJF2[JA>)?K9F!9-T)J(0N,3OB(8`O!55*2CH,W:VX(27CXC'`&5H3':N4* MC$[XB&#"0Q0KEH^C#Y7#(E]N.0.KRF]+6JPY@=$I%XB0UPI:!8ZZ;^@8)-?9 M:6&V_^D7*0/+VCU5NH`(85ZX"I6D[.?CL,*58DOGPUX4Q[>X)-7Q,ZH96%;M MWVB%X0+BVDT4B6/HP_+!,%VO-QKCI9EHU@IT60`Z2IE@K`B1SY2 MBGP:?BR?]:+%I8)$YYIOB7!^E'\\&4!:^8)'%)3KHDAI"JF60RH:Q!K5\@!$ M6YMW)-=1W$LX)9P89AO_;7?CI;5_#$FU$#D$UKZ6AR":W3P'OE*]"=(UQ"&" M$<+W]U@),-4RR.K!IR?4,[2\`%Q'.4,E2("T"1@A?`%X2@I3+8,LG[6RY>:+ MQCXV[$][CJJ)&3B[L^N/!KCU]%5>S!*WAW`I7 M(N7['JWA^'K_/86K'/]N3Q/@)M5F)_Q'UIW*AAH5/L)/.58$=G?B+B9>>M+R M`_2!]'"'XO^>X&PO=V]R:W-H965TGM>N/QJ[CCAGY2X_'];NWW\] M?(IQ=K^+VOV\^?FGU4M9/=5'(1H'*ISKM7MLFLO2\^KL*(JT M'I47<88G^[(JT@:^5@>OOE0BW;5)QL+"Y0XC$_Y:NMUFU!OV3BY=:^[]3'\N77ZI\]UM^%N`VC!..P&-9/F'HEQU"D.Q9 MV0_M"/Q1.3NQ3Y]/S9_ERZ\B/QP;&.XI*$)AR]WW6-09.`IE1L$4*V7E"0C` MOTZ1X]0`1])O[>=+OFN.:S<$Z%'4S4..I5PG>ZZ;LOB7'OJR!"4',AD^9;(_ M&T73Z606S8'#&YFAS(1/F1F,YOYX$5[)F\@\^'SG&X%/*Q0^968X&TWGX]`' M7ZX(]LBT=@SBM$DWJZI\<6!B@SWU)<5EXB^A2F<^"5?#\=IHP#!@D3NLLG;G MK@.&US"%OF["^6+E?85ASV3,O1WC\XAM%X%CC&5C$T@TP`,!2@4,WP]0@550 M1??^^P[H904&Y2ZB2XE-(-$`1AGFS0^@C%5@Z.#C#>(P9P@ M(1%\:`3-R:N"%$$+272$$9QQ@K@*9^&HWTEN7HA8B),G9,+)F]-8!2GR%I+H M"",/R_YV=S&8$R0D"M6RVUI(;"&)CC`V>"PP-K1@.@+Y[]S2L`XG2HCA9&C, M4Q6DG+201$<8]P7G_O9"PF!.D)!HT3MI(;&%)#K"V/C0RH>M?)M8F\>9=1#U M;]S;MQ**P`RUJGRS:<0R:MX>(=JFD`PEAM%$C0/7@!U#FPY7F%-_@>VT&[U[ MGR#=5!N*;2AA$.>$+4'CA*N=IN@5=M1*&#L)Z;X2=,U7BF*^#B2&4=\HN`9L M!IJ&*\RI=3#F!#%?+2C&Q@:37(M*&,0YX?ZO<;K95^H;C)V$=%\)NN8K13%? M!Q+#:/;*?,46H6FXXBLU%,:<(,VQ+1ZFN8FQ#24,XK[BSJ]QNME7ZAB,G81T M7PFZYBM%,5\'$L-H_HJOV"\T#5=\I>["F,N&`UZJ[2J,(O6V=F_:^BJJVT!B M&TH8Q*W&UJ#1_/A!P*I M^S":LB'I3ON3?KU(IU54QRGV+2AA$*,9##2W.?R<>O`7:Z4 MB?JRM*&$05P#=B%3PQC`=QZ+`^IF3`!!AH#^0$8+5B8R`2JQ'P0=X@*PBQD" M?'_RH4'`4L:2)H%:FFR$@9Q#=BR3`VSZ80=/]5B.H@MN)TJIVL?,;[11BWS4K!=/EY'TSA]K/=Z*PG,W@RPRYI/9EW M-Z;F$W^QQ)XTE#.&G/97CID3X/UK>VMI/0G@23!8+80G[:\8*V<"3R9#.4!M MD)D/[X!(-/($+Z+M!E4AL(/X> M;1G`[T*H,_AJT#%H%G@U:!6H&Q0',V)P0H#FP?>"XE:PI_R#B^U+>A"_I]4A M/]?.2>QA8H[;#:*BJW'ZTI07V,#@UK=LX&J[_>\1_H0AX)?U&%OKOBR;[@MX M[:D_BFS^`P``__\#`%!+`P04``8`"````"$`AGV!3%$#``"X"@``&0```'AL M+W=OU+D7O/7&DARYC0 M04`\7B8R%>4V)G]^/]Q,B:<-*U.6RY+'Y)5K,'T0%:\A"\;J0IFX%5M?5TISE*[J,C]81",_8*)DCB&N;J$0VXV M(N'W,MD5O#2.1/&<&8A?9Z+2-5N17$)7,/6TJVX2651`L1:Y,*^6E'A%,G_< MEE*Q=0YYO]"()36W?3FA+T2BI)8;,P`ZWP5ZFO/,G_G`M%RD`C+`LGN*;V*R MHO,[.B'^#":!"$%N+?FVCP(I"1>LM-&%O\@WX#6%4/UT#D0US$YAB;*MX*$Z)!DA2PQF1`/_&NH[/,R"NC"?X9J)`?, MGVC."T3.6"T.Y(T;!$.)X*>) M/IPUO,ZSPT0MR*A!=#P#Y/($$6P]-QDZ2V3;VJX;B.!R6@1W:0\6J-^Y%#L) MC*_QA."N)V>!>;C';X32&F?>1(.AA"(3'L5";NI*8-)WKIG35;,"IT.O, MP70FI=[>MQH/ASCP/Q`Y/1T$M:F;T_2-G'!_MXKYOL[Q7#H5>G_B'5`7*)U> M-3(LNB<2-S2F;5\T.@;4[=^Y21*,!Y./JWPZ2^!*8$L!:YO!&`7]0\6=^NYH M+;C:\B\\S[67R!V>Z!&'V(`W<&.S?#&Z('$Y2.W@W M4IKZ!5S[S9US^1\``/__`P!02P,$%``&``@````A`!7N.OG;`@``:`@``!D` M``!X;"]W;W)K&ULG%9=;]HP%'V?M/]@^;UQ/@A? M(E3MJFZ3-FF:]O%L'">Q&L>1;4K[[W<=0QHHI=%X`!+./?><$4O!=/*J,(&0$>\T->>%V1!@&F]R@4X<+$CS8L, MWT3+VRC$9+WJ`OHC^,X,OB-3J=UG+?)OHN&0-LS)36"CU(.#?LW=+2@FKZKO MNPG\T"CG!=W6]J?:?>&BK"R,.P5'SM@R?[[CAD&B0!/$J6-BJ@8!\(ZD<$L# M$J%/W>=.Y+;*<#(-TEF81`!'&V[LO7"4&+&ML4K^]:!H3^5)XCT)?.Y)HC28 MQ.EL/H*%>$6=P3MJZ7JEU0[!JH&>IJ5N#49+8';.$LC'Z^B]OF45/#J2&\>2 MX1E&4&Y@/H_K23Q?D4?(E.TQMQX#[P/,HL<0T-.+`B%#4>=C/O1V8-?;Q>[$ MW/H;1XV2\'RCY+C1P?WEAJX(4AH:2:*>WVOPF,D`D_:((ZL`&5H=I\`591A\ MOD29Q#V_5^`Q\VX843I+0WCUD",)L`2'$BZ;=^#3UDG/ZUM[S`CST^/.X\R[ MHO?B]Y@1"F#)#KV/4^"*3C,XC=]CIC[^Q(7_5OSND#CS!%X>@RLZE3`Y&8/' MC`AA\3\*7-%[8_"8$0I@\SX*X;+Y#GWJ_N7Y\HMP#SH\`&U04QMW68>P?#ZN_U!&ULC%==DZ(Z$'W?JOL?*-X'""B(I6XMPMR[5;M56[?NQS-"5&J`4"2.,_]^ M.P0T"8J^S`CG]#$GW9VTJZ\?56F\XY86I%Z;R'),`]<9R8OZL#;__>?U96$: ME*5UGI:DQFOS$U/SZ^:/+ZLS:=_H$6-F@$)-U^:1L69IVS0[XBJE%FEP# MM%7*X+$]V+1I<9IW055INX[CVU5:U*906+;/:)#]OLAP3+)3A6LF1%IU*GM&KDK;MU/SDI&J`8E=41;LLQ,UC2I;?C_4I$UW)?C^0+,T&[2[ MAY%\560MH63/+)"SQ4+'GD,[M$%IL\H+<,"WW6CQ?FU^0\L$N::]674;]%^! MSU3Z;-`C.?_9%OF/HL:PVY`GGH$=(6^<^CWGKR#8'D6_=AGXU1HYWJ>GDOU- MSG_AXG!DD.XY..+&EOEGC&D&.PHRECOG2ADI80'PUZ@*7AJP(^E']_].AX!N[#!EKP67-(WL1!FI_A!+F6NYBCN?]8Q18K MZ@S&*4LWJY:<#:@:^$[:I+P&T1*4!V=B'1>O]ZR"1R[RC:MT6N""0G[>-S// M7]GOL*=9SXD$)S"-"R>8JY3M0.$[R'7CX<4U!JDAR<#@Z0-+%U^P6[HO#_)^ M.V.##1ZDV@AFZO=%8XJK,K9C1J!M13RF:"+)F"&)*$8]U>BT04Z&XI-R@.8+ M=?V1X,PDCIZFAXSX(2.98BC^8"%R(J?] MRC!RYAH-3F3XQ?>OQ:-8@CZ3+?&>F\&[:6L\2+6&?*UJ(L'Q10,Z MLYF6VJV,>Z'K:\N/97SFN'.M;A,9]Q9A<&U&Q9^O^IOVQNF*J;@X)*3-FV*D[4^\[7OC00'*N92JQIC^Y`1 M/V0D4PS%'Y]5I(M@VA\GJTD;]9F@W.TS&;[19S)\H\]D^'Z?A:JEY_J,!ZG6 MQGTF./?[3,9O]9F,W^HS&9_H,P07VO,YZ]BZ,ZW#HYXDK*$@O'9X=R%O%=QU M@D`]`&,%1PND]6+2X[>K7JE'Q&]VJ2"?RUX7I9O4CL&H)_7Y<]W1):`2D.>- M;(JQ8U!P?.U(2A2%J13RBUYR.=UV,...BU/[ZJ@GW3TM=5Q+4:SCVJG$!VV^ M"*%_Z\`48[28,BO<'O`6ER4U,G+B([(+I_CEK1C?([2$T0\F..U]S,?Z;C"_ M`#!5-^D!_TS;0U%3H\1[D'2L`&ZF5LSEXH&1IAOD=H3!/-U]/,+O)PQ#I6,! M>4\(&Q[XZ'CY1;;Y#0``__\#`%!+`P04``8`"````"$`8"JZR34#``"2"@`` M&0```'AL+W=O`OWWK_N;E:YQ@Z'LD6<8 M"PT42A[HF1#5QC1YG.$"<8-6N(0W*64%$O#(3B:O&$9)'53DIF-9"[-`I-25 MPH:]1X.F*8EQ2.-S@4NA1!C.D8#\>48JWJ@5\7OD"L0>S]5-3(L*)(XD)^*E M%M6U(MX\G$K*T#$'W\^VA^)&NWX8R1!` M+KO&P/*C3.51^OU+:O@ M48K<295`7^H:N.!0GJ>=YRZWYA.L:7QE]F-FZ?>10X/(%92Z83/P7]?NAT0- M(3VBO$ZS+`8LT0X2T131,\?)-(ME]R&WIL'K"F;#(*C MU/'@N:N!3\5,^9PEPEDBFB)Z/L'3QWW*H'X]/7=83\4LU-E;6I;57X=#][VS M'@-A%_"\D4#4?>^N';=+]"PN^A:G3YZ$!]:\0>I[Q4R5<)8(9XEHBNCY@W^Y MCY=0!LUM5<5,^9PEPEDBFB)Z/N7=9=`9YH^D#!K4<[15%7/=J@N_NY'J?_U# M%W#]\5X,NX#WB@+K5EA@=L('G.=WL#?6L\'L*5I!XWVP"X$E3HA+\C=B(EUW*I:EV/@?HO:_;G_]9?TFJ^?Z)$3C082RWOBGIKFL@J#.3J)( MZY&\B!+^!46:E[Z*L*INB2$/ASP37&8O MA2@;%:02Y[2!^=>G_%)?HQ79+>&*M'I^N7S)9'&!$$_Y.6\^VJ"^5V2K;\=2 M5NG3&;S?691FU]CMFT'X(L\J6O/LFWWZI\_T=>"EAMR!-FX$G*9T2_[?$C&!P, M1C^V&?BK\O;BD+Z80+P MZA4YE@:L2/J^\4.X<+YO3AM_,AM-Y^,)`]Q[$G7SF&-(W\M>ZD86_RJ(Z5`J MR$0'B;H@;#J*PNE\<4\4N%X[%?A73X6QFZ,$RJM=)IXVZ79=R3>^!VM10Y9?MU'$UL$K9";3S$XQ\/J3 M"96/K-GM%`-EVJ7(6OW827`GD5"$X0<3 MZ?MA;4[@#D`G#@>U^[5SB":VIV(6;:&RZ7PZAA\S4;%"X+4+8RT%=Q()11BB ML/'N%\5!EF@T,2UVBB$L8B?!%3%K%RMDR\%2)50(0W-F:M)Y1-C46T26G4(H M.R?!G41"$88>W/[Z6:3U$'9M1\50?DZ".XF$(@P_[(FL1T4$N:<]<9"9QBBR M\Z@8RE,1J@89P^UJ[5?NC)%0A.&Y-#UI/X0MOXF]"Q5#^3D)[B02BC#\&-Q# M^XFD!5O:5:D:HA3="'1=>??:8BT57$( MA.LH4]4NL44XZ&.H&*8K-@WWNZI6PW`=/"J9@O36F[1;S]I[L69(616&0!(R MBJF+'41/UU'`JM\P-0&JHGY$HFIM0_`EDK1QW(PF)F,K82_0R>UO+AU_H!KX+ M4V6GH;ZOI1*[$>Y&$HVH#,^M#6/:8FMAVQ;U9@8GE/KUK-C5/>B]^T5P:^EUGCN'I^0B)E/ M;#%N]U,-B>EG/0-VC.I:M)]"=`8^;8[<41(2,2VQT>A9WKA'57MBV`Z^KC"J MA]&V"E&V<)@&/^9&Y^X@"8D8LN%=O5)+6S?>J?WE4T/4UG0CW(TD)&):6KT2 MO3%#U9?`X[#7(PTLJ>9%I5+'(1:"NY&$1$Q+*+[["S?$459.!QVAAG[V*;+H+7N/NW.FQ_"]L2X^P,<]U[2H_@SK8YY M67MG<8"AX]$E3[*!@][VUQ,<[`LX'!QC3W:0LKF^P:/' M[K\*MO\!``#__P,`4$L#!!0`!@`(````(0!6C&7=B`(``$0&```9````>&PO M=V]R:W-H965T*-;R.DS6'JU_OQIM=?FP=8`CB!#:W-:.]=E MC%E1@^(VTAVT^*?41G&'2U,QVQG@1;])-2R-XSE37+8T,&3F(QRZ+*6`&RUV M"EH72`PTW*%_6\O.'MB4^`B=XN9AUUT(K3JDV,I&NN>>E!(ELKNJU89O&\S[ M*9ER<>#N%R?T2@JCK2Y=A'0L&#W->C;V)KO?]J9/%=MH#%QC;Y!FRU?O#0N\*'<#,[V7W;-^"'(064?->X MGWK_#615.^SV#!/R>67%\PU8@05%FBB=>2:A&S2`3Z*DGPPL"'_*:8K"LG!U M3B?S:+:()PG"R1:LNY6>DA*QLTZKOP&4]*8"5V_MACN^7AF])]AN1-N.^^%) M,B0^>`H,@\NW3*([3[+Q+#E=4(+Z%@O[N)XL+U?L$:LA7C#7`8//`9,,"(9N M!DMH8VSI?'D.RA[LE7VYO)7K$!C+I.=E)O\CX\%8(GP-[D\S#*#I"#,[+XV0 MCV?HP;WTD&*(3/N^C@N'4S"F];U,YWZ6WABQ0PW]OF.%EPB.^"C=Y?EDYL>J M[[?+@X^E0N0T&1RFU\E,XV6$\/<5_+YCA9?(>"2FW_ZSQM@8 M>?M-%)%,(G$5?+,7$QW?TC\F01`$$A0K/=__^?#]Y,_[YZ>[Q]_?#B=G5V< MGMS]N'W\?/_CZX?3__E'_+>KTY/GEYL?GV^^/_ZX^W#ZK[OGT[]__.__>O_7 MX]/OS]_N[EY.2.''\X?3;R\O/S?GY\^WW^X>;I[/'G_>_:"2+X]/#S5WKX?CZ_N%B?/]S<_S@=%#9/QV@\?OER?WL7/=[^\7#WXV40 M>;K[?O-"\3]_N__YS&H/M\?(/=P\_?['S[_=/C[$(G?[K_?O_QK+WIZ\G"[ MR;[^>'RZ^>T[7?<_9\N;6];>_P?(/]S?/CT^/WYY.2.Y\R%0O.9WY^_.2>GC M^\_W=`6FV4^>[KY\./TTV_27Z]/SC^_W#?2_]W=_/4_^_>3YV^-?R=/]Y_+^ MQQVU-O63Z8'?'A]_-Z;99X.H\CG4CO<]T#Z=?+[[=_17?/M]2B)',V7QFEV\?O%`#]_\G#O1D:U"(W__QP.B?']Y]? MOGTX7:S/5I<7BQF9G_QV]_P2WQO)TY/;/YY?'A_^;S":6:E!9&%%EB)R=CF[ M>+>X)(U`/2K=.Z=_6N4NH,^Z0V:1'C@IVQKU@_F4,-]@N,^JP M(4KIN:,:U(RPH:+TQ.*X*+DO9O0O'.7LN*K4?8-3Z<=0M.?#4-_?.='-R\W' M]T^/?YW0=$1-_/SSQDQNL\V,M/B>&4;0>!>]=A/1W6-4/AF9#Z=T&71_/-.= M_^?'Y7SV_OQ/NEMOKFDT&;L)R`Y(#"0!D@+)@.1`"B`ED`I(#:0!T@+I@/13XO0:S>O0:_/5 MV?BX/'JR,T+[?N/VOA[(DJ3&GES,%JJ;1B.N%@'9`8F!)$!2(!F0'$@!I`12 M`:F!-$!:(!V0?DJ<;J)&A&Z:K<[,(L._D.-GD*GH=LM`EOLEY_Z!L@42`=D! MB8$D0%(@&9`<2`&D!%(!J8$T0%H@'9!^2IP^H)6,TP?AAC?6;L-;,BRRS9-\ M"R0"L@,2`TF`I$`R(#F0`D@)I`)2`VF`M$`Z(/V4.`U/*Z@W-+RQ=AM^((NK M\2&_'8E,3;/5TIV:(FM$:_O)_*6,=J,1SU\QD`1("B0#DELB41>ZJ!:V=AQ6U$7'[=B#3O@42#61)&ZVQ(V>KM=LDN]&(FR0&D@!)@61`\H%, M0BR`E&.M0(C5:,0AUD`:("V0#D@_D"%$I]=H\/_[O69$W%ZS1);=VY%,&T#= M;-%@M)SM]U+SBYDJWXWEW$#Q*,LD&4G`43H*F4T;.5*KEFPL9]E\E&52C"3@ MJ!R%K"-U1=58SK+U*,ND&4G`43L*^:^H&\M9MA]EB3ACPF0LG$'AN64IW\+W M[-[<[7Y&D_X7%+B*R%HM*+;Q5I[/+M2M+%9\,3&B!%&**$.46T3Y"98O!$E< M.#6+EEA!])58L7R-J$'4(NH0]18-T;O]:K;:T[3'@7X==N:T4^,XKTUNBN[T M-2UCQ^ZY4GNWK36:TSYR-(*VBOQ6[W1/6X=FM/WY<;:\2.6I./>,.H'=(7SJ@=T)J6+N,@N5(S_M9D6\U#+#B2(K'B M>V)GT?QR/T0O+Y5PS%5H]3MZA]LA8:N@^U2LV'WFNE\MU5R9#8/<6HASP7XH5^Z]8?KC^]6*A4NPU&P3]-Z(<\-^* M%?OO6'[PO[JX@@GO0/N[@]`DB::#\,!C>L@I40PMY590X-HB MMGHW:NT0Q8Q$/A$4D$_92N0S1#DCD2\$!>1+MA+Y"E'-2.0;00'YEJU$OD/4 M,]K+N_U*H\_IUU^;7(R*6FT/Z')_3CQD_,QCS%A-'WGPT(G8BHPGCR9U\^ZL MU7[%3R=<%W,U;\4L\]H4NP\I8:M@2"E;!4/*W)#FE^_4NC!GF6!(!5L%0RK9 M*AA2Y89TM=![UYIE@B$U;!4,J66K8$B=&]+Z4D_+/04ZWS-^6!-V;NX\U1G(_;!%%B':(8D0)HA11 MABA'5"`J$56(:D0-HA91AZAWD-L7)@LXO47"]\5\2!I.9S"+)F4\2YR6],;]!?Z\@A2^+< MMQ;)4)8L!M%8LRHT30M-W5/B05+?_A6R8&K)R+,J-" M4,!9*5K6F8JF$@-6KD6942,HX*P5+?^5=6+`RKTH$W+G\;=EMN:8V6(T'0_6 MZL!X&*P.'"Q:>;+BJXD1)8A21!FBW"(:NBQ?"`IT0RE:8C77QZ*56+%\C:A! MU"+J$/46#=&[_4H;`^?V/_!\-N9JPAZ0DQ]?S-3\MJ4T@JEHYJ'Q80P/O[29]4O]#E7-!L&0&K\S%5+KMU(A=>R1D^TZ]]>SP6LAN4/7I)"F M3ZX#0W?(.#F/J`$YIXN+F3H!V,YMQ=>"VN=((['B.WAGD3U>7$/RE:N0?FB8 M'N,^92W9L62N^Y5N[)RK!-T7;!6\^E*L^.HK=L_G_SIO5'.=H/^&K8+^6[%B M_YWRO]+^>Z[SFG]WL/E3:F]\1XZ&`DR?`U+3ITJ*;VW%0]/GH$56W`H[6]&^ M\[!6TW)LBP^<+A[E/14K]IZYWA?JJO*CO!>B&[A-2K%B[Y7K?;90-W9]E/M& MA`/N6[%B]YWK7M]^_2'O[O`SV;@WS'5#\LZ9ZP8T2:5OZ=_WSV3ZQ^OS3\16 MLK#:(8H9R3XW$1203]E*Y#-$.2.1+P0%Y$NV$OD*4K`XMU8T282ZVUJY\ZUZDN^L%CVOS>;"<[#( MSEZ;7(>#1;8*AI2R53"DS`W)<[#(,L&0"K8*AE2R53"DR@W)<[#(,L&0&K8* MAM2R53"DS@W)<[#(,J^%Y$Q+"YUIU3[>"0N/76DT/ M%A'%HL7RB:"`?(I:&:)0E#W04YB(I3R)6>9-#Q8118AVB&)$ M":(4488H1U0@*A%5B&I$#:(648>H=Y#;+6]+@BXP"*I+Q9Y1@FB5"I*$(NY>F4C$RO6RE&K$"1:<$&E M:(D5>*S$BCW6(L^H$21:X+%E*]ILC'N1Q4(E33NQ8OF>$6ZE:,7WI@%AS-6` M&)`S(`!%>S\?3E7OJ]!W8L6AQQ9-Y!-$J52T:>?C79IVGJX\`$/B2KG"7H@)Q^!111L1D0JE_5`<9.K#CTV**)?((H ME8K3AE>9SDRL6#Y'K0)1*14G\@NUS*[$BN5KU&H0M8RF_;K0&[%.K%B^9^3I M5])R^E7G!([Z:W)SVJMOXP&19XYB:ZTF*++H2@YJ=XABK)@@2K%BABC'B@6B M4BI..U+]M4LE5GR--6HUB%J+Z(48KM@AZIV*SG+*O$GC]%KX;MR;N[.L1>Y! MACZ:W5JK`P<98L57L[.(%NZ0:HC_+?B/+T:I7_5JS8?X>H=Y`[ MG'2BZ,!P&O-![.Z:7O\Q$X![-KM0J^"MM3)_#?%ZIT=BQ?([B^@09C^<]%<$ M8JY"Z[_7A1.VDNU"K8(76XH57VR%J$;4"`I<QM3+;$1D? M:S6=)Q($-U:**!./9BS.9F=+-?GD7F_ZA8Y"I":6F)JS:'KB)"@0>L16<@:\0Q0SDM5K@BAE)%H9 MHIR1:!6"`J&68L6M7"&J$36"`O*M6+%\AZAWD-N)-`2=1>@O;1W,D82^]P?D M/C+T]Q:VMJ(Y-1EO81BID;5R'AF#/*]-5Y=J5HE9F>Q>5T[8:O@^L_D*72K. MIA75XR&S5KPV79[IUR]SE@X&4+!5L`%*B8E[N7(#6)U=J/5DS=Q)-QW"P-@)TZ>"9=ZR\+`IVMJ)]"V=^J8=X MS,HTGD+SCE66E$G*%=U[`^:=H:+=1-'"]9T:HSGK!`,HV"K8`"5;20-4%O$N M[NR=BK#F.D'_#5L%_;=L%6R3CD,:WHQ:K-[-U<.@9YW78G*'ILE>AH;FD?/. MD`1UQN:`)A/#=CFBP'")K)4S[PP5)R@6+;XG$T0I:F6(H=Y#;N;Y4Z7QM?NSAY`U['4R5+@>DUCLJ8[:U5H?6.X.6 ML]X9T+C>N5#*,2N[MXJ:'!*VFJYW1F?3=E=W=<:7QZ^6NU^6RUDWZ+U@J^!B MH[16DZNO7.^4B%/'(#4K!_TW;!7TWXK_0(-TK,6+'?@J9L\6K\7DC,N53@;_ MVF)G+^,FB2V:3CJ"IE>HQDIDK28SS`Y1+%I\0R:(4JR8(6;F%3T-6-M\@MUO>EBA<8:*0D0S^+:((T0Y1C"A!E"+*$.6("D0EH@I1C:A!U"+J M$/4.;(R*JIO!^3T+:#(5C1'T6-'XB\(B!6W3HPH090BRA#E%DU"+1"54C$0:B56 M'&J-J$'4(NH0]18-H;H=:;(YKSRPCM^-KH:OK@GX`TVV?_I`S=]"8],P;!LV0S7$&S8#(*NTZ?-4U*P1=-VPEKEM$G7:M7VWJN.+Y>W?/5^=J=Q?;`T.3$JHG"+*7&>KBS,U4>1'.2M0 MN414N\@MR/?EM%:8T;+(B>C MM=1OZF[%2KH',UIH%2-*$*6(,D0YH@)1B:A"5"-J$+6(.D2]@]SN^>6,UAHS M6A9-,UJ((D0[1#&B!%&**$.4(RH0E8@J1#6B!E&+J$/4.\CMEK=EM,RC4>VT M&<2%*JX8#"X4A)S1=B-*^PC3#9,N^ M%118#49L18O/<(J)&4FV)T&4,G+D];%*)E8LGS/"#,V:UEYO M:2QCKE95`W(:"U"T]T--ZH:NUEX[L>+08T;3E@'YE*U<>?5XSL2*Y7-&GI9Q M4AZ'AQ'F-LQ&1@\C0!%;N:&KW\P= M+:=UZ.M2;NN$9^&]N=L,%IF)?C*9ZAR2M3JP71,K#GUGD7U193:[5+=@:^ ME_:&OZKBBL%6B<2*Y7<6V?3+>@W-;2.BR7UT#VQE7?R#S/X M`Q,)@N531)E%/'HOSO1O>.9>;Y,_,'%;V-D^4`O_TEQZB5L)B]Q!K:]YRQ6G M[0=C+Q(K;IF=132H9=`N]`=^8Z[H##8=1,)6LM).$67B<3]M+,[4&BKG.HZS M5]O=V1\<'MFX/[@N*"AF-'FZ(TH92<4,48498_;+N8JW29UM;\<#+EM;*N>\'>7Z&S5?Z94M6#@[LA*WD MJ"P59],^5!-69JUX%J!YULW5Y:S\FG]W$J`A&^R%X]YGOC0RJAL&Y`S2$4TO M4#V4(JLU?;4046S11#Y!E&+%#%'N5!R:Y_SYV]W=2W3S[[=WW M[\\GMX]__*`GY8Q^&7K"3Y[NOGPX_;2:;3Y1HI0FJK'&4$)OW6W,BV.^DCF5 M[)\J4&=!)?M7CE3)IS7YH9`]:E1BTGF^$O)#F21?"?FA9(:G9':U,3^VY"MY M1R7[&U_'MJ#8Z%U'3QTJ,1_`\Y50;/3M-5\)Q48W&I;0[GIC%L)8\HD"\&J1 M>Z]W9'R+"$ M-B`;L^/`$LIF;,S&`TLHJ;$Q^P\LH=S&QF0N?"5K*O%=/>UMJ<07&VWWJ,0W M7&BK0R6^"*+5Y69'9^*>"*C$'/IC"9WH;\RA/9;0B?S&'+ICR35=Z;4W`DHR M;;;>$DHL45O[6H<2*U3B:QU*+%")+P+:6%.)KW7H$UHTH'RM<[VBJ.G]$+P> M>JEJL_661%1B7FW".O1F#I7XU.B]IXUY90;K%%1BWIS!$GH+BMK:YX=>JZ$2 M7QUZ:8EN!5\)?;AL8SZL@G[H^V4;\WT5+*%OEFW,%\E\)13!\/A0TQ-]-XE* M?/U#7]ZA$E__T*=-N:C,UA"WW;;F"^W^4K65.)K M'?J8%)7XHJ;/$5&)+VKZO@V5^"*@K]YMS/=V,`+Z^-W&?'8'2^@;>!OSA3M? M"8TJ;]3TA2TJ\45-WVBB$E_4](4?*O%%<$T17'M+Z".!&_/A(8PMHA+SV3]? M"=W!WJCILV-4XHN:/EQ%);ZHZ1M'5.*+@'ZPBYXNOL<+_:K29D<_[X.QT4\@ M;3)O"?U>T<;\)!'6H1\7VIC?#\*2:+XD-=]SB7X)A^KX2J+9Q2:C%0ZJE532 M>4NNZ4JOO5=*OPZWV7I+(BK)Z"?-T`_]GAB5^-J-?L!M8W[H"^O0[[AMS.]] M80G]=AM=J<\/_1@8E7CKT$3A&P4E31.^,=#3(]O'(QH:OI&1TD#W\9)N6Q]O M:1+R\>O+S;7/[_9RL_7QB&Y*WW5%=$OZ[//+3>[CQ>6FV//S<8I]_OC^Y\W7 MN^KFZ>O]C^>3[W=?:*5\L?]%CJ?[KR:Y,/S'B_UQX]\>7UX>'V@Q39F'NYO/ M=_3W]1=GM&GY\OCXPO]!G7G^U^/3[_O5^,?_%P```/__`P!02P,$%``&``@` M```A`$B!$S\&UL MK%G;CJ-&$'V/E']`O*]Q@\$VLKT:;LE*B11%F^29P=A&8XP%S.WO4WVE+XS- MCO9EO7.HKJY355U5T)NO;_79>BG;KFHN6QO-YK957HIF7UV.6_N?[]F7E6UU M?7[9Y^?F4F[M][*SO^Y^_67SVK1/W:DL>PLT7+JM?>K[:^@X77$JZ[R;-=?R M`D\.35OG/?S9'IWNVI;YGBRJSXX[GP=.G5<7FVH(VRDZFL.A*LJD*9[K\M)3 M)6UYSGNPOSM5UXYKJXLIZNJ\?7J^?BF:^@HJ'JMSU;\3I;95%^&WXZ5I\\'_/G<_]V\_EY6QU,/X?:!$286[M^3LBO`HZ!FYOI84]&.[ZIOZ/"B&FBBIQF1+X M'5%R8Z''%B[$PN7,7?G(#_#N-Q;"4V(V_+(=76^&%O-[ZP*V#G[9NN5LY?N+ M8+43_(^WVW:YM6"E`:'=-<<'Q`4@C+N=FJR",1'<8``8"4/6,O6 M7MH6N+B#Y'G9+5"P<5X@X`63B4P9I$K$7`)'%ZM-="#5@4P"'&`D:$$$?P(M MK`73X@9%'!AXNAH'+L&7)#J0ZD`F`0H'2*J?P`%K@>#"CQ2;I6IU1(46LI"O MBL1"1#`SD-1`,AE1R,%)T M6DH:*-ZJ4"J$>-)D0C<@"@L\EAAEE21$?ZJ*IZBAO6C$^QZ43UI4L0Z5'$,D M<@*Y18X*+>:D,+MSI)%/Q7/!2ZC5>8 %XC]D/#XP2PL$J`(1(!@=PB0(4" M^!%'VD5S+3I"2+`0NG46",:3Z32(M,J#00$4A,&BP.AG>)NM[4*!%U)FZC%= MFM1:8\>D/)P>+SMON5YK_#,N`2=_=#C?D"S^RB;5YJ@O&/1ZZE"TDR?2R0^M`R]F,:X8Z(O:7?:NRQ2U68DNGG!\\ MCHCV:>BDW,J(05H:Z)V326D!U@@E@Q17GW+ULO?LHE"-I-!@Q=C9$")":4FE"F08J;[0P,+D5;;-8,\4E=I MV1Z@X7B8)8U+`2=QB,S)>)#BB9-QR*SDKC9[?*J2$R4:1SI&*!P-*&$+/YZ& M!X&!BZQPV6=S.'SP":$660])(/$"RR_5Y@4G=&8H'J8$,,X+LJ)+!+7KR M87!I0Y=[*8.T>4@?BYD4-DU**8,?5:^.-48OY3LJLX?13YF4IFO84?4";L_3 MO8&I'\I+RA;RT7CEZY4]XZHGC0^@1Z'[N=-( M.[Z2"Q32Q2F#`ME]WEQ+M8Q)J8'_:#9VM;'CSED6TP6W M*2(*R"#,H7B`;D:9ZG*'03CE"P>92D'<\&LN6J*U]N4NX[M-2^Z/!Q+BF&FS,1YW];)-(7DV M9E)W9F,F)0W"J0GAFQ;V2@691*L3O3FAW^[KLCV6<7D^=U;1/.-;$>BVNXV` MZ94-M&"XLR$W'-J3Q'7#%.HO*->>P#7/PQ@>P?7/F*;(A2W&]'CA`Y0V,2H14\H85`F`W7 M8=?\6/Z9M\?JTEGG\@"),2=?.5IZH4;_Z-D+X6/3PT48>3<\P<5G"1]SY_@+ M_*%I>OX'&.6(J]3=_P```/__`P!02P,$%``&``@````A`.`1$YAG#@``,4L` M`!D```!X;"]W;W)K&ULK)Q)<^,X$H7O$S'_P:'[ MV*)6BU%V1UGBOC-Z9LXJ6;8595L.2575_>\G03()`H^"[9Z^U/+QX2&%!$$L ME+[\]L?+\\7/[>&XV[_>#*S+X>!B^[K9W^]>'V\&__[=_=?UX.)X6K_>KY_W MK]N;P9_;X^"WVW_^X\NO_>'[\6F[/5V0P^OQ9O!T.KW95U?'S=/V97V\W+]M M7^G*P_[PLC[1?P^/5\>WPW9]7Q5Z>;X:#8>SJY?U[G50.]B'CWCL'QYVF^UJ MO_GQLGT]U2:'[?/Z1/$?GW9O1W9[V7S$[F5]^/[C[5^;_].?U:F M@XN7C1T\ONX/ZV_/]+G_L";K#7M7_P'[E]WFL#_N'TZ79'=5!XJ?>7&UN"*G MVR_W._H$HMDO#MN'F\%7RR['X\'5[9>J@?ZSV_XZ=OY]<7S:__(.N_MX][JE MUJ8\B0Q\V^^_"VEP+Q`5OH+2;I6!_'!QOWU8_W@^E?M?_G;W^'2B=$_I$XD/ M9M__N=H>-]2B9',YF@JGS?Z9`J`_+UYVHFM0BZS_N!F,J.+=_>GI9C">74[G MP[%%\HMOV^/)W0G+P<7FQ_&T?_EO+;(:J]IDW)A,I,FE-1G.A(6A&%VMZJ:_ MF[H7E]?3Z61V/3<7G#4%J1-ST!^I;]$4H[\_5Y]%::DBM3K-])$:+6X9\8]/ MUDF-6==)G_8SG]*:55WIZIWKM:G]>V7 MP_[7!=WRU&&.;VLQ@%BV16[<+VN+MJ>>ZZC40X7+5V%S,Z`/0GWP2'?7S]O) M^#@(=A#J(=!#K(-%!JH-, M![D."AV4'7!%Z6ES1)WY[\B1L!$YXM:]8R"3-M(2P@HNLM*!HP-7!YX.?!T$ M.@AU$.D@UD&B@U0'F0YR'10Z*#M`20@-$G]'0H0-W7?T5^>NF:@IN*M%DZYH MJDJ6K:1-$Q`'B`O$`^(#"8"$0"(@,9`$2`HD`Y(#*8"47:)DC09JR-IH>MD^ MPCX\V`FC*F_R(HG^1+("H@#Q`7B M`?&!!$!"(!&0&$@")`62`K\_W_6A(F:M8;(:?>R)=T&T/KVJA9-K&HM-1I: MVG6GO1P=Z7*K8/$(6((HD,]K%4L7V"*$64 M262PSZ6*[0M$I8+45(O5-^Z$?'+4MNHU/*WI.(J[!HUH7=+F=J'=94LN1S.R M5H2/Z7[50NU,#E:PRAN3WJ[0:`S4D:SC5!"'; M&$.*6&4,*>Y7:34F:D@C:SQ4FS%E&V-(&:N,(>7]*BVD@D.BB87,RTR+JV0O M):Z9W$I3>[78PNCVZG<&L'K'0^F^-1K)R=E2[*[24XY0)TZ84[)JT=X*#B*7 MD;3W)#+8^ZR2]@&BD)&TCR0RV,>LDO8)HI21M,\D,MCGK)+V!:*2466OYE7L M0B\A#YB`)$(:((48PH090BRA#E MB`I$I8+47(BMC&XNQ'Q_3'.*CT_VK7HWA.J0CXT:C96)PTS?H&T*CNFQ(X<, MO!5KKY%,K,,%Q8)#;-9/)MJ)L4SPC)'(9R<'2D\A@[[-*>@6( M0D;2/I+(8!^S2MHGB%)&TCZ3R&"?LTK:%XA*1CU#/3WH/Y-7(=?R6B,EKS7J MC.LK"Y"#R$7D(?(1!8A"1!&B&%&"*$64(OL*D%LBIFZ]>_[-QI2>GK$CU.66C669S>.>#V!>FP'N0WJV'L2&>Q]]`H0A=*+IV611`;[&+T21*GT M8OM,(H-]CEX%HE)ZD;TZC(D-KVZ^WYDJ-/MCW=EIC3H-O[1JI#Q2`#FHX,ZN^Y+B0S=:,4J MRE)GA-=&.$>JN)>ZB#Q$/J(`4OWX1ZHX^A11ABA' M5"`J&>&T;43#I9+7OW0*5+EHZ1;&-`S*!ELVJ@Y:->B=DR"IXM9Q$7F(?$0! MHK!!G;@B1+$LV$VWMAA+I(I#31%EB')$!:*R076HZ@VJ;Z']M43BSAJMAJN9 M>N=H2*)N4V@]?]6HSA\.20&WE2N=&7D2&2KSI5?_<4H@!>P<2F=&D42&RF+I MU52F??1$"M@YE72J_^3%5+`SJ5T)J1V$[%3]O%GJICI:\NT!HDA M10[',VTX7K**.H]4P?1)JCAT!Y&+R)/(8.]+%=L'B$)$D40&^UBJV#Y!E"+* M)#+8YU+%]@6B4D%JJOLV_#Z]"ASAGE^#1,UM;N&HB,NIJP3M1EGUJ[0UGL,5 MGCTJ8AME&:'W-H]5QI#\?I464J"&U'-4Q#;&D")6&4.*^U5:2(D:4L]1$=L8 M0\I890PI[U=I(14.2%J"KYS0M2H M:'K#CT2'"_+Y")X0L8*";Q]7C_@80,`%SY\0L<(80,0J8P`Q!I!P M06X!/"%BA3&`C%7&`'(,H.""YT^(6'$N`+7WB0VT[A3UKZUDZFVX[BX?C0RB M"6C4KL3)[O+BM6R7>'';:O9RG6?*&=D[EJXSU^ZR2 M]0=J_:/A7-MD"+F,L?Z(5<;Z8U;)^A.U?NM:?TO/624W7HL& MC96",ZT12EFP/PEJ5Q0[@]VN:-Z!I&-$&/UJ1+7RB+5L5"*0\]U@Q2KY/'40 MN8RDO2>1P=YGE;0/$(6,I'TDD<$^9I6T3Q"EC*1])I'!/F>5M"\0E8PJ>R6O MXF&DY/7##[BJI#KO:)#V@-/>4UBRRCBZKAI5]P''!9OA?32"%^58<6YTK4[I M/589`_`Q@(`+-@%8X[%V3X6L,`80LJB\A!Y"+R$/F(`D0A MH@A1C"A!E"+*$.6("D2E@M1<_"W;IF/<-FV0-MG0.NZ2"RK/+'WC8L4JM7=I M7@[7>/:HG&V,SU^/5<:0?%890PH@)/VHG&V,(46L,H84L\H84@(A:3N7*=L8 M0\I890PI9Y4QI$*&U'GFP5$Y>REQG=LEH=^(4(<8?0[]L:/RRD9[VM4[PLK0 MTZ)._-B):U7G7-QI[#O(;5#'WI/(8.^C5X`HE%X\'8LD,MC'Z)4@2J47VV<2 M&>QS]"H0B5_^J!8PG0E-_4L>]6\EO&P/C]OE]OGY>+'9_Q"_TC$57\QIQ_94:!*N^&U/-?7QBEY,>3J>C5$-?U72$93OU7$P+ MELZ;;'&DA+73X9`MSG_P"IWDV.*P!J\L1S-;;#GA%=IULL4&$EZA/21;;`?A M%=H1HL_3=X5>?K#%NP=8AEX_H-;ONW)'K7/7VSIT?&^+,UUTHR-[:IWJEV:T M=J,#7[K25X9.V.F3]EVA@W9;',AB/72X3BW:5P^=UM*5OC)+:VR+-\'1C5X& MI];INT*O=MOB+6TL0R]J4[OU75E:E%-Z*PW+T)N(5$_?%7JOD.KINT)O"5(] M?5?BN5U41[-:2\?7=E&-$QHOYW;9QU<+F[ZMA]'Z"YN^7(<\7MCT73CD^<(N M^OC=W+[KJWS6WZ=B?QJ[8AZ`>+ MWM:/VV1]>-R]'B^>MP\T5`ZKKU`=ZI\\JO]S:EXG^[8_T4\5T6.0?G>&?IIJ M2U\4'XK?8WC8[T_\'U%!^V-7M_\#``#__P,`4$L#!!0`!@`(````(0#F_&;Y M>PT``'Q"```9````>&PO=V]R:W-H965T-I M]?ZT>MN_;^ZKOS;'ZI\/__[7W8_]X>OQ=;,Y5<#"^_&^^GHZ?82UVG']NMFM MCC?[C\T[/'G>'W:K$_QZ>*D=/PZ;U5.FM'NK^?5ZJ[9;;=^KRD)XN,3&_OEY MN][$^_6WW>;]I(P<-F^K$_A_?-U^'+6UW?H2<[O5X>NWCS_6^]T'F/BR?=N> M?F5&JY7=.AR\O.\/JR]OT.^?7K!::]O9+\+\;KL^[(_[Y],-F*LI1V6?.[5. M#2P]W#UMH0=H\K[Z]G9;['_W-]N7U!.%N0H^P M8^'3KWAS7,.(@ID;OXF6UOLW<`#^K>RV.#5@1%8_L\\?VZ?3ZWVUT;IIMNL- M#\0K7S;'4[I%D]7*^MOQM-_]3PEY9$H9\:;2A M\1(]>)IY#9_4X*UQND2O17HP^TGOLO8ZI`>?5[7G03S5\&)@:7Q+>^;E`8$? M2,-K7#0HG@X#_G!5]SP=!_R!-#LWM\UFT+H]$PD/0J=Z"&-[7:-MK0D_D.9E M4?0@?*I-$T=P7,:]IB9[ECOQZK1ZN#OL?U1@08*Q/7ZL<'GS0K2FLT:9R//H MLS2"_$$KCVCFO@KN0X8<(?>_/P3UUEWM.^3KFF2Z4L9S)2(M@&*<:91/2=1U+/UF&9^OAZ76[_MK=PQB!4$&.-J#.>;='6#O9/2KP',[5N>NJU')< M5Z@%>XCE5,.='Q&>\*"#/GP8*9'2Q5(\/TBJ@2/Z_<%KMIML-J9:`M;4PM;< M(MB$$@'UNV\><\:C-@8=EJ]"#ZAO)-7) MTR'1B@:E&A4D)>Z[U2R`EVCHH]HV`KJ88I M`Q-/H)20,N]V";=OV25]EW+Y18@J`S")\G$,ZJQZZ'I*JO149V1T:L82)1*E M$O4DZDLTD&@HT4BBL403B:82S22:2[20:.D@-Y!8T_!`^LT;F-C7WFFIZLC) M7(7<,V"'G\?Q'@TR%Z1,Y`1*I%0J44^BOD0#B882C20:2S21:"K13**Y1`N) ME@YR(X>5'8^8%U[16]4&>STABIC>R=JL%HN MPKH!EBI<3O/MRJ[EU.:JI=SB@!<9).6WL_*YR2KU5!N!7;FP*;?[6&->T7TJ M2:U*PE>HX9QI/%YD::GR(HNDH`<,F/;X7>3/BF>"39)F6Q-2)$BV_)8Y%-M^++0PIA],<$G*#BY95S/9Z[3,+,VR/\TZ`!$`N;QY>XUPYS)6ME?T%L59 M=!5RHAN(=8N$SN2MDG*"JQ#E[6U;=)8,7Q9:K.KLSO[6"1&/L7P,%'(B[G58 MVD5:$5PN#`PMWF3>#CF95RNU%["[JU0;OBSBO&P[L^_*6LU72)W*,J0)'^>8$[]RUS-Q=[(2ZMB[#/S=#[ND(JDS)0-)V;-5*]*Y M'0[NK!I)M<1%\Q4=N*:_LD3*+-Q7G:LGO\[F3T129ZH*+65-3(E2!SE+3>.Z M$BD39]%3U0^.89Y``5L1(M)#/W(A>_E364923O"4=5TB\&-BJ@U?%CJL-_[O MI0:N-OE20\A9:OPZN_N-M&+Y4J.E[(BJ%JET\!ILJJ1:Y:*EIH&EB3T(9_*5 M*AFK*LPL9#>'NI*+#"J-K[(%:XE63+2B0:E&!4L-1-EQ_;>VB@9:87-8(;8" ML>([(L5SDUC9 M5>@!Y2=)F6`E6M&@5*."^&%=8+O^>_%3U85=W#44ZMC+BU\7BQ`IPD=9)TG* M#08K&Q)J,;N(A:-+P64P25Q6\<%W2^4C<]EE<&:&!9O*E"P:JBX@J7/!5HKV M93`I6B@UMB"EW7G*2QH5[*MO$!MYK6.B%M19/+HD57H9;&3T\A-+E$B42M23 MJ"_10**A1".)QA)-))I*-)-H+M%"HJ6#G$#B-YI.UI9O&)FX.P9%4A6DR1&2H]. M*E%/HKY$`XF&A"R_1A*-C6*)JQ,CI5V=2C23:"[10J(E(>6JFXW_R'D"]RQ6 MH6ED+Y@D55Z\D"+,O>Q&M<[O:A,CH,N.5X$\7FED M!Y^DS@1?2>%.GB>V[[%[E(3,@Y3N32I13Z*^1`.)AH3@VD*;'TDT-HHEKDZ, ME+8UE6@FT5RBA41+0LI5-XAX(+,/*F=*'G5^LT\D^.TV)+7S-9COL8-[1%)P M5C3#4+#S*EM,BE7`"=F"NP"13OUB*^330+2J? M@J#19!)#+5'JT\BTIB?"V""[,\S\1)NGKR'J]7:+Q6"J14H]F!4WQU;$>;$4 MRJ^8K.H0[TQ6A9P+R0X;IPB^\L^VJ<]\ M4E<$1DI'*B%$1^6@V62%6*IUH(&R>7E)^WUMR]R>#73[ZJ*^X;-P#+5*:?,C M+64,CR6:Z+;H&\UVFZV^4ZU3VMA,2Y6.]=Q(Z;%>Z/;MC<+WQ/2BH72T;2_%BBB;:EU@_?;XE)IL;R MT_O$K+&9L6P<%]O!W$CI'B\(L1ZS4.%KRAA0UPFKQVJ2J3>1U=N4N\WA91-M MWMZ.E?7^&[YE##=-#W@&YWP$8R#.^P)7`*%>(\AG\1!$&*Q(I]`)1)B M;2"?P*O6C]G?*O!6X!7L['UESOUP623_V`@?X1)0-M!M@+=%/(!WO(MX,UQF MJP]K^-%KAX_J=,*>P-DXQ&.5;!N.R-#MHF[`F0N>%.G`B18<*WH2!XT03Q:R M'3@CP,`7/8$:/\0R7NI`00X>%#U)VR'^M;Q4Z8)KW4+7X'(CQ$.PU(GA"5XQ M%#WQX4F1#MP_A'ATE3I=",)259(L"%WO%IYD1W+Q!.8K_,U8@;5VB&\=R`=1 M.XP*'\3M$%ZGD0KQ;9@4M1UWPJ2H97@Q(\37+@HL>1X\R9RJY1V!=_\_5B^; MR>KPLGT_5MXVSY"U]>RO#0_J?P]0OYSH;YF_[$_PUC]L#_"2-/PO#QMXX:F. M?U7ZO-^?]"_0="W_?R,>_@8``/__`P!02P,$%``&``@````A``^>O&7&ULK%G;CJ,X$'U?:?\A MRON$6ZXHR:@3[MJ55JO9W6>:D`1U"!'0W3-_OV7L,M@.=&MJ,__GF?5F.1U4=7P_QI;BFF_&/ MM!I_W?[^V_J]*%^JL_M&0CD=Y8H>G:U'&SQ?(^[LQC1/D;OY0 MZ/,L*8NJ.-83H--HH&K.*VVE`=-V?<@@`R+[J$R/F_&384?&]7Y_Z@Z%^]^F1W^R*XIJ`WS1&;@N2A>B&EX(!`,UI317C,#?Y6C0WJ,7R_U MW\5[D&:G35@DH"C03SZ7RY`)KGM*J]C'".1\EK51?Y?]3*8%R4Q60L\&0LECE9&/K* M>H#$8B3P9"3&XY%,&0D\,9\VD($,(-=&!WBR<1[#,H4:J6TPV#<,F+K`6:0*\.ON*$ZJ2L#P1FLT8!(6RJV!%O6VGIK[6 MWF`5),QFI]H8HL4>+4C)$UI'!EP9\&3`EX%`!D(9B#J`!K)P;6!E_`IM"`W1 M!K/:(="*94I"H`4.<63`E0%/!GP9"&0@E(&H`PA"P.K^%4(0&J@S>/`JL70I M]1TUFG:-9I(ZW(3+HR"N@G@*XBM(H""A@D1=1%`)MB]!I?O;.:X88MV(@4GL M*#*%O:LCSU3*G1OA,$=!7`7Q%,17D$!!0@6)NHB0.P0MY$ZWD0DY289E(`-% M&2@RG?/ULE<01T%00$%"!8FZB)`S'"-"SL.)$FLQ48;0$YYL=WL% M<13$51!/07P%"10D5)"HBPB)PK;^0*+$6DR4(>T.N.=(6^K&3"IUAQI9<$[R M]6#,YN)Z<+D1K@>/0&R%WQ+D!$40CS;IZL#8K MHCYGR9P6$9\C`XX"3D1Z`-51R']'VHC3R@K"Q`L*WE$*>B:4BEB+4C&D(Q5'!C)P MJ)%0=J8A]3(N-\(T/`7Q%210D%!!(HH83=1"09'N[`$]&G-1$`;-81?G*\K2 MY=.569G0#'`KM:#N6TGKQ656%JGHM^U*7UKB@O+0`#;9?F?^?6=2#0?WK:20 M0O1(0S*,U7PAQA2A15],XJR0YK&[SH>KU*"])O1`6#@[!LUA)^$2R#KM<5Q? M3*Q=9NSMD>*R@=L:QESJN3UDAMV?NU>FVT>K0?]!:X79A9+_V5)1F\7< MYU]4FW2H#ZA-&UI!;0I):T`Z5?8&M?IH#7`K3-=E`UG!&[JIR$W'6(-"^I_R M'[16Z#^4_%NZM$@B-.CS+\I->MT'Y*:ML2`WA83BMG2I!O;D2D`V[[Z@6'5S M*TS790.QNG5=VJ<]9.ZKKH;91ZM!_T%KA?Y#R?]T*FVF$8[I\R_*3=KK!^2F MW3BXP'AV!H6DZEZ*&]R>67U4W90+K)#>17IRZKYM%PLI6X_]_E%Q<^*!'2=H M@T3WH>1^I=0V)>YU+XH-DRV(W;FR?+Y!(R4KM1T,DDI>.H;V.'"PY)S6"D5P M&60NZ!R8TOW9PR%]%<ZV<`6\M"JI?=;:(`^0*N6*U2A"*&&7E2& MW"NZ6\'/52>[G71W"`K-.]=KZ#6)K!85J>TGUZN52CI'@E7S>@%=FN.4P_O>RF-KQD@LU.QFRYJ M^/;3E.(9/O:E\(9)GT")'XNBQC^(`_[YGY_O''Q\N9V_>7EX7%\\OMC\^WWQ]_'#Y<_G5XOOSWQ__^K_=_/#[]^OSM<'BY M((4?SQ\NO[V\_(RNKI[OOAT>;I_?//X\_*"4+X]/#[?SX=;C\/ MF1Z^7\W?OEU?/=S>_[@<%:*GOWRYOSOL'N]^>SC\>!E%G@[?;U_(_^=O M]S^?6>WA[ARYA]NG7W_[^:^[QX>?)/'+_??[E[\&TGVE^]4 M[S]GR]L[UA[^!^0?[N^>'I\?O[R\(;FKT5&L\[NK=U>D]/']YWNJ@6KVBZ?# MEP^7GV91OUE=7GU\/S30_]X?_G@V_GWQ_.WQC_3I_G-U_^-`K4UQ4A'XY?'Q M5V6:?U:(,E]![F2(0/MT\?GPY?:W[R_]XQ_9X?[KMQ<*]XIJI"H6??YK=WB^ MHQ8EF3?SP8V[Q^_D`/WWXN%>=0UJD=L_/US.J>#[SR_?/EPNUF]6F[>+&9E? M_')X?DGNE>3EQ=UOSR^/#_\W&LV44Y/(0HO07RU"<@'[I;:GOUSHF^5\M;D> M"@UD))<&;^FOSCB;O;E>K9;K:VKD4)%KG9/^LHMO9LNW:U7+0($;G8W^C9?O,!KL;E]N/[Y_>OSC M@H98"N#SSULU8,\B)<+CP!C]:60X-C#0Q:Q4/BF9#Y?D/UWSSS2:_?YQ.7O[ M_NIW&H'NM,T-VLQLBRU;J#%"R>Y<$+L@<4'J@LP%N0L*%Y0NJ%Q0NZ!QP=X% MK0LZ%_0&N*+P3#&BB/X3,5(R*D;R`Q$`2("F0#$@.I`!2 M`JF`U$`:('L@+9`.2&\2*P:T4+%B$&YX96TWO";C[D!-UUL@.R`QD`1("B0# MD@,I@)1`*B`UD`;('D@+I`/2F\1J>%HFO:+AE;7=\"-97$N/GX@,3;/5TAZ: M=MJ(-@HR?LV=15H\&?'XE4S:3-*)B!"4EDU"8C2?.^N+?#)B[6+29E).1(2@ MM&H2$B,HK9Z,6+N9M)GL@;13+E-Z;;=M-QFQ4&\*6=&G1?8KHJ^L[>B/Q(P^ MD)TF=JB=U78\&;'/"0BE0+(IE]D<"[LY\LF(I0L0*H%44ZZ`=#T9L70#0GL@ M[93+E':66MUDQ-*]*60%D5K6"J(Q?[U\N[_[]>:1KC%:SWO&U`5MC\9-DQ*Q M8SL2,[9`=B-9#L<[@TX,)(%<*9!LRF4VB3-FY),1-TD!0B60:LIE2CNKUGHR M8ND&A/9`6LC5`>G-7%;4U$F'%39/>.A@A^,SF-L!8B2[J*T@J2T,4#MMM2#? M9/1UM\BQ6'&C)(A21!FB'%&!J$14(:H1-8CVB%I$':)>(SK_H&K;$5-[8O-\ MXD3$QBTT;:FX_6[4$15=96M:BDK#SZ_M`6NKK>:TXYNL/$$(&D1[1"VB#E%O(3NN:FO]BKB..W$KKB.: MTW9OBMA\[F['U+FC&F-I$3Q9>>+JM7*T8JTU#!"_?YR]6UX[$TC"I='*[WAI M*5L%?,!ZUK$K(P[8?5:=+)A]5DWZ.]()6P2#G9[E0"96 M[$"NT5I-IG2M0(?4U0^67HJN-!)FUE"X9YPMG_=MHJX7EQ-JQVJ-\ MBZACK:G!WTDG&A9I/5M8I1E[-+NKJ8,3Z&IT8T?E/GM]J>YZ.`M,C>Q1<^%L MR[:<\9BO^G!>R\MU&;.\#OMZ^"567'@MA9O=SG&BX8R6$]CMH'%;SBCMW7&)4WMOG-)ZSF25 M=K3;496M;G=BM:7,G?7QB.;&V82:>]4@1GNI::B#JWC'5N^,I97.*"AA*Y%/ M!07D,[82K1Q1P4CD2T$!^8JM1+Y&U#`2^3VBEI%H=8AZ1H.6/790J*T@_JV] MJ;J-Z<9V1&OCI%5;+6A='(KMF-&9QIS9.F:M<0A]MURNG1UCPA;4+XZ7EK)5 MT*=,6X5]RK65GL;P]BPG.I:?(F6,)WJRT]*6`X:5W6'549D[V:9[DZ-^J&^CCT,-H*D@;TC$9CQH5T]5AG-%`B6BR?"@K(9ZB5(RI$B^5+ M00'Y"K5J1(UHL?P>48L9.T2]E=$.KCI",X-[8DH93]RL(([(FE)&M)1]^$X] MNT"A-E",*$&4(LH0Y8@*1"6B"E&-J$&T1]0BZA#U%K)CH0[&7A&+\1S-BH5Y MM#9=AP[F]GI/ M(_/$&M&.D>7ZW-EIQ6+%KB>,I&521!DC6]Y9">=BQ?(%(Y$O$56,@O*U6+%\ MPTCD]XA:1K:\LV/NQ(KE>T:>N-)D:5WH?VL).%L4J%4BJB2C*>]<5+58L7R#6GM$+6;L$/561FO$ M5LM3*Y#AV7,P=R*FCS:-&Q9L16N<:2R&\7.GK4[:LS*D=" M01RUR(K#$TM&1@FB5%!`/A,KULH1%8A*00'Y2JQ8OD;4(-HC:A%UB'H+V7%U M3^1.7(EX]#8?D2IBBAC>L-!6:GL_67DNSNETR+1R=]1KY@K%6?Y,B)[T(3[%9SQF*]#W]B)%3=\K!'5=7QE8;-Q+LF$,QV[X'2W MTYX''KTG,DJS;C,[6ZGCNE>L=@:3_7,`XWYB,S#)4'2*IX9 M6&>44_J8,PI*&,D.,!44D,_82K1R1`4CD2\%!>0KMA+Y&E'#2.3WB%I&HM4A MZAEY-JOJY,X,XM_;K([G?U9L1V3>KU`WH6B$.7&_0ELYLY@S,L2LI4_!-\NE M>X^=+8(79LI6M(_V#K3#").=Y5.NK?BVNS/U%%Q4T*&2K8(.56.CCIT4A/LL.?=KY@K&6>V M&Q%YPX/H5ELI!X_WCIVV,FY.Q(@2T6+Y5%!`/D.M'%$A6BQ?"@K(5ZA5(VI$ MB^7WB%K,V"'JK8S6E*(6N)[@\LN[9[\0.>@,T96:+V?.D>>-M@J_W:4\HCL; M@O9 MX7%/-HU9_T2D](FF7`\WBQ&9[X`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`3K5AQ*W0:'6^%GC,= M:P6K$ZI=AS66GGLW>\AHKVXU4J='4R^9PVU%;75B5&4M8P+5*#PL)))1G(#Y M.3W+B4RLN/ESEM=CP'KIOAM4L$4PLJ5(!]RL1(L=J#4*MT(C&0/R^[.<:,6* MG>A8_F@K]&QQK!7L3OBZ4\4EGBIJY*S=G"<.MYSQF%/C^"=67-\848(H%11H M]$RL6#Y'5"`J!07D*[%B^1I1@V@O*"#?BA7+=XAZ"]FA=D\HP\>2].:!.]5I M9(TR[FG)5AN=&F1&=5JZ<65BG3%\>27L0[`CI6N4_.L$&P$?:B'/"R%2LNOV/Y8^7W;'"L?+O?O>X(5MT[ MP=/OP51%3YD[$1F0?P<*C^T,Y)P]KQ(K# M$R-*$*6")/K01S*Q8OD<48&H%!20K\2*Y6M$#:*]H(!\*U8LWR'J+61?G.K0 M\_QSN:4^(S5.VS6R'TQU]\Y;SD@7Y'0E0BQV;&5O@YTSG5A;A??TB5_+.6M* MV2KH5^:WYGL>6B]8QZZ?XU/)5D&?*K:RM1R?:FT5;JO&K^7XM6>K MH%^MW\KQJ]-6Q]NJ9QV[?N*3W8W54:W9C<\^$AG/>,V#YN6(K,T*_B*1MCJU M6]%:YFYE1*=V*U/&P/62GN5$)E8\1N1TE1R+QLL1A8>%1%NI7[DX/FBG;!5T(A,K;OY<(ST&J#[H/%Q0 M<*:@`R5;!1VHV$I:H=8HW`J-9`RTPIZM@DZT8L6MT&ETO!5ZSG2L%:Q.N/(= M#JN7Z%[Y'8M!9UC42:V7,^=9C!MMI?:-4P]Q3_#$ANN\0Q0C2A"EB#)$.:(" M48FH0E0C:A#M$;6(.D2]A>Q`ONZ`=84'K!JI=?X4G/G:>61H*U82GE&+,C** MT2I!E"+*$.6("D0EH@I1C:A!M$?4(NH0]1:RP^,>BAK/I(4WN"L\']6(ENG< MX%M$.T0QH@11BBA#E",J$)6(*D0UH@;1'E&+J$/46\@.R^O.#%=X9LA(.O\6 MT0Y1C"BQD.VG>YYVHL_@P=E*(^-01)!<\+C)TE;6H0A]),L^XHG%BKMD(O*$ M[-K0$`,K'_.'J\[Z%?"54K'/$1B9E=16UGUM=[^YTQGI=%"]SSA_.Y.-P[`H MBL5`ZC_X5[ODULH]WW-7;5EN=V")IJQ//XG")M"V:FF$&S^+XM23T=J=56RQSN7XB MJ...S-PIKD9DW\%<.VNDK;8Z\4,&8L41C#72*\/UV[?.U)UP'HJT-(IQ*=C5 M54O^5U17;QJ,/NXOA<(@'<_NZ MU<@)L?2H83#9=W;73*Y#7/>VZ:J%SN3LT;F M;6)!P688M>@)9XDUH$2TR,KNIFK%88[)8Y5>O5FGUYQUG<3;Y(VAXT2D, M)^.BV-R;J`TC-18]W#C6K+0M\*S^9U^XK!W![N M-3+#@VC'R*Z@CD?HS%0I55YM8P/%=E!5ENO\Z>& MC=ZI&>XO-K9TXIS]*JM)4:I.2"NI:!U(Z%N]D]$8MI3\L5O%$? MQ:8UC16+$9D;(FUEH!A1@BA%E"'*$14:49.RJR5:51HYC26KE;&QKIZ_'0XO MN]N7VX_O'PY/7P_;P_?OSQ=WC[_]H":>T2FRP2^>#E\^7'Y:O8T^T2$#%3[E M&%/H_GRD;C'[4F:4,G1JR#.GE*$J3LJG]2KZ1+7PJ%&*VAW[4M:4,@P8CMK- M>D,IP_T0-V49]?[:D&.>,CXMJ/[TD(2G=$I1OXSD2Z'ZTX_R^%*H_O2[,)A" M5V:D.@FFT-48J;Z"*7111JK+8`I=B)'J.9A"%U^D.A"F?)I%GWR>W5!EO'6A MJOCL/RU(Q]]@5'=/P33!4M5]*31=4@5]*31%4@5]*30M4@5]*3051FHXQZK? M4*.H`0!3:#R.MMX4&H.CG3>%AN)(C0JH1B-RI`8'3*'=#+6!KYEI!T/A]Z70 M1H9:QY="FQ=J'5\*;5BH=7PI-]0Z-][6V5**FL31:UJ'41OX4F)*45,ZYDDH M1#"%7N.A<="70N^^1.K-%LQ#[ZA$N3>%WB6):F\*O?-!,?6IT0=3 M:/SPML%\'JG/`:`'NP7Y1K_'@RGT$T:1^H$B3*&?&HK4#PEA"OTD$+6U+X4^ M,A.I3\A@'OI,2:0^0N)+F5&*KS[TY9E(?_01.HK,YX4 M\D!]I\27,J,4GQI]S"=2G_W`//0!GTA]GL>30N6HK[GX4F:4XE.CK_I$ZI,@ MF(<^[A.I+X-@R@VEW'A3Z*-'T=:;0A\ZBM1GC%"-/H(3J4_<^%+H:O2JT=>/ M(O6=%,S3TRK"6\J,8D"?T\8I M:.[UI52;J/8M;ZKKJ/;:4X?VU:391/1!>$_)FX@^"X^\W42=K]SV.NI\Y;;4 MC7TZZ29*?3S;T)3F*3>[CG*??D;=UZ=3;*+"Q\M-5/KXS2:Z\?'M)MKZ^&Y# M0[O'S]UU%/O\W%&']>DDFR@9^-6T3GW^^/[G[==#??OT]?['\\7WPQ=:F[\= MOM/W=/]5W5P8_^=%?Z_OE\>7E\<'6KY?7GP[W'X^/"D#VKE\>7Q\X?^A0%[] M\?CTZ[#^__C_`@```/__`P!02P,$%``&``@````A`$#,C@,\!@``C!@``!D` M``!X;"]W;W)K&ULK%G;CIM($'U?:?_!XCW&8&QL M9#L:F[MVI=4JN_O,8&RC,<8"9B;Y^ZVF+]!=F$RBO(1P7'VZZG15=]&S^?RU MN$[>LJK.R]M6,Z8S;9+=TO*8W\Y;[9\O_J>5-JF;Y'9,KN4MVVK?LEK[O/O] MM\U[6;W4ERQK)L!PJ[?:I6GNCJ[7Z24KDGI:WK,;_'(JJR)IX+4ZZ_6]RI)C M.ZBXZN9LMM2+)+]IE,&I/L)1GDYYFKEE^EIDMX:25-DU:<#_^I+?:\Y6I!^A M*Y+JY?7^*2V+.U`\Y]>\^=:2:I,B=:+SK:R2YRO$_=6PDI1SMR^(OLC3JJS+ M4S,%.ITZBF->ZVL=F':;8PX1$-DG57;::D^&$QL+3=]M6H'^S;/WNO?_27TI MWX,J/_Z1WS)0&]:)K,!S6;X0T^A((!BLH]%^NP)_59-C=DI>K\W?Y7N8Y>=+ M`\N]@(A(8,[QFYO5*2@*-%.S=2,MK^``_#LI MC,68KA8+:[GZ`5`Y&/S+YF`^')!BZGAC5K51\99D":T54G^<96],-:ZS2%VHQTDR;9 M;:KR?0)E#DE2WQ.R:1@.F8+G(O5$9.>CY(2$(BQ/A&:K@:"0=S54U-O.,JR- M_@95D#*;/;8Q9(L#MR!Y2FA=%?!4P%>!0`5"%8A4(.X!.L@BM('2^!7:$!JB M#8]JSX%.+%,1@EOP(:X*>"K@JT"@`J$*1"H0]P!)"*CN7R$$H8$\@TV<5PRQ;L7@0>PI M8L'>)>0Q5RM9GH,PXL-\&2[.R#$ M18B'$!\A`4)"A$0(B?N(%"ALZS\0*+&6`Z7(?-6MJ$"Z5#<6RGGA,B,X)T4] M0',BUX,GC'@]^(*;(X%`^D3*;*$@ZHS,U5J>+1)&G#L6W(!(HI%F'1^L;44T MESQ]V9<0%9P\`UDSAP.4'JN$1-:2(GTM$>)2Q)JUY[`Y4P]B3_S.H_`11X"0 M4(PBISMFC<3OG#7N2'*3O^@$]6G-9$`8M87_N0ELKH1V8 ME0G'O+#"*@U;*97@,:LYR=6WW7*V4%H8GQO`]OEXLF!X,K4VAZT4ER(^(W,) M-:`Q-WCDDKPHI"OL%_!XDAJTB83FAN?-GD%+V"*$`N8:];QLX".G6",LK#B] MQ^C;0GG;+6Q#:15\[A+LZV)^M-P!MQJ=/^RL^/R1//_27"J1Q7S,H_EEN4GO MV9>[UT%\?+\T:`<&H_H& M'YH_[*SX_!&GITEOF/95(:UO7YF?RT_:0,,T M?`'W!H7L]LJH+?8#@^"D&(G(Y5;RPBJ;HL>LV"YAS"T+)2CSZ5&9MCX%?+91 MGT)N->I3I/JTMI2M*^8\CWR2EP9F&UV:+^7]4:O5:S/(#9S29S!(2F9J];UD MIE;S[B/&8UP]R,?T00>-+'V(N2(,D2M,5G>0;%0Q>B5)+X"*K#IGA^QZK2=I M^4JN&R'A=AL!T[O0_<*!+R`@4/#0=J`;'L!7#G2"&(]M!_I!C+MK!UHEC,,= M[%.[S2KS[LG=[(#]WG3@^F*`9^X\@1#XA_W<@4_Y`=QRX#-W`+>=_5``!]LY M#.&N[<#'">9Q5PXTX!CW;0?:<(P'M@/-.."Z4`+N@N_).?LSJ<[YK9Y/Y<-W`*W)7"!6_\,/C5G4TB.4UDV_(5,(/Z.L/L?``#_ M_P,`4$L#!!0`!@`(````(0!>4%)3Y`,``,X,```0``@!9&]C4')O<',O87!P M+GAM;""B!`$HH``!```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````````)Q7 M36_C-A"]%^A_,'3?R,GN%D4@:Z'83C=`XKBUDQP)AAK;1"12)2FOTU_?(6D[ M4DQIL;E)XLSCX[SYH))ON[(8;$%I+L4H.C\;1@,03.9"9:K!T1M&6*DZ%05K6S+^X MYZ+21J5/4KWH#8#128P&_J-[;-HVG_F7].N%L\"GMJ5%\$QPH+6Y;#(_GF%\/YM,9XOIA.#3XO[V M9I(M\>4JN\UFX^D'7,Y_Q6>QQ-WN?FF;O@.W(61[`5#@W9C65I#5[]!P'V$EG37`88()3>V[?C3 MCB6FK%ACK^LZU@+6UOR0WZ`JQ360)YX#F?`@BWYYPVG4J2]9HDK!;9HB.ZN. M,_=K':;3$+L/NE_S,/1[T?OP.[3O<^D/?K@>;5[5QJ65*TJL0^8$G_"B-L'@ M=^N5Y7DX+5IZ62M;GK38M\O@+K88R2,M:MEZ#+$_#UQI92AM=DBEF9:5V7;B=-'H(N#6(X!8WBS/I[CC1\ M_.8`V[/Y68_H'6DD3*QWIK7:=NOB^.ZJ>,O%BWZHEG*"_>)P%VY_3-P=)<=; MXF'][4/R':_!JK`@OM#S@\WI@KVY/_K?D_3\R]GP\Q`OY8UO2?SV(Y+^#P`` M__\#`%!+`P04``8`"````"$`P+G0=3$!``!``@``$0`(`61O8U!R;W!S+V-O M&UL(*($`2B@``$````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` MG)%!3\,@&(;O)OZ'AGM+V8PZTK)$S4XN,7%&XPWA6TLLE`#:[=]+NZ[.Z,DC M>5\>GN^C6.YTDWR"\ZHU)2)9CA(PHI7*5"5ZVJS2:Y3XP(WD36N@1'OP:,G. MSPIAJ6@=/+C6@@L*?!))QE-A2U2'8"G&7M2@N<]BP\1PVSK-0SRZ"ELNWGD% M>);GEUA#X)('CGM@:B)]7>#?62'%8$>%`QY`)O$]>K`[)L_SV[O-"K%93BY20E*2 M;\B"SA`6SP_OGG[`L``/__`P!02P$"+0`4``8` M"````"$`S+S0P!<"``#3'P``$P``````````````````````6T-O;G1E;G1? M5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+```````` M`````````%`$``!?&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`'SU,]NT`@``FP<``!D`````````````````]A4` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`"^YX#,O`P``E@D``!D`````````````````Q!X``'AL+W=O&UL4$L!`BT`%``&``@````A`"F6[SAG!``` M#A(``!D`````````````````Z2<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``/]UDJJ`@``A0<``!D````````` M````````2S<``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`(._)_SR`P``W`X``!D`````````````````6T(``'AL M+W=OXH4$ M``"8$P``&0````````````````"$1@``>&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`'.G)4\``P``;0D``!@`````````````````;J\``'AL+W=O M&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0`VWB:LR00``"L6 M```9`````````````````*F_``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`+Y%Q2(P!0``H1L``!D`````````````````J<0` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`.@^`S6D`P``KPP``!D`````````````````*M8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*_C,'.H`@``&P<``!D` M````````````````0A4!`'AL+W=O&PO M=V]R:W-H965T`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A`/'H#:3G%0``WX,``!@````````````````` M>CT!`'AL+W=O'8&```N'```&``````````` M```````R5P$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`"O>V*;'`P``8`X``!@`````````````````WET!`'AL+W=OXZ M^=L"``!H"```&0````````````````#Y?P$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`&`JNLDU`P``D@H``!D`````````````````,(&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"-^^#$1'``` MBIL``!D`````````````````LI(!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.;\9OE[#0``?$(``!D````````` M````````Z\0!`'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`$#,C@,\!@``C!@``!D`````````````````"_4!`'AL M+W=O XML 14 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Stock Option Activity (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
6 Months Ended 12 Months Ended

Sep. 30, 2014

Mar. 31, 2014

Options

Outstanding at April 1, 2014 3,492

Granted 313

Exercised (222)

Cancelled and expired (5)

Outstanding at September 30, 2014 3,578 3,492

Exercisable at September 30, 2014 2,787

Options vested and expected to vest at end of year 3,502

Weighted-Average Exercise Price

Outstanding at April 1, 2014 $ 13.27

Granted $ 22.26

Exercised $ 11.49

Cancelled and expired $ 15.66

Outstanding at September 30, 2014 $ 14.16 $ 13.27

Exercisable at September 30, 2014 $ 11.94

Options vested and expected to vest at September 30, 2014 $ 14.00

Weighted-Average Remaining Contractual Term (years)

Outstanding 5 years 15 days 4 years 11 months 1 day

Exercisable at September 30, 2014 3 years 11 months 27 days

Options vested and expected to vest at September 30, 2014 4 years 11 months 19 days

Aggregate Intrinsic Value

Outstanding at September 30, 2014 $ 38,287

Exercisable at September 30, 2014 35,928

Options vested and expected to vest at September 30, 2014 $ 38,013

X

- Details

Name: abmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract

Namespace Prefix: abmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 15 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Investable Marketable Securities (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

US Treasury Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Market Value $ 19,487 $ 31,487

US Government-sponsored Enterprises Debt Securities | Short-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Market Value 58,494 24,176

US Government-sponsored Enterprises Debt Securities | Long-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Market Value 16,473 41,761

Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Amortized Cost 94,465 97,440

Gross Unrealized Gains 20 14

Gross Unrealized Losses (31) (30)

Fair Market Value 94,454 97,424

Level 2 | US Treasury Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Amortized Cost 19,487 31,487

Gross Unrealized Gains 0 0

Gross Unrealized Losses 0 0

Fair Market Value 19,487 31,487

Level 2 | US Government-sponsored Enterprises Debt Securities | Short-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Amortized Cost 58,480 24,174

Gross Unrealized Gains 17 6

Gross Unrealized Losses (3) (4)

Fair Market Value 58,494 24,176

Level 2 | US Government-sponsored Enterprises Debt Securities | Long-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Amortized Cost 16,498 41,779

Gross Unrealized Gains 3 8

Gross Unrealized Losses (28) (26)

Fair Market Value $ 16,473 $ 41,761

X

- Definition

Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation (Tables)
6 Months Ended

Sep. 30, 2014

Stock-Based Compensation Recognized

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three and six months ended September 30, 2014 and 2013:

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

 (in $000’s) (in $000’s)

Cost of product revenue
 $ 148 $ 139 $ 357 $ 347

Research and development
 773 540 1,626 1,285

Selling, general and administrative
 3,103 2,119 6,331 5,087









 $ 4,024 $ 2,798 $ 8,314 $ 6,719









Components of Stock-Based Compensation

The components of stock-based compensation for the three and six months ended September 30, 2014 and 2013 were as follows:

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

 (in $000’s) (in $000’s)

Restricted stock units and awards
 $ 3,334 $ 2,162 $ 6,754 $ 5,098

Stock options
 624 598 1,423 1,523

Employee stock purchase plan
 66 38 137 98









 $ 4,024 $ 2,798 $ 8,314 $ 6,719









Summary of Stock Option Activity

The following table summarizes the stock option activity for the six months ended September 30, 2014:

 Shares
Underlying
Options
(in thousands) Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term (years) Aggregate
Intrinsic
Value
(in thousands)

Outstanding at April 1, 2014
 3,492 $ 13.27 4.92

Granted
 313 22.26

Exercised
 (222 ) 11.49

Cancelled and expired
 (5 ) 15.66





Outstanding at September 30, 2014
 3,578 $ 14.16 5.04 $ 38,287





Exercisable at September 30, 2014
 2,787 $ 11.94 3.99 $ 35,928





Options vested and expected to vest at September 30, 2014
 3,502 $ 14.00 4.97 $ 38,013





Weighted-Average Assumptions Used to Calculate Fair Value of Options Granted

The fair value of options granted during the three and six months ended September 30, 2014 and 2013 were calculated using the following weighted average assumptions:

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

Risk-free interest rate
 1.75 % 1.39 % 1.60 % 0.85 %

Expected option life (years)
 4.19 4.23 4.19 4.26

Expected volatility
 48.7 % 50.6 % 49.3 % 51.9 %

Summary of Restricted Stock and Restricted Stock Units Activity

The following table summarizes the activity for the six months ended September 30, 2014:

 Number of
Shares
(in thousands) Weighted
Average
Grant Date
Fair Value
(per share)

Outstanding at April 1, 2014
 1,174 $ 21.37

Granted
 664 21.88

Vested
 (465 ) 20.48

Forfeited
 (121 ) 23.10



Outstanding at September 30, 2014
 1,252 $ 21.80



X

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Sep. 30, 2014

Jul. 01, 2014

Mar. 31, 2014

Income Taxes [Line Items]

Long-term deferred tax liability $ 6,865 $ 6,415

Amortization period of deferred tax liability (years) 15 years

Long-term deferred tax assets $ 813 $ 874

X

- Definition

Amortization Period For Deferred Charges

+ References

No definition available.

+ Details

Name: abmd_AmortizationPeriodForDeferredCharges

Namespace Prefix: abmd_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: abmd_IncomeTaxesLineItems

Namespace Prefix: abmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8

In-Process Research and Development Activity (Detail) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Sep. 30, 2014

Jul. 31, 2014

Indefinite-lived Intangible Assets [Line Items]

Beginning balance $ 18,500

Additions 18,500

Foreign currency translation impact (1,302)

Ending balance $ 17,198 $ 18,500

X

- Definition

Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, resulting from a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_IndefinitelivedIntangibleAssetsAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation adjustments.

+ References

No definition available.

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) (USD $)
In Thousands, unless otherwise specified
1 Months Ended 6 Months Ended

Jul. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Level 3

Sep. 30, 2014

ECP Entwicklungsgesellschaft mbH

Sep. 30, 2014

ECP Entwicklungsgesellschaft mbH

Level 3

Probability weighted income approach

Sep. 30, 2014

ECP Entwicklungsgesellschaft mbH

Level 3

Probability weighted income approach

Contingent Consideration

Minimum

Sep. 30, 2014

ECP Entwicklungsgesellschaft mbH

Level 3

Probability weighted income approach

Contingent Consideration

Maximum

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Contingent consideration $ 5,797 $ 5,797 $ 5,800 $ 5,797

Milestone date 2018 2021

Discount rate 22.50% 8.00% 12.00%

Probability of occurrence 0.00% 100.00%

X

- Definition

Fair Value Inputs Probability Of Occurrence

+ References

No definition available.

+ Details

Name: abmd_FairValueInputsProbabilityOfOccurrence

Namespace Prefix: abmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair Value Inputs Year Of Payments

+ References

No definition available.

+ Details

Name: abmd_FairValueInputsYearOfPayments

Namespace Prefix: abmd_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8

Segment and Enterprise Wide Disclosures - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
6 Months Ended 3 Months Ended 6 Months Ended

Sep. 30, 2014

Segment

Jul. 01, 2014

Mar. 31, 2014

Sep. 30, 2014

United States

Mar. 31, 2014

United States

Sep. 30, 2014

Europe

Jun. 30, 2014

Europe

Mar. 31, 2014

Europe

Sep. 30, 2014

International

Sep. 30, 2013

International

Sep. 30, 2014

International

Sep. 30, 2013

International

Segment Reporting Information [Line Items]

Number of business segments 1

Percentage of total consolidated assets 66.00% 74.00%

Goodwill $ 36,867 $ 1,964 $ 37,990 $ 54,100 $ 35,400

Percentage of total consolidated assets, excluding goodwill 9.00% 9.00%

Percentage of total product revenue 11.00% 7.00% 11.00% 8.00%

X

- Definition

Percentage of Company Assets

+ References

No definition available.

+ Details

Name: abmd_PercentageOfCompanyAssets

Namespace Prefix: abmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Percentage of Total Assets, by Geographic Regions, Excluding Goodwill

+ References

No definition available.

+ Details

Name: abmd_PercentageOfTotalAssetsByGeographicRegionsExcludingGoodwill

Namespace Prefix: abmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Percentage of total revenues, by Geographic Regions

+ References

No definition available.

+ Details

Name: abmd_PercentageOfTotalRevenuesByGeographicRegions

Namespace Prefix: abmd_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 22 0001193125-14-405601-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-405601-xbrl.zip M4$L#!!0````(`*ET:D5N>XID4\H``*1S"0`1`!P`86)M9"TR,#$T,#DS,"YX M;6Q55`D``^T3853M$V%4=7@+``$$)0X```0Y`0``Y%U;<]O(-JGR+Y+TD+RJ8A"74H0`%`&TIOSXS("63(`8`28"$?+P/ M2Q$#$/U-=T]/=T_W+W][O)]/OD59'J?)VS-T#L\F43)-9W%R^_;L]VM@7[N7 MEV>3O`B363A/D^CMV5.4GTW^]NL__],O_P+`Y.IJXJ5)$LWGT=/DKVDTC[*P MB":7B;YE&JF+T\5]E!3_,?D2YM%LDB:3OYRK=Q-\CB:3NZ)X>'-Q\?W[]_-H M=AMF($WF<1*=3]/[BPD`S[_QQ_+]WDPF[!RC<[)VZ2I=)+,W$['VE9M%8:&& M3V;J1=Y,,$04(`00_(S$&\K>4/X_ZZ/3AZOD.DUR-?K^(4R>)O9\/KG2=^63JRB/LF_1['SUT,^";_E<_7E^IN2%.OD5Y47_+\EH--7&>4HQX$\;+$<\W)&$\S>M_I+RD?P-M_D82 MW2H6FAE_0UYDZ3RZ6`U[N4LQS>*^_J99D5T43P_JGC0!:E24Q=.7^]IOVKPA MCZ?U]*@+-=3DQ4-F&*^NU-RPR,%M&#Z\W/,US+^4+[2Z4#.5ZHI^T[SVGO)* MW4U%U@"QNOH\4%^857AQ-8Y=+"]N#"UJAUK+H<7ZT'D#'RF-]'>MNU[&ZR\V MQG\GY6@DI;PHK[X,S>.Z@>JQZ.*O]^^NIW?1?0A>E(%2'Y-)J4#F;_+RVE7T M=5(^\4V8336S=7O/\HZ[+/KZ]DQK%O"L0?O1MX4Y+)";I1JG(63>/[<*XX M$5AGDU@)<3R[L0CDD.$;(FWIV@X#KLTIH)8O@0AL&Q!!I40>"WPI;LK'+-2; MEC^]TB8WOU][9[\B84'][Y>+?+B22TL]VER7:33OU_?A5F4 M?UP4Y:*K[MD5`@2K$%Q^"+8P8(Q@@AT/",OU`95*P0J&&?`\/T#4MCR?.#?X MIB346@,B+U_O[%<*A:2,6[]<=*-BDPW<-"_>1\5=JJ#2&EZ;"'D0QMD?X7P1 M>7$^G:?Y(HMVI)U`2]-^(R$5E#PBR)`EL/K3XA@]2H2D$"V$2TI'!(,%+E!<08&/B"0V$88ZNQ!X9HIXQ(1H3H\B(7C#96RLP M`I_9`C]*B!&U6FBVJ>L&EN4#@:A4-%,+2"TI@1"*M5Q?$"HU'^`;;*+94J^R M2?6F^#]_ZRQR9?7FN1*?+W%2&J]7T32]3>+_4ZIDII")O\;ABS*QI_^[B+-H M9B>S=^KK>!X7<92K:\H\6/]F=]4)JZJ3;,'B M"DE/4MPC4)9Q;9>,'EEF6XR'4$$NYM`1T1D0.$.\SMUP5=#OH5SO2:=5)J- M*PL93I:W$!@.[4]9^A!EQ=.G>9@4JQ]]T);`*4$G)M`9DH.A;D2B%_"?55CM M3W^(3@HW,N*M/EB]J)@V\@>W%98CU5,B)5/JSI,J%:-EA@5>]!A6*T6A27HVNW8+UM/I]EB/-M;HV6&R!+O(P#0 MRMZN`BA.;M7/J$]Y/-.A.?6UG67*FHY*C\N5_O3QZ\=%,4WOH[QTOOQG?'NW M'[@W4GU+M(.%4XNKOP1E\A%!@5FKOT5R3GV/N4"[8(&ZSP72]C'`A-F,."ZE M#FWQNZ'EEJ29VP\`992`[P`Q8P&77B"`;0D":.!#(`GCP'>$&_C"\3&!HX"X M%)X?3WD?*U.A2)/H4_A4WOTY==3G>'8,T!S/<8/`)\#SI-((01``":D$"@C? M\;"/!58:H='WR9\QZTK7&@KV[6U6QA?'`@>W?0$I5<))=>A$/5Y*!8S2E()A M7S+%1RUP(&QM`+(+B147^7*OJO^WME^U"S?,LB?UI)*M=O:/2^TK;EDGI&U+ MR_)<$-BV@L$1$@A;,.!ZU/-\@I"05,.`;XC1WD80X8I3O`L]U2A!)>1RJ9:+ M:'=6V"*Z+F;D^[[M(J6C.6)*@7#A`)MZ`KC8@RC@3H`IU#OHVG@1$FIIY'P] M!%#[ZBWT'1`8ZY=(5AL4LSA'A#80:0R)E9<=G22CLTRB)*\J3>?IQY"57-C? MPVSV\4$/S/]0$E/:#O[C0S15'S^G^JNUW_NPN/\298>C5B,/)+`=3_H,,(E] M0`GAP`EL#[#`(P''"`4T6*H%7@,;L2#>$(1C8='":_:BN$LS;:R=EM5H#6;+ MT%(EIF9\_WY9;0W'/R.=!J6P_J96^=O(?XRR:9Q'G[)XNGL@9`LTO*UX`TY) MP#Q@!YY>?[A:?[A:CB&%GJ!8V>APQ6@&#__-0Y3=O(!(SQ'KC^TZXM+O9*P> MK;<1HQ#P.KV(N>"]"O@6T8-A.EX&-SA,-AD]^;,-DO#)F\*M5%Y'C MVB[=16_-(O@49A^SZT)GJI;;B$]15K[&:?G4$/S9P!>>0U1KY)A(:I?3D1AV M6)H-NV9A-5EVFV-'.>?8$!AIF/-N5+5/^QCVQG6+3\MDU^V+>S151V$UUKD, MB,5%KU9CR_[ONCSEDNE@_&PQ+?X,]8.+I]+S'L[=/4-D77!"V%8K#]8N;RD` M]0-'?4($N,3VF1L(S(C5E(W#^6;LMA,E3?*RC^>L&ZE=M80QHF44EAKOV%JT M9,CIZTJ3.3E/.XTV9G#[S8TK^\GGRNSBI(B;/!0&7V:\S`367M!G;_!TGV#? MBKP])\J4'3AYS.,W23Q_>U9DBZAZMD&)U^)^,=<+4QD:U4HJB^Z4GHJ_19>) MCG2\2W,=H_[X]7/X>,HIH\8(#[`DVU0F.Y*UAY>5. M1>\_U-P?898[+I7&K+(M\[J%B/K4YXAPAJM:OIZ`ZNY`62UWZ5S!D>OH[$`3W'4!-X>5N661 MRKYIZ]4W22N7]?')LM%&P6A3A9O?OX;.X_)KQ^7*>!R%8[Q-:D>.74\B2V8C MX]^&M&_+HL;-4"TA%84TF\5:7X5SG3%RF;CA0UR$NY\VZM,,,]JAV#[5&%&62!JN[0Y\_7'8(WG MUO8Y5=8C94;=S(F%*M$U,P6#A5PNDR*+E;!,AV-RCT+JU,S)M+ M1GG%F.M`RI$KY/2I0,P'!3B2FYO0_4KDK(5Z'I0UK',BDCQ2(Z2R5^U`R+'3;UX2\$>EEHP;1")TEOYQ4VX,$%4E5YGW19H]!8K-\[OE MP>-E7&15)7`@TYZYA'HV!,)A`:#,MX"-N0\$E`)SS_.1S1KM&58)'W<@I(9' MO[1/P)?VO,)-@-&)F="(&;$DKDE.&`0#`Y==A=_?*X[,8D6F=HLL'A[FRR.P MX^`WHW')H(7K^:T+21538;^CMWVN@<8=_<(# M)]XYF`L#$4H-:G)KJ_`<./Y1ZD`-&8&98F95]9RMJ(B1A*[6^@@H-EH1G$N! M.IKJM62OV6TC$5%SS-NJ;'IKW[TA:__DOAABW-`C;E4\%=MO7K=DC(`WS44; MB(4EJEDX:AGQ10W]F69_OTP^9>DTRL=C!IB+6'%4W2&V$K)^,GH9/=!7PFRJ MW6]>]"V:IZ7S9K6]&H&[V;Q#1FRM5,0.U*QA\$YQ>F2KK4EI8+Y75-[-GU:V MY7Y$*[-7O:+%']6[$2K(.@C;^73(@Y!Q+P".L'R%`9+`08P!9BLFD,JPIK;? M=C@>J\W'"H0FS6:J.8^LA@+"+`Y=0"UF`<M0#JA4^DP*R@!DU&/84?(.90O5C/U@^--3+;D@ M$C<3;4$72IM)8#-/,;ACJ4^^[0.'09_Z4C#HXM;J#[LP>+LQLI:E]5N6YOGO MB5KOYOHHR&]AG#C1US2+]LXNO9$06E1AH_YG\18-Z!!'<**4G^,[&-#`(DKZ MA04<*#%TA90>MFYH0\$QV-'^ZDAR5P3'`XW1'I=JKT$[HG,XX^@/!R6AB*"ZJYG)WHVV$NNBE8#GD0L@;B3!!EOJ+ M8)V(<3B,#76\*X<87I6>&AXVHPZS=(WXUZO#AD?.K-]^$O4V/(3FS:6@HK-Y M\6I4GT2<]P\C:0AS_`R:;RC4S,71=T@#&+7F&PHY<_*O^.E4WU`8FAU+C,K. M,(Y>]3T#QPC&?0#7$--]O9JN?Y#,NDU2T=4>'J5NZQ\KHS;[2319_XB9==<. MW-6@NXYV6N\'5!R)-L7>Z>Q>P^+8_]F]$^&D&W%)0AXE@A:SF@K0UH1="/-= MX4K@>T2!R/U`P>DZ`#DT8%@!A%'0XI'M'\>7QF7OR]!CZ=W],R[N?D_2+SIP MM4SJ>5B4X?0TF:I'E(_3?RZR3/V0$^;Q2Z;$TP'QUBVD=93M45+)B=@-:+P.V+&4FU',NMKSE#`HF04XQUS! M#@60=J`42R`0DMQ&EM(IN#$?4%3+"AP)]KU37YH@QS@$&41 M>LCG+A,06\0VEP!#V.JI,O2NT+P.[;8]`]O:S;(M"Q/N`.YAH1U_4XX8(U# MPSFM?<-*Q_3S[-!,R")<.H'2&U!86,D+1,!19B+P;=?W/-?!(N!M/=:KC>4/ M]N7TF->O&`0B1/028EEM8`0^=VQH2^!2+P`TL'5G)0\!GQ#"!%$V-++;S+1J M3^8.>?[]B\@.[N)N'E$M%&::]XY'#-,]BI#V+H.=ND&W*[*F8X3-H_: MHGGO`MG8U#P**3:1UBF;1_5*9%V3%"*EN@F+?9I']=FZJ%="_U%:%VV!MF?7 MB:;VBYM=)\@YYCWX10YI7=1'9Y<^NY!> MB7U][4'Z)/_5M`?IE>A7UQZD5X[_:=J#=+&#.[4'V5H17^PE*OOM&GF2]B!= M<.ITU+0A$Y]7W"Q!DV@4, MW!YD1=Z>$S7.]B`]3EE#>Y#2`SFR[B`]4M[0'833470'Z5,R&[J#6%!6*M>= MNCM(CRNEN5)*M<;/3MU!>N^,T>?J8NZ,0=$AG3'ZJZ??IQB;2W1R'<`]3?^' M/C5T0Y1($*M2'_%X_1_ZY%AS_X?*,:$3]7_H42$9,V@%'%'_AS[YUWP$#%H4 M\3^#WTNM.;^#X0A4K$K3M#_H4=6-BLFM8TY=?^'/I<88TDRRMEQ^S_T MJ72-3@3"H65LRS)T_X<>^=,<24:R4DENQP80PW0TZ'-RS3I75EH?'K.C09]" M:?:A\-+L.VY'@QXI,VH;)H2L!`2Z=C08I,Y^CS0;C7B*..M:`\AD#`Y14;Y' MVLT5Y:'`U0#0;A7EAZA3WHGR+@4CFPP(7$E_V[E.^;"ULWO$P%Q"CR):C\'1 M:F?WJ:[-!8FW=P%UN<`'58WND9"&JM&2&JJ<#ELUNL^]FG&2*+%XK4_T%%6C M^]RO&=--+<:ZIN`.6#6Z3Q$TTBK@*8I&]SF+YJ+1S*KL988M&MTC4>:BT8C+ MRK[SR$6C>US_C*X_ABN&WWB*1O>X1S77Q[!6R<[[%8T^I!K)8;5]2G!V*GY) M1(!\B"%0/((`]3P.U%(J02`#CT&/>U+:3=5E4=NZ#,8-.;JLISBUU*9 M<3!T&JLOOK[*/8/A9#Z!P,M3BJ^OSE@-5`<<<.L$8\.NEKU>-34\:@U;#\2[ M(C="%38\%+[=A4WU`8&E6?XCXN?QK5M\-1Y4[`O?;BLD<" MR9QC@%Y/<=DC8?43%9<]$F+F?O8[<%>#[AI#O;B]L>^WY%[GT\H8G9,^3BO_ M`Y;<:YFY?4ON&8_5H>K>YD0E]PY+)S*7.4="NOV)F%1SZ*V9&:HN9<;I;,;,!C+=]O2*N\+D@Q`/$(T(MKXX+ MA,<9L"S+I:[DF'NXI5+7$%ZY0W'8>8O4"8?F2EW[[]%[S`\8I/I40VI2M1+7 M<8M//9/M+=M9,F_TNO)#&)`]/`2*3J8 M`70^^"&.@\3S=F>_+"BJ97-#D5H>/MZOWZIJDB(I4J)LR5)F\B&()9'=5=5U M=W6U98S:MA7;!'QQDST_P"`>XEC5_\<2?`;GWN4/Y#.`4N0AGB>\=CUP`0+_ M!4N^7_2;4QXE]%^(7)M^?*O6=+?@6T7BS(#2GBR*((LI;Z]#&'1'QE`&QWY@ M@'>HC\R^9/7[0TG5]8EA]*W!L+:U^%83R^B;402 MB-'J:\12+:&AMJU>M)DA`22@3:#WJ`OC61JZ:NK(\/, M5.GO.*PD&Y)60Y!V2+R%E*RAO+F_[01"QZ$I2P;>4:$/K+[4D\=CR;0,;3+H MROK(V'8%N%KU$O8A-G7=/0OQ:33BD1.Z%'/N@TSKA#&,B6F-)CVIW^UIX#V- M9[9(K,4;)D2I,/` M?V(4E3.(+IQ["*^9G7$'6X;!`R`;73+VRT]/JJRJ'QB#5^RXPQ(P1_0VMT// MY2$+YNR]>TY?I;$(O:-8'R*`Q.%`&WQFG.#1$=MGPS&[ML-OV.S,7N),M@?/ M>382&D$FR,"[P9?@#;%7`!#<@M#"%C%"'6(29F(V6*I M9VP>!@LV'G[NL"`$$,LPLBE>^()3XC1()RSMFR<0#'NVNP!BP,A1##_%]VXX M@SE".M2Z6/+8C7%`^!=R&PPS(@)PPN('"]>Q/>^9\?Q8$P,7-?:(K.=L#N\@ M#*X_Q]D%L6'^UHBX,:.`'=:1?7V.G`#6#^:V<[^!O3,O9%QP#_GQ?;J0,UH[ MYLX%/P@,`985;&P6@)/D![3V]^X4)D)`ZW%?K>\\"=$19PM84(X+V,'WL>\/ M3-^A9>RPF1O%H3M-Q'<>=AS'R9,H7>)G]N`&Z?K#]REQ\%,Z%K`KO`TK#I2U MJ=L_6P`WQW;XS&;V`L+@"!DGB?!U^*,_=8,%("U83O"ZO<#:<20P4/G4Q.0/\"+P:8G^YQ_HJV81 MFKMA1&(:.&"7-DI2D4&#Q0+;)F*NG=01OHC2#=@O$*,PB.V8T,3IUP0H>H$$ M/<(J<\$]V2"V\$D+!'D,0F_V"/P&)*'#J!%"]DY1NRN:``_[:6J&$"T^6>0V M3SC`/*J5W@)=4DWQOG\N('T_.&>XH,C>R11[;L4NR21].<>'5F_;%$&**8;G M.3FJCY7(TRFID5P<"QQ%W(-61BSI\SFNC@1L-L_8"1A[[@*E08?Z&9V)N(3. MC$S*%'YP4SZ!4>\")!DPZ(*HT6'V/(8);'$H`G_+M(L31#'14ZRCT$^PW$NR M7O`IUXG_/H?5Z185!H)-(KF$A7$#$*DUXW%^\9*&V`TF\^W]D&W)BO;FMME_ MU];Z*+9R1-*ZZ_50[S,/87$7MN_P5=0'7[K!"[WU;3Y'J^;I:63[^V=5_C,O M&M\)^,K)[K3W3]94<>1Z2;Q3/-+31)]LJQJ\KV=B]6'/TD=#`R)V;)@[5"=2 M?V`8TGBBCS2(3/J3L84%J@W'/$H;4))\(:N%D]WU>.RWB2+M.4$\(PBYQSV] M78@(%.RJVJ@GC2:*`CY[?R`-^F-#&I@@*?4=QH\_P&37/DWF?[L@W?S($YAD:Y+X+OT1YAZ'Y1^<5OW_U$: MC_9V%;5\M/=U:-9P\W3[>DVKZY4O03^*DH58/#QK$E=M*-LW8Z6#/9E#U+?%O\RN2MJ0>P3W\Q3 M=?V*UMP["79+0U1JX)EWJ>U99GDK:$><-AM@O`[5.:[Y;3B1N(OY)2P.*&B9 M0/^+8EB\\V5?HK;.+"U%K6X3O:M8!Y*T>@*TDK4UAMP;R[U:=0-0G')4CJY;F4[_E*OHUN&NVEQM:M$X@@G7O?'%@U'FF[+Q-6:*^ M/Z-/GF#!V?\FXB*RW5O5[N9/=:V1;$P42>T;8TF7!UB"-K`DR^CIPPGNWFF# M3;11-;7F!/O>L:_I>IJN0M:.Y,C"TKAA;_0JUW/7`=^>@4Z#'9J/C&E:>W:H M7USX'?L$\!$7_^-YJ;HXLO5K>QRL$?XU!0<_`?8\VJUF MZQ`J36LT=E265E9I1;#K<"(O"/S&NE22."E2&.3:]4$;8G6W"-W!)I1'$<7? M:U?7'ID9&NFE*&8-O=Z$)%L+7:+/83#!]#P(WL%5I#JT1OIP.)+&?05OB]>Z MTL`:#R35F)@#6=,G1G>RR>F&!RMN5FN,MFPTD?$Y/"NU%+WF[N1;"\.JB-1X M%*>J3)N7O7*'P&8L:F/M(^N&YCYHIEQ!+@-X"\->4\4%ND0OJ6L^B`OX$'AFM#6?4USK$52#?%K.NM[$\LMPVUC%(BJ5LB^+7L:D7V[3-^6T`[@P6 M*>(="UC@'X3UN>@C"W$C6^MJO0SOBE^UNSM=PT`6;.;&2;@J51XD\:<@_I/' M)Q`1-/:'K%R6V!:=]MYI:A6/ZYFN-3?09'[_*DW,^`^G^]R MD]O-"?+;#%?(RQS,-IQ&*-`M_5E4H?X';HK-V#\>#BI3R@#T=!,HWG MB9X5UQ(9KT!SS1(ZG,\HA7\510E6R6=%1'_X,TSE8J#RR;#4786O5G:`JX*TD2F2= M3EVB&C6,I&#=;QN9:HEHLTS1E1LW69TBGIJ+]G.BY!5T:30M7:U2<+<5DW4# M*NZ3)B-[Y-1PHT+M&5;EAH`JX!O6$UQ->/#:CG&3X/EF?H+[((W)`G6]K\.N MJ+5-+JW*7WX@NJ! MXZ9-&_=2)*77+72_V3/2E6Y0\,8,3T&`:[$2)]$FCL_$H(ME$M-@-_/J(8*^ M./_]0CIB7U+%,K!;EEEN$7;U:;+>8M'4QDI_8$J&/.Y+>A=;D4YZNM3')G'6 M0)WTK,%Z6Z%5BT6KTOM\'YB?(C'QRD9]+\14J\=Y\[)_2]4.3&V-KM= MA\'8DDU%Z^T#875C'T*E6^&)EZ.\CSZG;W00>)?VOI.A)>M=V90&^M@"!U'7 M),O4-&G4U\W!2.Z;2M?:V.^OW-Y7NU!Z;]$Q]E6'A@\'UK^HBVT&%K4]/>!J MUK5O;+V<[=MW'8=<;Z*&#&R.N@\UM+D]9%?>0?/6=\_-2LUJ^N>^@@JB&6Y7 MT71E#\UP@:_,TJY,?G2XU]04>`-:!V:`KF'TP`XILKF-`2:J/E+[0_!#)C"D M;O8AFNY/3*G?G4Q@O-Y$&9A;^N$J:B6'#L:'T MC'U@K&WTKKIR;W>4*Y$SYNS7MIY&;N1X003"=`MD&'B!\VUGFNA9E%AM?JM; M6D_1\.91$]N"J#W)PEZX776B:=U)OVOI!O6__/T7+_XP M+V_=!02^G_@C^Q(L;/^L,,<4__X4Q/P7>['\\--37_Y@7K"41BQ+0N&3O]*C M]-=R"Y!&`XQ(4@5^ MJ46$9BUSTA;4*V_L]"Z(![*D3SY'(VN09'_ERYCCP?W5#)K#G+7 M6)!40$S9,V)_&Z[)$!/Z*].2RH4,RH=%@>?.V$\BP,GEE(B,)O([Y:730?FO MRF5&G?CF='SO^C#&.Z!O.K[H1'E^8-I.[P"^`$ST3\/A>#R9G.U(;45N)#>X M&L5?JBZ4Q^+'T@F?.1>_:U%=>NXG>V1[)0 M;(C,TRC^^Y('6?T;RH,FZS_4?WONIV9:Q.\N53RP&$L>OD=F!P_W;\?LNM[] MH?Q?P_[_:>-.8?S\W3&\:1YXY4\09>N'9M^!M6D_^_OC:U7]N_%U3SXPRAOY M6C#5\NE#B^S6&Q"S*B%IWI!V[S!I^%27-&S>6SJ!*7=GD1\TW)6&QW!36J\D M_((#KTM=EE)N7&M\=)>I7IHTTSJF<1RU>_JT,3L]R_JAGUL(NB8$?18DN)__ M-LIE+W.>E(;^RU*QS.6_4M7'!I^83(=ZN%J8VBV=K"`F8LO0A7GA?7'_F:B; MF09^$O&H`Z]G7^$=>BYE#Z,L:RA*;++AI^*$.OP:8[JEMDZ`X6XGO;Z^U4Z_ M7:Q3/ZUV*IPH>%FQUEHOX(4K&CYB7X;L"C;GP(5>QGAB#C5E)*FFIDKZ>#"6 MK+ZF25USH.BJI6N6KFXM]+KN?_G'U2=I<'-[>W-]R8@1)C>?;J6O5_\]OF3* MZHM)__KJXY^7;,T!2(>XO?D,SU=V?&FSM%SLI<@7K$`Q6L$2S6BE5KNLQ07\ M#TEB3]/0ZTR#V3.3I,-B]'$\N;UDZL]E%(T:#/$/%_\H($;`NSD:]0@=:AVH M'NYV_%^WTM6GT?@3H)$67<&\5S[[9P(RBG65Y>L4:2N<+CZ,`V:GEX6N+J:- M`WC;$:>_\.Y(D>>GFQ2?7#HHS+`8#6]897W;N>=^A_V#X^5SSS!-&"1W]S`` MSET55E6[8+<`R#1QJ7$;BWCX@"G6J'3O9'$S'K51=JGM/;=G_Y?8(4`O^.D^ M0)7#%L&J3`^@2.:V@\<[_3MX.5@=U,:K&Q&+*]!IGF=G%Y\RS_6Y@$M0(KN_ ME]DA1VV&]^<^@<:+.5!3TSO=0KU`?_B!O><`X#E[7W[PCXNO%^R=KF/R=;M^ MXVDK*P;`\NB<+?&^5UB"^W7MULQ+3V5>PL\EH5673SE+-]NN0_&JO)E7)WP: M)GC9+-+C8/PZLOT'X)X.&),H`MY-\'9>9+*4<7,P5@12>\2ZR@6[Q@6!I<4I MF$ML*ZI"HPTUH5NH2!)<(5.+11)UH>D4.RY*M1X4RV4\>QGQL[:%IHHLERI- M2QYZV=E*W\AJ0=MY@QA&9F]J/^>1!Z8"B\/0A;^M!U)V!Z$Z+^DN9#[B`-0G MY),($5ZIOCXX2)[X\A%XY)UAD!+(99IN+'ZY$_B#H_[:'/5B:C10\;PS MP:QT?W#4#X[:24<9#3S5$Q=L3SDPEMPQ?S#6#\;:C;%Z]8RE*@7&4LN,=7$P MIGIUY%<;W.:AWT?7H=:A_Q\?Q,>[<^X$7W&'/ M('B`SE*YW)MAQ.;8X;)T[@-/@=8U\V?N)-0XBH-#5<(43(*/\T0](7]#7X$ M.8^ISBV/_S!ZG,-H^,P[O31A(/"P5S>Q$S8I#0J5HC#&(K^/?9=8[DUY.L_+ MQ)BBB=Q9&C.?+&OW(S9S(R>)(F)BAJDGIEVP5>I@^*'8X::S^F'T`5_(,B-Z MAV*_%8/9XI*(&1L//S/LE7,'[.8$BZGKVQDS.78D2H*7,"U0CMA]&42Q9*_F M7*U[SE#$RJ`ZUG\!'GR&,:;T#5DW&T^`8,D9D(@%$+,2E#Y_B@%L]LQM#&)G MG'J_`XR"(2GW6LN2)(4HF!U0WW>YK/DB28N-S@B)`J^2V"WL)W>1+)@MFLGD M@@2R$41ZH]4(ZH[-B M4*?(H"*^ZE[T\EE.5<0^`E/_((%O-L=T&+_V"';I"`P7A>(HN!A4(F)[858.V=W6+/&9QWV2&P8 M.'*!.)S&"##,N0.>'81IIG2K8%GQ-85/;-IHQZOH``3 M1HU(A:6+X2LAQZEA1"&W8\I3/MYS'T?#6V2`A-]\;)P)3V5\S)&`0+&I$'L@ M%XE8VKT);/,4/2X[`M,T!9V%G1HQPS@KV448(@1SR1^C=/;LL8AQ&\\OK.JU ME]2R`VFX,GGPNNO/L048"54.)ME)NOM1)&@)B676E9M0RQ*DX&C`=+"DA1/#UC'^VI:*G/KHHO%MV$N M=1L4N`5;&-C#@F1/<] MD!MFQMO6T=OQGLG*+Y;PV$Q$!PAY!IO8FA&O+-R8YL18`30QM0U"WSZ'2D"S M`VND5*QQ(W";:^MF5QS0LJ_'-[M!T6'+),3.RNCAP\!D?\KKEZJT]F.B_Y7$ M"=*W$)T@P$(W+H'>3IKZL.,$AT,-Y@*-5SMEE:@,<#_RZ`L3KL/G@$Y@\[^0JN'"!"*K-D2^`JU$OX")@T,@4L2&(Z M*0+$FG%@/*`X1SM)[@I*[#YHECM(T&\['5/Y"8*SBAXR MB'44*U?KCP&JBV40(E%`B,#)$`YOID=!G&)T;D/,C7A-$H:N=)9FF:-+01D* M5!UA3A[:=LYMYC!(PCC/UA1,*;Q9V@'ML.HS]&J'39]1GW!4`(`"Z((()\NG MQ^@1K0WVS>Z@H9SR>]N;IVR[B+CWD&H8\#LC5"\P#\;,U$(Z5379P"0!>0!> M'#H3@Y6%BA\Y.9_]Y`[MHUF_3U`_@,1O`5<@%1YOZ2G M!71-731-$*`EFB;;RC*AY2N/6DI1V>4ITH3%YE8,41\B7J4/G\79?LL+4UD:8OP'-Y/PFE$W3((HR)B!'A!'Y"PYJN MN\0=!;,4O8(/H4&&>7RDY]?;D?9?I!!B*>36*>/CQY8',B0Q%H$>R^< M$V.&/DQ&\"-\*`!!$&XCXKNCF+#UH.IBM+PCE(+14H]:&/D1T8=]0(K]>:JN M\%.PS-//RPREF(G)\9D:41Y`O(!0Q""34]"SR>$/0`*([0P$/&.9>/S@31:P M!IC,[VY8M"SH#AO-.9)6C1\]D2K"2XFF0\4*'30)9Q75:T[>R)?^$[47W9Q> MJV;_#4X2.Q:28PU!B>)+RXIP0@X!HK^CN*2L*S1U\B1A*1@XX354":KU=IS98^96B[8[4IN9/#PBYO/0+<=-&N"NZ4ZA8DF M&X0]1<20$;D@_I0E2K(ON,048DA$F3M+[E;$>'Z0O@7H#%L=@;\*42SB*:%? M$"\H`%`D1Z*WFR/S+-)G5'E1$;8-1GE.?73T"N"AW@P`?,03[JG%34W*1#R+ M_FL1V?F-;-BE`@ M,[)L*@XY#SBA:W).`#OA$03/)2XVA=SAR&-SQD`.8V<@`+5:!.8!K3(T\XVT M#ADC[^\3[4RLQ)AA]X^S,#OWK@(<$I2"-6X6$IYXU2GK0I=%@6A1BI3P.E12/,1T!"O!!,H M/(?22G0+(!?; M6`F=P$+RP1,!C3`?3"CW/CDTXA*^%C-G]EM,SFF\(N2'T,P#&9A,Z"U=53YL M&"#9_@GQZSXW(_^);8A:T9ZO,0U"8^L^*%-$()1[AR+X8O8EI`),>$?F@ MU^P6@!6*042+`&>!V283O$J`"%JR`DJ'TA(IZ.9B;VIQ=[*]25PX90R*_Q38PTNO>1%_E=`L6-(Y8001-5@Z M":1L&HFH"H91A7,7)-1,D=6[%*18A`P.`].^J"3H?ZHO@^UVCZO43KW4:V8` M;6IJ-+M++WMMJMV_50\X;6TOM$*##[DC&[D.ZM7+V+S6_5]ML^R185B**ID# MV8$.#4/)(9ZTU%,-W=1,S1YU]09>;5,[Y,=S@;;!$JZ@8=:/`J&2@&1J6%9' MSXW]L1!Z\Z2(U56`\X5,3&0.$/8Q]E.BZ!TALX^:F?R&:NKV3^8#29R2K&H6HWLR"2*>90B:V7D+,CYM^R\Y<#Q-6$%-_9#DW9!IHWB:@D.!"$YBJ+T#-X.E+WHA')]'` MTBU"]_E?4B2#KH\>O!G$GSI"ZZ"B]'8P'3'Y)2`%>&ZRU::9-91-D\R-R*.6 MD4C#H/D8@I=U4Q._4*CEL)CRL.M4X`82`<./4J'B*/9BFE/C/9,421-R3VO:89/N!>4$0] MNSDG7&'@BABIY`G"EWME!P[V\]Q\Q:550Y7':38P"01<5:#0U"2*ODKY66V M+0#_&;79>ZK%AJ#%BL;;;23\5#8%6]#-XM!DNR&JOTRT'*F.02'.VM6M2=(] M:EQ;C",L6+NT!?,=/K@6>=[>>[-:4*]Z4NL*G;[D$HH"!5`+GK]$/EK!+R@( M4`^T.'B)T%,]Q^?,Y[PG%7`\@=G.O;[PP!8SIQ^G'Z??">FWE68M%SM_P%C>+V_L]4HU>R1S M;O4V/-Y^CWBS@?Q/.7#-HI0+5DB$1IDAA'=;'3=__2J+3=4SKH-B6?MZ[Z;^*]:-+HLZKI]$O.M1532'%$U3V/DMHA*A)=4P^14>H:7;-&QJCL3 M[HU*W)UHJCG"Z[$RDES16A3W5:.1PN*I[66=M\ZEGU0_XW--+`X!3D%.04;8N8KYO.F M-7DFLZVW\`NV>IZGS-;*!C]R8G/#:<13OYNP1SPQN+Q@GOI][@OFJ=_U4K^3 M2\L\^9O/F<_YHN#IHTLS3_[FR=\\^7OGI5X4G'L^T5Y./TX_3K_VTH]G:YR= M3\R3OWGR-T_^;AZ5>/+W5KS4D.3O]D`>0UIM-U_3,2MX>/8:6A$MY\#LTGXB MJ:)L69Q(SW&2K9QU$N,S\ZXQPBH1X:=T2(C/U28+O]AS?JXFIQ^G'Z=?>^G' MD9$$&5E;+OJRL!%55$\4LFP3E111T[CM_3POR2;GI99@(SP@T%JP://U37:P M-?[HXA_.`4Y!3D%VT[!HH;]"7L] M5(S( M3R(_6.:ZV;_&[G+2[$XB$Y'(%+QEZ5?8WC/_0D$W#7Q?UBKN]:ODY57OJ.@< MQWK&I;U.R0!3/_"@+3GV+7WRH+DSZQOJS47:0@P^8AWM$*+"[FT(4V'WMM>O MTJ@P^=YCK2PSB[\A/8637=^EFUK%GNM\S]NWYSM)NK:ZZZIS7%'7#)UO^U%% MO6+3-=%1M:VV?64#R:\547'LTB8F`R&I"STQ5SIBSN[(&`FA5WK`5C0TS;70 M3/I0OL:6LHLH@E^R)I=AOHOIZNF^TL%Y;6?B8@/CD>M'?[O!PON#]6+WO?B] MYT)[Y\F'\!,D"D&75VB.$_\5SFYC+WH"4^`Z)*Q%OIZ%8_(K7/K^>Q\/9%OK MFR-3ZFJZ*NF*+4N]@:Y(AFW+CJ5;]D`QC][[>!/_0B]1VK03.YS2_IB+*8C] MO]#G%7CE`5O#D_V$Z0'NV_A$1:&IJ83;^Y%4VRP?KL4_O">O$#0R).$TK&8 M]+4?)[VXY_!G[!/.IHQWAPW7=STH+ZUK*'3]?$G74'M#1\H55(/]1E%X%\L= M8QN;[[RSW]W"W[R4CTG=AN=J M;*[LT//N_3"DMU0"L*UK`3#[S$[<#D$_C_S))H4[-_-)E]@'Z`DN41+_"8VN=OE"5`Z>2&,0-]_"GQ/.>M8XHK7>7A^6W";#Q+NYFJ><@@U)<8^4'CTV@, MT7(.G")\;@)[09'X5>C_$)A^,6IP,W[P)HO`^W"'L84>!*Z8.=V%\-4-1%D^ MT"`+S`3'ZL;Q8DH_^PROVW^\P!E9LJK)/4E71YJD&X.19*M&7U+,D6-:6K>K MZ\JQXP7R<^&"U*8$A#$3-T3XP+B1I-%A)&$-!0*$:L,WR=C/(OPXT\@4$:C M5TFLBOQH$;.QR3!9U&(E9N5F^W9IT0)'?5FTP%)WCQ88APX6\%_,HQ3F\>=7(3[3,8U>9Y[O9HMT\=Y#PDQ]_ ME>[`3O>!G%X\%R)B:M=R.D\)#"H=J_:=IA\./=W]++#^U?26++!^Q;U6+%#N MV(=AT3-#2+\_>IC!2I$%(?#O/.%JZ;G1"6K?OW3/]YZ[>94JLZ<9!%X#?[YLGPZS.[5C.:TXF`VY4YO-6[%`W>G4ULVM M6*"A=`YC'.\R][V#$$U\'7[$ M*SGU8U@3;^Q/W2#^Y8VDK42TM%&W-W"&IF0ZZE#2-J/N0#)'`VUDJ8HR MTD=?E"_$CU^$/GTYO6+TYE=-T619SM%RK^NMH.7M\V/?KAG[;^(I>Y-N.$DT M_.<9?/0ANR:55%_KTJ#4)V_J^I#@VR=DC]SQ?.$&G[UHJNPOECBTC+ZL&Y+= MUV5)5]6!U%7UKF08YFAHFJK=DS5">?W-KQ_U_U64]XHS*-&Z$?38D>?C9YA@ M^-V+QG[LI7Q0FD?R_O+7S>#+X]>]"41$47IZ,X.$K)7ZM"=F7C^V\%LO("A M/B\?7T"S$IE4P[!'AFY*>M>P);TO#R7;,8>28?>[3D]1-+NGTU@XC/H_/Y4G MDDUO&,Z)H?7)N_=CR'F;_^E.]S=-T]143>T-)-OH$P7G*)IDFZHI#0;#D4*F M/AAJ/1`S@#25-[]V>][!H]Q32^:%^LBF-'L4OG3LV5%^^3@YT<]-X\'OCQ.)A!P("<$P^^,ZE#Y&L[$7Q$G+_;<:/P`GY,! M!G#)=/8(!"\A_<>X"VY6K`3^\.&/9`4X&S^=U]%GN#9[)R7Q@QO3Z_B1-X;D M$%8.-@S)T0V8VS=__I"_WEVXV44&A$%DH"NR>$3!*[0)R>+/XN7 MQ!:8QD+WG2C,HN1+$=ZARK+!-G+8_XA;W;V^@6]^7P3+I!!&+$R(B"QB5J<6 M6$70.J]?Y2X)]'_NYN;0R;X8_(Q)2F,WBO#Z?)JH=)_G+YI"E-ULAK6RG$RL M8[##I60R#B8M^3%,G&8E75S:T4DN*M25L&J\`="CVL0U!7\M(DX93<6)EX\COS;`@"X%OX3 M"_!?`4Q\_2J/8U+@$HI4YM%'^/\4"/V/8G<,J%\:I+4QKS]^PA?`?P<=Y`XO MGF/]S4GI-B2\J_"X\`W0S+1,(AF-WF%TA<=H=DLONRZE]`8CZV2"%3[=\8-( M"ZHB'#I;A'.\/IFD%-TMY@N\'AD_"'<`.F)UUHAL-F%,G!&=*QGJO_07\"@9 M@3Z=?TBFH`>R9YJ8;@4GR,`U5[1@_`"(>3@H[\4"F@Y5O$6;/[;7@8L"( MUM*-O+L`6AW3Q41^_!6I11Z?+,80*IM.(?Y*5/2_:'PG_)!GZ5LO\,FL"14C M&`19YS'R87YTP8PE7&RD3$:?NM%7;RX\NM'<'_MDC#G\+-O$7338]Z(.@'^7 ME&IVBJX_(DYUDWDU2+`NYE$2:A?C>#R2P",)EQ)).#34O3[>D+L8RO%PCH5V1O>Z3ZP?P+G+XW;B!=P,E_+"L7ZE:WV'*ZO6Z6M]6 MX2J,W',DW;84J:N8/8F<66I/'0[ZW<&H<6UX*G$G"M911":E(6"=FR$D0*;> M`^:?^U9)JNM%`%0]X86=!+%*B^E=&MSTTGIYYH9..>O@)O-TE>/XJSF\5_7; M0\-[W>DLFOO_KI1ZZ\_B\C6.O7LOC2+$NV@6QR4B_!5&'H1X5JCSSO499L#) M4T&>/S#X?F3ZG((J4!XYF$[-`E*M/@[[?'`L?%GL7%%Y^#XX4'/=3;JFBZ. M!X>\3O4?-`_%^)<@!%>YG3UX40GZA=.N.OT*C]M-ITI=& M`0V;\,:!H\/-6[72JD-D'RN^JET];F.D]TC>^59L[+3BRF!3%-H?L_#^#/69 M8A)&.'"PM'FK/G79WN.K,[7V'K="GP$;6P?>U7.+^9]/E@ZG'Z=?H^G7A$4T MCFJG<8&WWKV@\8ENCB[J9NW^&B\%O!M.'/4T3GKS"7.E*<73;2J_.2WKU`0M._/)&,=?KU-PS6>J,WI+G M6Y^\Q#,RCT0(GI'),S)K960*/!&S9BX$3\1<-1H.FHBYYBH03\+DBV7A3]-F9YF#JBFA9M9LYMU6Z+R[I]$JM+>RMT&?`QF;M MW(++C*B?3S87IQ^G7Z/IUX1%-(YJ/`?SI6EDEJCK/-6PFCC*:7STYA/F2JO- M,F>5@TF$1^4YF!>;Q\4IR"G8>`HV8A7-H]O.579?6BEW7=W=I'KO_DOJCG3+ MD;MR7S+MGB[I(UF5>JK3DV2[/]0&2G]H:$D2U_2NFE]XZ;7 MKW9IW<0;-_'&32W+O:M,<&2_NX6_U[=DXJF-Z6\/G6C*6UZ]D*-32O)DTO:W MO'J!>ZU9HN.THI-14[:ZQ5VK1,=L`)+29CD_RZ95FBC7SZ+C3:LN.*C3%+&\ MC*95FBG:9@/27=LDL1Q.JP;`UB%EU^$3<1)FT;*/)]S\0)VHY-Y`MGJV*1F. M.I!T9:A(MJ&-)*UOZYKL*)9C]9^%S:9N1*QNB:B;MPAYL7_3_7J+&@8F*_GA MA*SDK?[#SP)(JA3[_WIOJ0;"?]^Y4S]8OEVCW!`QFTT?9R$9!/O0^XQ&/NTN MOQVXE7LSX%BYN8/>=RIQ,`IOI7\L9$R93)N0$S6@%I6 M#5#+.EVCI(._>IW6W7(3[)5"!DV%'I*%44Y,^%WIR'(""25ZM(A2G*@/>N/I MLGJ#]>`T.5=>-9L(DZTXPCM26Y'7DGN=E(,=@4+QX?@Q;=U#1%V:AN\%R^K7>BP=S]TD6;HKKF2L+AV/S,]/K(#_V8 MN)"82-`^ME=$TZJND7K&;*^(ZIIJZ,?1[I3#'K__W$PPB5GBX*"C&?Z]R@S? M+YJTYU<>UY"^3!H>WG[9>M^"(GZ]ZG&=&KY6-%'73Z-FVT`;1S^PY74FVEBC M8DTA]B.IDKV\LU'Z^&RI^((@R>;8Q[J(R.X_^?/E@6(IJJ*-[&&O+VEF%V(IMB/U=%V3-*/7[5K#GCK2[::E M(--X"<1L67;N8DK\$Z*#8II>#-039D@^P67D@_1C^)8,L4OZ\:4E'#OJ"Q.. MC=UC,^KI8C/\U4>-2+4F'78O&N$'IF\]>-,U6?+7TW.CH MS'K:FPG=^_O(NW?G95I>$Y+Y8>R/2Y__O5H8^V1ZX-RS=S\LYO',D.-[=[I>CN89UFK8' M.Q&I#FEJ5PCN**>Q?UK$-D9'YH64UTB4+:I-Z!+6)L/NG,HF'-.TNRBZ-=!0 M:N.N"FGBM:)FKHVUI13.L[9FRG_S]Z5][:-)/M/,-^!,";8 M!&![>30OYVT`2A3G>9'$?G:R@_TKH*26380B-3P<:S[]ZVKJH`[*NDB1$K$8 M;"R)W5W5U<7J.GYU\`W@VCA-L*`&IIS"&U+!MZ/&E*NQ25()*FK(MPJ:175< M\]G[Z=*T=>Z%1/$\:$AZ\$<B3>44X3=Y>98T^?"VS(V1[UN"J M<"K_G5!TOF%C]-78>*D$%37D6P4-J#JN^8"*\WUKQY=JT[\TVU;5^$`X=;V*(?GLPOS[:=P]?X'.?T)_28\1^>?OU#WCZ]2/7OOM\ M]W##A4_=]P)/__DX??)"O&`TXWSD>*SYV9#TW9[CP?=N M#P`(`LZ)(I=>98*0#C#RG!Z9X`Z,DN$(?/Y,)XNO MLRN>+\CX&'&]9Y<,Z#@I&?!$G_3<"$8:.C])R+WO$RH.0TH3NU!UV<1<&QX# MSWHOH=H`%G(W&-"UAA_HJX.NV`]B^KSO/!$.F#2BBYBN;,JXB-!/*>>\,0_$ M_Y:V<7,\JAR<*26464$2`@N`/90'E+&,6_0[NN`!;".T@0/,ZRXH+:#$STZS M1"W57Y!UY,#U<$XRG2;QXNB:/FV.1F'PZ@[9PCA5?<=FUO"[I>4OCAL',=VN M[.AT*%ANG.)Q,YH(`!K$SY,.=M^O'Z\!IYL.N^%R"L/0^5=!==FW/*P<+KMT M"[QQNLOAM$(V,S\=9;H">JX!UH+21M?Q!P'^C=D4KM_S$GK:%QKOIR;K.A2$GY7\+7(#>ES#!^#_N!W6;G&\T]B.L"FCGQ;4\FGG`UZ[HRC MC)^W]&WE>0[G]/Y*J/RF[4]\.N:8#B(HJ69KW\/3B[_X=^*-V3R4?VP;)WP+ MDC@"]3?9=]@O^C!Y!38!>W,8E<\F9Q@D?BH:]"`9J42M",YLVPX3C6LH[R6A MSXX2G0)42\2]7]C^3A+2,_"!L:27KHTAFHAB9FTAI0 MD%1KN:]TB*U[+[+SE!XK?74>.M($5&5QAFW'E_E44N>G8N5-U0VYGD>Y_*\K M>M@]@EQ@5-I>$OGD%U6;Y"HM=\XQEMXV;I:LH;4VE1F&,"4,U1K/?W+OC.$C M\Y<3]B<6%ZO)BV[]>Q*Z07]:+S\ID&=?6E1R;,<-_\/:9^YM68'JI^_%B%64 M+YM9V%(DV=*198LBPBVSA5IF1T4MS>[H.E:EMJ4Q,XM+?#>=VXT"+(G:C^^/ MU@^J:W]$#)#BZI-Q+2@9=I;+G71K^L2]H78.-6-MUR-AF_[B*0C'1S-*5566 MJ!%J(5UI=Q`V1!GIJJ0BR^K8(C85JR.W*+?9[AIM1'CN/;YF+IFFKMD#IMS4=8 MA*>=,#8`#ZUXXR;/R*>#26JF+F3J!AQJ?;>([*W_&ZBJ^3*^,$TU_[L#*FOQ M@K\.]J6,9L/5Y.6!FAR]+095E$*?(O.#4F7FBX+->F.Y3,R_)I\IO+IU7B1;5V M`&5[=\+2E$O95X47C`JD6->GXN4Q`U9>O]Y'JE0[P3Z49*5H^:X>R2*/I5-# M]IV`:*5HHL_=,NL,1UXP)M..#*,$0G<1X4:>X]=/U=4/1>G09/3+4W3RQ0$% M5\%:JU-N=`._U/"OX5_#O]/SKXQ[\-:[YE6^$`CSPHDNJ]7GC<1K)[K55I\W M.B_G]+%O>*/RFE@PVL2YV8]-C5C#P8:##0>KP\&=*Q"/G,.\F"`]2_Z^]4=) M''UVG:[KN;%+HO]+',BN=J!6X-9G]40P5T%]<75#-BU!L9':$B$A6C>0:9LJ MDB6YW<$M65.M=MD)T<*.?7%'4-\"V=%_95C'N7/><4XW2.))>9K+&,[BYE1& MD_0'0Q(_!_W`"Y[H#G!)-"D[R:NNHL,,Z`:R`0A]V`$I86*0UG&X`Y=`!0[W M&8IM.#DMG?EM8[U1DV6]6Y:UM$<+7GRZ?.,-4\\H4H]*T6Q8H01&U3YOJ^A4 M.5#X\R4PU3__TXG9FKJS)[;/J69577C5S?[#;TM+NGM M-P_$JE+?G`/^Y-,73X^^`[GO?M"-2/C"C)P9_RJ)\&0P$$+`Z?W7)Y$K=$;7UR/1#%`8$`=>U3V]/3=JL]'B(/LNUH2B](Z MFP6RE)?UJ7Y7QIJ/)!O@7`!\`PYJJQ>/[WS@8)#Y=Z^7A"'Q>Z3LI>KO`!Q" ME-XMO4N%]'-!>'<$9\N!_I!%Y\JM_T*7'X3C(D&>%$T6=*G51KIL"@AKAH5, MJXV19'0Z9MM63=7$;WI.AD[XY/J(0R7R/7[=-@;P"O:8[FK1>[N M?)D,K6:K8O3,S.`1R:Q=F/\Y7_K6'I(M'1H:O;YG/!A+!O#,4S+]QT;.++-Q MPVTCKPA]DV<@Y]:OG2_7+3=!S\A+!>[$&[P.4\)229S*NW@M"-,K MU_02MG1]S*T1SNC\RE4X%L^7532CPGERKK):R3+!E4OZCMP6A5QVY]T")Z\B MCPQB)H!P5\^^1M'TPSW>I0_.+PZ@XD+7\=(H1Y2`TX/4ICY0Y05E?;3BG*R;H]%ZH#*IF'C_&80_40IM]Q22J'ZE9`JOB>MST"HLW8<2K?*2 MNL;A4:B8GYE>MUW?C9Y)GX$\UD_L15[5UG>@/V.Q%WE)6U];5XYV3R5L]/IQ M"W.P!'8N'Y>))8J;QZX\K= MV;*ZR,@\QJ=1LW7@C8$+MKS.1!O+Z;%.\S!+4B5'F;-2^OALN?A&<&=M<$,J M-GJP%@(_&T0(B>?$!`)6`)K4<\->0C]@^,HI&CV]4/:37LP!UG;$9T#I%Y#< M_3YGMA1(8)G^?D2'@:`4@^I?--+9SW_-+ZP,BSV[*)9[$3&T^KX;DAX@TD]] M-SSG.71CV1C!"PF?B=._YJPD9'FO=$W+".2_O8UFS\#(%SH>T$E!>/K<[\*U M.H7&_RV%<:5Q&TG M>KX/@Q>7KK,U_AZ1_JU_-VV4,&G]0KF9YK0D]+/)E]"#[PBXXTA>!1XW34-1 MK#:R31,CW-(-I)NZBMH6MJR.+(JZ`:$_45V//'[UR3`$B0K1G"&'D;F$[3[K MG#,%IG@D(73MR$EBG[6WN!L\4'%X\NGIZZ?0Y>T@BJ/CATZMMM'6K8Z-%,U2 M$#8H$W6C)2"AT[$$P1+;+;E3=M*YNF/2>90,04'\34?,1>2&MH]^1+CNF`XR M<'W'[[G0^""F9YSU7P!E0Q42&7+NEBU"Z$"SQ]FY"^;"_G:7@BUU1).*W@!^ M-U,?*\)\02GP#>!WP;R\-X/.1U&2U=6AZ9L:#D)&Q66\(,STK!P:22+O"I=',ZQR$OZ^MR`BBFU MZIIDC\2#%N8\]T1\$CIIHV6G/X2P7QRR$K7::3R9%X6+TWD2+Q:-Z%<]HE5> MEM=GX9XQT0HOZ!4PY>J$W7@^V,$-_QK^-?RK+_\JA8CA51ZGN,'^WF3Q-=C? M>;QIL+\W&.KX-S0@UN.-APL.%@W3FX,QQ583G4>:G:\Z=NH1:"`4B; M443BR.S]E;@A_]/D70!YCZ=3P4X?QG7,F MC&=.7F_.>O@>>,^Q2HE_)UX&L4U,,ZG3(@M(V(8QV4"1RU+"W[-$[R")Z*#1 MATM+M%;UPQ*M=7WW1.L-H-K'^?S<@Q[F[!RP<[$JLU6S](O_7=V"]_+F1",G M2@/W/?@'H;M-UP+U)97?Z7V[MS<-CP\2&+/'L$NAJK)'W!1DO.JB%TN%14\IJ)$2BSBM"P2E9 MYZ5M_@B"_B_7\\Y?-'A#+=A1?^X:YG/@/R%Z\1Q2G3(@(=QK8N=UP'2 MM5J(3U6$Y2Y^)N&R/^CLA43$!6>)G5O`JTFXJ([V5S8>Z&]!#%F[%W:@)8D7 MM8+SW>NF^#?[/#^ONOL;O^T!M>$]L_^4..BRQ^;0WW>A[HJ1_@KB6MWG=LW@UWD-:4"<8$Z M'=LFB?%XV85+J8OK$R%#UGD;XG2M\?PG]\X8/C)_.6%_UNF333)BT*6=5\`6 M)GW+!?A;O_\`F7-'P.Z55C(;)4,290EWD&S;,L*2T$&Z;5L(FQ:65+2444$7;4/6="0JIHVP MVE&1H6EM)+1P6\*`B:P9/^@(5Y_N\7^E+X:UQ,Q"J#N2R-ZE0]M!."!N3,4A MNO73Y-Z"`*9EVVQ9!F6A:D@=A&590RW;M)!J6[*M2:)H8YM**9K>`JI,OQ`$P[_Z=3U5.$@)8.=4L7P,_G/Y)9W*C@M*6;4J\ M:NH6E4%-0%B4,3([IH%TP]`[DH5U32P];3E-U-TA;WD$B0_@@\K%@YXA2?\& M[=:C.$Q2-.@9F+L3L\3F-*UY"BV=19'FNHY'AP#<^^B9D)CG>AZUHMA[@=I1 M,`Q;4)#!D^[1!Y]2W/H^B7JAVV5XTDXW>"&7EL=\*&"TOD=SW@T8T\?ZO)FZ MU*EK#WU9--KH9\CZRA17L$5TB_.35(]X3KI`FB\+0Q@LJ/D2F"UU7/IKKV9R M&2OB!H:V^/*?>%//D#VCX@>X?4[VNV;-S9IKYSU_XVP?D/5:Z6UJUMRL^5*3 MF+Y?/UYSWT+FB1MS$3C>#LA4V==(6Q."VB[NM=R,=24.-G<,@0%RU!4>)+@' M/+LO\+S!XZ+!+1NQ:,3B#.R@S2KS\3D(X[0JZ`F:K?K@4$==I_>3]*ND00\; MX2+.S*&948K.8^,T8'B-H#2"35+?9=!\ M>4E]W'^:7+XW7SI-+E^9K@`SYKX`IN:D_)S997;/ MW`ZJKYN4GT8L3B$6]3>.FB2@"SE%ASK-)%P\8&8C*(V@G&4TNDGY:<[.-F<' MB[RF%HPMV0A*(RA[*-DMP+6.`7R3UPQT`C.;2=PI"C!'M#NF8`G($D4-X79' M@CZ?&M)-79(46;7%-H7?)*\`8T5^PC('AG$3+[@!IVUF=#TPST,IVD#>\KU.0)DJ?=K^')/ MO[;!"_KZ9/_EBU1Q=Y:R:!6AN]]Z'_[1B#U0D51,M!^.VB+TA#="=KR#).4@1C69?*]JL[W+]Y%J2+DVN=:%@DC?*=2I4 MH]>/6WBW2F#F\@F9^`TAOL2O2VJ*)LJ\IIY&[5:?-QJO&T:CG[,_N?3)--^HH(0@R6QAO25VD*19 M$L*F8*&6;+>1H+4%U=1DR[*5LCMH"6\TT.K1>_`87)TOK-W5)!]H;>>LV_L' M]@'\9\WZAOI]>(*.UGN&MFC3AEF3'EGTS1JROR/WE1M2/C]''/&AS=;ZQ`DZ M#C"8_YJ43=D/OG9"WEI4?49E_V M9'=3%'^,HO@6>7)]'UX@$XV_EXFR]UZ?<7EDW2I7W@!/H&\YUA2U5/G87?.L MN0CJO)(38JK87E=72]A!2.C4'&3S$[\WYN+0\2./95-Q+K4U>_5+.WD/(>?U MSI,MY.+#H>)0IT;RXM0-6,1U]J@3EO,ZK\JQ[/C]@]_>85*NO([C_C;F=V)__33GZD)6?4OLWCL[5QR3#M)/_@1C_MD)!; MN,:0*'YP8K*_VZI/>N[0\2*`7USV80FZ:!NRIB-1,6V$U8Z*#$UK(Z&%VQ*6 M15'7C!_R#_&*2RA;V-RC)"17GX1K052%#!.+IC]E=Y^X-U;08TW<[TGH!GVJ MU*R#V+/LU5,4W5:PBK"IZ`BWA0[2#;6#%+UM&BU1E/46E/E)5Y]@$"082*9L MR%W7HI2TDLCU2129O;\2-V(6\GT84'-IZ-SZ`_@_^.CXKLHV;@DM6VDAR1(E MA+%HH1:6;*0IJJH80MN01#'/59GG''O32U"%YO'JAE*X/-^8?+K"O6;JQA>Y M[MG#?9&;JX>^/5-MRWU)'?8=<-BS9U]KIC3[5=3@#H*,['2E%T[L[J!_)"_*3< M0!9\N:=[2Q%Y0R[8O5498C'F965]5EYYQ!9+HB@(=8/V.H!:7>,%O'<4Y1(C MJ;=IN5Z7#(*09(KWN%$8O+C1*?`)#@VE85Y1:@7+?`RB9:DF>NQ00B5>TPJ. MGU=O=]^+O*[L3?7!T>$ZVU]?23Q5:^^]()J8K_729Y)8.XOL8(G'>]LL&\6] M.FI,4B]/C4F\*A>SKSN'97>,E2T&VKXFX(&]&]R-6)M/_^F1/$%L+CI&&/7V MJ[T283-QNVTK2@?I(C805K&"#*7=0;:NZUAN=W09&S\PC#,+I$Z6=/5)G!.= MN^XUT>;NV]'6[G*T]2X-L-XE<10[+!WD3]:GC_3-%SKC$WD@0\>%!$_HEQHZ MO3AQO&\D'$I'BT4:'4UI"Y0_>AL+"$N2A4P)FTA15+NCJI+>$N0TP'JO_%=4 MK*48<[E4[QCDC_*BW),54.D=$#=.0A+=^FF<>&DEG5<2]MR(W(=N[R@Q?VEU M`VP-R[9*V6Y;&&%%DY&A4:$5L&#I6+*,EF#3#<`9476C`$NB]N/[H_6#2N:/ M"(B,J.0JUZJZ0Q+`D?DSSPDPZ4A]&,WVG*>R\5X?^` MYU<=XXX@6%A)HKJJ(KA6N\RR[^_4G!42"$MH@P,:BI7[]R\QSL!*@2(H+ M2&'FWBE+`@[.RG\VS+]?2K>O=Q51D^0!IIZHXJ`W'(F#SF"@&GU- MZ7:-G:KD_O7W]U_'XM7G_A!L$A?U`8=;&5^_]/^XFGSZ\A%_[UKPZ*O)-:\+]_918-LVZ$_RD8-/]34F7W8?SUZ_A+ MNFQN"[&A0]\2'ZR;[S:.RWD,Q2#TO>^62*D/]/>LN45.^S^\T,K$CMM"1@,* M"K[]C:OD3@BMSD&AA?^P\1\9*&%=XWCX61B[X8,]_1XXD7L;W%H!YAQ-[\QY M*"QN_D[PLQ-(7BI,L87\9B#]Y`K_B)RGE/3XN,M6MD94H#B4A6W$0D\P!6)2 MPC+R`:X!UH6:M[Y%LEYXL,,[P0:5^^'.1[2USC=T"/\"X-:@W_EG\D_\9>>GQZ*'Z9- M'[:Q2/<6!`G^4?!YH]!6MDLHG3KTPJ"WLV@:WSE3`.5P&H'8 ML3S0#:Q'^/J,=?TWX6D@'*"4Q1((PI[>P0JP+YS#"'1^XWC>3)C:\#8O$YG[ MWH(^<0>[X<0$=`,4;/DN`&WFV_=(*P&"J$W%S1N@@:& M-J!J:3YYH(T(0#^F@_3S(]@-Z1KP9Z(1X"?Q-28+#M;P6'6Y.;VS@1:)JP`. MIY8?FEAX;DWO7'N*[3Q]ZQ8)Q_.?B!T`X2_03J"-P'>L(`3P!T0F@97^!K_- MW`(+\TFX@;^8,PON4LB+W$LIRB-;I27'8(&E(YKZS,T[)2E'M6U/+7A)O80H&")KA&,=_ M?P<8X\5;XH4#5N9;#KGE\.[2%34=ZJ)!DBF1=B`XT7M#7(R)F9AE+4UDB@)Y M7(.4N9*P`P[;0M[QSBYLNHH1W>"H)-P,B5Y@)5,PZ^:1`P+.M!?`+>"+00A_ M"N]L']GI$B0ITPJLT`[Q4_#_00(#>R6I+EA@]7D+9*F@KUFP.3@S[!?YEQ6& M#O&>OR9JC^W.<0DP;);I#HB%A^O#]5(`(/W8S(N(=YW=,[0#V M;,\9ZV0GA?VD^Q-F'MQFUR,F>6??V,3,&0P8!!`?"0SR()U'/K93Q+E,WRU$ M="NCXK0(W=BT9&;#-;5O(O9;!W48W$04<&)X$NYMCU,*_)X#"G_BJP6X"KP/ MU`&0-M$%%F##%"L$C5B8F0O0QH*8R&)9C&#W8M$"[S-:9;+"7&`3ZS)9"E($ M``VR+=8/^:J.]V#Y*&/GV05P^[<@9F[1-17O@^['/;R*LC6+F+_B'85?;NWN M;Z14(Z5>M92:VWY`&J`WG49;":LLGT_47/O/1`5%/=+#B[W`VP]6F\FH#._N MBHP*$B%5X-[P?K60>@`6:3$&'"_#5?24><`"#Y[OS`""L`N68QG@_GZ4E8SV MWT(CT(G(G,8C9YXD7I\P;6!?4QQF9P7E0K("6$P^(W#[F>?I%.\&F=^0<>Z3 M6P+,5S1;D"\[L7&>6Q5Y'A6$LIT,,\O$0"QY*R\66WD+(Y6&&9 ML"!PHD@"6QJ^EAV)P&7]U`M"0A\C!^X%`%N(QREC[04A_939:-[4>X?'(?FX M!$3;Z"18,7[^VCX+:;*1==X[CNMSA=0*OM#^^ROF4^O#-;5=$J6NY<8BF@'[O8A3$M9A_BSP<&WK[V&V`_X-7*N:?Z_Q_FV&HX!-]?[6Y M#Y!YV[)>P(Q#,_*#")B>4.+137T.J/;2JR;Q@7]$;C9*(<6^XAOF@0%UDC$% M^BFW5<9!YUZ$BO',!KT^`B#09^\\!]2"H(TOM+AH@ITRH&1X$%,26E(N0RQ)S!7>5!#9V;N!6@30&]G?C_8"Z`_$ M\H]*NU?T0,:=*7/+,T29(]## ML&C<=/<9N+3(DP0'<3U8`0VH4'!,_#X8G2X9A$]@%J1COPO[*J"J_88FB(.% M#H\Z3RUNKR(0L@C-&`GF[#_`ON+\RLB9D8ML/B='&NR#65-)1"\#:NYV"E:0 M0IM@H4L_=J_-+/[OV(8!D.4;&1<`QIQ3Y2`S`Z8:^2DAVFE:*;!Y[P$=MVPW M+78L0$K@Q9V/Z22>'P.QG#Z8Q](3;CUOAG32XN$I7(PUPJ-U4C,*P!`YS-+* MZ)JD+\7(*]ZL643^/@9PRT5K',WXW'Y8^)E3+$9V`=Y3FQV5JVMP$NY$("@G]+N M,AG/3N$OE$R,W=0*OZ?F:L([N_A\>.=%`3#R>O0+6$7N82O6JAG;)C5K0[0X M<_Q\A575M`!;UEO=W0L5#UF`O>GU/@F^/5)TN9E_0JR_M,"K4SD_M>F-6NA4 MFF/E1VIHO(]O-OP9-'*4G-4*]V[7UJE]ZV-%K@=S/[/K?;SNQWOYZ'87?(M@ MZ>/A;$DX[/.6^3[-J^=MR;JZ*#:WJ;?S4&0<2,R*CA8+T[?_Q#RS@E.NPK%: MX66K=-=6)]@SGR+Y2>*4`N[,>D>^O=@R:3PAC2=D?YZ0-6Z-*D_(&N?)T3PA M9Z^-]1-&08QC]5+73?TZ_'/G:"*KS[M$*+B!_TASQW><`%5_95M73Z]HUY\S MK">:/HLAQAGFI*G6G5Q>W%A(/P^ZJ0^5?(Y3JRB%&3@+E:1>/*%TY`-W#'P- M'.:]*RY]#Q/FD\)F(J-,;?/%$U)]1QK6F>O\SE,V+I\\6D9'.P_JJ#.G^>"Y MMR)F=`%OX7D=V*:7V3P73T2][IF04'T(YA-5FA:<:1=/*/+N?4-?;8"BB3_6 M3A;H&\0?7]O55I26W.V<_G;730RL]XY^6(V<-![22V$3&[J_>-N&^J/]I1S" M:)Q?V].('UFY`.O%DXF\>P_R1D=L=,2Z,/]-=,22O(F+O]Z:4@,EL;G>YW^] MZW.9<8C-N9E[39)IDV2ZIRM\/AUY#E'_^?[S%P(5_O\1=E->^K8[M9=4]4PM M*7/YE/FJ4-XB!37]]U>LI2UH++=/K$DR]1W!7H;4I='*=K9-G\5^C?#^W#(# MFW=]@1/1JZ9#[9*QD8PPC[!K!#4IY,TR?#94,,Z3IV+EW&'BOKY!``1HS>(\ M4&J3DBGD9\U>\#3WIH]=G5:`4N"-K[Q@.`XM(JT`[JCG-6NL0VFQ22$W0#E\ MP)X)K,77BVJ,TY[=Z5O;9O3&[1YN,_M'XK0>L9\QJQB_P69CU#`3$U3GU/TR MGEGYACI%++W@U9>,]P%XCG6+K:L199$3)AW5*"K$VJUE"O$+1?_4JXVWVJ,W M\PURY+:<-MB[,^\MUGH#\40-C$R\H8"7*"8-P63#19UHQEHN8?MY:G]Z:[E` M3@Y[:+:P76Q]&G>FX@M2PP'LYX1G0861=AV$\!_6%`+;$BXY5?+^'+S1P9L? M\G\DBLFTC5K96%4'KC<_4#L==KZ-]I&T*5G2H"'J3\&O2&G2>K[I`MX_[-5G M+6'Q&\M/'X][86$+BVPK==_"GAH6\O.D+4;:[Q#/FV`DBT#"E.""@HG3$:UT MV^&=;UG8-#:\PP;^N/*:W;RAY@T>-GVP9FDSLPPX>'=\UKFD$@IY/H2X!"9` M?3$XEK!7S(]26TDZ-'$BB?>-B&(=-.!8I1RLM-0R?^PW/VQ\\%?.:?*E'Y%K M1C/J$`?\0J!V)[FV)[P-2\!1@8U^2"O(M"4IN4",$I&"`_LQAQAX=0UJZ!7X MATKM6.RY\&"1UL+;TUBS6$-Z\T/*#S+#<'BC?F!NM[;K\D[8YXDZV4W9 M&["'!^Q1S<;():![H*8OR(QA!6+'>-25CFA3S@)XGUCB,WQQ;%N#BATVN,9= MA,(M?L\"=8%/$W@"7GUK8XM4%"!"8-X#4.`GNF:LIS6[;0C0M&E/"QNDQ1PI MUPHFOKL9R41W-^#,/Y;Z[)!IBY\?9Y=)YBIL<533:3-I.+>%#4YMHD4M/+G\R[:@*W?3$ M6*4B!0NHD3IFL<*W,--]F'?1O7DBGA-W/HY[*#.=9VG:<7_(-]3DB=A30<:: M<=?(3*?`C%8OA`\>]3?&2TN2'JF.YWT`E,-]NNC6EV M<]Y+F;?4C47[S+H)B>MDN4P?K%6G*.95SNFP%QQ>1B\S(6\6^3&&V`5@731+ M9].SWLL(&-ZEBLQA#F_>.8L#/;Z!J_!"0,(J6W;5?%W5K%7U@!NTT3G35DY8*>[?3F@>NARP.;31_YTTXF*=:+JK.]$10K^1Z;8CU%CHIW<)`^E;:62 M=\KU_OQ[^X\V;O#&$>!U!690$5H9&!T#-`UA;])B#:W$(Y-D'.Q>`"?9D8V_HUFI/V++M*P-NN>&B7M)LJG5B2XC?6M]VO879K6N&&*'3C?8 MM5N!W#+4WD;O[IRU49O#:EI+U0][YK'T]):G4[!TZ3K0U">]V6I"F' M/>PY)J6M9U'OF4/NAF5YE+GGCLZ]7IPZVM+U[KD1_4L/K2IGPLM>7![2ZG8/ MG%E8/^R^DUN]W?,I_WH,EE9G/0PS;SEK>X<)$G\]0YZFR&>GF;V8ZG*H+%5!=*T'QW:M MM\S]2J_/['O\]R\_18%X:YK+GP=\N-4PG6TUL@.:Y*ABO`_ MLB9+XO])DBQ=7WT=7B*IAR'U)511CTKN6X<7?\+C\M,]&3,\F.6&7(7%_>&%F M7J7<%OZ@(7H8@(X125%LPA_^]C.&SS-M_E/OR#FD>AQB4!P?F-A"PZ(MO,-@ M?>I%&OYM)5UC]#=,DLD^PE?(/D)CAS&%4'`LD_(+>"H6#3U>6'B),<%=F-H^ MY8IX_I,01$O*#4JF3U.R@H=YT[@2RR&,H@7E"F$&:>@)=Y8);\Q-VT&T+P&Q MF"#2SJ9HOODA[@L6M`2`:33''"Z?9V>R_"E*%5OZMA5BIV3X-^8Z8[X<9GSY M;`H415.S[+%'%B[`0$*_CM,)8[P(#W<>S_T57`LS53"1Y,Y:>+,GUUS8TX0&$!UW3P[F M]TRIX@)6L1:6CRFD\!.S?EL\:P6IQ(]SC=Q;VUN"U`CIG,XFO.%WX3'B#8E2@=G]Z8QA/$*2 M>HJIKYGXHL?0&\[U,.B!@XS\Q4X@3O=_\4)6:EUDJWFC` MBH-"KYAY7\51^JZ+J:Y?"-28R#6!PP-`Q?]-2PM84=!%3T`%^]&@]?^=U][_(< M?]OE`@(^;-X2MEL\3[?L9F]$+%FBS^424^$:XH9I5R8_!0JZR*?403:_N)4D M4+.AQR9+4\X.3R:AGJ3WQJ04WW*>?9C.#LU5EC")4ZQ"M) MQFF%2D+#$9PU0\A"+CDXB&X"N-*8L=@D!C-.Y5L9MN_&HU.#=74\`BI/]ASP M0"/G2])]]U!VL#K[-?/5S#=AG>2K,S+S;M97(:UP0E@!>6'&\JA@BANP1%2` MJICB>-@2K$<4E?'$9F3D*!9`@SPC0CS2I/#WKOB9MP7^DFT+/"JT!6[FA&>E MR;.ME(5W66LO5P*I).$<_7':;&'!3('1)'H`#.>"7@;G;@FB4^NYJK\ M#6S!<^,L=U[,&J?@5^X3#O(?:\HTJGRELF_E:J`R!6I)%32RC*3VV@KBNYGA M"7$E;2P-XT*ET%ZL3+PA!@F7E5155N2=J^S.U77C.?@+);7=L`28A'6+G>2)G@-5,)X!C].J;9_!V66CS(G3W:"_A/2MA4<[F/M,"&)1 M5&Z(-6`6W?2P@X=8-8!?TKCR@%0A&DT.ILC#X:K3PH0'T;>%M[/"=(/=U2EDB4<.TA4]!BWB;7"#A'0 M:X7IWK.GC;$ MW).7WL'_67JV2\/G MD;8)<@5PL2'WM`2AEM]8]"-EB0/5,*)LDZE9Y`N`/6'Q4$IZ0!=@G]-5R95& ME\-BM;8>163`5<,$[;GZTU*J(0=-2F.-/"W*T\R`U.'*@-1&B&9\J`'Y`**` MN]W0+2VH[;R7-%/BVLJ[4]V5HFQ8,YVH5A`_LYQ'(@BPCV``-\B*B[WAY;$; M/MC3[T[DW@;`<;'V!B[9/!1^7]S\O06W\7>XO\`JL68KS/0A?!*XY=AB@AA6 M8SZ8'V6U+27%W\C`S>`N;B0RF]G<6[B$@[LA<]'P,K5`B)9XH4U@!H_V@KEO M?Y3US')9[@2GO+.!U^"KS%"<6GYH(BM"^8FRLY5CNFZN?0HL"+H2!0JW[N)=T&:'-(@_A%U M-R98Z+&8O#-TQJ2MFY&I\0X%.#%ST0%YNG`J5&X20>_;P?>DECFINDZ.A+(X M!,LTHJ#HFQ]BFT]@=$-S^LA&>#9C`>EX&,%JPZOZ"X`C;7%R<"J+5QE#';`$*C.5*3ODXX3_XC> M7O1'DDO^V)A%4#<:!J!_]GW7/CWE'EQ&_ULU67^$3AA MJE)-$M]W!HA76`MO^K-`&'CP'ZY;O?FA_)EO=`OROI'^U;>B1P2_*4I&*Y\& MP]%(Q09D77L+DIB^B1%/>#8\8XP2LGWU$;TSSQ2"[P67Q9E!<4(+&9N8O\\='4(_XEFM\2# M6/;!POS._Q#+=^YDB%Q,9@B]F5G@8C$6N/Z)7R&^Q^(J<%HXP)PL5![Z9RB[ M<>Q;'M*(X_:<'I#U\H_'?)8#%-@DJ@.DUJR`,OEB'./+-,S`6.N4.=EYO[]X MY=6',-_!I-!/P%)GK(J-Y^D+U#S6PH8<64F3J-B6X6>BRM!I,FQ!>$/ MV?WB^F'P?(1L51KM*TMM\XRS?,8:0`F[)`6?+?\*S4!\<[I[4AKH64!J3D`E MB84,-6W8,[31L"/VNR--U(;*1.P/.AUQ/-%&:K\_[$_&QK5Z+7??POVPV*HO&J#,0^\I8[ZGP2%\W=LK!6Y\M71")JVK%,YEO1CNN"P'X\%D" MY6+__Q%%X?'&=UHWWNQ)$,4C[)\D>D%RQ^<9Q5/5TD(6BWDX$T$T2T.#YB-= M4')%3V.]GK=OPG`;Z?]II\T@WY0'WKZ)\P!C5RHQ^5Q33*8;@_*:[6&5))LP M7W*B)#-V!4O$P;[4EV&Y)K,VX+..^G;`5J6=H"A">X2 M3R/WE-`VBX"_8XO"DM%W2??*C&@G^Y!DI6-_MZA+KNE2%)Z);C#?T`.^;03] M)3='64-Z^2Z.Z%`B:8/=&,G*1#1SFXC`P=SW^.L8'BA4$XB`^*-74[,77TA< M124P)&V+:V'92'6:SI%H(TR'L9C7';\`&$/3'#6+S(:R"$(6_:#M'2TD._Y3U3&%SJ3HH=ZE#]!')JQ5VE+$P9Y^W]XC^F]P'W MZ=W\AS0"LEO'\2/Y3>2B6'&>$F::V0%='(`ETB2W#P$4K('FFTSKTSG%K0)2 MD/!5ZQ'>95N%.V/["5)B9\K<0LW)X:E').P3]XO%PB\"6E?DB`R?F$L#8PI2-S+;'-5V6"@B8CLG$*? M![HH0/CY8[\5<[!BFVRQ/Z9J,^CS1#\[R?K$$T*&O M-0Z4Y9S@^3T!-D%=91YI0`5H6W$^;PO=0'>L<=H_3'B*K7*+,1\65_8M>W$3 M^0&[:)9[;_L\XKRBK98GVJ[9%SPRM\.8>\S)'/&9T<[$%((C)2B2.SXPTEGU MDDDL.+=V&S/;4]\YF&PVP`#E6^X"IU<$[;8V*!@\_!6&A\?!4N0TB.9S3#;"!`4.H2P0 MB3DQEQE39&+9CZT_>3:TB1P'G9_DWT0]B05=G76[B*]`\B[K5B33INZ\Q1D[B:*-=;2JQPW6B_)`,APP%PZ"9'[@YFF*9#_XR.Y M%A1)TN.L!D>XIPBWKG.G0IK!0/&Y^"]*-6]39E_"Q&\_[GG9UIZO! M>E6702T;%1!`@^%YE]Y\'N``E5M@<<&:$%MA*7[A08\B=L##!W0=3' MCS,N^&$`!SBH(>EB"U`(8D>($)B+^(ZUUU)2:0P6::D:$DEFP1R;9?>8NY_( MAVD,J!IZE08*`9VD<,92R215K;;O7\D>H7:F*=UP+UI",!AFWJ5]]C%4<#AM M$)'L01B1YL#5LHQM2"VE'RP4;ESCB[L?8!HT-MQ?.E:LP+FD"8*`KS:3Q9_I#5Q7EW]I@:*6YH<7>4*\A&3VYCVW]N";![YEL+C%=G3F,] MFDEOU!O,BOD/OXJY?;42/V%L0\0`R*@M9JHD+#SW`61>8YI#:@%"ACM'230`NP?R=#/6PD/F+,;*R"EG>9,1RN]\ MW@AM<=\L>P[7H<[RL%@&1%QUN7EB:4!@BKBT#BG5$2S`J@/B[+/\#JGDB6]L ME;1776[K7$E%IQ//*(T32OON+)-.^AGSB)_VYGV2I)%FR%U9U!5-$;61JHL# M75+%?J<+2K*LJ+JLGET%:)/\6^.X6)/\VR3_-LF_3?)OD_R[[[#>1II#7MFX M0E81.=:G>6DX#!>PG0C._A6I:__!KX'4&PRED2).!A*H'_IH)`XZHYXX`>5# MTK5.;]*?'#OXM2YX]+7*I+RA$"A)"`8PTGIS#860C;*TV3<_;%![MM'`&W*" M^^1N8L-Y`N$=69U>%,`S05+,E7P;5]H_]?B?[G-??W/RW8SK7- M_V61]D7T@-_K@8_=WO_D!VXP?(J&[44V M?2`5'ZPG@Z^@W=?/-5SS9Z;/>^)!1SOPJLU[PJ\8Z=[M=533]WM^UAG ME5O2R:]<7]S/.!O]-Q["*OX]H@>=Y25?"1 MJX(E"MJVS.J@'SRPQMS`KX%?`[\3PF\CSAH6..L=I?'_^K97S5331U+C5CN' MQ\_?(EZO(/\K+L$P[RW?O+7BOC!Q.VB,4]\4B9"M1L3<_I+&IW91K^,O< M<\-RC^7Z^XOO[2C(=])H-*FE::>9T7%&4%*-DPV].",H`2TI>J>!TC.TU&L9 MW0./MVO,B;JJ(PW\&O@U\#M?^#7FQ.ORKF?2U$1F,-3>)-C1MRFUI=.XK,\" M-&H#FBK0Z`UHRH,%`)N=)SN_JFB!"M)ZYD4WCG4L_6#W+]93P6H@V$"P@6!- MU'RY\[QJ#<^DNO4&=L%&SS7Y=[^NBWN4G^;I*_F^3OK8_ZJMRYEQ/M;>#7P*^! MW_G"K\G6N#B;N$G^;I*_F^3O^D&I2?[>B)9JDOQ]/BZ/,1OI0S.-G(BZ@@;6 M-&*=D"^>0\NMKG%@Y8*N]Z&H*.`\`FHOV?;P,-$T!9T7"3U/`N:%5 M=DFE7PT$&P@V$#QW".8Y[$\TZRG[BY5193O.'2L,+\/G:=0FX<2SP5/ZR&?S"7_5Q_&MGVB<;C!^Q#%Y`7XA]M?TF;OF"\W3A6T-0?;Y MYC2,3.>KY2_DO0T^,\9=?2AINM@;:I*H*G MUNX0GUE3>V$Z`=5"%<$_Z6KJI`-`GXPT4=.[JFAT-4.4-&G4TY21,9!P[AR\ M&+DV^[8=>)HB=Z^_78VNPQ&]KAT]!" MG#GOW9GU^+_6_F8$=SJJHBJ#D=C3AV-1,V15['64CC@:C2>RUM='8W4`P-*0 MR2AO?\/_]&1=,K1??JK<7)Z>TJ'(G^99L'UA`QJ'7A`&*T`+]C^.4-<4%?Y' M$_OCGB)JP[XJ]OMC29SHG4Y7[ZN]D:X<>QRAE/>0W."___!"*^7'O;9P%0(8 M1(*.D`4@<=^;1'D]QOCUY\8GLCF%-%J6C02,%@O3M__$F>=T"C8\=)HYA6`] MXK\M-JM[;KNFB^--V=1U&NF)LS$%&WZ@(:)50QIQ8BU&,Y"F8*'D=9SE&4\H MATL1FSN-V8Q:ZR_9A%]70#!YM/'^3334."\J8160E`O372 M;;`6$NG/S>S%I@''.>&H:<]0/'#3@./2#WS\!ASUYB([,O!WM@MK_`AHR2G[ M?ZT5.=7Z;.>?C+6^=0NZ#]#"6_K>+)J&@F_=6VZT8U+5"[S"NW8X.%'1V`E. M^FJZ5JCZ:=*X3G!2[<`G/;>,MT45U=&;UTORR M;O66YUE-.4H9[TT$KOP%D\EZZ275F.8[NW+>'6IHZX5-* MMY;4JX$J=TZ)>I=3K]7`KX%?`[_SA=\QC.2-L>;4/A==:TG*SMTG7R2DZP\; MI=4U+KZ+U8ZPZ;54N:&;*J6Y>VA+X=+TQTM*$6\@V$"P@>"Y0_"90H]#Y12S M;-@U2<68+>RY<2IO91YQ:6(O+)%-[=THL5=XL'Q8(.#9S$&3Z-LD^C:?WO;W M9Y^RU"3ZUAZ6*0B:1-\:X*A)`RT>N$GTO?0#-XF^Z]6-6B7#7O+9+CVKY(L5 MA+X]Q7:*9`)2\7;`(HW.J%^=$G2A@>LJ,J!/%04]X9+FE*:\N MQU%NZ8<^]*5K9N/%TO&>+(OK9U=?'Z$[49_N$ M1ZZ#MG9.V1F7DQW8P*^!7P._\X5?D]V[E:!KLGN;[-Y=8--D]S;9O7L4!Y>4 M%]A`L(%@`\%SA^#QLWN9[U#Y2R'=MU?2\QC_8>,_6)SD4R9.8B=L/0V5U[S5 M,68A!YF`CV!.0_O>#I_B'&58HMAT>%UF_,YVTX.& M=UX4F.[LZ)E==0!P/.^A`"D^_J'PVW@:1.'7-!SBR+`[8R@F,T\*O\^,0"G\ M!2>BI"=^]V29?LW2$`^=U=J_O?6M6S,LPO(]@,QV`WM:^/T_32%A\STQ9VLDY.&H%N:<>HTP0W?V+G[:5MY=4%G MK7URK.[DCCWL5V$@3K7:=!'Q*EB.?.M7M2`>E$6;-+;R$/5^Z%B\AR6SN_5J`-%[EX_6-HNNA%MF94"68]+FW_'/G'SBVGSX-[ MZ.TSS*MNN,%F"+_?F MZMTS2#/=!30[3_EJRZ?1?\Z(;/2VU"3@5MRH7DMIYC.\WMR]8ZIVKPIN-524 MSG'/E^52XFYH2H%\Y:J6NZ;`&TC=,$"\Y`E=-;AM(4 MXSHK&7KTZ]>N]*DM73I-WEYME3ZM M+9UF_/,9D8W6-L[`5#B5_TXZ=+YAH_2=L?)2BU.<(=QJJ$"=XY[K.OG)C"N1 M!#NN/<(#118.@N+-=$%]XUFCPH,9"#^J;4E8V(X#?X-5XJ%0VY1;M^G;H1>: MCC`W;1^66?DH5Q]GD4\5X"5?>%,U=H0-FZ*]RNUNO-?VRF4Y&=3]N&9.B%S? MFGJWKOUGW'6];/`6ZL]N@!7Q"*K(Y;#)5\!3B_9G-&L$"JQ@+I>^]V@O`._. MD_"CG@*I);A6B&B`3\TM.XQ\*VB1#L^*ZA]X::!HLF)`86GYMC<3//A1>+BS MIW?PH!W`]D'+?X`UA1L\;G)$&S^OM'6!JOYJA)(AP-MTGP2`+,&%]1A`XDQ) MTS+A>#F@W[+:#`1I2"_0+X097J@HB`EWX)B`UZOIG>?`NOQ57)5A=^'-+*?- M]Q$#6(@!3"N*M&)F-WCKXIN2;F+-9=EP+AN1QX]&6]+IE_"O3A=Q+`18NMP" M5`9HRMGW0#C;8.\QCSW\N8">5'&JEFZ'H@[IN4X4.3(HP#T+]=QD/`Y_6&/; MR7A3TYE&CHF+)U1$K#9NB+%")6801`NVKZ:7Q>&'Z:UI?[&OWS>?/NJGFUX6 MS\S8V722WI&'PNWTQA&&Y=4/4@V%UV^XVHF.>>RA>0TVSPB;EQZ?^F('W\4Y MZNDV@A/#43YOQ7)6%6URN[MS3=M?CN%+??D!U9US7,[D@)V=8UYG<4"IW3L, MB5Y:.B0/CW/7D&//+2';%^NFT&=A""P2T\V.$=#\`D>8RDH<%[Q3[D05OX9\+V MLD$9P?1Q@4Q@)[?I._B6Y]OPYPS;Y!]X\T,`?P6)A/&*Q=>#X":@;/8)B/8L$1QH'A M[?25]IJ@:9KMB9!,`V:P0'+HS#[B[`)ZS[WMFP6)$!_`*K/"GY7M(-5%`0*$ME\=D`1Q3$QZC1^*SSCP+3X*P M70+$IF9PEWRO')^CO;!N8](I/XLOX-+R,9>67$<($4Q6N[(7MF'[QT^RC@?7<BU1=&[ MG1=&T7>8"-$[73SYX)]NHFW/!"[^B/#B@0#),]:RON;IV(3USUWX'(0UP-RJ M8S\U%$XW/(J#'VMA.\$4J'_&?>@S3[Q+LL.:1O,O;C0OG&M_>;DE=T]3M+WU M&[N.]I3;AQYJ?EE1C7/M6][IG`DAO_2@0-&]&M3)GS,/_R1VMI9D'9="'G"G#CG2,NR(E\V+:MM^<"ET9=6V?J*FN?6X1"U@]JEJQU5 MK7"%5]-!0VXI>M-!HZC--V)B*_[SJ@KY:W&*^L&MMND.Y27B567A@I>*!%AA M-?S&J\,K@WHMP7:G3L3?7UH^++K`R2^\'ITMT!),BB\_7W??;4NP#J\JCPO( MMR\?AS6*!>2"TI9J5SZ^1=EV66BT#&6$EK(BXRW[(&2+NX4?R>G#:KO1L.AE MBKO9)M+R[D*3!GX$P/YV)WAQ(X?\`8RVGB.K'SMI.XJ5(QR#0';)0/BK3_>+]EO/=`-D#FG"S!;I`O!V$HN?V<$T"HB?W,"=IY!_'.?G+(JR4*A) M7)H+`$O$3ZURIB0OH![P@ MB(A6X#6U:[2ZNL+N+"T$,@%N$U\$^P?`^_@&R^Z)`6<]6M.(Y^S,;?@MDP;6 M8NEX3Q9U^7`<7([8,"Q!.(B6>,VF=[9U;V&"&3ZPA.\"T&]PXY9_#VOA_8.G M/1=3DIY8^@6>DZ[CU%[:E)J&G\L`I.0EGJS2%OH!R]5:PQ;RZ2T@%F(A0;DB M&3'YYH=$4.9R[I:^=T,I%R`ZX7FD:9:9!T!C?X^/F1>(V7WSI;RL/48(KATQ MJ@.P5VF4#"M_X;V;Z59H;R7*HW/V2^F0`]T=)*E4S,L[5B[3)1Q\SIU/.1 M[E]+.YCT1BD'N5&RH;?D`]RH.%N9TRCE@&:N6(:.-KME3+DONV<;WS(.A_P] MV^F6X=5*=[CA+2/]-OD)X8'YAR'"88NKE"Z+XB.7:L`'8,]AG M,6%GKP2_"567($]DSPB;PB6HYOVEPJ;B$L`JFPJ;(N$K*@$7P<#`&X'AY3M/ MW"1+10_3XY$2$:=P%V*MB'#`I,\*1;<9J?@`O=4-+KR9/;>MN(-<%@Y3S^4I MS%YL5L1>#UTB8BART3<_\!SD;;G%C>4@+KE]88?$1%,=D'Y;`&$%QN*N=@!T M6(1MO"SCF='\,XR`_!MY5E!#1C!:W^'L^?YFK7PA"Q%M0F4_*FTY;]*KV8:$ M68,>KX#M;M0H44"&C44XC*[AK=B_M)FXN#.!H]Q85L(&P'#P>1E/:CK,.?KB M9]J;.N\R5DG>[D"-++?S]1T=&1W_V$N=('DKI[1T:!KY/C(U$TSQ(,CR-SQ7 M4GS$#A5COAQ.<3;^7AI#RNU>E6?OIYE]CS_^\E,4B+>FN?QY9`=3QPLBW_HT M'V8@^X6!6YUQ_'FN2H8KP/[(F2^+_29(L75]]'5W+/?4:L0)_E:ZEMX(] M^_6M/;O65:DK=93K7E^;#'5%$8=C=21JAJ:(?:4KBX-)5]6U25]6^L:U#"_^ MAD?F)S[TQ2]S5/T!$CJE-:V-S/V[Q2H4KD#<^L"UN9:3)@;#`A^I[(YI2:?Q M8*TF[:##XIP2<7`++SASEI9 MN=*B-5(YCY(L]?$R)@92>PX:%U[W&RM\($ZX\/R0LS*D[SP%-(\B>BS.XF@BW;8%?Q8ZY=D90(5TH\UU?[R.Z;65 M'+VT<6='WK[DJ'.ZDJ/FTTVA5=F[AZX-ZL=,FWZ3%NZ@@E20@X?.?SPM('[W MO2`H`.$;Z.?PRBIT?@<%OJ@F-.!)_O#!0]/AR/`Y!510O4VWP)3)`BR2JKBF M5VNE-$B@+6MKP?V.NE3\"+C+Z6)-:>%6^:']M2Z#53WSX#G^IWJNV?.Q]UR; MG9Y;?8ZZ]D9_NTI[&@5Y-\8Q+_*NT_V,EG:B*=>["JR2?6QV^,*+J\!(37)D MQGO=80.I>E;JUOC:G+\JM)YQ7MV!]2M2)[);C$6XZ)L6;\SI=PKBGHR3OK0` M1N\!;9QF8NH)3RV?E1#9QXG?[=S&\BR*6Y&,C0/W6[@L3?"#Y]Y>(#^3.T`( M!R[9K]^I3]T__/CL3-D9QV?!SY",N\T%7AT/4#FJG,8$W MQIYSO*X,._HI#*WU@H92+W5XUQPXRFF,]/H#YIUZU+Y-6P'DR)='KX$%?$X: MXR4UH&@@V$"P]A"LQ2GJ![>-^&I8X*MW5"GQZUNY4\U3,\^DJ3/:F3Q_]LE+ M34;FD0#19&0V&9D[960*32+FCKD032+FJM)PT$3,BE*@)@FSV?/!]ER;G5Y6 MZ/V\DS"!\S1)F.>36MA`:L_9A*EH-1A[=?13[SPY_%P/_&YG M%)]%SA)1\8&1>EF*X(7F8&IRJ]O=>:K\N=[N5Y=T^D[9^;*?!3]#,N[LG%OP M.B/JEY/-U<"O@5^MX5>'0]0.:DT.YDO3R+HM36M2#5@PN51FAS,5YO'U4"P@6#M(5B+4]0/;J<:X%?6-CGMA2S\W;9\S/QXHEW= M))S[U*V&)]E^O<+,FMLNM1#FS>]QI`'UPG_P(F?&>W1;-G8_IY$(?)2"R7J? MFRZU$`^Q,_K2M%D+<]]T@[GE"Z;@V'$S<1SOY0K4V]6AN1_X$$X%PW;EO+DP M:[<+Z_BA/;67)HU.8$WY%VE;:0%'ZK7Q(+9KNE,<(D%;8,VHXR]BH]ZIZ?O4 M'CG,-BG&#KRPRQL\1K:',KP\8ZV_66=>S[7B^1!)@U[6_!Y?A#W<>K!Z\(*> MO2_O8=Q+L/K!NK<<0?Y9^+_(P];",2P1G]3[GB:P6?SW;"2$/<,A'%,39RQR M$,)O,Q`\:7_FXMF4GX5/-SAT@UH6LW/P"0"VNXS8YB/72Y_AOT9J?L.&NTP] MW_=N/)^Z[=\\Q5`"BCKM\+CB6=6?A6\5)Z%SN%Y8<198XN2GT8I4B60(V[.= M)VRD']A!2*,[YLD%MMT@]",V6N?A#FX@NZOQ3)YDGL%_RXB;9F4!_[(>IW>F M>VN)P%O83,GLLHPY4-MM:CY^:O(N`DF)&Z<'%7!)D$^@`6X<($-:>#/+03CA M!%C@58S+L5D8"RN\\V:>X]W:5C+LB+U`"R58(5#-(OC6DTAC['!^#7^0/DM8 MF]'BONU%`;*+:+'$KP1L(@>?'"N$``:VPY;P9%L@0::1?P\_W'L.[(IDP1QX MD><'+9S!L613&5"D+"T+Y\N"1#(C)Q20L.%'X,>`8@"1#Z^VDL$5G`389!V< MSN##HA&`C!-%/&DH,^6F%*PMUCS_P7(Q_`$H M7D4W""(<7@3DS"9HO?DA'J&3@H4@G+O"3)#1OI>..0683$T4?G!B'^4KK#+W MO47V);S*?.@(D/ERZ?G\LF>><9!\2%#&H_(RLI5M@PU(2AO.9S;Q.F:V<:XJ MT/B1!9`(\9-YI;A8`3BL`:0;HM+C`_=-R(^/-6V7*",D;MBU@25H!["*"EBR M"`N@D*1:"7M^9F%(F?0Q=KN1F--;CC<-510OHH'`4S.X$^:@F``1PZX">V$[ M)E"]-;US[?]&-$/1)>W'`>H-4:'!:P;*.V@\4R1O6C9#M+@,00$!E85-33CE MU[PN1EC#.3Z30>GWB#X[BPK;.44 MQWBH1CPVE`U(2C5$0&LZ`)*FWC9S'K:;\]#3MI_SH)QNXD'SZ8-\^NPK<0Y= M%T4R)MV#7'`\'#I5HP:'%Y17>&;U59TY/X[AGTW!W[/\N2GX6U6SFLD+!W^N MV7.SY[/+^G[F;I-IWUSA9L^O:,_G+["?J>EM7[5/7M7[JLLWMWZWQM,T&K)H MR.("]*#SJ^9]!C?-G3E,J=4QQGWZ22WZ1A31AI" M:0CE(I7;]4Z^#VG^ZU$YZ7&\.FSV_5D_?T'-#V[W%]-$X,X\291N%J=YR ML`'9:2RV5M]UG/GU)?4US?LW$#I-+M\Q M70%-\_YFS\V>]W?3CW>OFY2?"S-F:]R[O2&+ABPN4CEJDH!>R2UZJ=/L&/WC M&T)I".4BH]%-RD]S=S:Y.\=H:M\02D,H.S#9X_5/- M#_E4#6'IA5;?`*XA3WW((W[PYCSG] M;V0'-NMV-*<7`-/_B&`Y9"#8)`CRZ7OF=.[UK\3W%?-Q].YV*33%ADZ@74-S';TPS[22V7K)^:*<`:-S&@ MX#06+"AX48A?J!$5%CM&P7&P[=V?%NL9Q:X24D&*1=X5+L-!;I[2)F+4)ZRU MBND"GH$FWU!C.$#@H["`Q^Z`9ESL.+55AX#+[@W5Z1V_-Y0L-[V*=@T\E@9R M^7L46"RG;?I($]<]5D`=.4D#\A=0=`+))I*^CTCZP+JU71=E,&^E>'*/Q:7$ M5,[-W?5,Q@7H!Z1J'I4^]F%U=UK((LX`U?5E$I]9+^C&FUE3RJD+G0Q+++:S MXQ>*?.`YNY?.+2:>;\&G>4?XZ1-K>^XPV]M>@.49GAU1O-,495>J6#N.[=)F MCS5S+^O)FL?N[,5*OE/[H8EU*1(ZHPO;#!P[O*.[S)/]K)<:_OZCU%9@B87M M.-QOO;776G@@AWDZYV<645S&=#'B@"&TXK[X`Q24F\^M:LJWC M.!DV=2S[U*:0S(,= MWO%-5`&S$I`8G.,C?'#0RAL,&P46E@^PV6(8/?"6M&7K<6FY`6":GZPT3@:K MS_`I/N`F'481A/`?MG78C[?D&]@J\'>^HUS6S@#Y;X23>0`^..K,=C$JR)%S MXT4AQRR?\X)(N2^?E21$.!\FO@=EV$$:*R7'(#L:!(@G$RXDRFPB/WN;"J+H MVT=^U@2+]O7['3Z=G*BSUQ,ERTI'`-39QP=.,;@@^=%DMFH23[CQA9\RVUL7 M6$M^6(WYE*WR#KG2H<,9I[:LCX/XRCAH%=^6"WS[V0NQRM374=A5)D\D.SXR M/?][%'T%5!_,/[)'N"9'_!>U%+!FZ:?[]Z#_W%H%^=.I^S"J7[UY23Z$DF&>LAOB:;:I1% MSO2"?10RS(Y'425\XZ/M6$&(DYS1=`J._7F0K;UTA=#+RFJE)$/W&+[`HPCK M4SUWC#WOB39&?)`G>23RUS==V)MG_CWEW@SKV%OM_04]-;+REX(LE=CO)>DO MM?&1=?*-DTBZ?Z*9ON^3W.XU^L\!MU7IT'CO"A]-RCY66UE_`\]&MV;HG^LE MWCG0WI>^-;=\GUQ!WO0[K.'-*1O7O@=:8@-@T9/Q1,-N8:DV?L3DJ17YC\`3 M"SMD6<*`3/9-=-O%CYL.?K^;?I_Y$U<_1FXJMBBP?=NZQZQNRP]-V/$BYL,T MI-VWII:-?\ZD:C/5S/>`%"GU&1.:>5W]'. M%R'4)H?:C@=CIWO#%'.CH768^LN*T7?3-`>1< M'ZL@?!8["O![KO/$:8V!%R$SP]1_\JQAFGI(Q)3Z::>V/XT6"/*IQ<IZ7O$P,V:V3FI`V=S^:M[>^=8M4-C5]G^7"+XB7 MTUMET'HP`^%'N:UGW.P(F=S--M=.CN/$6=&/IH7.YJ6%XZ@MYZF5%`&DOD@D M,0`2[>S-#_&4:C[L.'+-".@6ATK'7N?2`#0]_:OU&`X<8%F_P6O"+_&C0)1]1DH`2I"#+OQSRKRIGV$' MTR?V?Y.WR0 M^*MT+;T%"OKUK3V[UE6I*W64ZTYWK'0FP[XX'L@#43.TCFC('574Y4Y_H,F& MIG?5:QE>_`W/R(]XZ*O8*Q%A^`\;__'%0KDLI.`2\O`B7-B);*NCE&.L.C,P M/7.8*^27IC\+A($'_P$2#B(23:7/?%LB<0KO4D_6\&_]JV_ICZ.__96^*$I& M2\C`D&IPLRA7US"I>!N/`P`D&U`.:0@A(%(XHFX#]"M&07XC:"FX$W MPF.1'E8V@R/%@8':Q.()%^>-_6IDE:#R\';)L%A#S`7YZ M00/K;SUO1CP/'3LV,3E/F,;[)=%!DIOQ(F*`H"DXUI1/1\_'J^#=ASM[>L?_ M1)N"-3`V12]XP@WP1PRG."R4D<306&#$`^:XLB.4S+#(S$-,!5Z++XPQ%>3% MKL7JGB)X=^$!8T]JF)!A+X#5Y;18S)Z^@-9:\Z\)4NA"JC6<(D54*@@ MQM(O637@X=40WK)X)"VN,HMCL7PY^#7L%A:(]XOKAT%>QJ2%@6F$ MYJ&A+?>%U(1=Y=7,F@(I.L&O;]45X27UY(FA=GNBK/B--"& MBJ;*W_ ME%]^6KNG/*$,4,&U@@"@=`.42L=EE+6_O<-&C?Y8$97A<"1JZG`@]GL]P/!$ M'G;ZZJC;E88[Z2/_^OO[KV/QZG-_"&+=16;B<$G]]4O_CZO)IR\?\?>N!8]^ M^C*B)]__\3O/%!A^^O#IR\^"?WOS3FK!__Z5*05,01#^IZ`3_,^J/O,WXCZ@3`#2H^"@(GU/SS@4&I;R&E1:4URT,KJ4\BXL5@ZM4#D M%F?K>;\"5363N>_X3KZI>@+9&8B[UBG#MA5F'W&.=;`E5FAO4;&98EQQ69PPQ MP=W"6F63>6-B1D5;`R`@F/HW-NB+;"/P%W(A;>EI."4[40YP):JB8:CCH([N MSUCMOYFA/5)84Y_&FUQ"$/.%F'31N(N$P#]WO`?0<&>6(T0H'O\D-3GU2\`J M429P&Z4R5JZR5?>H81$-XA]9_?V<*WL)>6>];Z2#NIG.!;."&YK(TX53 MH=X2I\,)OAU\#^)K;'$9GQX)U@U#W[Z)R,W+/(GX9-Q5H$#H`G[:QYW-04OT M_(RSABN.3._>/(NQ%6Y,S(I@PB)Z0]9*D,]/4[^Q8]5+`DH`_^4>+YRL&@S+^4 M(Y5X]PSSS,$4>S<3-##L;],L(T%LZ7K(#8GH68,.1"*:$B@/'H!=(]>,[?6; MI]@63KR4";RS.^(/\:8JU;PV,5&>R\&\\9D7[M>W_>72L40;PRJ\?8MK/2!N MW[*(2KEU4ZUV%NR8Z9TUBQSKTSQ^(RO$!T^9G_;O2!N/%6DTF?3$H=$WT)$F MB8.!UA?'\J`O*5VY.YHH1W>D/9&<7GP_O M0%<`=M_T5M@REPO5L-,--'L^D:NRCDK66UW]+(KF:X/K.HRPVYZ+U;9=PCF5 MT#4UK^?"D4E.5BN/NUU6I_9EL8I<#W9^3I?Z%=7%KMJVN]BL558OQ:ANBF&L M+U80^C;:\U?HY^R[L\)OOKEV"%\-[7L[?/J*.SZ`==S5NL.)/!%[/6T@:G)' M$8WQ`/XU&&K]3GX. MI8X'-Y<;2[V^EOH?$67&>O.\*5U:5DCAN.>?0X,]K64XD*V^TQN'!N:_,M4T M6<]':>79[Z#GA>F&T0GR/&SS\R^S=6Q+P"(%3!NGR%8J^*=,\K49"OVE;SL" M3Y8].V-9;LE=[;!Z];ZNZLZF0UNM04>=\W$$$9O9U90\I=^GN=`T?7EX?^D:IVS(_%W6D??%?%KF_C5AK2EMG86I%T70IYX_MRRSY*6Y;(Z MY4NB9;4M-R[+5QJ'V!<1OBZH7;K:43`=TSKCV'NY&Q=WCA>_>;F]J>@[]R%^ M:1.&S8&T"VAVMT][C9AXM9&M8PJ*2X+;"R*"^X_G%2*'^/1[JD@91=AX@!5^ M,6\X_?%37-*&Y1J\(OZE97SB:AV?.ND/1L:X(W8,92QJJMH5!Y/^2.Q,1NJD MJ\CR1)MR7PT"1%[^0@LM6) M2@I#5PAPM2[RIE@7R6',O!?O75Y0&!=+RGN!F[X:9#;DR7BD:&+7Z/9$;3": MB,88:,GH:EJW.QPK706#S'(&;';@:8KU%_3&G!@9U_3(19IC^H_K/#3_*OY>"#8&+HQDCH3653Z'>!`TF`H]OL# M0S0Z/6TX,:2!K`[6P4;4%2U/.XPY"V./,#3V?#U0^(2`JKT('5EH/B,PA\N>-QX-]]?JLN#A.&K,8"6$>?#\N M.S[I\16ID@[TCM'-`6";4VW.(/KWINV@]@O<%EG-53)DO&Y21:T"U>8,9)O# M%D#("O?WGC];";#J@7&]4FRHLI3'^IHS%%J(>:Z7 M!PAGH"?6"*JI.V^Y5>Y_A>7#G^#T5O`9.Q.>E,NIE?)?,5:D77;;96BTIET!Y*J33KZ9)TIHBB=/)O<^$#/Z!HD?PY/2ILJ&)7Z55>7UJL7Q8.4 MZ!1U9:;5!JC26U46-F2IW`8[,6^HE!-@.G8UH\SU\!S%?C3][Q9Y7%-]Z,16 M0:_JE)I&#'`=W98=YQD(P#T'`@B?/CNFB_P0.2`;P'7:RUMM)6I&9ST4*H]4 M[*AZ>%:]Z:WM5/)J6^%B5'+@G%43YRLZ?,^-Y-\/@"_7) MCOM-GO#>5IJSHBQ+O6?L^=73E%_;+ZSUSE$=]@4'UHTV76F'PA-? MXDJREB59+;W$VQZP8,Z92SLT'9)A,SO$=LH`:W2BS@91^(<7_ML*:V`3="L- MGF[>[['I>3;73[ED3?63?EA\J>/G8.)VL\UFH'E6G/[Q&*M M$O-:025]YA3Y(X^IJ^VG^9@W'\9VHI]<@-U;7"UITM%M6"C\Q1M%390 M%JADE(Z3K85Q5BT.NUV]&#I=6+6I=_FE>\\B'NI+>?K(2= M^4:E8:C(1JG(/#`T"AHJ]OX/X`&0S",ON@GGD1-KM:>%6[5'L1!D6G."HII9 M)H18#D>199]8U:RV2E1-50O*YN:GVL`Z\R-K%A,+1IEXD#8)R63^=F)Y7!VB M5[OJBL_Y12>MB%0<147=U&BO5$_T3ID#_AG==.@%P$PH>^,*;+G3GJU:\X*/ MY.V.PKZ+-L;2M[#1*DO(`9;IA_:?-;"XJUVD^!JY=GH:*7G+3O#BA\4>?YG-KQG-GCZ%J"NS6E>:;KQ5!]<>,;W2CFY:[[ MC:H4(?!UHZMN0WCKI6>2:W;,]8@>).C;1K,^FP^ MU2"25MH\=^O#,S/;B=`22J7_^)'& MGLX8F2V644BO?IJ/3=^%-=''2A>=N=YW!>`U:"FRT7DT<)B,D07G^S\F*_`< M=(:*/`&2&@ZECJ@!)8F]#D!V(NE2OZ?T)JK2OP9IG_E[&I4VXB.Z7C)V%0&D:UT@MB[322;U:7[JM(;4S<"2\='+O+"[=B>A'*Z.?O5RY MCVSF*$(7DTB_9<:%LN6^6`#"*2S'&Z;@>KS#19!D./QNVBZ:!^_9V'JPZ&-A MNS<$;`;D$G58'XQ4M3\>BJ#L342M-^R+`ZW;$?LC=6)(8[FC]H:KHG%MVLC1 MH'=0I'V.<'#D"]RHI\!1=25XT6=P*&@=^2)552J?$]*JTT:T0LNADX'SH%B] MLL+0L?8KIK<0Q9LCJLJ'*SP&]L^N[?SZ-O0CZ^U/A_3%HK#M*0J<1E_) M`K/3O[>G5ODK?W@4W;-FY(H,R.>8_3M&A5AE`E+1K6O_:NHSSGQ#4SN2T='%;A=. MJ_6EGFCT)Q.Q-^G)LM'MR[H\B:FDRI]?V@RLXLBDT^[L\&=EZ>_=`!@5,5QB M^%_O3)>'`H"^YNC3!I7X*SIVPSX;@KYST+P:F&5F=J_7F_0UK2L.9%A34P"0 M!K+FT7@XT@<=H]N9=+C0))B5M>GCO9].!:C3H(F9-8[UU1M8M499F1-8ETZ" ML3*8[2G(^.QF\OWZ]H,IM+Q[&EC>NJZKSWJT^EUCT-7ZBJAK$Q!O/4D6>X.! M)@X&0WW4D]2Q/I$8X]*K\";KFF'(>XA#;@FN8R$IF22P-SRILF9HSV5P2MI8 MF:B2*,O]D:@-Y($X4'NZ.)+'W6&G)RFZVB]4(R0(4>3]!(:W!\U9*X`<+47# MH*_KBHK:S$C!"'('>)PV&(BJ!A<%M)R1I`ZS"F"=U;]]X)RUWHP17FCV2G_$ M^6N)<;C_R[+J(YP,@>?I$B)F;(C:4%-%,/E4<=37$#_]KJP;3/A49%-<+RW_ M.E$=<(K0,6[/EI`\4Z&T1V97UH^Y&#J^-.F3)Y(Z84,IP4:GLTD.U_[AF('P$Y?'$[ZO;$V&D^&DU%U*4^>\^&0J>-?I=IP M/J[.8%^,YGC(QO=YX*)&QU964OSJKY]'.=0)^[( MO3!D`&AY2ESN'< MT^HUI4B4F39*KPZFS0>LBQH_+FV6+X[8W(+\5.R3+P-,X!^IH)%`S<04+9`9 MF.[=,XS5D@'94+JZ.I;$<6<`-F%/T\1>!^`)=W"H2BJLI$C9]%`525'-D&+9 MQ@^0XK#WFA<*,") M):>BZ%OD)=;X1LGL1NF<'@YPHWC@H+XWJJY84 MC*-.WQCJAM$71X,)F%D28&O0ZYBBLVXJP\EL'![0PT% MCC(2^XK6%W6],QEW.DIO@%8`V`&_?=;^+Z>L#&8DNUT\R=887NB?O>+`]WV M8.55PWCW167Q9?ZGASU+,-]_3]=LE5(VO&9E-;X@+`YTR\K/?Y11T`>X9:63 MH%6C.`CJ!9.@7S"C^!!7=V9@8*L:&'GWRZ@$`5%D\6PA1U7#RZ@$N1V6+ M/%!V"\/ECC)X]0`(K^[RV.N=;NSJ(1C=IJ2]U=35FDTH/03/L:TWD((JI.?CCBC,X#'*R2J6B:JA4GW)1- MZ#P">6Z*HS7#ZPK]H`\UD_$0IZING*@7F-H'7)0RP&.5GDR[&VY^9B6W3NK'^!,U7.=%4-;/51U8_679G=N<[;-$EC7 M])CJ%@S#9S.V3]:E^``BJ+IU!+<4#M>C^$1=5'-`W+(AK6R,NP.`Y*@+MKDF M`6![ABJ+JJ+U5*6G3C#GL;(AK:H?O(MJ+4"Y63_:34!9V8]6*0Q_.0`H]\K" M#M-::8U]JF[.T@YZX+WV]EG#K?0M>/AA#[S/.J,U%H(B%R;=G:C.J`B$O9<9 M=5^G0Q]X?S5&:^A=5HVZ''B/)49K.+@BR]N? M>$\I@27C#G;,(ZD>6E3,(S&J\TA.F1*XV>2'C5("Y=*40+EKY)T>%Y826#DO M9).,&CE)"32:C,!28MPQ(U"NR`CLZL\QG'/-"-SL(F_(U,HS`A6E(*1.GQ&X M5TZ^84;@&DY^'AF!)4#;,2.P?.J'UNM>:D;@7F]9:4:@)FE:;Y-;=I2,P/UR ME>J>`EI97++>*8&;@6:CG)=U,PZ!&+2-\YSJE!.XWZM2:2C*W6ZA(O8D.8%[ MI88U;>W/-REPKQ"JGH]:Z/M?VZS`O5Z/ZL&YL70W;&S M`O?+ZJIINS#Y^^RS`O<+MTJNB9,[+SPK<#-(;A0S7:.,P+]Z&V?M'"TM<+]4 M5*V)%8S?8R0&[O5HE7Q%EXU"/.T`B8'[Q5)ECI7:4X^9&+C?4U4G*W0*_.OX MB8%[Y3"589!54CQM8N!>\5M)M+V.H1;NWXD3`_=Z[NK$0$/3"YVH3Y<8N-^K M7)T8N'*7#Y\8N->C52<&=F1%*N;0'2PQ<*]GJDX,['8+];G'2`S<[&R;A=G7 MU`-(RI:M7$^<&+A7$51=9:KS`N4+S0Q,^VAND1G8ZPX5>3@F!]YH8N&XZ[18\/(E:UG3$4#D@>6?-'8<'4IO?S_*_C8]R+Y-B4;\Q M0WL"TUXF+JZA-ZI@JL<-VVET;WA=/OO],U#4$ MW^T>?ZAJU8'WEXFZAMYE;?M4\UA+AB=N;)>%F%.%^8OEF"&^'NP<(EB3G;K* MYGJC3D\:C_OB9-@9`,%/^N)@HHQ%696-B=PQ=&FLKAUM!D`HLKG-3W@44MAC MCNX:94J5I>V)OP125];2!(O(.6?"9?+1C>X3_?N\QX^C2O>.6#;=Y0BMH+-."#4'-UI>CSQ'P(\#"<?'AX>VH$U;=]Z M]S\-W_\OD![\3T_6)4/[Y:?TM72IP+I-\M'YKQYO?&=F_VP]+AU[:HH.8H3Y*8."V#!J0"FY"ZFZ)C.Z\1F MUK56,VH9H&H\T+U2I@&,# M\X1.>;>:FE^9,W,,JILA6ST^LAO'X*4AM'$,7BR*&\?@)6&S<0R^"@0WWJ)+ M067C+;H4=#;>HE-ZBVI+$(VWZ'3>HKH11;V\136`CHHSZM&9IJIR#<&C;>9, M4T55/@QX9`8=':&3CPHSRTT%RTW7U=I[6XX=(][)JKR:6JX).,OL,F')3NU(;M71';J9F2G'ISLE(;L7A'9*9N1G7)PLI/+R*XAM#VB6MX, MU?+!4:U)W?IIFYN';KN'%OM=?A%89$!2<`:6(?5Z&EJS/<,X/.1>>"TF-I"T M]0%,T=E[-S3=6_O&P?[D5A@,GCZ:__'\H6,&!>OT@P6WI7_K6ZP^ZH"<=S5Z MD;A&(]];UBL.=3AJDQC;[309KX=FNYW-V&[G4%:^W%.;8L`#VHL;NBD.YL59 MP6^3]/,*L=UD_5P<1INTG\O%<9/W&55DSZI]?\#R&3UH"6%/< M-J[N2W9UUYSN&DI[%;AN,D$K^^7I*,D,8("H+1LJ:,OP[X[>W)WF[KST[FRSF2_80S,/AH^V:R^BQ?Z_ MA8>F8WRUIG>N_=^H\&'F".TOE[YG3N]6GVXX1\HYNIK>;3A'PSGJQ3G,QX9S MU(ES-/5$F%^AR<=O$Z2\&ETV<_F+PV?@$3]SCJ:84 MT?@$3]KDJ5Y442^?8!W`PZON);FI_CQ9/WSVV%&Q6WL9N1Z[?1.VYKYW7>^> M7+M7'K(^SPU^7[Q&W-:+K=4`.!(#CE8+GF^[``B@LS@*A*P\_MW^SZRR%B&R MHLHZ!G=41:G[7:>^'VC>!)_F(^LF[+NS,=SZ\*E*D_EV]=6WS"#R,T\Z"1X>=Y(LJZBYZGK]I;#I8(W'U9UE57CU/X5WEO_>O0?M!*$GO M*C*ENW:[Z953E?H;'"D^5GU$A+`/GGO[U?(76R/NP!?_=^_>\ETJ'5N"O/=\ M:S;&N,+2MP,KP$4NDB7$E(:!@\NAM*L[SP\;*JL/E?&^8JHDU9ZNUD0;IU[D MAOX3X/&BL(+=WLX8*\?HI'8:_#0AOS-#&*\\D'2]>UZ6TC[R]Y5:2-B+-N#R M!':^5D)-R:TQ7B[A.IR?*7.&UZ&QL.I[%1IR/R?$3LX#44VJR3DB[6PMV<9D/$]*.S\CL;'&SHC*J)TK M=IGI=O6$Z&39Z-6^OF,=F16QO7\26]N_E?_JZX-W8:32A$;KBI5F$-:>[W4= MPKK9&/3GEUYVXCTA-9X6[)M?TM>6:GH3`SC="5U-R:P*'EW`=SB^,>(;7 MH8ENUOMZ<:M=448V\I'#WO/H5??+WSK0NRP6*$P']E M5:UM*]YU&/GD7B0^%-!USQ(?%Y4?D>)#4K7ZAGW6X6/B1?[%(*1.F?L'/W-= MFOOEJQ4.C>>F9]\!+B?K2'9XI.6GW34HW-D-@S"]O2/K/>6U8VRG^[PFO?T8YO3! M205^5;F=_?ZV]4H.=*"XIW6;_QO M/\/??ODI_B5;#-\OK!1@*_E@91'VZPW>S^SD&C9^75AO9M\#C-+SXWM_1`M, M5/)RU_39W3/8E+]/RXXLUUO8;M7"92=*UUQ]^9>?,GLO/?H2EED!'/YR"["- MOWVI1"#\;8.5KAB?65F%\2WVQXIEWOS`V!C\\_\'4$L#!!0````(`*ET:D4= M../H(A0``%4=`0`5`!P`86)M9"TR,#$T,#DS,%]C86PN>&UL550)``/M$V%4 M[1-A5'5X"P`!!"4.```$.0$``.U=ZV_C-A+_7J#_@R\%#G?`.8_-]K'!;@OG MM3"0Q*GC[1;WI6`DVN&M++JDY,3]ZV](R7K8HAZ69(KI?MFL;3[F-QP.9X9# M\OTO+W.GM\2,$^I^.#@Y/#[H8=>B-G%G'PX^/?0'#Q?#X<$O/W_[S?M_]/N] M\;AW25T7.PY>]7ZWL(,9\G!O@EZH2^>KW@5R+-]!'K36NR'NET?$\7]ZXE^[ M!U_]?CZ^Z;TY/.GUGCQO<79T]/S\?(CM&6)]ZCK$Q8<6G1_U^OUU?[\%E)WU M?CA\G1^N"!]]^TPL*G[UP MDJKP?+HN?G+T^^W-@_6$YZA/7.XAUTI5%(UE53UY]^[=D?PU*,W)&9>MW%!+ M&)Y^.$"/ M:/?3>)@B'ST2.H>1$-+CA;)X)`H>Y;9U5)?2,=3\X\$#<1-]C*;7Q(7Q(2<,NAW&?X#GGP[VAZ[G-8>3@?N/8YXH2/IO<,+Q"3.F)@VU)4D5-' M"3719X/(A1SXGFP62('^+:#CDCB^A^T[[`62<4,YO\?LX0FFYNZ`JW?5Y`AG M==#TB);OHT%D`^M/GP1*E#<,J+CI!G%<(\)^0XX/4V+R!,("FLG&P2R8,.3R M*6:L^MI9N?T&$<$\=L@<5CJVNN(>`99A.Z*"2S(&G&./2SY#YS`?;@A@<8#3 MF,-O8*_40-Q0_XURA%X+V1'D_X)<83#B8*=@^7]W@)79.ARZL537&KI'>&^1&E@3!=(_( MN\5(%),#T_`J4K_K!OGPJX^$[R>M]407@T?J>P'7@31!EOSZ%GM/U*8.G0'- MGSBH$LHRZ8[=EZ$;#.'N_-H?B0W;D=05_0BW:`G_H:R6\E,UV+#>#IMM6.0+ M6VX0Q4=*[6?B.`,+!(9XJ]VIWFJI#2I=$#]8I"WP>$34##'K2;@!0B#I0@AJ MPT-1M^-&Y2V__]H#6+:#1KT/B_G8OGI98)?7F>^;#35(XX-'K2_G(O`LE`HT M+T=6F!\SE_Q5Q\(N;+DE#9O=;S/*5M%VD^/AS^?@DX1=C19R=:LM_+FMMBY- M#6NM*ITTB.TS%OL98)(OP3B=8>D!2D9*RV)"UWLZ26ZI2?G$,[FDR[TLS!:,=$)L>TA)] MM0TW%7?SD#LCT&VPW=CJ&%?LMUML:%H.=NJ];98,+(OZ\/<>K42'0%L8^TOL M/;IK,0 ML!4?FQ"G)E+`H2QV;1%D#[X5O3:1_![T?+31=:OTE,QIES0`%<"A5,^..+E` M65H&PH[E\80IXH_RC(+/^S.$%D="-HZPX_'U-U):^L!M*?*:*%RB8@C],0U90\HF=!70'EAO6ZAN:.NM2.@1%4=F#)BM8J\T[72 M7!6"K=>F#BZ(PT+"R(0_5W_ZL+0YTNST+A!C*Z`[S&;.1%NNKA94:@M:A26G MABX$U)59#+E#L%E,!ZV7.#@1,L9+[/H%=J"BL$ZZP38(%HR$=01&0^%L+U]? M,[HD715`95?3@64=G570'/VL@[8A^'53XA(/WX#9N14]OGJQ'%_<#%"`H7(S M>K"&NR4@WDH(%N.!ADCW,MX0P MY`MZF9IZ$-$%9M[JWD%!;B(H#7G80:W+C1S'&MZ\(8RF_,8;^O3G0,^)J2>!9@:!881MD3!?@S`O% MQ'@-LJ,+\-;<)HU98I"U7<"2XIV5&+5!IGC9L+1BUB=0OS'(_MX%=>[V`MW(^> M7$\N'8GX:D`EJ:EB>C+`UI/I&N9IX/KXH&%'BS`*P,_QE*;NL;HEKIQ.0W$9 M$N:>/&*=;"68U\'UK,%-SM*U4B:8[8\"?1P&NL-Q/LH=`@6MZ3):J`0M&PBW.PM("0=;1;&RO);F)&GR&U(YME@%B9!:@9D;FF$1&)J!E6O_IA)4] M\MO([+:2+,SP9A7;9AT/1Q9Z!9OY3EO^L)%9NI5@%[E/1J;IYGBQ:?ME;?X; MF<)7$N6V1:,X0=#QV;SIK*4LLDQGR<@LW#R8&=YUO81;;9L.RL=Z]=S>L$E& MP5U&>36^1D9S(W6*S3YU:OG`_I\?K,L%@])8\UWC#=`,L]H-4ENLE7S5%5E2 M*;FV_!2JJ"8X5:.SKO&M!A>V,>F)110JII3'E]8"1JY^%2%7S!\P*0!71;++ MLJ2.)C'R9$\;3*RV5-7S++399^*`V[5#G_G0M0G#EJ?#,"M_FF'`F'B7.+B0 M-WRB>#`7&<#*]XFC`Q`GBO5A7[UWYR*Y>PSR*")@(B$-7^+@K\H&KM*$SBNU MJJ5H%-72@P3TD$50J*A!M)A'_I(?E2C4-70@N)I.08>,IE4 MU6ZV&[S8.$E1&NQFO6Z@23W67A+)]GOLNE&$!Y37+,X\J%P:7JG&M%Y4^!F, M87Q)GU7+6D9!3>$VL>#<,[H$@\X^7XF7?(=NF._MSL)';,7!I8Q=2'5\KDZC M'>)#L)/6,!_*-MHA/D2ZODD^E&WT:QA:>;5>^`9/^$+/A(*1_YEX3^+<"O!0 M>/71>ST7J6?H,P'MW)Q.[!,ZL,!_J,Y@5&JB$QAO$?N" M/6%UQJ&:LN`RZW8"E5RTBP]@%-?K!!KE+7!E8:D;T'1]IX6Q+7.(AIS[L(3C MT50J`O[)M<4`6$`;60KS*UL_""#*06VJ>=V\$?%3(/$6>6)NK4;3*G.U57+YA9A*O5;&$]36B6A`,=L*Q=4O_1F_K.VKE7`U%7T9*D7F5U M+UJ[M>R1[1"\W=@GK&6N&GF;1$M,*^WK&'G=3DM,*^TH&WGG05VF58N5&WDO M0C,!E(U;A(N662.O>FJ!4SN[OXHK9CJ>-MJNK-4S[HV\QZ:9J%^62!9X[(HK MG:YDIOS8V0N9O,\RH]&&7FFJWDF%5KS)B5%-\^>K-P#(R\N:$,%%210 M&GF_0?-\VEN:LI$O/[4Q9=?_[/7UU2;CE4.XS?">B>7@T71L6(`U@ MP!,^FDJ=%-H2T47A0W=*60;A$G9;0:3D4;6E7KC@.;U*45.69DD*XM-I51'B9=TY)8 MB+*4=@<7'AEL#^[8YQTD[QH1)M]U&$TG3SCEWLM#]X'1TIT3UIGD53LFK6A" MQV)0@<"$E3T,WH=3I6?6;+03.=?QYN='ICZP45A-JT[?18!+[@B'3#%RJ:O+ MEKISQLSE#KPKA\P!+UM=<8_,17Y4I+NY5-Y!V&>=(P#N3=)IYS`T5?4X>IS; MOSL]EO-5?),U`&-LT9E+_@*OV1;I15."HO?5#X&#QH&)>/]C;UP4]7U*^%I\H=2-W7LEP;3 MN3R$]7A*7#!2;LA2?`2W>$:BNGO@<1$%IG.X^&J2MGHSG7/K6Z^MI(K;`P^S M^S6=FU4/[^ZG;X.X*JZL?B:.DXE0_>Y/6[WIO*UM@EX":A.D`4WQG%'PHGQ] M'>C6+%<0'_W0-0YF2!29G/YHU` MH8-C9(KU?L8A7A"-3+;>#Y,JV$1&IF*;-^45?J.1B=DM1R):-CSR@G=&OMJU MA^'8R\Z2D0^&M>RWMS47MO6/0>]C&LISA;"GG,VRV?_Z-KKIM4B-$GOZU"&V MW.@.+L3H4-I4<`Y;#$OFI08:PCCJIS\4@9V<"CK"4#E/EUB6/_?EC3`R[^63 MRS!RQ/3XB(@;/)RJ?DJI?KNF<$,D0K;!C72['>-&Q4XD:JM.X7@19%A*8KQ&@6XQ$ M,6HN(&CQ2WPO8"V`$$/EU\!X[=>@,4(ICA#!;,I%> M.(AS,.U%<#88*_T'Y*@K*!M-DZ>P=;ZY`1.4\*?`KPINP1ICCMDRY]V4XII: M7Q%1;YBGBFBE<8R>;V'Y8Z`8A6@_^(N%0W`U_I=J0^][+I1]$0?IJ85Y-6PY M-;6N[5E"EGF=3+D!-G*SNC0/\H;?2,NN-/(\I6JF'9=8KCIH/T1!P>`2@55' MJ''M2/S%^(.HB7252V&)4+E7WT%6%E'<"0Z'&P_AG2QZ8H%;>Q\7N0EJZO): MHCT!-3#44QAJ*8'7N"0$5:5J.!0'G\(^LH4O'.]L*BM7U_(0ZGSAT!7&X>W; MI:6GN)X.-,%-2!4G0D$E+4^"($>ZRU-=+*=3E&7S:W.N@_;UP1);.&@K>(Q$[%A%Z$!"1O!0H?*_HH M-)%N$8U$`*P&CQ%+W&PE>`^KQL8WGUPB,)K MO;-H=3.6]H!G,M`#5@)((P--S_%G8N.X1'>HOJ,>YA,:;3+#XNX%6W_KE+]+ MS"U&`D66O$:30R%)S@2Z/P>/[(OI]-]3AUC1;F)7<%PAYH*T1[?'=93=2C(G MP:FV3A&;D1MMF'5>?O,H[2)G4WM0 MZ8.)G>=U-=J[R/V-(TGB`:`L``00E#@``!#D!``#M?6MSXSB2X/>-V/_@ MJXVXN(NX>KBJ>W:Z8WHWY%>-XVS+8[NF9NY+!4U"$KLH4L.'RNI??PF2$BD) M``$2)``:_:%+EO#(3#SRG?C+?[\L@Y,UBA,_"G][<_KNPYL3%+J1YX?SW]Y\ M>7P[>3R_OG[SW__U[__VE__Q]NW)P\/)112&*`C0YN0?+@I0[*3HY,EYB<)H MN3FY0#,_]%,8[.3&#[\_.PGZ/R?X_]X)?/6/LX>;DX_O3D].%FFZ^O7]^Q\_ M?KQ#WMR)WT9AX(?HG1LMWY^\?;N=[N\%8+^>_.G=Q]-WGVJ_/$19Z/UZ\N?: M5^GMZ^O;TP]/IGW_]Z4^__O2?_Z_>.EIM8G^^2$_^ ME_N_H?&'G]]"CT\G#^\>WM5P_)\GCU&80.OER@DW)Y,@.'G`O9*3!Y2@>(V\ M=^6@08GO"5`T3'Y[4T/QY3D.WD7Q_#U,\^G]MN&;?_^WDZ+QKR^)O]?AQZ=M M\]/W_[B]>707:.F\]<,D=4)WKR,>C-3U])=??GF?_UIO#7!XZ:YY':R?WQ<_ M%JT3_]K`+TIOUO$:/;;&^=YZ>%U^NG#+Y\^X/[_<1&YV1*% M0!CO,DS]=',=SJ)XF4/]Y@2/^^7A>@]\Y]F/EK!N>*^EY<9]CQN^9X[UOBND M#]#SVV,*FQ//,9U=^2&LIN\$]U&2'YGSP$D2?^8C3Q1PSE&'1.'>B9'P`@@, MG2Y0ZKM.(!^I:[C_EF@2I"@.8>G7J`,6QV-)!W<*E(CQ_12C!0H3F*.8M`/4 MU"&E`W_N)(NK(/J17(>>'R,W[0#U\5B=P;WP$S>(DBQ&=TX*_Y_.SK($^%22 M3$+OS$G\9#J[C]'*B?,[8N)Y^59U@BZ7D(PY)6*.]T&6YL,"*#"_"W!<^$&6 M(N\.I<7.N(F2Y![%CPLXFNT1%I]*Y@J3)I"]HOQS2,1LXOXK\XM+-)&,4//0 M$O&X(J=,)FA.!;GG<+C2\0(SG'@+X'3Q9O+ M)/6!9,C;09'D8$R2!*5)3F>8',[#C0^X!$!IE,!O(*]TP%C2_%(I$EWAO8.I M'P6^ET.T%06D;%GN&21B=1VN$+O*/_TB-PLSLG8'I>&<66>O8I" M21KG4G+R@-PH]F!3I+L]T^'P<4X@D[,MG'`.-*R=>]@4*:B^,/G>\9\D%PA$ M.#@IR#O;W*`U"CY=A\"K.JR=E-DE4H.T@^"X[\"[10YNEB^,9"[2?6J)=/A; MYF#=+Y?6:U-,GJ,L+:@.H&&P\J]O4;J(O"B(Y@#SEP2NDB@FPEVI+]=AL83M MZ34J)*7HNO$4O<;>_[."\@[ M@53MPXTSY%V^K%"8=#GOAP-)A/$QC=SO9]A,C2\5&#Y?62Q^S$/_CRX2=N/( M/=VPY'GE7+:4L66N1[9<@DY23C5=Y=RM\^9GCMK[;I)\:XE,(A&WKPA[/T`D M7X-P.D>Y!I@3,I/7DO/0@#S6,+/>>7/IIH4V$WD[I<(SR=R?:)ZS]-R7A>)5["?H*^B450O9V+:>48Y;X2Y*4?(4[0P).]=`LC6@ M7Z#$C?WBWJ_;TA/L\\O-?.@E/0O@!(D20>K<^I'C/@I\MX6RU@L,?9/GTHE# M.*8[^WP/FX(^A3+DGK#Y1>("-TTTU":'*_C9#_.M5-U#/9[SAOGT0%OV8@O- MVC<)=M)?C>_TL.#L:90B*7MY>2;K&^&MP6S3ZREFSJ(21=E+RC%7W^CNV=U2 M)YS[,&WA;NQUC07GU8L,LO=!J]G[)LG$=:,,_KUW-GA"@*VT_=5\S[UND;8` M:$H8V9NF&QA]$ZF:&7M4ZT97;!L"+3Q)DUPDS:UG@$/>JX==U!40S0DE>U?) M`:=_)ET:JGJ60QBS](TBPVK5*]*"\_9-AM*<]8!648PAZ15WGLE*A)W8Y<69 M$I*_#?;'L?@_YZ1P@N#-23EP'9U=+S],WWO^\GW9YCWNT",\,!4./(["MQZ: M.5F0BD%WW'T86*.EXX>M02UZ]PEI/L/;)5H^HU@0S+VN/<*X@"%B-WM&;W>4 M$8.4-$`)K[?+3L+)27LPPR%#H8>]4\6W>"@962/YQ#`U'."]^0*<6!/%1"+E MJ"7(?3>/UN\]Y+_'MQ;^D%]?;S^_BIPYMOA`N<9!;^] M.?[]?>_PG&Q'WE7\%U" M`)/>=F@X,8WXH*Q:#@=C;=O#\4+7P-E8@!*;*X$VEQSY("V:#@=EL=OH1XC< M;CCXGF!8!ECYS_U#4UR[YS!AC!V+'GKYOVA#`(O<;C#X0+R-PMQ!GZLQR31+ M<4(GSK6E`\OJ-!3D%Z5<0X'QHBZX]`_-E1^@^!SV^3R*Z:N\WVHHV![0W$]2 M'&QRYRQ))X/8K'_H;M#<"8JY)R\^Z5H^;-$_3$^Q@W?QXV;Y'`4$B/9_W\%3 M"7&3>!\RD`"WPY3"()\>4_:9Q=&2@T5MIXP:F,0)3EV(?WMS^N'#NP_P'W3, M1=U?L5Z'O-_>I#'.E]A^"=HNR*"70:X.@@Q=Z(-O3E9PL<>P*+^]^?CF)$L` MI6A51%#T19(#+4$&<0HVL27(NP^GF!Q&8W8@=E>H?30>-8KL4:'X:30H'HG5 M%9(_C0S)/1VG0O-GX]$\8",5:G\R'C6R3%%A^)\CP?!(!62+\9'.4.U75;T=Z&\-C=LKE]WA?D`N\M<8FCN4\D%/[*((AX,PBT8$*.T509\M M\P0=CU9A"-=%`1I/9T_."QTGH5&48+I+<[AW?.\Z/'=6?NH<&CF:6BN!/`_] MH@%:_*@.KLDS%H1=ZG;?;Z0.SH93N==&.91<1#ULJP3JM>,'^!:^BN)'IUXL MHH'>C?WTPN8N"MV6"-6ZJL")D`=`J6FR94F;1F2[C:F""K@0'0Y@@G\N_Y6! MX!#D(4WIN1/'&X"[K)1#Q):OKQ*LZ-%9-%P8/51A4"IOS"4X;*8"U@M45!M[ M0&L49@U2-J6Q2KA!\BH81TWV!)&L\;3S]U>,71TN`:3(W<;BR&U/V6T>`H6" MNY]5P(;MDKF.CVY`Q3C*D[A\<8,,&X`:1@VN95X0'#8J'K4FXW)=MZ=; M[5Q3R%9OH1A"X,8Y>UM$`,&YOK:V+5.0:# MG_HZ:)6Y$:FX@AL9.;FM,JA%9!!&!Q7PW\>E3-0HCI-:*H)XY?C;\F-P;]0V M`_N@\O14@U&T0G&ZN0^-"2#'99+6.7B,'UP=U$Q4U5 MKH[:,%85:R5JL*\O'\O`7/%0_?*N9.#.,O-6N.N7D"4#]X[!1!5Y]%7)NY"G M.1:AHH"^BKJDBZ&.K+X:>Q=DF>%7%?+ZBM5=D&>UKG#75\26M,LI?ON*`OI* MWLU>8I*F<9AC4HEN1K`\/DQI&1T5LD8P,`YD:4&-%:9&,"H.3-GKJ8A#'=6Z M:'8Z[E_"^ZZ^$=:W$"/(H:E/YR(08ICQ\ROE52$:4U[9GFJ-DUUY%E-$D""& MW%16N[&@>1SE7^&HKS%+#$=J?F&%JLY7D`BJ/`$^%=;ZBH5B6)/")RHL]94' M!;>Q:$)P10)]!<6NFFT=2SY!4;^Z!/<.%GD7*/5=@%)MJA?`,HUSL/,GL='V M02I*/!)/3\7):T7ED4F6+F!?_%$M(QV3HQY:8'"=)!D_]&5K+2"G5^[DZC*6 M=*\>H/GVT:84$>5UP6N,L[-ZO#@OLX9.NN#!O-(8'72!O_EB:^IE@^;'$S2_ MIX442TT!EM2R_^B)[=,@=3'
$@P#_58V0-S7+-L;R2P'@,T$TR@G*S M7Q&]0T_:8DB MY8#J&V3"AR=1JE6>6J*+'U.1,;FP]D^"%,4XU'.-U%B-$P`%9X\ECU%`MTSN MMU)CD4SR.,`RBI]>@>V@F0ZP-B0R4YNK@'WK==QR[C,G\5T*X.2V.D!]X0=9 M2C5+T5IK91=65`QKZX*\@BNXB+G-@%3351EXGIRA612CW6N]*+GUP_Q^O08M M%!A+FK^K7A^E)L6](+965ZA+=0@V=U)1:2A!H*SC-^P*M41#EY3+8:+#[J,$B MCSW'C/`S?E.)MGN.VRF$M@%(M;`U7"-'S91XW)P`)24DN>9&9]?$IDI@1D&` MBYF`D!,[`9R@B;<$)1Q3$2O([(/'V=EZ:\?CK?V*_/D"%+?)&I9\CNXR;"B; MSDIUCM>_+SJ*1I@>`[%MP#^Q7)J2(BR#8((*8D/(M@BXO M!S`AT5MT'^];-]5G=[^^FAW<>N-AX9PCLX@)Z>FML&U2[4S(36^%.!?.^CH* M::K+WN5+5!E,R)?CP8Z@!IN0)B>`6J)!-IP-A)/KNC]>_O&$O-$%I/$$NQ&- MM^.).)>#FJQW,\L7('3KWQ1,A1HD'&$QHG:%A3'C37V\KN M(F9,*-+<:6WIYF'EM35?>4@DK22"HGSZ0S`:GFEG]1A+9)F-Q5$434$I%$(O MR#[Q?L\*8;)AVTH;7C?:`,S``,*B&IV[>8J=,`&-!%_5H9?_%>12NQ1*=9A, M-[IUH(+V.(&TXV-%R\49$>@"%?\VQ'-(&-A&'?0<=6!]7QU%:GFGY\A=U,/] M;()1:7B*BDD#)EB8AJEPM3GGE)A[\ M7-I5$/U(KD//CQ'L/`629L4-DZ?H`<%=Y_KYTU[5L7F*,*3W<;3V`>>SS9<$ MO[ZX\^9-0$Y9%YR5K3OT,I4*Z?R,^VV:20RRVSQ?[^1\@3]>AY,E?MT`EK_A M.9M3"AF'FEU)MG!1RCCWCGE^FN%2"\63-MY9EMY%Z3]1BHL>T\R.O-W5X,;U M2"(%,9Z^^F!%YK!"R%&&4(4COJCQ\TKPL?!-X^LH],HRN/6KZ<)/L!@)FZ\I MU[WKL"IHL7W%0RQWMZF7&DQ`-')]I]2RX6*,4_^/_$\J%O0>2C+]9S.0&J:S MRQ&XD9*RCA,&&#ELI@G3OX@3.O_^L$AWVAGYZ M85,]1RN,4*VK-C@=/`>U?:!U)P'OO7K'CZ_(L'K0XN"U*&YD#_OI@P&^49@`#WP*Q]'WFXAXB/)W+AR#::J=DG^NO77V$_11?2# M)NX0&MIHB9WYE&2H((CMI-!8>GA%ET'-HT-3"1(Y@VM$ETK%D[@_>``EUX^]X=?/GW(9\;??"LM4=/X MWHG3\H^)^Z_,+YYXJGU\0/G#710K\@'$C37G6SNIP4V<+'#;9UN[@,GQ-EDV%2Y*B(S M^-"B#Z#F19[(1AX0S6ZV*<$`GV+IQK\-9%"\+ MYR!;,>'MK2ZZK,^HH'I\&M,':T+VY5"$8E^BRI,U-:(4[:HVH1K>4#0BN0!, M*)\WW+74$.1B0LV]H8@U6#2D^C*`^A!=Q#EK0@$^62%VF$:239D[\GW2MX*) M3/)58_+&XE84TK<$BG@T`_NXD>*/3"CX*)L.>Y$M)E1_E$T`OJ`1$RI']G5$ M=@&')M28[($(0C%]RJM6*J#14:Q?1015NMKK2WJ7&\IS8+MH,F=7"ZZO\MDC M@5I[ERNZZ:N'#K.QNGG,*CKJJUKV1\>NT8P5]?15,.5&HI%.;T/L0$4D?96# M'HDD[L"M"*:O,C'@KF)&W50:N'$"1A^T.HYSJ0BDK^HQ(($8H3,5I?150/JC M5-?`[8IZ^GJ9Y`;=\E25^62<5"^!&/VX`BJ:&B?QR]E@G>+F*^HIDO-M'2OI M=:RD;+7Q%,"2Q1O'4P1+EN*LO%Z6O(+W0H4C3"@PR5D.3:A8C0E%(;O@?51Z M2'F51VD(<\=GCN?UCNXA`,H?]-"E'J"211:+*"8^*K0M2E-)N7SG>,CZA]7& MN\/V/S2=;0U;L%'QRS+)=):[U,N0,<_S"UAKQ%!1)W$'Y4$,48P0L5P1?S^5 M%0SK4!U76VAJ+27GE+C\"3X'Y=8CYBT(=1T`3E*^`G"*"QFPI<\D/,X"G5[\J@ M8^Z&>@OM(?SV4:'DRBT9[6*S.:]@]?869A08IRQ%2I5@D$JYKG)DH6XCI>V6 MFDMJ&J$5NRW1^%F!SA;KKMC+%DZ5V[(;+1NB*H:^MHY>4&V\:TNT/XX3[9HP M52+Z29TM:VRAT14^:.9D04KF\D?R[-'Z'(LMZC%BB"V\"(%LJ0%*S6(H06"N M8W2@`8KZM-282'&DF=9HGFX]PT>U0C=U ML59+':V69KS)_16!CH4/X1ITLCFZRS"'+0]FD8L#&EF2.B'.9:J"(BGXM!U- M&\RG,QJT(A@S1M$(TR/@6+Q?;`QU@B279YK".`IN`.4&ESYH0!%TU9NI MQ7&E2%N-*\YSK9L012:+'JS+OJ*#O@E_+>A`53F4A]*1/1<"TGSEH&J2L,?J ML1`D%N=5JCRP<""TCTZ/\@J6?%9I3H527Y^#8INTHOA)D@%0FWC)"5#4P^?! M7]>RNB]?W"`#Q'$:^)YQ\W`+%F4!*9J$G+%5Z%$=(3_;D`=@Q-GT.:.!%*19 M\*0/KP]M[IPE.T2YL=N(<*E'2EE;IT:VS@<$0I/O8E4*EXAB1[X1VRJI`^\N MD)<%:#KK>'$PZ]W+G41-7?]=V2_FRAZW4^OU'X!?[Y4,:+ST-!>U-:6;%C$, MU-1_V2+-7B*DY`MJA(:/(99!DC9D@FN!5W#;+VMQQ!Y,\""T094BYZAW(HPL MK(\_E[@7$4Y?6YD&A!E$2A"-"%9CQ*L%,B<2;'>4B*&)`VL97H=AM'9R6D68 M9C#EYR4KXY&GFY2(ILE\'L-!25$5Y7_K!W!31B&J,B'.4)'>3@!4I+\N^=;C MRAZ7@DTGZXQ9V?"]07Z!:_G,ZL#!V<@%\%-^A%B#:()GDR67V463C'O2*S0) M]55,@0$TP:^?=Z!XB=/+[.90]@(E;NSG0HY4FM7'-8<:)E6NZ(U.CT5='11L M<#W2>>C_@;PG`#]QW%RNNT/I9V##.#T-.Y6ISRA+&=H0FI2/DF#`4]G>"&I,8<1@FN<&,#E_F,0I"H`OP*N+?T0Q_'4&*C4_F@ M7L+V&PN-,>9:.1J_`"Z./)?=4OW#U7RQ!".K$S1\<22]O?@\)BJR9Y[WBA^Q M[UV4>*)V3Q,W*RR\-I6_VWC`TVK,7FE#SGYEU,R-B4@'\7BZ?R)$\]2$0PE.N*,FI MPW'848]?9J":^Y0K,WPZG$RDM=#A^)ZX;S;4[JES8E:L:L/;%^Y5A36*F59' M%=$ICGJC04?_"JPRR<"\$T5KM*H)/;UR_#A7A*>SIP7:8\VYJ#-#,7Y;VD9[ M28Q2(9)8+*2),H3F.&Z%/1\E<'2R?&=UQIHTZ%A\_=8W:WVS%-^L=6B,SZ%A M]GL/O>%U2,5Z9%JM(;[&`7^$C9FO+E,4G^)S><[32+) M58D)W%II4MYC'C:15F<7?LN6KU&K:'A5LG;:*XOSM0/MP$'7BNL`P MZS^00F9[GE$3/:0]2GD3?MVDZT3CH%=#V?X>)S2=?N73[+5GV0>@(6%2X^F( M1<(P+5K"*`@P@YZ#4),V]4AH6O_!=;%/+P%UA:':#@N#Z52^#DN9#=WX:_QG MZH1S?]=W`!HW06`ZA>D24=^SC8AR`[)XTJRF4W*:+E!\%Q6FBRVS&("6Y'E- MI^9]'(&:GF[N`P=P*B29%>-5F6'F-HBJGZ/(^^$'`1'#.R29CHVSJ:#(G5G^&U;[V)\D,:5(.D($4IQHL35?#T$9`?3U;-# MHF=!C>4%59_-I=4J#!+9I+[LCU8T[]UO6M%;E39H(TU?6:1I=(5?0<#1SU'@ M>WFD*6SIT/65OVY*6(@MN#7(0"B*\:L4\=X+Z4?FL^:@TQ9C:U*EG1ORA.7' MD#"PU&C=^OFK`-F^Q5L\7()K'F0`R715!NXG9PA`144[T%K8X;FRIM!D'^QP MV'NUF'^Y*?UUPZXLG=("KVW/L?B*!_#'JO-1MK_K&U+IA:_+U^7>[(WNQP?8 M4(=F-PKUP^0,=7/VO]D.>*%R#R>W1B)/T-.WJHIB=5.-SG4=KE&2X@6Z=>+O M*/]4/:RG0M.:K!T_P&#`[GIT]J`A"UF,#DK>L:>",W'=;)GE]0?S%.\O<%J< M`)MI<&FYXAZ%&U083=YQ3:$&OAS[H,;^N)I18QG%*0825Z84QWFO]U@TBO9T MWN4GES;//5OG+7+PS>=-L9VT9%:A5^==9T[B)TU6&[ESF$HEEA%'WOA*J7.V MV7W\JP]2;^PN-C>@-02,QW0X.RO%ZSI<96F2`_.1^=8&JX=2#,H]E`N9QV1F MOK$C-H::EX.P9(;A>H*IF`\W'354#^\Y\-\Y"+Q_Y(H!I[`%H&=4VT8 M)F:MAE*#\U.<\[@--V;4#D-;XGN1X^O&.HDB$@-\[TO`[=>;$+`MDIJ\5J8 M3(B\UI*.![8I$Z*T%=)1@TAL;A>'=&N(OIX.M301-;"84V>^5W)QZWZBQ>A' M2B^2_:0DS4^:^AC;F1Z)9XK/-*;$A)A7R+6/B)-2`9/Y2YXWA=Y:,9`^I8G MF^!,6')^4^)>J0B&<<*$X)YV6#>9EM3'XHPLBI_OP`I::@49O3[$:-[6PI;= M.BU8QBL3JA5T1+Z-M5*TF("BMXBJO(XDC;/BS5[D8N"]2;ICV38`2=8C/+(!3S;@R08\*0F9>,VQ.:V,6,JC<6RPB6XTL<$F-MC$ M!IO88!,;;**2`I_T\=E69P+-G"Q(R5084[S-H`%&WS[J@+(-,;(A1N$H0HQ8 ME]1KB3'2)N#*E,MM@)`K?1\J41IRQ9>5IB;DZGSAA'.0RG8"VG1&,:E,`$]` M>>F'R#LK=(!/A32G2>G=LH@U8OI(FOMI4DR4X:&CM992W):R^D1;.4<'*3!= MNBLX;C]\]WL29.$\F:,$!4'B+IQ9>ON\H,/&U]%&IXT^L@@NK*U%^#QP$I;_ MF]W'1A=UPH!M7B5WRN'J\(7D=3;O)::$N=5 M%)<@$:\C]U5_)+S1(U*W.R)<`;NRIK&QE:/!4O5M48/QJY\NCK9?LK__'@[\ MW.7UAVMPX/H1UZ$;9!Y^$/'2B4-HUGB%]#[_**F;VRW/H^4J1@ML05J75?T"3Z)11\BE1!N:1CSZ5U M_+D.;RF0+72[)RY8X;7H-KT,-&%1PVB\XL54]D(936S$PJZI'8E'-108F4PVSIWA2]A3F6>F35:,J]>`U/IU*>C!U M$GK$I9YXGE^`7'LN5TDPK1,XH8L>%PBE-WB:AOA36G,EH;,$8-@1P/0.AL.O M*"""/RM_$L55)<.A33I[EKA$A6PT3JQ"U0G&*M,""051[!F$5,?2LAGXV#: M:/8N5SHUU.]6K@NV.ZIM;!MJHD3^ECGX0H'K%(=5[F(_)L]1EA:Q/,!9,2,N M+URLT41!-(<[]0NHW%=13`PHR8/K+T8F& M>+)=\;88W2#%Z#!/PS;*!V#>33@0>FB`@E5,E&;4CWC*VA7Y+M-5JLX+."7+?.B[_, MEDR2[K=1`J4?-D.YUT8%E`_8=\R0*:O?E4''I&"]A0H(CP\K@YB4QGK`S;R` MJ23?&@F=:ND\X+64&%SQ37]_+1'IH4J%*`](U1P&V5N19Z<"\:O%K MB.^30N!6%G7UKL:AR,1C+%!>/&3P3<,TF.[(<:IO)$%_FX-J[ZK(=`_4TKDQK0'5#6SK)B'A5+MO!D>'ZZ%2;%$)-,'3OO2^\[TLP(1^I":-] M'X[R+"+.$%NVN9\M=QAVP+JC:DKZ<),_83]G@\_/*QH4K^A!YVBYBD+,#J8ZLF"!R6Z507\&N21;(^QQ%7G*'TNGL`6%1 MD/JX%D]/I1@=F8EH"-PH#3;;@0&D:X(4-U$*XX/SX]9)4>P[`4XA>,Q6JP!. MO]!^X1I#*99?H_C[=7@?1RY*Q'!C]-0Z%$>14LZ\,_4U7E+];?2[YS")DX#U MB-UD@G3ANV74:]'2$6==/"9H<(+HLF0.]>J=='1S!J]YL,U(RV;7-!7)5;&M M^J*%^F*:L/\5#@FZB'[0(A`)#:T`:05(*T#RR5'5Z5(O);Y&?HLENA]^$$S< MU%_C,+57SU^W%*'<][N?5<)6QDA[%QGV"-^#`A9Y#?`2NZC$H4D0.&ZG$MJG MV`F3H"C.X?V>E14%&T"G=-):/ABT;C*HE%F`IK,=P1BR+*WUT)R?NG_W2]-0 M4!LQZ^'6K1KN46G:E6()-?1V M%E=L?<1Q7?#=!0[8BE9X$UJ#D7:%6BB%)/;6-'7"N0_[M2@U6BT\34!L,\)P M4)-$&-'>*@7=Z^7*P5QLXKK9,H-['GG%5_B$X9>!&V3>YOYJS'GE-05[8HV. M%N#R!;]V#%R[0?D3'D9K4;]G@;G#2=]%*(LVJB/KK"`=(5M+1&-4@R[MX:"VMGF MUOD]BO.DIB8#%V]V[ M?%D!:;KDV[5G[24(M3H"Y\R'N^GM50@F)32@"LY`%XWEJ?$F(]YF9M^=?!;T'!'%+NT83]P];4RKBRU MAN/>V7L3LYF]FJ#A,Y6.RFT4JD9HY6Y',*ZM=$0M#0UW8N*T MX8:ZQS1ROY\YL%5QJ2P@1VXZQH4TYZ'_!PRN0/X_CY)T.LN9*/-IG.-V*BU& MCRA>^RYZ7#@Q.B+H),@A@$^X:L26N$5Z!$:CT8\O>Y:Q6*.Z/FBV>V?[IJ0< MXW4C5@^-,&"^%<3N8ZV"!968RAK[N2Z.GFH#'>3<)'SQ$#+G4D(U%`38_8Y" M%#LXI'+B+7$5H#3.ZV]OW5O,'2$VAA(LB.B@EIZX+CG>1>J1&:'" M,.2B4/:J>HL*5\UA#J'CN!@OE<.;8"#F$E+J.!.D?Q-,PL)X1\X9*"XNHS%<*>+P8BR M/!UV MMJG:E(_5YGNTXH2AAZ^D.V?)?IF^EZDLS82G^O91\;-21#FKV:[3E<#*50D^ MJY`2ZFCQ>)6U[UK[KJ!]]W461AZQD<,:@?B,0`=<0OD[X!P71I]BTRY(KXVJ M9H)=O6_B<=A,U)O>U9.)SY`CZG]4%.V7+9=.O"DML,5:CZV@D"Z&)=FFF?;[ MG,\_P/-;O@Y/L#M`6$AQ0_GYU&8WU.9$SRA>#G``>>&Q,2]?!7% M,^2GF`->),<5*_5[&! M>_IQTE8!L^P(E(EWNC#*0QL))`(HIR)=QSW&"2W%/*T$!"WO%ZK?9M^X5!E" M^KA/Y`)A))T))B<5E!8%PTA:[UNL5)!9``(U-38C]_MUDF3[3_7F*"6UZ(#= MP:1JA.(#V0B]OB+0),4(Z!N51XT7EA<)0`X1[DS9$8<%]T3[GJRPZB.)1T!1 M;BOB*`(MA:BM1O<91:2FDEW=$/.DOK!,CX05"?OJZ28YM,;NZ/W1X+#V7NC= M4T1:1?!32W#UYO_:>HQ0/N'RD/=TTVQ=$":4(#>'P(\]H[`I^,5*H8C,+][O:+[JQ`>!(.9%!A#ZDLR0@O( ML$LBT^M3+J" MPB7I&HE7K91^6H?*B"V9ELY6D=>5R4T_$6TL"],JF;):&/V$M+$LC,RXUFJ] MM*Z"0BP_7?D(KD-@(DM;DYH))5>QJ[LH7!?;*Z^^]!2E3E#_'1>\NHO2?Z*T M]N(<&>/^YAL5]0HA'N3Z\BON"V/U`03)6D`MDY^^89NL14/ MJ[@=U77+R[W1*W!W&J^/2N+"&/0(L:P252ATX,!_"1,0(/R9CSQV@6-J>UM@ MBS6^Y*2YK!#>'=G#YKPQNU>L0SGF6[XS\C?&GA1,.4O9# M=/HQT_9`^M49A1E-W(!]./F;:Y"JKN^F4"8Q3==V!/DB1; M;LVTA1'PPE_['@)=`UB);!)SSVL4-6]L25DNYW]^8@:IP<(UM8DT52RA#B*' MZE3T8XOC#I=^2W@0IM-RE^K]YI6BM/KRB=:MD8OAPR&W?7T/46F05CZVT@$\ M(3E-5EM"+NN^R5!Y+)@MD*`;32CWB/*GBO2@"H4YE-3Y9(MJV*(:NB?+\VES MK[S$1B_ZQNLKI#%`I-'KK9HQ=`#2J,MH]'KE"AM[1IW?W@^I^2WAHTYO[X>X M\AWNH\Z05[0(;!_;J!/FM=CV=7N*QE8CPVA\Z)4?=5T"(HW51>^,NA:!%K0F M1_J,NN!`BWMD)+G^`[[V;7+B?0\ORC>$[%=D,U@ED$&V;KD;ZO/8N5RD3`_O MOIF;ZF`3]1*I29,\4,1JJO&7!&>)GCN!FP5US6PZJXNV,+W-F3H`2(LGY65: M2>!0WZ)T$7E1$,TW?3T5+C"S45%&++M3+T\%-4]H_([O__F,/WT/?O+]*D:XJC&*0=H; MZNP1Y[718LKU=7&9H3>'#GEKCCI600+U>Q)K1AW.H-&FITE#RB,?CH+.!A5S MNEMKN:2'$<:G#;Y,@YY&Y6$JC9&J@\F\TF*<%17YRI9+)]Y,9WQ6R(F;^FO` M8NP%OZQAS9;N&7_Q&]T3VLNZRPKK!1Q#,$H*X\K6^E5P$0)N7.MB"Q=I%$>I ME/BO;>?O@NFW;[4,3/W#^4=*7<)3/,.3N`[$2.FLW_4B`-IK71,M#H<0E.-: M*5LD;"CD]+N>1.$S:G5H<002!]:2'J:4P+'%9'2)(S4O/,"66=&-)KJ66>G3 MI]Y)`QPFV>Q(PU?N37SE"T)_FWR$F?$&K`U(0N7X?P*WIR7E`BX5%B2FSK9!G%J?]' M/N"N9N,%FJ$XA@5;X/HRQ*10KGXJ?#5;&(!NDR1!:7+C`[$#(!]*[E`*!\W- MX/>0EIS.WU\Q=G6X!)`B=S,YDIRRLVO'A^:6I+>3#0$UC?BHC=91]$/D?K'6 M;7??'Y-VA&(C%SGX;P:=Y3;^E>=C6#H+1FV7M8F=*<_EY$M:H]V*^GIY%7OR MU4B?(*PO_327ST&:/H<+TP=Y/73]7J71HGHAGG4Z.T=Q"@2KE1.[]0.0ZJ,0 M)<3(N59#2.'T%45N?!?V"KI"*/FR@NU'@*8"@0A_RZ%42*-G60)W5Y),7-!O MD^*\X8\Q8@K7]\04K6@QCY2 M(+MT5\")?_CN]R3(PGD"DB(*@L1=.+/T]GE!3^#EZVBR#BWG?%UF<;1"1#H2 MFZB`\0I+3>C&7V/W7`JWDP_[JQ"MSS:WSN]1?!XX<*W3;WZ1$33#L(*N,1!9 M=)17@^FWCW)NHQOD)&@R!YD'WWNW<.L6^%5EZ3V%1K^UR7_5CH0X09#W^5.!OQ7![_/OB,LL[XUD"5Q73A MXJB-Q)FG(9D;$YM(G/<)VC3.7&\D<^X?4>/,NR9*LHD*8_-G%,UC9[7P72=@ MIP11VQL-O?`9D_PT=QTBGN>YC]I+V;-?5ETX53'TT'%=J6X/%J&['YR"5:LT)YWA9?#`"OCT#?F`#Y>'(H*,HSN_O#6L@L7]+ATPCI0%4I2IQ_ M&A'.1V;'$L>?=8CT03,G"])]##OXD#CW.MEMH?RVXU.'AR7+MX\Z$*;92-+2 M276D)QU[6M3G]8ZLQ$W#\:>X20ZN,AVQ(:R."#*Z'S6J?^<`FYH[1.<,:EYT M:IX.Y?FF,M"I.XUT?JN9%Z&ZW\^(1Y6;7#M[#TCOQ?I4M\,ORB\[EN36Z/W9 MT\3H]%!_&XJ]4MP)W3;7OZ+77@H40/.XQ*^[`90)^NI[J&HA(WC=ANZI<9Q_ MCB+OAU\YJ0[@V_TL*7D/-E!A=G,">D`!J9GY(4)RUJNH?X=?`\\-E>&\/)XT M5SN]O:SP$!=&<[`]':>B.^&F4,,H@2*4QM)A>8I2N)1+-;FZ?1_0W,]?[G.# MS`-B4'9_Y^'ZP>^1U(2/"[OJ:0I=(',J-LC"--QCX3]L_,-R?:G"77W_[\G@` M8.T':YGJK="PZ#UEL+--$O8FN.!DZ?'UPZFS#UVJ<4+C8J8\Z-$5$^7V%WJ] M.0%&3*DHQW^41QA4V)6.#"5,Y[C"MF@W:7HZ!Q=V7>I*0]0YIE#:R@KKS3J' M%LJE"E/[5A\X.*#M6F_+]5V4HN0INO)#)W1])]CAG&SC@"Y0XL9^#N$D],Z< MQ$^FL_L8)7B]\;=/,/T9J&W?53Q9W@)*LJK:8J"QI-N/R^:[V\&-5I;CADKA M99KL]AM9FT5'E8"Z1XA*^"N0[;D(TN:R52[B\YMNB`=1FDW*5*Y^'P4^#IY5 MR=UK&0A)#H]`5:1MA[%PZ_;4O`[OX\@%ZCS`,L/Q6,#*7X"<'D0KO#>8A.7K M:V60TN2!?DSLO#4:>8OSPE8N M8DD7,$G\W@B[*1>6XMQ!N375"M%U(?K2B4-8.IP!G+\;HM0"1@>&S-KH[<:MN&;%-2NN]-`2!/(MC/YR#W'T7A?'VSSSACIK$QXJ&=/UHX?8+J!)OGH!.@1$S8G]@$-Q:R;+8>U\K&5CZU\/!KY MN/LUHUR$EJ\K=!*LQF//[$>44&[TE$^?MD*G\@II5ONL:Y_7X1K^B>*-U-C, ML:B=3.J011QF%ROH6^'6"K=6N.VUI`3KRE(NN%KNR\M]QV7Z'1G_VFF0NQ4\ M!\5@NUOY#5(-W2UOMKS9\N;1\&;^:\/R::WX]+;`^R0\>F#;ZLV,9Q0YZ46^ MLP4'L;*)Y=^6?UO^W2/_%KW6+!2TJ%T9Z,:,(W9W*PU2L/%:7Q\H:V'9>1:,?**24]GY]%R M!03)LSP>4`!-O/,H29-MK6[D`;O/>RE5W;N"3+Y)NXYJ57DMA1K+]"W3MTR_ M#Z;?^1JVDL"8)`%U%:7K@%<`UE&8Q+$3SLOZV)LC)"8_G-@3D0]DS&+E!2WE MA>JMFN4JB#8(/:)X[;N(LN1!#@M\JE<2O4=PXHL#(_!$EN3YU%(O!__Y$/P' ME*2Q[\)M\I@"C)/0._CF"UQXR<1-_35L`D&C4P]3:D##HRV0`SW-&4@G2K49 M6!=ZU&_4.MBXCD%Q3G"5WN*[UK3I,(G5=*RF8S6=T6@Z/0H%RG6@7M1!*5*X M\MBN'O9/>Y8^GH)#LAFZ\OI#?5%&LOAE/UMRBWMQR'4)K].2\V'Q38ITF M!G7(LB*SB[5O6"W!:@E62^BU3A/KRE(NZ%ON6^>^(%8M_;0(90Q!R`*$0#6! M1MHD*`A"2+X9!0>Q/@G+LRW/MCS[U?!LT4O6 M&4OC6#@*W^#H:9FT9=*628^&27-=%I8STSGS7][C*;`[`?[X_U!+`P04```` M"`"I=&I%]T6U`:IE``#N*`8`%0`<`&%B;60M,C`Q-#`Y,S!?;&%B+GAM;%54 M"0`#[1-A5.T3851U>`L``00E#@``!#D!``#MO>MRY+:R)OI_(N8=<#P39]L1 M);N*=?>^3*AOWHIIMS0M>:V]3\<)!U6%DKA<(LLD2]W:3W]PX9T$";!`)$H^ M/]:R6B(3F]N@9AY$7^/_ZW>3'\7<(^YM@Z_D/__K=;[<7 ME[=OKZZ^^U__]M__V[_\7Q<7Z/-G]"[P?;S?XQ?T'QN\QZ$;8W3G?@O\X.D% M?73O\3Y"'SW_CWLWPB-$_W^+`A_]QYO/'Y'SXP2AQS@^_/S33U^_?OT1;Q_< M\"+P]YZ/?]P$3S^ABXNTJ;]QI7Y&BQ^=R8_3PE\^!T=_^S-:%7[U-L1N3)Y& M6Z+.S\@93V87D\G%9'PW6?T\6_P\6_X_Q:>#PTOH/3S&Z/O-#^3A\?R"O#%% MGW_\_&/!OO\;W09^1)Y^.KC^"[K<[]%G^E:$/N,(A\]X^V,B=)_8BX@W_>A? MORN8^.T^W/\8A`\_D6:F/Z4/?O??_QOB#__\+?)*+WR=IH]/?OJ/7S_>;A[Q MDWOA^5'L^IO2BU18TZN3]7K]$_LK?SKR?HZ8E(_!AGE)0D$D?(+^ZR)][(+^ MZF+B7$PG/WZ+MM_]&VWP7\)@CS_C'6(Z_!R_'/"_?A=Y3X<]_B[YW6.(=\U: M[,/P)_K^3SY^(-]R2UM8TQ8F"]K"_TA^S0+M.T2?_.WSE="@=4D6?^DGKN2> M_H,&:DE-_"W&_A9O4T7IZRWN8M*9IYE0*C;8E`3NJ<^#L&RX>_]$#9O,QNOI MF)E%?_/[I4L^DW_E^\$S^4[/^#;8'^GWBGYYNG_\%3_=XTP.TYX+DGKMITP_ M^F))PQ!'P3'<8!63M\'F^(3]F(533YU^W]^3+TABF;Q(V0;[%[_=?H>\[;]^ MYVU_GT_'R_'"^7TR7CF+V>SWZ>^3[_Z-2T6Y6)3)150P^L)%_[__\A-31J_1 M>QYS!HR=P!L;$_K%'XU9[#"+KVZI9?^.6DQO,O8R+&/.#3>ITN3'#FN3)W[: M!(1>#_%%Z2OOPN!)`66I%H&BFWY28H_$%&;&SHWNF2W'Z.+!=0\_45;Y">_C M*/T-XYF+\22AZ/^1_/KWR\V&]*,QZ>AO@KVW\7!T>1_%H;N)*Q] M[_&EOR6_"8]DC.&Y]][>BXF2[[QHLP^B8XCOR+#B#='FC_:/KBS-/.Y4590- MVO%DZ91`&:&D)>3Z6Y2TA0J-H;PU](6VAUB#L+`=U#TIIIDGWG\[8#_"(/VA M)A`T0+R7_RS`_]MC&)+AL%QPI`_#H3?10#+Z)K/9:M(,SA%*1%F!NCYF.26S M#ER01:"J1%8+9HK60T+B,]Y@[YEJ]`G'KE:54"2BQLA M(M`2L)QL9!DR8<%('S?:9AHZ;1'8!""A1]1@)%K5X1U9VF$+9EFMCQI?O6G6 M0S)*YN/9>)HLV%1&*T-/K\1+-!HLFD!8U+$.H\&LQF$E\#Q1!CCY*DN+$X`Z MPLK(M;,7%#QOM@ML5D)Z-+6>C,L0*QTM_ M^PX_XWUPH`/4I$MO!I#RZT"C:!G=)(/.6:^F3GEDG4IG$5>0GX[DAL5:UWA; MN^T3>VR7&IEK=P!CG)+AVUPN]%!=!<75X;NTIX!Z]N/3<4^32*[C1QS2G*`0 M/Q+5O&=\Y6^")_PQB*)/.+[>W;G?Q!V/DA2S?;^*:O)+K,M%AMFT`<1:0*4F M$&\#?4];^8$MEZ%@1Q/+P,8(@_G#J?HC8/[8E/RQ)]*!1PQ](KXRA%#VH:8Q MQ:-'*(3RQ_7N+0YCU_-O<+@+PB>:0_>KM\=1'/@X(K_T@FTS?:N),#^V4-)/ M,C[7SG2U2L<760,4B$D3J-`&RAM!O!730XSA7#"QR@5=(XWA_,#G-^P]ZH*G M5!;=*`,>&'0H>XT/=RTW7HQFTY]]#9T:$-G5;\=`K])HUR-Q@_?4Y1Q MKNJGIV2@+N;.8IUP5M802EI*EAMH8T@`Y[Q!P_1EP"L36[W2P6@&7,.8+?6' M^Q!B)G6$GMQOWM/QB?]JB]S<>0GE1>A(_>:6_5:8A.4L"9BL>AK+Y#1YPI<` MF:=E^MZXWO;*?^L>O-@5#O(%3YN<=S6K(+\(N9C54$XE(8+A1!;0!$J#84[% ML$-BV$9LF+'I47N@E:9!+9Z`P<@_CE',J.PN^(RIL1[+?,BG9'?!6S=ZO`F# M9V^+MV]>?HLP4?SZ0$][>?[#Y2;VGMF.2U?*^!!-&46G?OUE$3`>+].4@UP+ M%`B?J3HHU0?=OZ#OJ4H$-C^@3"N4JP6?\`[M8Z?JXQ#_>?1" MXC/BS3!SMD^<[27.WJ?.IK_<4([F68_PY+5<(@O,]U`GU+/S.N! M#.GH.<"W`=N4(VIF(Y:;9&QW%[S!E*4;1Z4J[QN?8RDH)WTR:SF>39*952H> MY?+S.0)*6Z"0>(/9`,3P9&HP\R<6F=\Q:QK,!T[9!U^#<+_]2O!+V/$9^T M?[&^C"^O?@C"=WB'0S+H>OM(R:%YO5/F/>,=KX12LFP[':\G:7I'06RRM8"( M8)1*1HEHP]VL=F,GX,9V=*K:+79J%A^R_95M:G#L?B,=)D]L)#.X%^R&T0]P MO:$"8/->4-9S(&L@I&/>>O0P_C.^Q9MCR.8<[[_100S>?B"FT\WJ(X?]]>Z] M&_JD(Z>;0;=$,V2I-R_-`BZ_>=7QE8D6 MSX?1VLR0/[&_7K3SW!1IKJ_!QG2%X?/1]?Q?AI M(*;*Q9\/+64ZRV]OK*=:QUKH"]4!,27.D[GZ^;"-IK3[\$PXK@90C816_DKV ML-UK;A7<):6`37 M@[0;F14_@2`NBG`L[.WY'TVBA[4H71=E.D[7,ME[0*?"U75F1\#OJ&#D"C4W M%L^E$"A%;6X97&QV)3N5'S(>JZIU(N>3Y;(8L_"90/W-X(1]>_O^[A8^@%M3 M9.HVP@5T1V&"TC/&PUGQ<.QXZDR*T3SPV5\Y*NYC0X&1-_QU:YBYK5Q`S5[P ML):BZ^JS4&&N7.1W-ATWAKLE+'Z*68S,WY9B'S9]LBVJA""`Y_AGU]O3HG8? M@O#6W1=&^Z(O)W[!)"R$6L@.;)?YT:=4UL4N""\B(JUC?=D`//28YPC,BPKS MU)WKA>C9W1\QVF:E
Q^AF']X$1NR?,\`_4LE_=\`\_P23L<$NYBY/E6D$[DLK*AO'"&2\E MV&F$BA4B6,,H;QG1ID?HGC4.6"7#J-,8]!L]`3LVU@4?.9I0\>RYL`D]&3($ MFY3E6LXF)65E@;%RLFH5)[`);7HX-FFZA,L*M\T:"84*!,X^T`6A4QFE[EO+ M&(7GF.+MVR`2SO,EW[:#'8HJ22_DKYRQ'`>DTA$5C]ZXD0>U4S&`!Q:%Q.K$ M1$M!W!2UDE"M><^9P4(5>]$6#DRRPW016^UFILD(9-@O"`M/Z$G M-A=GUS5%K0LL\.AK6\26\I%=B/M$?-$3=(57K_>L#*0;#B*!`4?G7#[1UII2V#OO2,25P5&Y;=;R$3H31OA;Z. MZ/NPB>F]K7#*5H`&?U.TCQG%Z-7A+9`L?-QCD(AVD MLWDGDR0C.I&$F"B4R@*-?2W&.;V,,X6,KI`K@J35';;@I34;N.4%8,RHY<1. M9\M5.VI`4W\U&=B*'`NR?;O#KPL]P!F^;XZ1Y^,HNMS\>?0B5A./_1CB]J3Z M[O=,HJE+&>E$:+!ND(E%!Y@BE4J'!I=5>YT1[C6%--E1+D)-RE2W(:QGH M"9X&1IG"A&`U6[1@"W:0I\$R(8IL&.&UAUH77D#'=W5]WKDQOMX5%4PK14_D MOV^;$%A,M6BF0.O3MFZ,-D$/0A:C-&O%&@CJ1@)BK MA6('PLJNL01/-V'P@5ZA#UDPR)476'Y M]8KUK*W3)2TCUC0JM,UVP;+64=Z\G=`?V'LM,U'-W@/DE/YP[""?GA_GW%@J MNJ-;D0/$;"+X3/B):RM=I6Z9IJ/I@%>$OK#6SY"8>KA-&RNUNNT<&*D,/5UT M5/@D]G+1'?X6OR%:_'%23.92K&.93#79'GNQ6K0N,C1B(T$`HJTAUIS5'-+/ M*>D%](GY;P,_"O;>EJ7Y?_!\U]]X[K[H%?OYH!;^ZN`O^U)+T?*&AJ.\Y?1Z M$U[9BE;]/Q+>2:XU(4_R)'K^W)W[K;F^N>XF3)="UZR_;%GM\6+L)%73F]@A M*K$#N[^'JH$^\&IMJ2(HUP1Q5=*GF3)FZZR#>E+(LQ9[LKV(.Z@[&4,G#DA. M6"772-$B[^S>J`B(EX!]VO-:LE/R]C=,6 M!BF.U&J7UUDS.-/@`0;Z3]4;XRP;>[6';\>HJ\5)MJ'S,[^1JD<`I&]:@LA$ M'>E#\XN5Y$),(M@^!/:QF&&OQ2(;$%<)25FL%=VA=U;C;]EIT.O=#?G&Z2!? MM$FC]"K8+*1=+\F0FB]FJU5U'#;Z1TSQ@T6CVQQ6K)T;U& MTQU-IIL=P3Z3D&W&1`0.F._,!KOTBO@`MG*9.CJ: M)BJ2W\`2^-,=,F^;>/\N=/V(WTC9E<\M)0*6`H1Z*2Q=5;=92R10:@`56H`I M(C28"XHEN$LFQ^TF`^*V,ZP[D-ON.,NQ^S&Y*=?#T14O$K$]/62:A-J)[P9- MI<-]N:H.Q^40/T*%5E':K#6#@:%1[E0RX#(D%#WQ,]O:1_GCE\PM?KW>"5U)#7]1&"_I;!R9O(K:C1#7CX[2N89T4"YZ->>ZET$([A#0(?-S#XZ#_0I3QH;OOQVP M'V&T"T)^`W7FV4+]^8T"94)U&+#.Y#U+D^](9!IUGT0Q?QL=.&GU((O,L^FW M!^NNNCOX83[B^8P$WN%H$WJ'AG5_?7*M[[T+RLH??YXM-?3+A9;/J6_HZ[#R MOL"FZ#`16R&WY+!MWK)M:XG]T'8Z154_QOF0SV?ZT_7N^AC3A*J(76WS[][# MH]98%39B/2V)-)<=)\QF\VIR8A^.8FK0046JR(A?0C1"5)ESHBTM#N5'4(*8 M"*1G30[N2W",(_I?UL;YD5(7"D]GJ%:_VTU7V<#NY$#,)5E)/)EZTF!8]5N9 M&'IY02-W]/.)\J*I75/8GH&07U37:QIO'T76D-^/!\ON/!.RZZRR?YI,NPE0 MO43]8K(^E0KA:_:;\]29[2HI(N5$FK"@[G^#UN^R"U5E3^MWO`Q+`0T:R5?< M:AOVH%PR^F+-27R-EO-K!PIG-2S#:TN@=@!3Y!FMJ>"%]C[C3?#@T\NMKK9T M+KGS:.HHOU,[J:.[O?2+F\WD;\\5H6OZP;%G+Z!_P4U@RC.MO%GM$?IAQ:D.PP\,3M9?/P:\5#RA- M&T\DNE'RH#79RB;=6LAI=KF[W*0%RP:LFB#9,;C5X?K7P6&7]U$*3:$I_-I.7,:$_3SZV*Z*G"'9;S25SAW MYGOK1H_D#^_)(\_NGN[(&HCFAD;/E`'KEBAD:K:>-SF9!:EJ[*\%Y<(RN*03T4,PH^R]FS(]]NX4\2*9A81]XTPI&BIL^5*07V MR,)W-1T/S)=
0%)C#5\170I@[OIXN!--V='OU/I;P:VNQ`^V#DV?9Q7@F% M%O^01-"-^R)QIX09'OSA9&V+7P1UI*)>&21-M7P[.:/DB9<`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`2GNNQAFC+`J#R88W5K(TV MK%QPZV>CT]=&0`RK+GM9N69UBP]NZ,9X_Y+S!+N[@.A)=2;@_\7U?'I]&;W! M6&6S4ETT+#J5]57(VVI=7,H;+HX#BDVS3AVQUGF_S]JW!O/#>BZ[+9S>$FX9 M!_2&3P=7]//HF7!*I"AFU0+QC:< M=_)GSX9W-/FR>&7ZN1%0-]9.9*(.'UM"2=%-L/`)PQ<"_F-YVE+ ML;D(<6GH2_)?&PO.];&X6B#RK<4%(BN!V#5E*'@#$DF%.P,$]QA+EGE4$`2` M/'GMY">WZVK-GD(CK'?E5UT'M:NN;0'G0$[AHWHWIJ4OB?&9>ZHN8;V/)3A6 MAT$3OA4="H'[M^[!B]T]N[QLZ]%OE%U=^.88?PKB_\3QC>N)QNO2KQO$N*Q. M"B/#!-F)9%04G=WYB>Z/,2+2T0N9P%+Y,&`>Q'I>P]W[EI:00;CH`2^1/T)^ M8OY!8+XI&*M&=1&\2@Z$@2RKMD#_4ZBX=(9<,&Q/A_+J:8>ZRQ*$7;-_[VW:LZC9^UEKAA-I. M@IKVMUR_`4V_C=TP-FO\O-/X>_S@^3[]\L.Z0(*E=1MO;VT;);XJ,[&LD^RA MX1L65*3#"+$;X7>8_U1,H;0-]G[;R`TR>PV". MR)(7OM^F%M)A%+?:\SE^SP/([1'?C><6;T+!^L,^^$KS:[_H;^O(F]9Y8XD=\-T)&K<+)8P_`_15?9U8')*LUY8$Q`F^2WW=!_9:TR M&&3MHKSATI4:P.D11EW&NOK;X^&P9[?HD0GI-O<$&=CX@7_!?.B5?+C+?.AF MFH">4=(%M2K'G/PA0'@G>'KR8G8K(N7(=(U[(SXUWO:&2;80JR&_^9_6.R\( MXT.$HC@@:&NRSVFR;U,4A[[_%,083<:-HQUCJ.P.Q!+@.MQC&9;D.VPE&7;@ MK7^_,IVGI^):$6A5ESN8'QJ1VM,/%J!6LN-4=J>UR.[:HE048ANVE7?AQM/) M3!7_$LPB[=L`_$&A[>/;BCLI^Q^`HD4@IZ*,34 MJ@TN!9&68*:OD0W`Z3`.##T-(=@*H:I+@''4FC]>?0P&+TKIL;/9=-R$$2;$ MFAY%W:0&1/S/'\>3?"93&(6A"S09CT=C_C\4L;C[Y\1V\L?99+2:3D;CY3+Y M&\V6OB6!CY_NR=1O.AXA&CALC8(\.W&8 M%62+`[H2,EC=R<[48TT>6-0]\#TMK\+RC8E08"QUA6<%5JTNT;3OD)XN+QTN M_Y4Q5?.B<-L+YG<<6K21#)S9>CE=I=L-S6?MT1TQZ#+1 MNF()\O@J;"AT>4,SZ'_U]I@,IGQ\X[ZP?8R[X`UN.``M_1H<`0AUDMW37BW' MTW6-!S*Q*)5+N\HW>+@SSQ)TH,G6*BN8MU66'#09S#B"'76.,-H>V:C'\W$XT7)UXV.XN5TDKZ'G`1MBM&(H).)1@79(T2E)WN6N7RHR?T` MUCN9]4_<>B^3/4([:KP%FYAJ@5P>XBOX#`JEUSM:13FZ#?;B?9CR4X8Q5VA: M.KBF8,FBV9(18E?40H=\4PQ5([YFN@T! MWWDP4O`X(`!4C_DMUHN%"`@6'&S48)Q3-@XGLF#/^W<$6ALZ-)T\C/#FQX?@ M^:8UD+D^V]W M[K<$H6^PCW>>J-/H>LM@W]&ABG31M=4T&4NE`M.=92(R[4S0]XG4@>I7=74E M.FUU2K;&Q$@RQWCV(N"*O9+Q6.Q;9+P"":VDT'X"_8Y/6WD8`$AE#61C:KY, MK\K)8BH1-$*)*%C,G&!6&2H63,';(ZL)&PW60T*"@)3?8U>XM.X3CO-+CSL^ M9O?[`,#I5$IZ-CP;3RM8HIT0%\Y2G$:%"\EA8:77:(:TCX'_<$$4>$+;8O?D M"N]=-PT[Z>AM0J*Q]!F']X%!6R@MS-LF&QKFP$2+_VN/L-IFB9,8KR9:/8#YF@EKT6.Y4+6?FN@5Q ML"CK#,PRP-J=`H*M+(WB>D=SJLG<-[D_>D_/C;.E5W8RZ=Z-\#9-D.K8%CA1 MJ$F$GJ2I[/+C/`=QJ3AOL464-(E8F\FIO0O6;)YP"+T=8=!=SN#N,L826B!6 M(I+3/X/57/.FJ'97!<=3I=K(-LVJ2IN@&O/*C28_Q4NKTH-X%DU;R MUUD02#MN>C%(BU^A*237KVC!91BZ2<)Z].:E9L/E5S?Z8-C,DI)!O!T,EU,^<&Q M5"JZI"E63"XJ"!YZ=M-$F\-8.['`VO;#8]I-=DXWVAHWI4'&1ZB+!+0:Z/0V MT"0^VD*O"A*A2T"0TG1Q0.NC<`A1J2<_GBUFLS9T0!3,UV97"RC@RN/+!%@+ M%G04PU?%P4UZ([W@'$OS:B_8Z(;?DL[,^&8YNV*7V@>[JL3H+IZW!QK*R$Z6\R9@MAD0U5#/S M(#:XWKNA[_D/47I70T>FC?!Q@UM.(AUD0V0Y&2,:+%N.<7L:9 MVK7I"KGB]DNK.VS`RQLW\C:2WY(_"X@4IH#T M0SZ.DV*T:6G:`S$R&NRZ(8G4<0U?C1GX26P:ND#WH@\(10,E)+5Q0.X/:PA` ML=0' MUAM*$QEK&V?)5Y1^S71VH(1.TE>ED]A*KI=H6!\IY!(/OJO;1!K#6"M:ZC)I M;7MVH':310M@"B8;R0Y4`&F6'"CKK(%9I&D_6^H5>]A#93]XNEZNQU+$,>"& M=P_.4+=1ABX@-O6U&RI#$G"[_"KPD^`&';O^^H;Q70>BQ,\##MV5C]*0.:*X M]X4_ZZC'OFP*?`;C\]:3/NWNT-.;;@[O_?BKM_DCVA])4P\XPOM]M'ET=_&O M]X_B>][D7C3>L\IH)7TGD+.8S9,.=G-`0L&(2`:Z`6X`>R<6V-O1X^HWFG>\ M;V]2H^LV/]W_.UR?JP+2O.>5=A-(_[O;X4U\O7O_C2CD/^#/;HRO_;=N]'CI M;^E_WO]Y])[=/3W#*.HM5$28[*45])*O.;M,*JIQZ?3\:RH?T090X",JFU4' M8C\46@'JS8?R@U/V`T[]$%(_$\CZH\-:0.TL^\1XZ7^7]6!($!^.NR#%XR3 MN@F%NFGM%7N[WS,)V2YEI.-S,DF[T$3D19B4&2E5/P2MZ:O76J=H+=I8?<:;X,&GE]WSO&-6ST2TSCY4*P`( MUJ2Z[(33F:3'$F7J?+26^1B57V-75\&M@MO@US*S)!H("ZJ,4*X&'1;DBJ3' M!?@%,-#+[`-#NHG/='X\:]GO4\#NR,1;AJ:(W7I5_#NUY5,0_R>. M[=G&B'V,D"])/I^6QT(2&,X4XJ08-;$B40B]X+B`<(NY<7`/,Y;\S0]SNHM8 M823NW>)X++WWRGK6.P7*ROS7^P.]*B9,*U>$R:_HE5 M4G,KMQCA:_'W!B5Q&C'7!ZI,ZZ72XNFJRF)4%N+"@"^;UF-> M7D`WL0KTPIW..&O$7J,#]&PV%YNX(9_PD6#[AKBU99NYXQ7C&\SM^LCN.LZ= MQ3(I"5D!0RH34:%0N\HZC6Q"O$$C.[:2=5KJ=%D*MX$L![Q\ZUC"+<,7K^"% M)M\2.(;N_LK?XF__&[]4OJ+X.4/E+!H;E^TSU@LG/??/2X4F>_R#^6&TOF<5! MBR;R11&S4_Y)##&AG%"3:QHB5!`,AA%=QCHG&FL0/Q+A60%3EY-,(>M=\.1Z MU3%=[<]&T<+;5"C_MBKAX@M_'Z"276_U'4GUS45T.2S*L5LPT%24?O#V.'SK MQO@A",5CG?)31F.VU+1\.4]G7`I=)@6E8J`"N+\MCI(MYJ*Y,7S*05TWVE1L M?\8/'CU3ZL>?W*>F5N5A?"X&43E0\7V"-8Z:->8BO#F( MRB'>8#?(,N^?1Z+,+=X<0Y9#UK[&V_RPR07>1@WD3\BOTM$)DX-R0=`KNZ?; MY33:!;JTVQI;I75=L?D@H#B&P0&W0Z'XB$D`%-J5SU/+CLRPMZ%CO:\)3FX" M:%@W1$(:\`.Q!1T0*D2B%T! MFK3+GBHJPJK&=2>+#@]I.()9NHF0S$A-B"K!--<]1,`T"4./`$0!)X!!0_>0&^J*-F=>LK M$.AIT$-Z`#9W:BN$A;**$7BA:FU&5J>^\D8:1U1+*#8"2N0:6_`D/;]L?`<8 M4:ISFLEXEFY]B:+-GBG>R78R5/WJAG_@F,U>"[O;=)HK6&JR#65R,S.ALT!Q M=N4?CG%$=0N.?ORY?FNKS!L0&*NK(;\SNZPCC(L;H50@J_X&#*\334PN5DCL M"8>R1^(*%FT?+>^%G]E7\Y*OMNVRTC@]B''52`X"QUA`#6R.ZK1FEK2]`4<- M137DER#F#8LM*3?!9=(I4ZI";.90Y02?>;S<:T_5P6&%9E1PWGG1-JP*!>J%V!.8@M+LIR4 MU)5>@.XIU7KN4$[,F:XF,RTD8E$^DP&/,6(1>L2]#XYQXD6V/$[5XG_Z%<>/ MP3;8!P]TZ?PW6BN/5AH4K)_S36!OYY''/!]9.*'IBCT5\0252V*0R06GB!/,$Y&#$/"5..,%&OO?O[7$4!SY& M6Z"=.WE8=#9UGNRFNN%"$5J;](PD#KPS94:HJ`X?#J&R0C;M6D&YMW9XQJ![ MSY`]Y?;!='_,,^=(J;TS7)I! M/1`+6K+SI\$0V>U`G4V=*1.J;H,1W-8V#@?`K47;BE!.9N3XEM_P[OG%K<)@ MA]X&?DQ:IY?HDA\C;XO#9`\R0N\P,>Z)#&FV;(*=)'CRI;#70H=2&XNZOQPH M+1;WA^L'U>46`*5D0!"9C&+2!U%(V[6%N4(Y!CO6X[1;7%U;D[/8./95PK@1 MU-*.LP6M?_?BQQK-1&6>*9-2MGKW"['E8Q!%5_YF?]SB[97_W@U]\ECG^M?@ M[0.SQ"!&R:8FSZ;IC13%,5!!._25J-.].&,_O:&3G3ZU4P;#\O,P*]W&X]\#NXA\;I@"Q8=OTK(+E;',=[W)2" M;*#!\R6Z@A6R(%S.G-K:XP!45]!,+]FMN9-]_.#&>&N0[GK[>L:.*[2D6Y\I MX35@=D#*J[K_G$@O$MC$9&F.WO:VSH#J6@V0'FHLUGI8+FJC.7$M^),]>\"A M%VS?^X,PG#X7S_AEE/3*:'3ODA<&.F3&W7$;NV%LMT/FU"%O\(/G^QT^L9WU MI4A+!^%W.Q^$ZSW?B_%'[YFN,<3DPWM$?7XSPIN77]U_!&%GC7,%"29Y65XM M^<3AK%X0$W[!I*-E4*:M@.=QS*@/R1`KN@/"Y#>!@-)M`L= M"X'X7X)@^]7;B^(C^[-!C*9M2F\YK:?)-"9]$VZRT4MWR^8'O6R0'](/3VJ] M#'"Z`L@4^5016625DF60='&Y^?/HA7C[[DBG)#X0,0EPD;^R3;:LP$E$W%-$!&Z`!0V?FTTD-]6T7&=D9H,"&#) M*"8_35Q-RDACE=CJT\2\"?`[D(9SA*/3$<:1JQ+TC5"6]J>6VD]2S7X45##H M(\%T=2@U]63+CLUGR_6B);C8Q@"P;(J=A1"D!1B&VS(^63Y8ZSFJK#&/HL_H"^:(+T MQ4T8;'!$LU4B3(^5LM^_HP?I@P/MC^_A34A\7ST=7+H@<[DA_?UQ M3Q,3^:_HEZ"G%3J"IOM]`%1W*B5]^G$YG517%E/A=(TQ$X]R^8@V`(MDO?;S M5<>"K5YN*PGG:(0>+%J@EP[H)M#*.0X2KZ(5#O%S`/A3G):NQ_.%4]DLM*"> MX6G6.$K6F$9)XT2YW7#(J+_+#RE>;O]QC.*VXQ8=+P'@H5D3A:V?<;43*DA$ M!9&P0-%@YCF<494+RB9`M3@(`EW\L.GEX1`&[N8QNT[G#F\>?>]/F@S;2JX<.]0)AKX@MBB-WA'6)(_=^=^P]&OGA^$Y$.1 M22B)C4PSA%&S)(^>S%9+4I$D]2]H*&. M<@U1KB*Z9SHBWG!R^QDJ-#U*BV(P`T;H_3?2@P;AUO/=\(6/0D?H$\$7D4Y< MMJ?B4_.&8;`@=O?=#&;?=UD4ODOB]83_8O<;(NSQ[$5$.W@2-,H5=28U]^7@ MZ/@V=F-V,J@C)4CTM'&:JZD@G2B^7I7'/IDD\&P>'98Y/2PSBV9AJ-61U^P* M"U#RD;9$9SKB8V9M;\"AI:B&_)+/8B5`3"H.],B8+A.;H9.*LP@X3='7`IZ: M0RP"4.NIKO9WX$&D6&MW.IUVP@CT:)8^,]NA9,6)*ZF`E$`5\&FJ;.@IG=7= M]H9Q3#6JH3#@69801:39E)VMRT2GKXEFL=0:A'4DB?UB"8ZZ,H!:7X%%DG)& MRVKM+%JA!)[)H\W*"IJ:J_X!(JPOK&:(]>?%SII-UFY20#(C% M>N',>%IN,2``SPB<;,S$O#'M";4G6U3#*WC"02=&LF18H?&@71R.;EQ/='BV M^A1$1\:;5EC,GC?$/14!W%7UL(-?1^!&C^A`7D6[("PLREO25Y7CI[%[*EBN MNT<2'BBI/0/8$RF=$%B-E^NF7@CB_,=)-C1T/F`'.4XRI*'/`3Z1(0)`4U<# M>[HB4^3]MP/V(_P&^WCG=:Y&5)Z&Z';**DA7DUVG-2T+4Z=$%/H^$09T>8,. MTXI8L&QC6!ADC7U2@P^`\!%B-\+O,/_OE7^YV01'/R9=YDO+#>.'-9RV5!5XO7;/2N!+FRU$!YW]4"5@U[% M.]:@+SR2[YW?JGOI;]D%04DFE?]0^)M*1*B(A4:M@J[R`[35M`O1M-G2-=OT M2"J_;"QKNOAWBSK8H3R6]K_,-9@/"[E?`N:7?>`_7-"KL-&^W2^@/-$#4IT< MHNIQ._CE'=[A,,3;S_@9^\*K&[K?`V6(BC+RI23GBU8*2.6B1+`M^#[%7@;@ MS+!0;!@<0`4QV8[`)I_8`3&:JNR3UE3ZY^([H-`J*")].MSIZ%D+,NT9(_.HZH?[,!0UHN^=0]>[.Z[$[5D!8"B2Z25_)F\];H5:ODP M-6G!ALRN(9Q0N(L\HH:[O*(.'9@6!J(_VP7.KJAN1VJKW^R`[4V(Z5YLVC"N<#2YPCS"U6'0#'=%QUJ(_???-OLCO;RHXRXI93'V8+ZFF_0&QWQ2 MQ[OHQL/OLV90VLXPF4I25UD-ZA++KKP:U%:;KL8:U-"$S*TNN]N7RQ3(N]F) M%A*W4JW#?K+LH?"32@82#693V7&;9343A_?+.912/`D*"N"WKO!B0L8I%U_Z MVP(3WP1[;_,B#!R9=XTB7$(A^=.GLRS]#G7U6"/$A:,OR7\M.("KVQ?GT7LK MA',9M;+NTG1`BGQ`G[&`NV\L;BI\S/PQJ9H.LH=S)M/9)#TI51`R;(G2)H+0 M8LC$L"%=!Z9.L\:I60-X6$H(AL)YJ69S8?I,GJ[P\I8-9>*F(X[MSQKM$QL4 MD.7]V7B6[?4G8D8H$01S6%"?68ZZ6>9ZL98`*_=:(B^`XD*AN)'X#0B,]*_\ MXTR7LPI2[*IMI,="IZ>%QI$C6]JHW2V6H*B[M%'+*[`X4B[Z,QO/QVU`LF!B MI!2L6P7B=9?QS$*=BB5#8PK34;S1`44 M;[6=;-&G_0B3KE%M7;K.\'*\K/9%-N1KZH3F!8QP`_^PZ1GNHO;!P3%@*\$8NI MD:`H_.Q^_=4E<>6Y>WH.]O9X..R)`Y5&?U(R('`LHYATG(WGJQK020,H:X%M MZ*1MV#8ZU.X*QAC4_J>2_5$BV`H$J@1W(T2EO0:*X;\'X1_91IP2A,"K M6!WIO(GYRJFAE(KEQW"88-N@JSX1<;(D4:*#TLH;C(K.!`M]+)=H!CVHL M-:.A9#Q4\/.\*UYLL'T"5WW2ZG$D-`%0(\.5G)]E3C?\. M>\S'?S68FL._9#M\]+\E,Z.'(/3^BZ47=5PUWODB&#J:M)'?W%\MJVB)P.\W MTVJ=HV(=#'+:`E&,)*%GM&2J?J3G_R_)'(Q=H_9KX,>/^Y<;]X7^J_+ANI\W MG;O:IHQD\"R7X^64)[$R:2@3AQ)YM"*P*.]Y$/CK-6T"95I[?JLV^_@^L+M) MZVGNJ>!HA.ZIQ2SC[X!#]$0;`,N`E0%9E@K;Z1F('K6L5-3:B38_:[#?;%1` M_BQ$>D*_`IH(*!UM+VT:J/ MFH9"I7W9*;GC3)TB$G(QB,H!1,$I!N4@&-$R3ZE%6X%%1J$@B*D:$IKL[P^$ M"&]^?`B>?]IBCV.`_%`-??(KTO2#NW_OQU[\TK"@T/2$@4!O:%8Z'%;.,HUO M(@!Q"2#K!Z=:X2A8,71$MX0*#621J2!$WEGF'JAB?8]2ZHOLZI;!J\=WIN\HVFY#_?5R??C;.-C\\1CLMX1IWO]Y)`#K_D;-K\%$>Z,N M\E?;_\)O?\_OUW=_:?-4&P[0Z?D-6!H)L=DN[]_^B`,W)+698E_NES7@94= M:`;OU/I84^C&-LFY;/M&?)5H$H"B:+X=X2_?%U5?`(6#*OW.QLOZA*=PSM^> MWN84`_DE!'6,@%X[T!US[6`![S-8=56ZN1I=[][A^YCT;+PWN\6$CWAG)\Z9 MD7W;()PD59)>5)I.YAQ;3#!+1(EH1B*571S3Y>)!\VZ&,-]1,A\2CHK17,2F MBN,L!2I/\^@?&,G[=H&5*R7;4XQ7DX4R7$&3?X9Q@1IDK<@04@YP1?06O`B# MWV_>T_&I-5^@_(Q1'!8:EI[US^;+%&OL=>"T@/Y&.`4C8"'0$"/E,*^:"!+* MGM\=RJ5G3(9RL6'9**!W,"2AS%^'#N7>1C@%(T!#N2E&2J%<,Q$BE#_A^*T; M/=Z$P;.WQ=LW+[]%M)+Q!\]W_8WG/UQN8N^93]@"/_;\(_E=&^NM0\-?'YET+%9J$GXVY**Z1CA>I65= M])$,^-(I@`O3:F(UB@%=9]4++7U<`[Y^*U"?'YS1/("1%0K/,9*:2I]*GXSE MN"5K]\P&,$/XJSR`.5(7[8*0G>3G+K)Z]*(((`E&4?'Q^3%)O]&+JO"S81;5 MKI<@9J6;86P=O0SIPL+95_M'+SVAI8]K;!V])!KJ';W("H7G&$E-I;,G)NNI M%+=D[9[9Z&4(?XF77X+,2U8/8!0Q)$$J*FX^/S+I-X!1%7XVY-)C[6"NFV1L M'<`,Z4(V@+ENH!@;!S`]H:6/:VP8P/`25Q^#J&4\4GC&+`/D#4L?KEFO%CF0 M^?OH>RKA!W09QZ%W?XSIY4LH#M"-.US>M00V>QKGI,9YB7%[:AS8B*:G%0MI M*PR21!T+%:Q7C(6![-?+S28X4C9Y(+SCDQ\WO)H"O_R2_W_7543*8HP"7TTW MV<`;+Q?93.(KRIM`Y3;LNR-V4(?PNMIX0_/2A3Z!!6:_B"]CMX<'M=3E^D0, M)".$ZY#T-G'RC\O-GTC?&6#Q0>B&KDIXB,*D)AV2QMLDW7 M^]*EN%R@3\8K9[Y(;KA-6D-!2/O_&*7_+K19^CE1`.4:H)(*9JN)P3AN(NFX M$;SGVHN5P;B/'_W)O;`IBD)AXB8R('4+W@MVZ/W;&[!*9[II*ZN*IO43@`S` M2.>13N_X>/#]MP/V(]'-PN+G30ZI1$I(#]K'Z:'PHJAL@I5(@YJ&:+%NT6G= M"+&CKJ"#H:[H*XUZ6OUB%7BZUB\[W[,!3*I+9O/54@94\`N)6@WF:X3Q(P[+ MDW_8)4+9P)3"%_S"WI'FI5_OLH7(6_S`9CNB+RQ\WB2N1$I(GX:93]+!*A-% M!U'Y8G0J#0A#6HQSRL;='R//QU&$HA;;C$&H*^9*T&EU!P1DKLM(;ED1;WK2 M($P:FI<=Y\P6TZ3#N:[U-A_AEI%/M2BYC9'906,RW>06[/2;`D1+1!6A(+(> M!`3A@^LG%>KI="O8>UOVCTM_>T.^?;JH<[U+,HS=_2WY#5])ZQC#Z9%M$F@Z M%):G=R>I>5=LEFTMYPVS\\_%IFDGD#6.\M;!AXSF?><8\ITQ]M`)Q1+?:/LT M(`Q%)PZ7FTUXQ%OIBF$=+YGDE%9-Y--PZ6B@/0MI9.T+GB"$B9GA'))D-@XQ2@& MB M!@3HJ:._R7`PT+\-G@XA?L1^Y#WC?+)Q^>QZ>YH3]2$(;]T]+E2,VO[CR,.' MW89[YWYK^\HZQ)NF%@TZR\]4':?(1J6FR[/P$^R\R]F&+R#CZ`3VXGA\A,KY_UT!,N2 MW8D?QC;J.X'(;*,E90`LIS-IDAF:*SKW,'0;OL@-WY0,Y[OER=ZYK7COB]ZS MP.(-#KU@2WX?TDO:M)4<%#YO&?$T#Z85<+(/_(<+ MTNZ3+3<"=0=>#35BA\`AA[CUCGA5J5L1OV0<02)-Y.LD+CI>,@VITT^_S">E&1C`"1\I1.DQM-!%E:9. M(^3CQL[7**B4SO=(>`4"5#?N"]ULHM=,LO07=]^5&MKVAD$XM:@A705G/4_6 M+%-A;(^:J'+1*>OB:;0)!&$12AU^04(1ZR/3`["W@5W[K>_>_$CO;:5 M@)UNYCZZ(7[C1O24[!,%?=.)^Y/%F45@+QVEKZ>?SB<9//E0\7-^_IHN*Q9: M8P5_67L7][1!5&Q1+WS7W#4^R^?:=@#8@(=F)1=Y/IG#X2-=>?6BZ.@2\-&? M25_S%/C\OG+FJZ?D]IF#^T+,V:/8_08[Y3L5016&Z.]X2/JX"]BA>J):C^D4_V2;O(E[PM?DE<^=;VM#034A<$FHFGUE66$PC9BWJ:E/$*\58^# MN@@[B*:FEW2FXGRUEB.=9%?S;59.A[0"/;[0[PDVIKBLE;CADX>K6S;_9L,* MZ@:7C#.>FKU@`7:%X2Z)XV9/6H'I7[.DV3Q+5#94&M^%1'&30O)E*JR05![#Q*)5644 M!GS5"7L!A5([\B`(/,W>$OIDCW.!X4X4H*V8:W20%7B[">EZ>OQR0[Y4>A/W MX4FX)"6(78?,!D=!T\'UW_A)R@K7[?C8=/5;(6:2,;4 MS)E-E[PZ;2Z*30BYL.3@LME*LWJ,FH`8U5X$5H]E3MTR=D:`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`=3140%AQ@$8@7ONX"X?Y(S`PS-J7'K9,IM-R+SGOT*&(`U%%3P5[9=(_SNR#.=`"P^!`/! M@@:2RP'+U73ME#`X!<5@7PLFYBR0`6%?,^HH7#3UA),5,!`;\%"!8M4#.L'X M->B$8O8($!#3]J5W)L;K2;DO=&!QV,^`B3D#ISXH""E_*/6$1@PMH#%9A M4$5@R7B0_%DB"X=ALG1ZXX;7(;LN:/LW=W_$1$MV++;R^11?-IDW*Z61;+:H M,ULE1?$RN7Q]?40O4:=WJ7/AB$E'1#P_<`YT`E6_[?PS:<"!'*1 M*)=I`^I.LK,=;>V&PL!-%)5BF#4ZR!9X747140E:R0O`L.):*!#[NAU27)X] M<.IA7SN4Q`9"PJ@2/6UM!U70;NID.!JB,TNA%5]!`\S-C"5^LK\23`XL>:E[\M8+$1C M/":GC:]-HT?=L';$_,\?QY-\'E48XZ$+-!F-QV/Z/Q2Q>/SGQ`\LXZL`-?*H M'_@63<)*82I&6>Y+(&31\D))M\]4[V;J_314\W"RAJZQ!O%M!Z=94&P6JRS M.2%O&=&P0U>%>I')STZ^/L3F3ZR`^M:I^Y8` ML%2/DQ?BY.[%3X=]\()Q\LM#6DOD0)J"91^]4"U3E,;O`LUC])Y6HN:O;DP+ M$KU<[U0*5D8;)>CF=-%$0;8223-D.Q8J!^5Q\ZT>\0`6]$J5.> M"DZQK\177T"(:$'>O^#XI[R=='/OO^%PXT4M"\M=[T'ANTD9Z?!UQO-&/!=' M`"@3:P%X3[96`%:<",L[^4`\_@'!9ENP"K$H=!<0]IK+&WW"XFE\RRMF$2?4 M0WH2.YGF8"L6\BK7\6*U:L&0IL=*IVAEN5P7^!TP,E%8P5.[4X"@].Q%!-8? M@O!=<+R/=\?]Y683'%N*5[:]8A9*0CWDUX/FBPQ*7!J['2&5AU*!8#C28R+# MT1MWB[;X/D[7O(#!TQEW%?"T>P("/)^)XW'#*>'ZWPW"(FM4=JMO,D[7@=FK M(.=L3U/>D5'>5&37@J(8QF7[P&*V]1;*XA.FXU8I0W^29S@G'Q_D7.NI!CAR M!AB-7_'ED%4K06(81Y@>QR"#J'?X&>\#-HQJOPBR_1V3<=ZFB/S@>)GLHJ?B MV."X(##=S`/"@C8CG9J1VUP@*$YD@K"$G$Z?6(>E]GY"XDU;<*5VF^]DO%S+ MH0OX\F+=-I\GV%HZ*TG_:#D+=VJ%-:LKJ@U0^&HZF:UG_(2=-=7`F@AF6/LG M5MG??H9O,"VH9*<#]M82*LG7'EZO5 M6M!K\P[JLHFV>4MV=-ZZG=',(<#.4.K)=7NDRC]IMAOU".W572;8EEY<@05$ M?;FL`V%Z]-CU?+Q][X:^YS]$EQO"'4=V,?8[O/,VGFC/7.)%HWU]ES;R5YQ. MQREHN4R4"D7?%\2B1.X/4,,`K08[_$K7W+HM%P([+)`-S?(800Z\_9Q1)E<:ECSA-IMFJ,Q/!TYZX$"B0G&(+KRM#L["W*+1RV4L0 M3F4X-+D`,/H[@AXBUN7O]%RMG%*(#Q37]!X(B;A6TWM!]>:7)'V&NS%#%`T- M,0L?JI?W9,#F;L1#H,IC`*&;MBV_`K"NA##ZDLH`6]$XP12G8,K/-@1T-6:: M`KMD*42`T^QY.B-Y_XWFZMZYWV[<%YHZWW[:M>LM@^'?H8K"V#?)$6$">8HL M$XF(3)0(!3[AJM-6IVRKYV^")XQB]QOL\1#)>"QB2<8K8-!*@$XODHO$:>>- MCYH&4:5]^8(&:;$3'DV)F!&[5S$"S"X_V:@TJQSZ;C&9@*H!HLEP+6OCMQOL MNZ$7M%8VKS]D>F6[IH%L*5'RY5=)9>54!EA]\Q.-F)@THGTE^41+^*K4=NO1 MSTWF+5?^,XYBEF)#^JTG+X::@K=#(EL';C9?*QY;JRO7'X+"HW)IW_EBN9Q7 M\`A58_E$(R8FC9##8T]+6O!X<%^L`*.XS'*S[2!#Q$23W_SH@#?>SL/-MV%U M/V]RL"A20G:Z/ILYTS(61J@@##@_7X]Y3C_SC`TENP*O-)YL]8BF3NP1;X][ M?+V[W&S"(]Y^]-Q[;\_.[G_T?'P5XZ?&2Q;E7C3?V4EH)1E/*V>QFJ7]'Q=+ M#XTG@E%!,OI"92,FW'C'J-O@B14&=W6BNJUV=%AMJ)M50&RAZY7UV."TQVBW((ER<&2EX"QJ@?>UMO?Z3%`O/"8+P*)=[2M!A:-?#( M>^'K79HUEE[YTC1<&*@1&*QKT%SZ$.'$F33P04�@4_E.K`L\@*6M"7LHS, M[)XEF`[=`H?6^__A'0K`4QIA+.`R71\.F.^>76]/=?D0A'1',#?E,Z8>)SS- M+%`=J?03"\-IO725SSJ:+1M8+&WS8A>$%ZPF9P%ZY79M'.X,[S+&4]+%6@$8 MYB3@"#BEOUMA6>3-,?)\'$67FS^/7L2V>Z(W+X5_R8V+),6`L(2<;M(WXBQ7 M#7.=M`U4;&2$[E^*O[!EY#*`0VICDY,=8IX7U*#0S`,*KK4=]](C!@51EN)? ML9N;.(O)^#0.L&E(,)!_^*$:UPN3BW*)AVAAY+=$NK?%(1\@W86N'_'K@L4=,=$+R'-1W+A!.VQ;,%RC MSP#Y(?FZ(<$B500EF@AO^?,F:K#D]ELUI!4,A"LK1KL`?J;TR@MDW/QIGZ98-[0 MJV)!R7'A`)\%E@WI<;6OWGXO-_8K/PW"1"45Y+=K%PT\DHJR9=S4W[3:R$?& M-/-8;0RV9J35?6$)3J3[_?H;L'A1WSI<3#LQ8U.?>9JE?!'$#<,7>D-NMD*: M"K4,0'+=5;-'8(%TY=/Z9KX7XX_>,]Y>^3'Y-AX))7X-MEP_)"4$!&XRFLFO MVCN+.@+S%BY8$RAO([D6WI;^3+LO:MW<:;XPCU^5X&^&M+1/[4>Y?%>J)LU: MW*NG,$^SC_ECOLY[;BO_`MV46I$<\":+PLY'TZ0[._5G0S- M$L_D,P3A2U(Y2)D66E\'XH$VG11&I(W`3V1G5;&L!+HV!V3[DH%/!$5%%UB3 MNR@7PB*X=KH*%I_YZM75ENC'#J)S*F%Y$R'YEU\\@D+^=GQ23D_0TPH(VK6H M+K\XNVH@A<*:=JY#.@Y(M6`]7_'85Z*(A?QAWJ5)U3&\]YX\WPU?T/LH]IY8 M*>X\6RI*TZ4D/6L'.VD%<#.)Z?M>L%QWBQ_HF/`S/@1A3$:25_XN")_8,OZ; ME^2/3'3@E_M80S8&W5BGH$'=",!->H`J8"P-7\H"'KNO6B!W MZ>'E)O:>O?A%<4HW0)-P;*?5#OG]CEG3H$J8Z*1R4VFJF86S/V"'*7Q_8":)3^+&/8(O&?-W:*HQ2&A:V MQ%S'49SH;V7)6TBNZQD95.`)3*$$W2R[8P3''D6%2=KC[R(2==..._ MZ\TV)S0"S#S]-5=(I&RHD22<`M5H*-,$%52QFI,,^93QT]^Q]_!(>OV+RV<< MN@^XY*3?J'?C`+UU]QMV7R0J'U-.].(7&MJRMJX3NEV\=N*7`N$XOICW"PX> M0O?PZ&W'S)IE'I(3T.;35+%FW*LJ`+K"NQ2I'R2IC>.P*LQ*T6AT! MB))L/;SCVD/AX^8Q4M-!=J(]&<_3T7YM*P3Z/D0MMCE];#.,%V'`-<"EV1LV MH.6=%VWV070,NP?#$F\"8JA!'>DIX&HR$<$I%TO&H>`C4,TVEV#&;H\D8\/P M$-(;)/_N;7'!>MA<,?F@;0.?R%TVX+"PB_M1<'>(TJN`2&S21SJ;:#Y9B:!8 MD`MXB<9@5@OZ/!6KH?#8%KQM@!3Z#`:1>R+SX1?LD]GU_M+?7FZ?/-^C_36M MJIM4/A=&@]3+1E$IHY'LJ&PY6:=[:5SN""626;]1EIU6B8<"IG;#G9+A#P7# MW9)L6$RJA&\9E=(.LQ>74>,]DOUD6(?22.6Z0YHUMUHH@S4"NMEQ>$^\'O1& M]YO/Y-+W6E=TRP(N[<$E0U[N> M;M`$PJ".:Z9.M\IIM@KN%JE6J.171XDM!^E]&S>&11S>_+#)_K11`\FX<<9. M5NU4D#D!U#>>;E6A(A6W:M-AE;&>KS7`2EVSOBJZCA]Q>/?H^LF6Y(<@W&$OIJ>/>#)$IBSP_J;6GEWW6_%/X^($>U%/G'PN^R(S5 M8T]EV$=C@[)!-S<.]X5>)>'2;8XTR2;)L6'I,N\(/F@V#4NF@8*(G'*OB::E M+);/OUAU#.T&8W!JQPBEEJ`T>XO9@MZ54[5L&E]:_2F=OP[S*]&2T4Y!_K.^ MKOZ"&1F!CLD_X$CR_49QA?+);",?< M!V?HF$F^&,FJH+CL!/"#!;G8ACG23/?4\*5>;&E$[FA$\CJFNR!$87[61GT/]"G;)ED\H^(?.ZNO5/@?],HA)O/QW;DIF,M?\JNN6*4?+G4%9C MT]UNIBKYD2D[2+]P8/AZ[P-M^9SR/=A^#]&<)D:_<C_E7V_JHM=_?\E9C64K=(J?]J_:VUHQ65+2 M\B_6!ZL/XNDV_MSZ[AB^^,\9?]SRII+RL.>OU.O`3^R4HT#S:5?=AMW@D)7" M()__S@T?<'RY>?3P,ZYV(&!JP)W3-6:C)%O,5LO)N'X(N+,K2)[KUQ44E$9< M:Y2J#77\B8,[EG-WN`-MJ3G;%3I%?>B3?9*DL-J,B/_@>]14Q-H'>U[_/H[V),_ M&7QG:_*36=/WGOS=VOMA+T9>A`Z99Q_=F%W;>B"/;T+OGGR_>E<=H:_>?D^_ MP5^DSV[K(SS,!07!] MPW=_SLA/ZORUQOZ690_V^;)GU8=D MJA>NDKSTM[_B^#'8!OO@X:7K;CH#+9\#[\N;(W\UO<;R?X6$N^(5K'1L6E#Q M?)/Q!G*_8Y/[K>=Z=3+1PN**W_[L^9E>C$&GDN^\9V^+_>UGT@69P%-CN^?* MS4W&**S*K@9FYA%*%42IAHBJ^`IH^63/,U+.W+--W?/BX?UYCI%503X8:PH_ M#1AGWG=;=J]BV1T.GR9M43Y,@Z99/5#5`5H3W=)D.`R8.[;T= M1M^_8#>,?@#GQ$%!7"/#X;[(JQDY_BW8$S%[+WXQ/7:LM'SNH\>R.?+5-32> MD^\DR%S'US:"/,'[9=)\S@2!S']7D?' MUZF4BQWUCY?Z)Q3X MYRR7J-I0/M@"E?#3G!5IBM:K-`H^!]I3G8:/)_H.U@"N;`#Y34\R'/C*A'[P M:2&K4]88@-DH29:^W&X]^H.[?^=%FWT0T;MVATH?EFKS'#A,QA!9F*YG/EPT/(#IC3T6SH^9&W.>/*FRJ0UD)_TA_EK%+1 MKM-=41QNO(A.T+/@8+&A/16MN\%S2$7KM$)VKW^U7.H[2)T18D&OD0S:+4Y% MT^OI)*LBDX7<&-T2BL+L#IGI>(0HP,`)<5`D:\E'D_LLYSA(+)@TS(V1PG;. M:#!84UX^(70V'9CO!KSEMMX+,U@J.['^2,UPF:G.>,6]8\^96RA;[+R27).%,:%;0^ MQQ-CAC[/F9`T#),,-+%7^I!G/$K&4:GN6GD]8]B!3'O3YS<^;K5'$O#.V%D, ML%>4:5BL"F;/$JE-OJ_L&GF9D[)2DD%2)@8G39][I<@>A##`*+G["YXCRWX( MPAWV8KI=-E2E^9:6SHA#&]17F,CJ.[>;469!H:'*Q!LH@*[+NZS6^5MZ1\1^ M3YQ&*V3A;P@[P0OL^$=>_^\J:L9ASI9J\')YT]8QJMM]]3B;"E/6YEE M9S5=FN#$5UD;V\"G*5]R[B;.8U>_76RI\W;Y_0N[(,QFS0^OC7O-UL8^X M(WM?'^,H)K,-SW\PLC0I;N^,&%EHA,(E*@-L"A74>B6+CWHYMM9 M;W[3Y)W;V`UC>_TS;_#/Y2'T]FCRJJA_N-S59O^?.=5_#O;[#T%(_SA\V!8; M.T_2+UB@,(_55TZCB?G1%ZH52M0ZTP.9&GS,1[A?.:T! MI.3+MGZ>Q*&3LW4`@` M45<_XCF>/1.;*CJJX0QT^J>/)F=T]JR'>?(W:2^'7GE_]6?/AOX\U[!"]5?AU ML_1P"21*W_!U+4"'Y:^RZIK!3_?_C]!/HR>S/8*] M6Z$GK$TIFVVZTIM&!<]H$5Z?U0JC4+OZDM>V<`_T2<^\C['"X4-L"F@.A_/M M>](SK=G9U6%[DH;FSJY?J-L@NS`\G8P'R/M,6+YPR-Z*@_30?F;4^R$_%5\H M)?><>[IA$?UP?I?+G\;LI]\W M?\+7M'+K(A(9RO[OCNA'ID4W)`8_N4_X74#-[+O6VZN@O?\%YN@7\ M_L^C%[^DUP)S*;9FM0_M$$?)(=8LMY\`*:5%]+[N/R\>$A6J'F++5*\29\%= M?2R37_.<*)P,BDZJIW^>VY]PGZ5XK8GE!0$'H08]3-O[,YTE!S>4TH9@854U MSHF'%6U3.$VBD&(HS<2-9?I?*Q+(6$,X6=/VDZEJBO_2J8>*`/%QD?/QU?DQTY,Y`]"@"%K799@)Y/Q*NM7N`STA4I!3`PT M$/K9XZC98QP+M6!J!$'9=M#HO]Z]=:/'#_O@:R3(991Z!0(1#7I(U^]?.M,J M-H(=HO(0$PA?%U"7E4Y_*XVCIR48&W$D\@TPHCYXONMO/'=_$T0>6P&11I;X M51B$"?61KR*9U8HKQF`F%Z6";4*<'JOKR%.V&@"!G<$K0&*[SX`1>>5O@B>: MTT37)4/\B/W(>\;);Z7!*24%!J]!HC%=;EYV.S];9;0<%&?^$TF,*<1QZ M]\>8?@1:S>'&'6ZG)XC=?3L"3C)R08V\HXV@J&0J9K)@X2"*LC(D&NVW`Q:= M$Q;A"Z`P41V#+]>.HPP7"R8D6NQVZG9S[/QL%WC:YQ.MK@`#TU44'?'VW3'T M_`>>:,1RDB+VQTI:OO#&('5!IL&GI)W\DO)TJO\D=\.Q'+WH77.?^:P\<_NM M<@.[;F;/X9G>6*B!7-U?8.#GVK0G[-6>,PW=8N,*X34KG0/F0J"S\DXR)^\% M4ZX`!TQ3_-3P4#,8)-R/A\.>T;"[3[?)KOQ=$#ZY,GM2DF^;A(:<2O)KO.L$ M,$7!^>XH*LB&'U8.8+M3LWWK19M]$!U#5N1J0SVQHY[P\I9@QY]J(5W"I8(# M^Z,UPIL?'X+GG[;8XT`E/U3Q27[U^UWHTM*`MR]/]T'UD]?_;@!CM4:E3P1/ MTZSPY'7$WS<+D]/4=^34'SK*A8%!X[C90HA^Y2[$+J&(%];3\7&>@+2:GC38 M7S0T+[U9L1Z/TZCF0A"3,N+3F<9AR/"=P*D&.26#(FY0)#3(%*NW!%21P476 M@V.@[=ZSA@>A$*!R\Y0S=M;+9@`,4`U4?G9^JD&S.@)HP>1-$,7H`DU&SGPZ M6L^F"2B::RFS(];DT?%B-%TL"X_^2F+^$4TMN+-<')Y"0/6]JDI0?O.WPX
SE%'6:QKI!+P,A]"#&;&HS0\;!CAA[X2B58D<,._&3%"-M\ MOT.W=Y=W[V_-!G1/M5GX_N9[]'P^V[X'&<#5/SV-RXI)$,.SWVY_"9YQ MZ+.\G4/@1T&(M^]]\A4.(=UF>(?OXUN\.89>[.'VT]N]1!DV@0D.(MH3RIH`7G@?WB]/3+Y#CPE-P41PY]G8N#!ED`UU9R`M? M,`ILD1;2"6G3-(&"A&D^C;,'H5H,=,0&PD*M*^K*@&KU!01LZ(20S97N\.;1 M]_X\XI8T:\'#!N'2K('\\EB:UI#)09D@T)QK#78YZG:90DE[D!41TN('.]#1 M6N!<^#@H0M3J:J]7BT4+1D#KC6NQ38P3"TJ'=P5<.U:`2WA7"GGQ.YG?>?LC M^1U?R2_1URP2?.R^T@QBK:>*TKN6\_3"X%J5/MX42MI*MJN*5S2B MO#D8K)KP#2]1O=OA#3NWMZ72Z9&]R(JQX8EP*$+]%&=:PP37.Y'&*B'4(@4: M^6+59*-ZE2W%B!!/PKP.]E%*!!9!79,S&,13FON:.L5-G)+LR@6Y<)B#-$-Z M8%$*AXKEQXC?2[@)G@Z$^PCO;Q-?^3@F?V!'E[_?!U'T`[V[D+]F'2EV,T,G M&78XVR(2K"GXQHV\C5I@"63`$V"S8M+%`L>+62_Z8ZU817X:',&HC[T&1GRD MM?L`ROZ)H\9\]\Q5Y\5[[60@P7HM?N9LD!C]D<@C_R;_(C_08SKD'_\?4$L# M!!0````(`*ET:D5G$%"4_CT```*J!0`5`!P`86)M9"TR,#$T,#DS,%]P&UL550)``/M$V%4[1-A5'5X"P`!!"4.```$.0$``.U]V7+C.)KN_43,.WAR M(D[,B9A79>HS!:;DX> M8I"`,'52V-S)K1]^?W$2\)\GZ/_>"?SJ'^>/MRG"S2=/7+^_<_?OQX M![RY$[^-PL`/P3LW6KX_>?MVV^'?"])^.?GYWU7QZC+/1^.?ES[:N+ M&!0]>Y"H7TX^?CC]Z>WIZ=O3#\^G?_[EIY]_^>F__G^]=+3:Q/Y\D9[\A_M_ M8>$/?WH+:YR=/+Y[?%<;Y?\Y>8K"!)9>KIQP81CC=?`>U&JGG[Z].E]_FM1.O%_2?)6;B,W1XF#P!-B M"?37VVVQM^BKMZS#ZC^OU]&;K9$RRCTKL+43S;_;(=U[\:`EG`JV>M%R,[U'!]]2VWK>E]!'6_/8$USM`?4QGUWX(Y\=W M@H/$DR";US)_&3Z0Q>8RLGSL^( MB>?E2]4)VAQ",OJ4.'*T#K+BEH:DP/Y=2,>E'V0I\.Y!6JR,VRA)'D#\M(!; ML_F`Q;N2.<.X#F3/*'\?$D+-59+Z$#+@[:A(2DT?@1K$'%T6Z M6S,M-A]G!S)OMH43SB&&M7T/%T4*Q5G8^=[VGR27`+)P<*<`[WQS"]8@.+L) MX5W58NZD]"X1#=P*@MM]1]X=<%"Q?&(DWR+MNY:(P]\R!\E^.;=>ZV+R$F5I M@3HD#9&5?WT'TD7D14$TAS1_2>!1$L58NBOQY28LIK`Y7OV1*)F/C$+4#Q*+ MUO!#%+BK8=2UUO]/Y;3R!O!U*E#S?.@'?UN@)A MTF:_'S8DD<:G-'*_GR/%,SI48//YS"+V8Q[Z?[3AL)DM=W3"XON5<]@2VI8Y M']ER"662LJOI*K_=6B]^:JN=KR;)IY9()Q+']A4@>P9DR=>0.9V#7`+,@U`WZ(T;+<"[#82U3FCH&IXK)P[A-MWIYSM8%.0NE`WN M&:E?)$XPJZ.^%CD\@E_\,%]*U3G4X3YG]*?'L&5/ME"O74.PX_YJ]TX'$T[O M1ND@94\O3V==#WBK,-MTNHNIO:@BKZ^'NZ=U2)YS[L-O"W-CI'`OV MJQ<,LM=!H]Z[AF3BNE$&_WUP-JA#2%NI^ZO9GCM=(DT)T!08V8NF'1E=@U3U MC"RJ=:4KT@U!*3Q)DYPES;5G<`QYK0Y645M"-`=*]JJ20T[WEW2IJ.J8#Z'T MTO40*5JK3@PBF)$2:=CY^FL'/"JIAU!81-[(X>%0>@A+7OQ M+>I6AO=[WC7L'!*RUU^``@2B>!_JLKL\"B`![KMYM'[O`?\]0A]]R*?A[8?3 M,@;@W^%7WR:P:P]U?QTX\VUS@?,"@E_?'/_^OG-Z+K(8>9E?PWEP@G\")[X* MO4LX6QC2B$7%J#Q>H.B;;]MIF6"F9?*2I+&#O*;WB.*OUSV.6S(*=!Y`[$?> M-?PNP0!)+MLWG6@6^:BL2O9'8VTFX0$`;N`90B,46UP)M?D=S4=I4;0_*HO5 M1M[D^'+]T?<,FZ60E?_X'@)8EWJ_RP+VW[L(/=@SJ+(Z6(AS+EHJ( M<7.<(,_Q.`]3AO^].8&#*>(W;HMQ$XG-*4U!G("\)*KI1S&DYM=1PX+GZBIT_LNB=3PD)5U%4*?1HT05J#; M@7,Z;A:91VM0834*QGE/4[?%Z4BV'9F,A06%OM"V"'WX8")&!&7'_K[:ZK3Z M6RQ_>7]H(^O6SAUG5>B.0)`FVV\.E4CEU]\.'#_*:_=`H\0HW%S=U9[N1^`" M?XVHN0@V'%"MJHHQ86)`"/ELME?2 MACG8=FVJ0`$E(43.:_"?J]\SR#@$N3M;>N'$\0;2769)PHZ6KZZ249$]\TAC MH=10-8)2N*=.P6$Q%;1>EH+1(UB#,&-PV83"*NF&G%=Q<=1X3\B2,7<[?WW% MHZO3)3`H?#537$N:([N-02$@N/M9!6U(US[S0S\%MU#$.(J1N7IU@PPI"!EC M$&Y&S5C+F#"XV8CCJ!4QRYFF.6ZU?4V`K5Y",87P-LZOMT440-XI08Q&>NC; MQ5U-Q[$P1!KNZHK'1K_U-='J')/!C[X.4F6N1"J.8.9%CB^KC&H1'H12007] M#UO-/Y,=QY541/'*\;>IY^"Y45L,](W*4U/-B*(5B-/-0^`4#I?P\,M3`)+O M?FH5%6-X!*F#H8] MP%2/5@%@N)3TIKJU\N-$9R5,]6_EQZ=2#9GJS;JN0?P2#1^:K7M'.T_6*'6"(2!!T$?5`>&TU>[P^FCRJS4+1-026%\S-,M5Q2"9%0PN`S>:[:G"S:PH<1FXM?2.K*`U4QO7 M!EJV8U:%GIDZ.DD'81VH)LHZ?:].&4!1?6`KX,R4$=L`1RM=X6:FO"AI9Q*< MMBKTFHB1@]JN`B+W87!B)0\8SY;PH40*(ZR`,I[)X`"*Y(5?H60\,\&!$GT= MF:>$_MLU/['DJF:WGP'EFC2TG"AH.V M$08 M+T#JNY!2M2D*("W3."?;RP^`[2.Z!)]SGIJ*DRX4&14G6;J`:^./:AK)(SFJ MH<4(;I(DXZ>^+*T%Y>0W,+BJF)*FP*S0\WTY1O#8X*RL?ERCDB[CH!XA ME`JZT,\^2%BU;'"E#:[4.;AR3P(KEB^!6%Q)ZQNHA3S$8XW@O3ZM[8;G4AZ- MQ488I>V5;WI0;7.$\+GV#8VIY8.)2Q]@>GBM,%2T8\E,W[R&$!V?26:ZX#6$ MAW`@F1FOQ8<1EBTV]0T9ZZ9AW32,=M-0:(4I#'23`-*+0F'6%3[ETR@??SJE M/XU2M*#&2I/`$:#\%,E3%)`M`?NEU%@`DCQ4H8PB)6?J/BBF`ZT,#1>QN`K: MMYX-6Z;\W$E\ET`XOJP.5%_Z0982U=*DTJ98A=HD3=XZ&US#"Z`("\H@5--5 M&<^7G(-9%)=."<_.*TCN_#`_FF]">`""!.5,VF^E,,G?`2C#>"A"/BG"C@AS MTR<%ZA#>'?^,HX%46AWE$/'RG#H'(9@1LU*22JM*!5[,>4$5/2/X84EKG2VP M@5A4VXJ`WWX9)51")JTX*L)Y04JY`$D4$\MK13WCGJY+:>9\DRKK!E526 MC%IT"3$JJ4DFG``HWJ&$4)=@#8(H3V%('P:]CII1Y,%JZ`K_C%[1)JV>XW(* MJ640J98VQC%R5$R)7=T)0%)2DLN[-](Q#(N`P&!C3,PB)0,5[]YB>-TAT[^UKDTU/ M%L30.XW1V&?=#`_6"+?VX3#IZ9%RS?0,4HV08BD73$\?U0@T+KS,3!A%$MKW MSFJLL&QZ[#\/,ACED>DA_P*P)&TC^_7?/GQN8,>86?=X.C=M'>.)MHUV'O&F M;"F.>][ZQ/?N;='.M]Z4M4ET8K!^]1@;?SMO>E/6#,$ESKK1-]#OC\;!7FA% M[=P5V[UF90H\PM8QT]^XL.$(-AR!-QR!E$%L!U,9E?#3GW^B1R7LM:$T1N%H M+%4F-*R]F%;#%!]OZUNJR#N0D)R/_)S@Q/LM*Z0PQK*5UKQNV$":X8T>%BG5 MWEZ9_O''8=M$<6Z*CIBH.#=<(46WD4I8EM;:S-2!C,;J+,:.CM&EU2J, MK<)85&%\X22+ZR#ZD=R$GA^#V@8J-<5_0@YB5$TQ;.$D;T*%?KAB^)+GZ!&X M4>CZ`=B[D)\C1.)#'*U]"-?YYDL"X)6S<^&90#9^73"/=)&VDZY4R+WGW`]X M3V(HVLSSJ4XN%NCC33A9HJ=)XB?-Z' M,#">ND:.ZMM'C<:%Y[>%AD=H0M48T<5S#T]B^+%P>$/';.B5^0WK1^ZEG[A! ME,!-QKFM]8CY):F(7X[$88DU(0I5FT)V:E`0KE>#TLIHG3OX(0DN<> M[&$]/4:#[O80]B8R;?4Z>HQBMUQ*^8&=5I"W`3W&]Q"#%3ROMTMH&T]2;I;B M<7KNL7(UIBI/(5I7FZ^QGX++Z`>)W<$4M)YD.T,,3@=MQ\39DU[,VC0X/ M!U:Z03F-:X1+)>))7!^\C0X/AV;K0[1QC7#!*'#;KP_>1H>'0[/U(=JXB9[* MSLO2R_O^\.GL0]XS^N9;J8F:Q@].G)9_3-S?,[]\NZ/Z^`CRA\0)VO$#BN6V MK>1-3V>36P=*TIXC*-Q_]=,%>@\;A\`)48@Z4E7F"?QXAT5N0,V[P9$+@)?'UZ.'QB"3"[8AKE]" M#TV`"VGSUTB(Q)\/:"#$2975O&ILD",F)/'.2='>VDQG(GM5N!WEHT4/ATUS M-X[DZA7$KI]0'L)FU5,TFC6\V:,07FN74?:2SK)@JX(E#X1<18D'O\CMKM'= M/>"8D)W#$'\`R'&5P45[]$EGMEH%.0U.L$7N)IQ%\=+!/=1W.`#.VBH=\KKT MV:J[]5$MR:8G6^@+9/HU8GINAKY0)EUTIF<-[PM?G/'%]#3C_1W##-7\URR8\9/CZ7K&:9Z,>,ZY$SL.E9 MZSL`4,A7MUT>_/'A>^3_6P%HE@;")MTY?,!%JD_A@0J195>K5IF9NI@.P6WL M(E-A+J*6&=+MW<^2;N5'";J6CI<3U372TKA9:I4F^/2!^[1E;PBDC$%EY17\T*9Q')V.(L M(\ZHPKZ)4#U8UJ-A?`E/*L:S49IOY.%W:KT+0*^3&_`"=K M?FR*5YD7J$WS*E,3TBXCK"EHBB5A,CU'.V>B8:&DM8=WW_GFJP/V'MFHP'2V-:#``QF]#9U,9[E' M81F=X'E^06\-2A7)Y7=4'KB-QP!@![VXCU^JDQG962BQ/L6"U6#@8Y;6N15*CRN/@FYL;VX4`9J2&W\W.$SW3(%/]ZL#Z"(A%1A:+ARXA`RNSL:&'H= M8G$EK]T=$)-CS$EX458;J@5AWZ^CPRC*=M: M^KFK5S?(X,!1OKH]D]R1LB5_AH2@0Y+3M@H-6DO*SS?X!BANQ5WV.$`$2;8; MZMPS#8.=1W3.5VHN:]UETF>.K, M'I=3^G18]_?\7I8^YL%OJC35%5O`1E>8E37=RL7+?>RGBSC:W:8&;;2!B7#% MF1ZQ)H<'W%MODF]=4X]5C14NBC*\=,*NL92?'RVTO*C\%23XO0\F<_C_$V! M*B[XS@\@=Q2%H(J\/@=%*BT,H2+U=Y9[R1EC8BC`4W&QY$6X2+/=WT3%NH')$!AJVR?0=VP M%G'7O0\'V4N0N+&?,P92,:NW.QPTAI07KC.<6(8G:A5-QO!49-X$P0:]\S(/ M_3^`]PRG(($T(GKO0?H9,A(HQAQY'`"!TU2\Z8%@4KY_C`C/!U"5D@<.I0\I M/'5#5EH^!VVS-JHY]PLOHBIS,^J)SJG3:F@T`JK$1*]CC>L%2B9E8*R46A@1 M)CG?U/[B,ZIS-J-DK/"D@Z?S9Q!";BJ`5\?$6_JACS@.I*"Y>D7&%)#03>I" M;>B6VE!N3LA3,VVVXL!Q:0@KV,PT3-I4FBW1HOI;B.K>3'>L$,5/)`6IJ0'# M3=><_-2CHSD!.\!W3]-F>EPR+Z3\0GN[I_D,0TS,=&AZT+&$_4NTL;0+-AX% M=FWTBJ:_[=<#O!A5MJD!S/U>V`V,CJV"H%<1&LIZ(-C3#$9X+U5>197I(B2' MBOKX43VB/GBD:%'<\,6TA=66-6(8L2:/$9[Q,,:U00'1KGK6#<1ZR9"I\-!`A1Y7(T\K< M7O'F*DG]);(H[^3P)!?$)Y#!2).2Y?"0]:ZZ*N%OV7*,,CDA;`)S)53&T!L/ MSJ4_\]%ZY`!UXKIQML>8X.(M.NY1$^FU^9#R(OPR;]N.S,!+7%<@J\.AXW?A M)`OXPQ4LLG8")*WU@"&FT\'CB"2P,"U*PE8`'!FLV0N:I*X-P;3^@^LBEY'D MP=E0E"K]TC!TE&\@3S;S0S\%M_X:_9DZX=S?U>T!8Q8%0T>8S!%UW9M!R/5X MQ>-Z'3J2TW0!XONHT!1N+XL>L,3W.W0T'^)H!>)T\Q`X<$P%)[.BO%3:3]\# M0O5S%'D__"#`CO`>2,:1V9LFR`TN0+F("E+N?K;796FA;V,>D:6*L;;<[K+%\L37^2@&WJ0Q5;QC"<;N9^HJ26TL4=C]X"J@ M;1A+H/;PSB*"(MK45ZZ'/V'',]1$GA^7U$.Q6W7,3-.,Y:9&9"N8P5Z$H"0E*/5<\=`A2I*604JFJS)Z,3D'D%10E'MV7ND!%[*ZT&0= M[,9P#])J&/S33:BOV^C*'(\-QK6M.6[?)KV\?WKPL-'#,-_\[F(P+<<;8X1^ M)NW0[>;B&:'W2?>+_.!N&V&^^(;LWFAE1;D02E[\?8J9PU"3R9@N4Y>TQHHS M=3J,FW`-DA1-_)T3?P?YIR>T-@H]M`)>?[)V_`"1`5?MD[-'#9[3IU10(:N0 MR9FX;K;,\D<+\GQ57^`N=`)D*4!YX0L>"'(_PL/D;7(2/24E&'KU._'<2?R$ MI065V\=04:(I1>6UKQ2=\\WNXU]]*+'&[F)S"]8@H+Q5RUE9Z;@J)H"E2Z-6 M43J&FW"5I4D.Z$?JLZ*T&DI'4.Z#G`$_7BK4QX3%VE#S1#+B+A%=S[`KZMO. M1P75TWL!>8@Y9-S_R/EOZO+BJ*BUEK='C.^OTGVYJ[`QY MH?#6UG1DU/W,7U_%Z')'V]LHG#^#>%FM=_IKSHQ*2N)X%Y!7%AD#I8(*^K\\ M?8[6(`X1'4\KY'H`N2BXIT&\BOT$+A&X95\Y@>):7E'!PHEYI%5'TJYB#,GW;U["P0 M%;:MXJ8&\>:W="4*R]3XDVEVF4Z1%-7F&/_<6:""+J>-DKU7!'CU8Z=BS6.#.#ZLJ=!:ROUE^M*-D"G#HWB3=\6+6)U76N]`I ME`<@R'LO6&Z%B0U_6!VS)>N/:/T1K3^B]4>T_H@#\$>LT7,F/((S'49@/2JM M1Z7UJ+0>E=:CLJ=Q6(]*ZU&IW,:CU+O).O`U`[>17L+T).C6HTQK)*U'F?4H M,PYFZU%F/V5B\#JP_GO7'TPLQZX]G_?&L/YXN M;F4\_GAFOGZJU!^OZ[=)U?GC72R<<`Y9K1W7-9T1E+,3B!(-=SN#!];6MG01.`G-58)>QSK/C=[U MC*XXRS5E7\+H)0%Q_C)]3CYR<0]=6"L_&P]7%I^[6F?]#AS-(^-S=P#>ZN$Z MW7X@7![4LKJQCJ)]CO*KGRZ.IB79GY?'`PM4>2B@U%4H==)-Z`89E"QNPBLG M#F$QYM;JO'\CTO4.AX1?0AA/$=,H%SIZ7Q:U!GU]^ZAWN($>3T/A]6R[1^(X ME36FVHTX57J,]YP.,3;=+&+]@N0#2=9X8?'K3JTQ&LQ%?;&DR?&C0;AKW=ON M%F.804;CQ=6!>HYU>DM@&5NYB:T`G!/O*77BU$Y2MY*XZ4X+`YVA/7F_F1?$ M().G#VN6:-K:T00M#GW*R"K@T41`:CJ%+$U1NV0HDU5"Z8)/>P*FWB>7Y!]$\ZB>)F3I<0%WPF.Z;QE!&`T'7O*I!%+V?> M@701>;5@1XR%AP`-=W4;='`8OD7U!B<4'FH&XR.-AW[^4?$[KLJI"07;4G%ES!9`=>?^<"C,N_D\DJHAY)DSA%OR:(DQ`%0] MZAZ31D9Q#,Y%?\L<=*+`'E!PP0;O=\0.E$BGN9TEPR;^=2Z MR7!F/D5D(:/2(V1>6$/`U-!@!$/.W5K24VD[",S1D?&$,4"!!@5!-9U.WL&.YAX2+U.R"RG\")Y[.'IP-+H,>1X6!YYJUV8Y' MDHVVB%R?K%9QY+B+G43Y#-Q%Z/^>X5W:!"M;1\L"KCOGU5]F2RJD^V644.F' M;"KWRJB@\A$Y^U#XXNIW9=11$:R74$'A\6:E@$DHK`?=U`.86%RW-).2\W.: M98#A5+79_)PV/V?'0-K\G+J[1PA*RZ/!L;$6I9EG=LUB8+I-4P[$/$J(T:07 MD[)8J4K<5HG`1@.ED/ZN@O340HK-WD/S.O_9WD`DV)CL_WC\S%MC*)JERS)& M3$A)JI3Q.)3+7)6T[(=G%DD6DC6]Z!8U\^.9Y*V_!MS2B$(5]'O)P?`(:YNE MT+KI-U]&1S:RHXMB+'$N&'M<'8L#DZ?ID>HL-/;-U*;'E],MH71&?RPG".4E"^!]CB(ON0?I=/8($-].?&N9IZ;2$1TIL$D# MN%7JUKLC`T+'HA0544KCH_/CSH%GK>\$*.#L*5NM`GA^":T7KC:4CO)K%'^_ M"1_BR`6)V-@H-;5V>E04:DX\\5G&$6,9*R8JM&/.?,T3QX6+!6D?S=$L(JHY M7/!0-U5+U!`TVAUANKY`$"H::VFZ,D$0JIP';.>U&Z5.H"%,/XZP=IB9*H%9OA## M%R)AZ8#=QXX=R'MT61^I:;PQ9K0^4H62SW<3F5U#['3I@$Q57A_9:5CSXP M2"=4TIH3[_5YI`7PL@!,9SO`*'(OJ;1*1J?1CMU/^4F`P'06D7@*U-&IKIQ6 M?.$J/]*?4B=.#0(%?].9KI<7@HAT:)NND1<""3)L[=3QQ?:Z"CT]0=%8]%*5 MK)MZ[8Y6]<6!"V6#]:G[TD!D1PQ/:1E&EDX4FP&_NT1!%]$*';/6TF-HEE7= MI51"KDNN+DDR:9,6^J,:)S6)UE:YDFZ6*P=QLA/7S989Y->`5WR%SI';*&&) MV>SZ:FQU'ICYH9_"-;$&1Q-P]>H&F03;@9K;4+0Y+1A3>@J0Q2B_,3 MQS1Q;'=3S4"2D!0_6DQ5"T@"E"]M4A-M@=8O)C=D,48G(;;`J=$"-=>/0F-E MC$K_2+HD;YVW^K]F?("O;:&(M'YYL[Y+8KS)"DLZW"CIC0< MLX9BX.#&JLCEA$&FD,=`L[:T%O65.!*P<.3R+^!J9)`JC::`F7P1J9JN_H><&.U8%"U7E@?3%&ZXLAPKF,3@'7'JYV.WLH155(%"4MM>2O900707@@EU=(_4,SUE./)Y*X>HJ<+]:KH)H`\`CR*V:W*N'7<^4!]#-TCM, MTP6(18\*1B45XWAP-NB^1)EQ=)*66Z!BYS02O4Z,[C$O<].O3@QE6'A&%*N4 ML1ZXZBJS0#-XJ9VYF6,V3144K(!Y(#%Q'.UU\8B#@S'5-TL0,7%^UG2=I.!2 M8PDIINL8!>%BJ`4?$UU^U13,@:G7I?'!Z153@.Y?U3&KG?SYT$>.@!#LAXYGVAE\CFH?\' M;%R!+'X1)>ETEG,N^T_O',C=Q^54:`XJ+*>S?0QS60@1F3PMX")^02AO7ZAF M*,I:-JI2B_T$XK7O@IRZHX4U"7(*X">4ZGB[R(HL%/F@2*JMKGHQ14/>QA\1 M/4($^=X4%)%4!7(8_3E/#8U&@(6$N4NCZ-\]=>MZIEZHH0:T/)*+'30AH.OK!**50. M)X)W^)6Z6TP52#IFA?9FAK!635?G<7`KQR\L$ED#TQIENN!'& MB(LI,MUJ(XR:(`MAJAG'6IJ)OKD=,.0LE>A'BVI#5+GNXYT*U<+<$F;I'.4X MM-OU1Z7QFFX5^NW)#R?VGF$O%!W;?AFKU[9Z[;[TVA*00CMMFI\!5(T0N;P4 M[]2]YA\RR+%#/!\"!T\45Q53K`6Z:*D),P("^S>;JDQY`>9KM.((0@\=2??.$E!- M7)UTI9+;QO)-;*5H6W!-E\"MV4"3B=#";&"6DM>JVZRZS014"5>@5;!9!9NZ MN>F0E=TYZS81!4VWO74-/(<^QU3S7*]KFZF@ZL^90Z$#>K9<.O&FU,\7JZQ] MZF*K]K9JQ_X4=\U/"SYE7=OVM51TD4AF64HD-#PH/(HC,:D>1JL.$]:QTVV? MRE!\88_HA3"BJU<0NWZ"=L5-"#G(,/'=_`6/4QJ$W70XQ%58&\Y]1G/VEM[/ MP-'Z"OSY`E[UDS6(G3DH?P$/4(@AGO\]]3[P?7PPMD>`F!0_G%]$87Y.94[P M#.)E#QN&Y$XCL_VVFC0YMSUM=)P$O($*48\C!)LL/'CJ28)I0,<87_'21H M:&&>#169#Y\C]%5M^)/Y/`9S)P6]\*+-Z3$3_4Z9,N[NS<16P779DJ@AGNG" M0^Y;82610#E)Q%NN,4YJ:4^(]$V"EN<+T8:XK^BLE')=G"=RB1@DSACUIPJD M1GWZ'Q83=7'RUS(&^N.G(DKB;K MU$Z6#ANKA=6OFDO+!XH["'5T.FZMA*U>X5H5"JC4B5,[1=UXO)K^[%>/,]-` M#]OL*;%/!?IA?AIZ%O\.O>>K"?ID)TBWV^7;Q]H$G3;@NHO[Y2JT4]1=[%DU M09;35CLY_*Y=U9Q9CEJN$ZX"36Q].ANH7\?(@WJBEM\K:[W:/] M3&?;0(IJED6T.OK/LDIG?9F6NT9!=Y49R"PG$U,FM5$^F&I2S9)P3)E4F:%4 MU5P;G$H3^\)596V_">&UNC2/_9\?/7MU'X;K8I'D"YN\9W\R%>K]KIXK$QX!!U2+"O/,0@=N.&_A`EDP_R9#SSZ MNU/$\C9+,ZU]R='TK.?Q""7UB>,5"KG5B&X.&>OJ]PR>JC-.,O](IT]M%@[F<&HW]+,3ST$Z<1<^ M6!\)`LK(&!I^#W'T@BZ,Y^@<:((EEB2S3HU"&:7L1#[HWF1L M(J:*.=1>^%"=LO5MQ[@;2[>Y]S#=:;E*A_(4>:_YL."21\1ME5P46Q:^K'U` MW1@[NTT6IA!\FRSL*,450TV/2?^RKR,VWH>X[W1J9^:NM0[3J1W<4B-ZX[P# M,`D,RQ94@T]#F_!/]11(T[1TX*W/T%?8]'^-YZ83:=PF^6LR'QWZ\-F,?EI- M",$MT*;X4W'%"*MO6^6QLM/4G5W,)K#J=6+DN^XTRX%53B!L]B6R4]BGK;]9 M2BR[X?KR0VR5$)[R/9:M<5Z.;,Y9W_^@3 M3+7PK\`J%8YCX$:?[:DEQ`T"O%KE[;&02XCJ,S_/#LT):=^-A.@2T)\WA+I\ M"`?Z@9JVYTN"DDE<.(&;!76%P716EWM@]S8!0$;Y`=QI?0>K'/2L-E`0 M1VBQ;]!M=B2!28D$Y.U39V1PP?O=]S?XW??H)]^O8X`>1`*04TO[VGO8?LWP M[NYAE9OJY&R]O66IZL1YO\YL[O@CQKK>=3=S';&VUCM/_\U&XJ9-=>3KE=GN M;-9(B\54Q[[>!`%6Z(YQC$.OR/:T^?J,H5"8UC=;+IUX,YWQ64$F;NJOX4AL MBE^K81^OAGV\R3K-3'>I>PJK\L$FA1G"CBDP$F'T))9^.1N%B#-K7FRJ4HWB M'92"/[:5OPO4VSYMVS/ZA_U;=#OL_]M'4_%]/'X9NG^0ZT08BK-^Q[<`:79. MM)L3;-'7H M=DCY;G4=J+Y-!=^ZT:E."?K1(FE3@JH%4P9S9+-7=J-XZR=GR)%JM94[V2H7 M!)Y2)T[ME*J:4F*B'IM2;G!S24SI(Y2%[E,QER%D1-*RK)U-!;.)\0QIEI7. M3J@>$WIL&&R7MJZX/Z]".Z5-]/X]S[E(SLDF.?(L,S6$Y=`\#ZG-RF?>:A"V MV-C44Y]8`B+4AY3RE=$G5$7#5ZYI"H@Z!64<*95?N"G(K/WSW>Q)DX3R! MXA`(@L1=.+/T[F5!SM;%5]'JT*ZR.%H!+([8(BIHO/9#/P6W_AIY6J3P#/;A M^BIDP//-G?-;%%\$#KR\R/>;2`N:C;"BCAE_*=J*E!UZ"YP$3.:0VT%GP1T\ M!Q;!IC0HX38FM;P*[/<)PB<`I)=51O75Z\HO+F9DZ20]-(,MJK7&M\UZ+"0A M3(^'OTKL#;LKCW^7V.-UE,7DR^^HC,2>IR'^ML`6D=CO,RS#[+E>2&;?/R)F MS[LB2H+\P1P=2)]!-(^=U<)WG8`>J4\LKX3Z[:.&=7HHMSFYO)0Y_[*ZCN&U M5&@L(%-[#<"#XV/U,Z2B*FU7W'J,G8J4D\DVW765H3*IVR(X,#95Z]Y*&-\M M.;;$:2I^PBJ!'69T3MM4Q\1&>-&Y9*/-J8V6%O'*,]J2V@BJQM81H]]M:;I! M92O[38U];[%>1:V0S4+.#86PE;&E6:SW8!R<>*T&+,>4G\;&XI'3\Y`%86/S M'C4&2\@JL(5O=.($$3ZBM+N%RKAT9<)0'>F3M]"<66CX+U-S7>U:V"Z`J(2/HPCICJG$U^1Q%W@\_"`CT[7Z6%,P, M%U"A;G4"L@L.KMCP'=SDS%>1J7(ZFZYR!74X+[K&V5A&F\0\6?;/Q#=9S6ZRZ^_?7DZ(+#V@U6W MZ2`>-3^8[:LYS3`;L\U8-H1<1[WY=BPN_4_]3#;554BJ0JR![X\IT)!E>./U MA0S.E_!X(?\I9CQ'(VHH2U M:J8ZR$UQ]U$*DN?HV@^=T/6=8(=8LG7ZO`2)&_LYE9/0 M.W<2/YG.'FKD/,/NSX/(_=[<*-=<335Q<[M&6YY3RE909.<,('DG]L*IO"2;5X8 M>8@C%Z+S")0N$[B%9H;5.!Y:MK.>12;PM^U'92#$^6+'2+`Z1` MJO@_2V(2;L9*`U8:L-*`E0:(T@#G%3`:`8!+=,)Q'\:;D[@0$K_GC#DM75N+H]M!F M[7TK;UAY@Y-!I!S%HY$Q+"=H.4%)G&".G1)+@GI^T')4?82B'DXTO*3E)0F\9.-#RG*:EM.TG";5G:5FXJ@2&RE5 M0')2AK\`.2OKXM+"8*:I52Q#K25#;=G*7EZWHNTBRUI:UK*YI1][V5A.TG*2 MEI-LP4FJ4V!B7HAXB*-K%*]:"UOE92QY6[$/#T\6<^\(K(_/+E4F\2>MO'JY#+;))D2V'UM9Q>K/QA MY0\K?UCY@TNU+7*8CT8:X<1.TJ5@7;L;\!A"*S4*KJ,@25HT.M80=>*,GT660[WD9.WX`<+M.HJ?G``\(6!SL`\P%+-. M-6S6RG!6AK,RG)7AN$PJ38^NT8AY?+)P*V;5VJ.Z8XM&8[3BP[8I\VW\0Q=6 MJV.U.LVT.C?A&OX3Q1NI<56FJ',PZ#`T%[0:FHR`)<)1JUCQV8J,?9SA'#O/ M2HQ68N3.*TL[!4WC=FBT@RU;:ME23K94].RTS*EE3BUS*H$Y MM7K/X;&HAK%N.XW$%C]^=>AQ#=7:70_,_-!/P:V_!D>K0%C9*]*:9;LMVVW9 M;LMV-],&8\[>T?#8W`ISH<-]-*[D5D2Q(HJ8B%*^8YP\.!L$%KS=X#=Q!NH) MPS1Y&J$IJ7C6HFEK-BVLCI)+.8O)=AJ=@!4*3JMA^7=S^'?+CA[Q-: MME-NAA+F:60Y3!=1DB;;%Y:!!T^N MO)92Y2N)1"$5JU26$?IP_*VW5XY'$WFY(<3>R*< MLHQ>+.>L)>>\TS-=+5=!M`'@"<1KWP6$*0]R6N"G^FN$#P">?L56X5>2R^Y/ M+7K5$;%_B,!CPG?A.?*40AHGH7?PS9?01^:PU%_#12!H9>B@2PTP/%H".='3 M_#)MA523AG7!HWZBULE&.6V+?8)>^BR^:XQ-BTZLS&]E?BOS6YE?DLE+.BLR M&FT`MU)%BMPPFF@+SG7;G(&Q:?J[8'U&D[5?!%7)0DJ%\<]F8VP5K5;1*IKZ M%I8&S\ZKS4^&37I[A`XSZ2VYAB8C8+^,0*EB=9)6LN_C#.?8>59LMV([]\L( MM%-P-)*W90\M>RC&'D(9;.FGA=8TA!(97";A',!"VL3A'-D550)``/M$V%4[1-A5'5X"P`!!"4.```$.0$` M`.U=W7/BMA9_[TS_!UT>[FQG2@B;W6TWLVF')&3+3!)R@6U[[TM'V`(T-1:5 MY"3TK[]'\@?",L(F)$LZ?DF,?3[U._HZEJ5//S_.`W1/N*`L/&NTCXX;B(0> M\VDX/6M\&38[PXM>K_'S3]]^\^E?S28:#-`E"T,2!&2)?O=(0#B6!(WP(PO9 M?(F&WHS,\?=HC`7Q$0O1[^>#:_3VJ(W03,K%::OU\/!P1/PIYDT6!C0D1QZ; MMU"SF6KX-;;E%'TX>ML^.C&>#%@4^J?H1^/6!2=8`C7RP8I3]/:X_:[9;C?; MQZ/VCZ?O/IR^^^%_)C5;+#F=SB1ZXWT'Q,?OF\!Q@@9'@R/#K7^C(0L%4,\7 M.%RB3A"@@>(2:$`$X??$/TJ$"NTM@B(,Q5G#I(-*<8+S+Z"19C39T\:.G"/6XW3]KK7'*Y(**033\IYL/CN;]F&AY3-H>2 M5=&@.(X_GAP;]"&@$\V+_?MY*%RZL0J!B_B'*K;)M;D:7$1^H06L\@[RZ,V* M6=238AX:WA,AB[GB9\6>A9AZHIA-/U)<;8M+4*^8!QYLX)`+OH$%GN1Y).93 M(F_QG(@%]DBY"(1&;DY"><7X_)),0EYX!+U#/_Q)7WLX\*)`,U[#[X0YH7`Q+C@TQZ'<@7-EV6:^Y&Z* MQGY`&H*U.ICZDRL:0@M/<7#'A#;E(L!")#&EX!H`PQ\E&=SH02>*,D%P?=&_ MO>S>#KN7ZFK8O^Y==D;PX[QSW;F]Z*+A+]WN:%B#^#00[S"TW7)&)(6RJ8RH MYMX"Z[M=8$5OU@S[KH:Y!,P]&!'/22>0A(?@PCTIQM,F
M`GC]*]2_ZPXZHQX0U-"5@*X/D<[54)Z3&0D%@!*C5(S@1FHWD!]V`?*B?W,W MZ/X"=+U?N^C-=7\X_`[U;N%VMT:V!+(76,RN`O8@>J%/.?%D,:0VF1O+'W;" MLC/\!5U=]W^K*^5&Z&Z9)&+$LDXO*V1Q'@D:$B$NB?`X72C;.J%_C@45_F(/,KS@'E_&E#O5:P[-'Y40U\JO(")B!/X<8NENF`3E.K2(V*M0MT%)0O, MZS'QCG'1Q3RDX53<$3ZKN MM1VZV3$-M4^KXMZMAF\1Y<2[?9S'N^/]%=%X0"YJ@*L#?(4I_Q4'$5F5JJB& MJUN"&\YV'LX;S/\D$H\#@H;$BS@0DKB=5FJ0UH-N"%;D6GN->77,>^$]_&-\ MN6M5=@IP(_XVCW@J"W"NL:R.Y6?&_`<:!#!8ZJELX91"W>D(0:38%=V*(MUX MG^3Q3J7K2MT+FW><>6HLIE[78.[-]/U+[P4C6E M`"3NV89``.@FJM:.#Q5ASLLWN?#8BB!J:EE(5-='1Z[#`/4 M-&F$'W6OJ)( M-^`_Y`$WI.LN?TU^'0'5(V!(INK_@"P85R6Y*^QEY+BQME)OBHODHZ]8P%5=>R9TK*9>'>,V(F[\NE9]"954K\1W6>F=J0&].7B M8IL,)_AOK2R>(VN+WL0B:ZB?+7U;`?=*`MU!8.7^S%1NC?ISY70K@%U&CAMC M*]M7.;];!$S)7HKQ$$),>XPL)*`1M*W!OC%LK\5(-])L#L(K!1?U4QP'2DO MGQ*N$#)/T^".'2L/F$\/U['Q]?+$%6)D/YK)76:Z_+ M!(FJ75%L.^`+Q>P!N)F5C5@?/HKD=`WN2ZHX1 M*\-H:$696B-R1!HZL6Z4*M>C`$,]2O37@50ID)CZL!JK:LD"ZFO(TVF@HQ\H MS><.!BO/"'*1%HQ,R2@37?<*.P+=T[L)J.GS*J._2NCGX=U"[0;5RANNI&UX MG5`#6:%[7]4R(;G>*$`,B,>X#^VQS)IKJW\OR>:&UDKKF14SDXM2P0A+( MEJOG^LYY!X"YS\15OO.Z&T6C#+LC%DDXWH(J*O"U[=OB)PQGP5L M"N!\`4-A!%<8$JL=.'IAW*CD`^SE%+L#TW785DMGLU`5IMHN)%NQ4)2T+B)SAX25G5R)41W:V@J) M&K-*$Y.DW$IU05OIG2B^LQ*0)FYUW[$'0+.5*!ZTE50N\P!:S]V`63G%;!5* M*J!&9Q=TU#JA9`%/NGY'O;I;K=XI51N?*LZ-O94KK+P"J:[1>VFBWOWP34T%:#1*Z+T@JCU15@> MFX;T;_M-SE9Z-WBEO^)%*Y$UGCM.5(JQ#^VMI2H^$JK&Z([2]R-]7/ M>H2[!\Q_(^H(`N)W[@G'4Z)7$N@JI+.*(W:1E(JY3":N8^(SQZ&T>^`]2'1' MB)6.2C6B1"4R=,;)1\E0IC;W.B91C1+==?#LTNK#=$1RZD'YZ=H*TYWPV<4[V6RF=V]Q"[\;:2I69 M>[34'<6>!NZ;ME@IA7!E?C?B5H+,N4E+'0)[:>[CO5$Z^IR/9&<4M3&*\FNEI.G\`Q]'C M/$A)))5*R\5*#E*"Q/<(!T&C=;B>K\-8PG%@*'#\,A/S2OP.$@$)5T&V@*7 MKY6$5^)MOIJ73. M*"QE1LJC+IZD/'_:82GM&9.^>I)^^]S$4A88;,GUD\+!.H:QE!$KKOBRN1)0 MW83].GW>FWFD`51 MG$6=CV9JNM!`>"PDQYX\:TBN MOK+09\V>PD"(,G^D&?V()_.]D`:!6KJ./W:7A2O`TDLO]`-7X%GY;A,;^@NV*$/%EH5YXVGZMG#$+8%<)KR(N MIE-.IEB2U4KS\0OYBI MXX77@J(4^6%5A6P3'6/?@_1CVM4N&E>6TC>.`.E"WS7I7K-(>)M0O[)TO3V?`R;UH MK,O7[:>Q6^UJA5G/!T(ZH3C;V="Y#X&]F5U!$3V7HM?0VCK>1175FW+D!U1I M'`;G:\QVTH.L+AN^WK6F/5OH#FG"4VT(](\9^5PR+UJ]#:1RN?;QHS7I*T=^ M0'4QO_W\ZL5C45-3BOI5>)=O:+92'F0[T_46$&8/U/M3!!%8#^-J$@3"F^&) MO"E(LY2D/Z1VISM?!&Q)XB6<=Q$'6P6Y@XIN.[>-\I#0/CX5FP3!HUPP\WV6L8(=^RT,-BUN=WF,OD MAY'J,BZSOQ/Y*M(E=W%'36>)GNYXW`9-Y5&D3AHGM;C9Q&R9T=& M3.(@-O%\^9FP*<>+&?4&9*JRFMU'+XA\@"SM*#:X6EG*`1?&@-R3,")%CKB\ M=[(=T&C/>.VEOX8J][6$U;`_3/KQBOF(1+XJEW*/#,[P?D@UV&T\.S^S1#(8L&PQ?>W:`IC^P38:O MGAR2V3NVI*^WY2S\K,XRO_.`N;_5[5+,A^3\$+IQ#+*+&H:"9X=H>E$-*WAV M6*;/B!\%,.BRWQH6)0!*TA]01L!E<3Y%4(+V(',&JQ.O-C0.FP@.*A0S&]VILN3(O5&Z=LO^>^G!$^FN$P^8K<&%N/U"([M@;+L0;P"K]EXH;-N? M7=4A=0O/XZS5HSRKF@/OC"JZG%32W$XE`Z)Z)7!-)3N50Q$.1H3/"U8AO+CF M`XKG+XLK#F;&JY'!D"N27YNRD>+9LNT^&>^6*O[4BK_.@,O_`U!+`0(>`Q0` M```(`*ET:D5N>XID4\H``*1S"0`1`!@```````$```"D@0````!A8FUD+3(P M,30P.3,P+GAM;%54!0`#[1-A5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`*ET:D4=../H(A0``%4=`0`5`!@```````$```"D@9[*``!A8FUD+3(P,30P M.3,P7V-A;"YX;6Q55`4``^T3851U>`L``00E#@``!#D!``!02P$"'@,4```` M"`"I=&I%0#Y8H`&UL550%``/M$V%4=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`J71J1?=%M0&J90``[B@&`!4`&````````0```*2!91D!`&%B;60M,C`Q M-#`Y,S!?;&%B+GAM;%54!0`#[1-A5'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`*ET:D5G$%"4_CT```*J!0`5`!@```````$```"D@5Y_`0!A8FUD+3(P M,30P.3,P7W!R92YX;6Q55`4``^T3851U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"I=&I%`U=-[2,0``"SJ```$0`8```````!````I(&KO0$`86)M9"TR M,#$T,#DS,"YX`L``00E#@``!#D!``!02P4&``````8` ,!@`:`@``& XML 23 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Stock Options

Sep. 30, 2013

Stock Options

Sep. 30, 2014

Stock Options

Sep. 30, 2013

Stock Options

Sep. 30, 2014

Restricted Stock and Restricted Stock Units

Sep. 30, 2013

Restricted Stock and Restricted Stock Units

Jun. 30, 2011

Performance Based Restricted Stock and Restricted Stock Units

May 31, 2011

Performance Based Restricted Stock and Restricted Stock Units

Sep. 30, 2014

Performance Based Restricted Stock and Restricted Stock Units

Sep. 30, 2014

Performance Based Restricted Stock and Restricted Stock Units

May 31, 2014

Performance Based Restricted Stock and Restricted Stock Units

Share Based Awards

May 31, 2013

Performance Based Restricted Stock and Restricted Stock Units

Share Based Awards

May 31, 2012

Performance Based Restricted Stock and Restricted Stock Units

Share Based Awards

Sep. 30, 2014

Performance Based Restricted Stock and Restricted Stock Units

Share Based Awards

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate intrinsic value of options exercised in period $ 3,000,000

Fair value of options vested in period 1,700,000

Unrecognized stock-based compensation expense 5,700,000 5,700,000 17,000,000 8,000,000 8,000,000

Unrecognized stock-based compensation expense, weighted-average recognition period 2 years 6 months 2 years 1 year 9 months 18 days

Weighted average grant-date fair value for options granted $ 9.05 $ 9.67

Expected dividend yield 0.00%

Weighted average grant-date fair value for restricted stock and restricted stock units granted $ 21.88 $ 23.18

Fair value of restricted stock and restricted stock units vested in period 9,500,000 6,000,000

Shares of award granted 664,000 284,000 284,000 379,752 268,988 195,188

Shares of award vested 465,000 154,991

Shares of award granted, performance target met 234,000

Shares of award granted, it is probable that the prescribed performance targets will be met 50,000

Stock-based compensation $ 4,024,000 $ 2,798,000 $ 8,314,000 $ 6,719,000 $ 624,000 $ 598,000 $ 1,423,000 $ 1,523,000 $ 2,100,000 $ 3,700,000

X

- Definition

Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Performance Target Achieved

+ References

No definition available.

+ Details

Name: abmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceTargetAchieved

Namespace Prefix: abmd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Performance Target Probable to be Achieved

+ References

No definition available.

+ Details

Name: abmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceTargetProbableToBeAchieved

Namespace Prefix: abmd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested share-based compensation awards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Acquisitions
6 Months Ended

Sep. 30, 2014

Acquisitions

Note 3. Acquisitions

Acquisition of ECP Entwickslungsgesellschaft mbH

On July 1, 2014, the Company entered into a share purchase agreement with its wholly owned German subsidiary, Abiomed Europe GmbH (“Abiomed Europe”) and Syscore GmbH (“Syscore”), a limited liability company located in Berlin, Germany, providing for the Company’s acquisition of all of the share capital of ECP Entwicklungsgesellschaft mbH (“ECP”), a limited liability company incorporated in Germany. ECP is engaged in research, development, prototyping and the production of a percutaneous expandable catheter pump which increases blood circulation from the heart with an external drive shaft. The Company’s acquisition of ECP closed on July 1, 2014.

The Company acquired ECP for $13.0 million in cash, with additional potential payouts totaling $15.0 million payable to Syscore based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock. With respect to such milestone payments, the share purchase agreement provides:

• that, upon the earlier of (i) the Company’s receipt of European CE Marking approval relating to the sale of an expandable device based on certain patent rights acquired from ECP, or (ii) the Company’s bringing of a successful claim against a third party competitor (or reaching an economically equivalent settlement) for the infringement of certain patent rights acquired from ECP, it will pay Syscore an additional $7.0 million (provided that if such claim or settlement does not prohibit the third party competitor’s further marketing, production, sale, distribution, lease or use of any violating or infringing products, but only awards monetary damages to the Company or to Abiomed Europe, the amount payable to Syscore shall be limited to the lower of the amount of aggregate damages received and $7.0 million); and

• that, upon the first to occur of (i) the Company’s successful commercialization of one or more rotatable and expandable devices based on certain patent rights acquired from ECP, where such devices achieve aggregate worldwide revenues of $125.0 million, including the revenues of third party licensees, or (ii) the Company’s sale of (A) ECP, (B) all or substantially all of ECP’s assets, or (C) certain of ECP’s patent rights, the Company will pay to Syscore the lesser of (x) one-half of the profits earned from such sale described in the foregoing item (ii), after accounting for the costs of acquiring and operating ECP, or (y) $15.0 million (less any previous milestone payment).

ECP’s Acquisition of AIS GmbH Aachen Innovative Solutions

In connection with the Company’s acquisition of ECP, ECP acquired all of the share capital of AIS GmbH Aachen Innovative Solutions (“AIS”), a limited liability company incorporated in Germany, pursuant to a share purchase agreement dated as of June 30, 2014, by and among ECP and AIS’s four individual shareholders. AIS, based in Aachen, Germany, holds certain intellectual property useful to ECP’s business, and, prior to being acquired by ECP, had licensed such intellectual property to ECP.

The purchase price for the acquisition of AIS’s share capital was approximately $2.8 million in cash and the acquisition closed immediately prior to Abiomed Europe’s acquisition of ECP. The share purchase agreement contains representations, warranties and closing conditions customary for transactions of its size and nature.

Preliminary Purchase Price Allocation

The acquisition was accounted for as a business combination. The purchase price for the acquisition has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase price allocation presented herein is preliminary. The final purchase price allocation will be determined after completion of an analysis to determine the fair value of all assets acquired and liabilities assumed, but in no event later than one year following completion of the acquisition. Accordingly, the final acquisition accounting adjustments could differ materially from the preliminary amounts presented herein. Any increase or decrease in the fair value of the assets acquired and liabilities assumed, as compared to the information shown herein, could also change the portion of purchase price allocated to goodwill, and could impact the operating results of the Company following the acquisition due to differences in purchase price allocation, depreciation and amortization related to some of these assets and liabilities.

The acquisition-date fair value of the consideration transferred is as follows:

 Total
Acquisition
Date Fair
Value (in
thousands)

Cash consideration
 $ 15,750

Contingent consideration
 6,000



Total consideration transferred
 $ 21,750



The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on July 1, 2014, the date of acquisition (in thousands):

Acquired assets:


Cash and cash equivalents
 $ 53

Accounts receivable
 25

Property and equipment
 619

In-process research and development
 18,500

Goodwill
 1,964

Long-term deferred tax assets
 874

Other assets acquired
 141



Total assets acquired
 22,176

Liabilities assumed:


Accounts payable
 295

Accrued liabilities
 131



Total liabilities assumed
 426



Net assets acquired
 $ 21,750



IPR&D is principally the estimated fair value of the ECP and AIS technology which had not reached commercial technological feasibility nor had alternative future use and therefore considered IPR&D, with assigned values to be allocated among the various IPR&D assets acquired.

Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes.

All legal, consulting and other costs related to the acquisition, aggregating approximately $1.1 million, have been expensed as incurred and are included in selling, general and administrative expenses in our consolidated statements of operations. The results of operations for ECP and AIS are included in the Company’s condensed consolidated statements of operations for the period from the July 1, 2014 acquisition date to September 30, 2014. The Company recorded no material revenues and incurred $1.1 million in net losses for the three months ended September 30, 2014 associated with the operations of ECP after the July 1, 2014 acquisition. This also includes a $0.2 million expense for the change in fair value of the contingent consideration for the three months ended September 30, 2014.

The following unaudited pro forma information presents the combined results of operations for the three and six months ended September 30, 2014 and 2013, as if we had completed the ECP and AIS acquisitions at the beginning of fiscal 2014. The pro forma financial information is provided for comparative purposes only and is not necessarily indicative of what actual results would have been had the acquisition occurred on the date indicated, nor does it give effect to synergies, cost savings, fair market value adjustments, immaterial amortization expense and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of consolidated results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period.

The pro forma consolidated financial information has been calculated after applying the Company’s accounting policies and includes adjustments for transaction-related costs, to eliminate revenues earned by AIS from ECP and expenses paid by ECP to AIS associated with a license agreement between the two parties, interest expense incurred by ECP related to bank loans accounted as if the repayment of ECP debt had occurred on April 1, 2013 and was not outstanding during the periods, and income tax provision of AIS due to the elimination of revenue on the license agreement with ECP.

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

 (in $000’s) (in $000’s)

Revenue
 $ 51,938 $ 44,359 $ 100,761 $ 87,042

Income before income tax provision
 4,557 329 2,770 (1,850 )

Net income (loss)
 4,218 (41 ) 2,260 (2,631 )

X

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 25 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q M,V5D,3EF,S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D%C<75I#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DUA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DEN=F5N=&]R:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O'!E M;G-E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K0F%S961?0V]M<&5N#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O'!E;G-E#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E%U86YT:71A=&EV95]);F9O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;7!O;F5N='-?;V9?26YV M96YT;W)I97-?1&5T83PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S7T%D9&ET:6]N86Q?26YF;W)M83PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=O;V1W:6QL7T%C=&EV M:71Y7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D=O;V1W:6QL7V%N9%]);E!R;V-E#I7;W)K#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D-O;7!O;F5N='-?;V9?4W1O8VM"87-E9%]#;VUP93PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E=E:6=H=&5D7T%V97)A M9V5?07-S=6UP=&EO;G-?53PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO M>#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q M-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%? M-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA2!);F9O'0^)SQS<&%N/CPO'0^)S$P+5$\'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(P,30\'0^)T%"340\"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)RTM,#,M,S$\2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'!E;G-E'0^)SQS<&%N/CPO"!A'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPOF5D("T@,2PP M,#`L,#`P('-H87)E3PO=&0^#0H@("`@("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D("AL;W-S97,I(&=A M:6YS(&]N(&UA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Y M-CQS<&%N/CPO"!P6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO2!O9B!M87)K971A8FQE('-E M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!O9B!S=&]C:R!O<'1I M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4V,#QS<&%N M/CPO&5S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B@Q+#`Q,RD\2!F:6YA;F-I;F<@86-T:79I=&EE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D M,3EF,S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=? M8C@Y9%\T9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQD:78^#0H@/'`@'0M#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#9P M=#L@3$545$52+5-004-)3D'0M2!I;7!R;W9I;F<-"B!B;&]O9"!F;&]W(&%N9"]O28C>#(P,3D[2!I;G1E6QA8W1I8V%L;'D@;W(@96UE2!B969O"<^#0H@5&AE(&%C8V]M<&%N>6EN9R!U M;F%U9&ET960@8V]N9&5N$$P.U,M6"X-"B!!8V-O2P@=&AE>2!D;R!N;W0@ M:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!N;W1E#0H@9&ES M8VQO$$P.S,Q+"`R,#$T('1H870@:&%S(&)E96X@9FEL960@=VET:"!T:&4@4V5C M=7)I=&EE&-H86YG92!#;VUM:7-S:6]N+"!O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!! M0T4Z(&YO'0M#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE M=R!2;VUA;B<[($U!4D=)3BU43U`Z(#$R<'0[($Q%5%1%4BU34$%#24Y'.B!N M;W)M86P[(%1%6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT+7-T28C>#(P,3D[$$P.S,P+"`R,#$T(&%S(&-O;7!A'0M2!A;F0@:&%V M92!N;R!A;'1EF5D(&)A2!H M879E(&$@9G5L;"!O#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=) M3BU43U`Z(#$X<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$ M14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@ M/&(^/&D^0V]N=&EN9V5N="!#;VYS:61E2!A8W%U:7)E9"!A;&P@;V8@=&AE(&ES6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO'0M2!A;F0@;65A2!O9B!T:&4@<')O8F%B M:6QI=&EE'!E8W1E9"!T M:6UE;&EN97,@9F]R(&%C:&EE=F5M96YT(&]F(&%N>2!O9B!T:&5S92!M:6QE M2!H:6=H M97(@;W(@;&]W97(@9F%I2P@86YD(&-O;6UE;G-U#L@0T],3U(Z(')G8B@P M+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU4 M3U`Z(#$X<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4 M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&(^ M/&D^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+VD^/"]B/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=(251%+5-0 M04-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-) M3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S M($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#9P=#L@3$545$52+5-004-)3D'0M2`R,#$T+"!T:&4@1FEN86YC:6%L($%C M8V]U;G1I;F<@4W1A;F1A$$P.SQI/E)E=F5N=64-"B!F$$P.SPO:3YT;R!PF4@2!A9&]P M=&EO;B!I2!E=F%L=6%T:6YG('1H92!I;7!A8W0@;V8-"B!A9&]P=&EN9R!!4U4@ M,C`Q-"TP.2!O;B!I=',@8V]N3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T M9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX- M"B`\8CY.;W1E)B-X03`[,BX@3F5T($EN8V]M92`H3&]S2!D:79I M9&EN9R!N970-"B!I;F-O;64@*&QO2!A9&1I;F<@=&\@=&AE('=E:6=H=&5D#0H@879E28C>#(P,3D[ M&-L=61E9"!F2!W;W5L9"!H879E(&%N(&%N=&DM9&EL=71I=F4@ M969F96-T+`T*(&UE86YI;F<@=&AE(&QO"!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X M03`[,S`L(#(P,30-"B!A;F0@,C`Q,R!W97)E(&%S(&9O;&QO=W,@*&EN('1H M;W5S86YD$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P M.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P M+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(L,3,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH-C8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=E:6=H=&5D(&%V97)A9V4@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.2PR-C`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,"PR-38\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XS."PY-S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,#D\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XP+C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C`R/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E-I>"!- M;VYT:',@16YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L,3,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-C8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%=E:6=H=&5D(&%V97)A9V4@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.2PR-C`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT,"PR-38\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XS."PY-S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5F M9F5C="!O9B!D:6QU=&EV92!S96-U6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M,#$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,BPP-CD\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS."PY-S$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`S/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C`N,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($9O$$P.S,P+"`R,#$T+"!A<'!R;WAI M;6%T96QY#0H@-#&EM871E;'D@-#8U+#`P,"!R97-T2!R96QA=&5D('1O('!E$$P.S,P+"`R,#$T+"!A<'!R;WAI;6%T96QY#0H@ M-#0L,#`P('-H87)E&EM871E;'D@-#8U+#`P,"!R97-T2!R96QA=&5D('1O('!E&EM871E;'D-"B`R.3&EM871E;'D@,S4T+#`P,"!R97-T2!R96QA=&5D('1O('!E$$P.S,P+"`R,#$S+"!A<'!R;WAI;6%T96QY#0H@,RPY,C,L,#`P('-H87)E M&EM871E;'D- M"B`Q+#$Y."PP,#`@&-L=61E9"!F M0T* M(&EN8W5R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@"<^#0H@/&(^3F]T928C>$$P.S,N($%C<75I"<^#0H@/&(^/&D^06-Q=6ES:71I;VX@;V8@14-0($5N='=I8VMS M;'5N9W-G97-E;&QS8VAA9G0@;6)(/"]I/CPO8CX\+W`^#0H@/'`@#(P,4,[06)I;VUE9"!%=7)O<&4F(W@R,#%$.RD@86YD(%-Y M#(P,4,[14-0 M)B-X,C`Q1#LI+"!A(&QI;6ET960@;&EA8FEL:71Y(&-O;7!A;GD@:6YC;W)P M;W)A=&5D(&EN#0H@1V5R;6%N>2X@14-0(&ES(&5N9V%G960@:6X@'!A;F1A8FQE(&-A=&AE=&5R('!U M;7`@=VAI8V@-"B!I;F-R96%S97,@8FQO;V0@8VER8W5L871I;VX@9G)O;2!T M:&4@:&5A'1E28C>#(P,3D[28C>$$P.S$L(#(P,30N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO'0M6%B;&4@=&\@4WES8V]R92!B87-E9`T*(&]N M('1H92!A8VAI979E;65N="!O9B!C97)T86EN('1E8VAN:6-A;"P@2!A;F0@8V]M;65R8VEA;`T*(&UI;&5S=&]N97,N(%1H97-E(&UI;&5S M=&]N92!P87EM96YT28C M>#(P,3D[#L@+7=E M8FMI="UT97AT+7-T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE"<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^ M#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M=&]P('=I9'1H/3-$,R4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YT:&%T+"!U<&]N('1H92!E87)L M:65R(&]F#0H@*&DI)B-X03`[=&AE($-O;7!A;GDF(W@R,#$Y.W,@2!C M;VUP971I=&]R("AO0T*(&-O;7!E=&ET;W(F M(W@R,#$Y.W,@9G5R=&AE7-C;W)E('-H86QL M(&)E(&QI;6ET960@=&\@=&AE(&QO=V5R#0H@;V8@=&AE(&%M;W5N="!O9B!A M9V=R96=A=&4@9&%M86=E#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(#9P="`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE. M+51/4#H@,'!T.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5. M5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T2!L:6-E;G-E97,L M(&]R("AI:2DF(WA!,#MT:&4@0V]M<&%N>28C>#(P,3D[2!A M;&P@;V8@14-0)B-X,C`Q.3MS#0H@87-S971S+"!O#(P,3D["DF(WA! M,#MO;F4M:&%L9B!O9B!T:&4-"B!P2DF(WA!,#LD,34N,"!M:6QL:6]N M("AL97-S(&%N>2!P'0M#(P,3D[6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@26X@ M8V]N;F5C=&EO;B!W:71H('1H92!#;VUP86YY)B-X,C`Q.3MS(&%C<75I#(P,40[*2P@82!L:6UI=&5D(&QI86)I;&ET M>2!C;VUP86YY#0H@:6YC;W)P;W)A=&5D(&EN($=E$$P.S,P+"`R,#$T+"!B>2!A;F0@86UO;F<@14-0(&%N9"!!25,F M(W@R,#$Y.W,-"B!F;W5R(&EN9&EV:61U86P@2P@:&]L9',-"B!C97)T86EN(&EN M=&5L;&5C='5A;"!P2!U2!T M;R!%0U`N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M5TA)5$4M4U!!0T4Z(&YO'0M#(P,3D[&EM871E;'D@)#(N."!M:6QL:6]N(&EN(&-A2!P#(P,3D['0M#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE M=R!2;VUA;B<[($U!4D=)3BU43U`Z(#9P=#L@3$545$52+5-004-)3D'0M2XF(WA!,#M4:&4@9FEN86P@<'5R8VAA0T*(&9O M;&QO=VEN9R!T:&4@86-Q=6ES:71I;VX@9'5E('1O(&1I9F9E"<^#0H@5&AE(&%C M<75I6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO'0M$$P.SPO<#X-"B`\=&%B;&4@#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z M(&YO'0M$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-& M3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L M,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z M(#!P=#L@3$545$52+5-004-)3D'0M"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO M;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Q.3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(R+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M M4U!!0T4Z(&YO'0M2!T M:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@=&AE($5#4"!A;F0-"B!!25,@ M=&5C:&YO;&]G>2!W:&EC:"!H860@;F]T(')E86-H960@8V]M;65R8VEA;"!T M96-H;F]L;V=I8V%L#0H@9F5A"<^#0H@1V]O9'=I;&P@:7,@8V%L8W5L871E9"!A"<^#0H@06QL(&QE9V%L+"!C;VYS=6QT M:6YG(&%N9"!O=&AE28C>#(P,3D[ M28C>$$P.S$L M(#(P,30@86-Q=6ES:71I;VX@9&%T92!T;R!397!T96UB97(F(WA!,#LS,"P@ M,C`Q-"X-"B!4:&4@0V]M<&%N>2!R96-O'!E;G-E(&9O M6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@5TA)5$4M4U!!0T4Z(&YO'0M$$P.S,P+"`R,#$T(&%N9"`R,#$S+"!A2!I;F1I8V%T M:79E(&]F('=H870@86-T=6%L(')E2!O=&AE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M5TA)5$4M4U!!0T4Z(&YO'0M2!%0U`@6UE;G0@;V8@14-0(&1E M8G0@:&%D(&]C8W5R"<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ("=4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E-I>"!- M;VYT:',@16YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P,"PW-C$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@W+#`T,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"!P$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XT+#4U-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS M,CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#(V,#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,BPV,S$\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF M,S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y M9%\T9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQD:78^#0H@/'`@6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T* M(#QB/DUA28C>#(P,3D[28C>#(P,3D[$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF5D/&)R("\^#0H@0V]S=#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]LF5D/&)R("\^#0H@1V%I;G,\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D=R;W-S/&)R("\^ M#0H@56YR96%L:7IE9#QB$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUA6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%53(%1R96%S=7)Y('-E8W5R M:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ.2PT.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%-H;W)T+71E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4X+#0X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+#0Y M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDT+#0V-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S$\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CDT+#0U-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T M9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF5D/&)R("\^#0H@3&]S6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.S,Q+"`R,#$T M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C,Q+#0X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(T+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,2PW-SD\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XY-RPT-#`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XY-RPT,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M2!I;B!A;B!O2!M87)K970@9&%T82X\+W`^ M#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T* M($QE=F5L(#$@<')I;6%R:6QY(&-O;G-I&-H86YG92UT6EE;&0@8W5R=F4L('9O;&%T:6QI='D@9F%C=&]R2P@ M8W5R6EN9R!F:6YA;F-I86P@:6YS=')U;65N=',L(&%S#0H@=V5L M;"!A2!A;&P@;V8-"B!T:&5S92!A2!O8G-E0T*(&QI='1L92!O28C>#(P,3D[ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^*&EN#0H@)#`P,"8C M>#(P,3D[$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%T(%-E<'1E M;6)E$$P.S,P+"`R,#$T.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X- M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$#(P,30[ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M.2PT.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-H;W)T+71E$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-SDW/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-SDW/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^ M/"]T9#X-"B`\=&0@8V]L6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.S,Q M+"`R,#$T.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT2!S96-U$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q+#0X-SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(T+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(T+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Q+#$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Q+#6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T* M(%1H92!#;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;"!L:6%B:6QI=&EE6EN9R!A('!R;V)A8FEL:71Y('1O M(&5A8V@@;W5T8V]M92X\+W`^#0H@/'`@F5S('1H92!C:&%N9V4@ M:6X@9F%I$$P.S,P+"`R,#$T.CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XV+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(Q.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT2!T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-#(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XU+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58 M5"U)3D1%3E0Z(#0E)SX-"B!4:&4@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@ M=&AE(&-O;G1I;F=E;G0@8V]N"!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L M(#(P,30@=V%S#0H@<')I;6%R:6QY(&1U92!T;R!A;B!I;F-R96%S92!I;B!F M86ER('9A;'5E(&1U92!T;R!T:&4@969F96-T(&]F('1H90T*('!A6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=) M3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5. M5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@<')E$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.U9A;'5E)B-X03`[870\+V(^/&)R("\^#0H@/&(^4V5P M=&5M8F5R)B-X03`[,S`L)B-X03`[,C`Q-#PO8CX\8G(@+SX-"B`\8CXH(&EN M("0P,#`F(W@R,#$Y.W,I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#%P=#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS M1&-E;G1E$$P.V]C8W5R2`R,#$S M+"!T:&4@0V]M<&%N>2!I;G9E2X@ M26X@861D:71I;VXL('1H92!#;VUP86YY(&-O;6UI='1E9`T*('1O(&EN=F5S M="!A;B!A9&1I=&EO;F%L("0P+C<@;6EL;&EO;B!I9B!T:&4@<')I=F%T92!T M96-H;F]L;V=Y#0H@8V]M<&%N>2!A8VAI979E2!R97%U97-T960@ M=&AI6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H:7,@;W1H97(@:6YV97-T;65N="!I M6EN9R!A M;6]U;G0@;V8@=&AI$$P.S,P+"`R M,#$T(&%N9`T*($UA2P@ M86YD(&ES(&-L87-S:69I960@=VET:&EN(&]T:&5R#0H@87-S971S(&EN('1H M92!U;F%U9&ET960@8V]N9&5N3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D M,3EF,S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=? M8C@Y9%\T9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R MF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B`\8CY.;W1E)B-X03`[-2X@26YV96YT;W)I97,\ M+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA3I4:6UE$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE M/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@86QI9VX],T1C96YT97(^ M#0H@/'1R/@T*(#QT9"!W:61T:#TS1#6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O$$P.S,P+#QB$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/BAI M;@T*("0P,#`F(W@R,#$Y.W,I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N M="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!287<@;6%T97)I86QS(&%N9"!S=7!P;&EE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(V,3PO M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+#8W-3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M+#(W,SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P M>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]TF4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#0T-3PO=&0^#0H@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N M="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ,RPY-#@\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)V)O6QE/3-$)V)O3I4:6UE2!T:&4@26UP96QL M82!A;F0@04(U,#`P('!R;V1U8W0@<&QA=&9O"!M;VYT:',@96YD960-"B!397!T96UB97(F(WA!,#LS,"P@ M,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1V]O9'=I;&P@:&%S(&)E96X@ M$$P.S,P+`T*(#(P,30@ M:7,@87,@9F]L;&]W6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#DV-#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT2!T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH,RPP.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C,V+#@V-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,3)P="<^#0H@5&AE($-O;7!A;GD@:&%S(&YO(&%C8W5M=6QA=&5D(&EM M<&%I#(P,4,[06-Q=6ES:71I;VYS+"8C>#(P,40[ M(&EN($IU;'D@,C`Q-"P-"B!T:&4@0V]M<&%N>2!A8W%U:7)E9"!%0U`@86YD M($%)4R!A;F0@2!U6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`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`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT2!T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH,2PS,#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$W+#$Y.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E M;G-EF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B`\8CY.;W1E)B-X03`[-RX@06-C'!E M;G-E'!E;G-E6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O M='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL3I4 M:6UEF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E6QE/3-$)VUA'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$L,38Q/"]T9#X-"B`\=&0@;F]W6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ MF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!0$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`R,3PO=&0^ M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,P-#PO=&0^#0H@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT3I4 M:6UE6QE/3-$)VUA$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,#`P/"]T9#X-"B`\ M=&0@;F]W6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!787)R86YT>3PO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.30\+W1D/@T*(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT M.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P M>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]TF4Z.'!T M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$S+#6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RPX.3D\+W1D/@T*(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/"]TF4Z,7!X.SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3I4:6UE65E(&-O;7!E;G-A=&EO;B!C;VYS:7-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV M96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/DYO=&4F(WA! M,#LX+B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[ M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM M87)I>F5S('-T;V-K+6)A'!E;G-E(&)Y#0H@ M9FEN86YC:6%L('-T871E;65N="!L:6YE(&ET96T@:6X@=&AE($-O;7!A;GDF M(W@R,#$Y.W,@8V]N"!M;VYT:',@96YD960-"B!397!T M96UB97(F(WA!,#LS,"P@,C`Q-"!A;F0@,C`Q,SH\+W`^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N M/3-$8V5N=&5R/CQB/E-I>"!-;VYT:',@16YD960\8G(@+SX-"B!397!T96UB M97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S.3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%-E;&QI;F$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@`T*(&UO;G1H6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\ M=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$ M8V5N=&5R/@T*(#QB/E1H6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$-B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,#DX M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Y.#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0R,SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ+#4R,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8V/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,X/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S-SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY.#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT+#`R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#,Q-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XV+#"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0 M.B`Q.'!T)SX-"B`\8CX\:3Y3=&]C:R!/<'1I;VYS/"]I/CPO8CX\+W`^#0H@ M/'`@2!F;W(@=&AE M#0H@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.W1H;W5S86YD$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1&-E;G1E&5R8VES93QB$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$S+C(W/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0N.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R+C(V/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@R,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C0Y/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($-A;F-E;&QE9"!A;F0@97AP:7)E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2XV-CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XU+C`T/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C,X+#(X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($5X97)C:7-A8FQE(&%T(%-E<'1E;6)E$$P.S,P+"`R,#$T M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ,2XY-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N.3D\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L M-3`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+C`P/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS."PP M,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@86=G$$P.S,P+"`R,#$T+B!4:&4@=&]T86P@9F%I<@T*('9A;'5E(&]F M(&]P=&EO;G,@=F5S=&5D(&1U$$P.S,P+"`R,#$T('=A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!R96UA:6YI;F<@ M=6YR96-O9VYI>F5D('-T;V-K+6)A'!E;G-E M(&9O<@T*('5N=F5S=&5D('-T;V-K(&]P=&EO;B!A=V%R9',@870@4V5P=&5M M8F5R)B-X03`[,S`L(#(P,30@=V%S#0H@87!P2`D-2XW(&UI M;&QI;VXL(&YE="!O9B!F;W)F96ET=7)E$$P.S,P+"`R,#$T(&%N M9"`R,#$S('=A2X\+W`^#0H@/'`@#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9A:7(@=F%L M=64@;V8@;W!T:6]N"!M;VYT:',-"B!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q-"!A;F0@ M,C`Q,R!W97)E(&-A;&-U;&%T960@=7-I;F<@=&AE#0H@9F]L;&]W:6YG('=E M:6=H=&5D(&%V97)A9V4@87-S=6UP=&EO;G,Z/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E-I>"8C M>$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[ M,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)I$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D(&]P M=&EO;B!L:69E("AY96%R$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT+C$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N,C,\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO'!E8W1E9"!V;VQA=&EL:71Y M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*(%1H92!R:7-K+69R964@:6YT97)E2!Y:65L9`T*(&-U'!E8W1E9"!L:69E(&]F('1H92!S=&]C:R!O<'1I;VYS+B!6 M;VQA=&EL:71Y(&%S2!O9B!T:&4-"B!#;VUP86YY M)B-X,C`Q.3MS('-T;V-K(&%N9"!A9&IU2!E'!E8W1E9"!D:79I9&5N9"!Y:65L M9"!O9@T*('IE2!N;W0@8F4-"B!I;F1I8V%T:79E(&]F(&9O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB M/CQI/E)EF5S('1H92!A8W1I=FET>2!F;W(@=&AE('-I>"!M;VYT:',@ M96YD960-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q-#H\+W`^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+C,W/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(Q+C@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH-#8U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,"XT.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$L,C4R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+C@P/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*(%1H92!R96UA:6YI;F<@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO M;B!E>'!E;G-E(&9O$$P.S,P+"`R,#$T('=A65A6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(%1H92!W96EG:'1E9"!A=F5R86=E(&=R86YT M+61A=&4@9F%I2X\+W`^#0H@/'`@2!T:&4@0V]M<&%N>2X@07,@;V8-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q M-"P@=&AE($-O;7!A;GD@:7,@2!T:&4@0V]M<&%N>2X@07,@;V8-"B!397!T96UB97(F(WA! M,#LS,"P@,C`Q-"P@=&AE($-O;7!A;GD@:&%S(&UE="!T:&4@<')EF5D(&%C8V]R9&EN9VQY M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($9/3E0M M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X)SX-"B`F(WA!,#L\+W`^#0H@ M/'`@$$P.S,P+"`R,#$T+"!T M:&4@0V]M<&%N>2!H87,@;65T('1H90T*('!R97-CF5D#0H@86-C;W)D M:6YG;'DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($UA M>2`R,#$Q(&%N9"!*=6YE(#(P,3$L('!E&5C=71I=F4@;V9F:6-E$$P.S,P+`T*(#(P,30L('1H92!# M;VUP86YY(&AAF5D(&%C8V]R9&EN9VQY+CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B!$=7)I;F<@=&AE('1H$$P.S,P+"`R,#$T+"!T:&4-"B!# M;VUP86YY(&AA'!E;G-E(&9OF5D(&-O;7!E;G-A=&EO;@T*(&5X M<&5N$$P.S,P+"`R,#$T#0H@:7,@)#@N,"!M:6QL:6]N(&)AF5D(&ES#0H@,2XX('EE M87)S+CPO<#X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO'0^)SQD:78^#0H@/'`@&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@1&5F97)R960@:6YC;VUE('1A>&5S(&%R92!R M96-O9VYI>F5D(&9O"!L87=S(&%N9"!S=&%T=71O&%B M;&4@:6YC;VUE+B!686QU871I;VX@86QL;W=A;F-E2!T;R!R961U8V4@;F5T(&1E9F5R"!A6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E. M1$5.5#H@-"4G/@T*(%1H92!#;VUP86YY(')E9W5L87)L>2!A"!A2!E=F%L=6%T960@86QL(&%V86EL86)L92!P;W-I M=&EV92!A;F0@;F5G871I=F4@979I9&5N8V4L(&%N9`T*('=E:6=H=&5D('1H M92!E=FED96YC92!B87-E9"!O;B!I=',@;V)J96-T:79I='DN($5V:61E;F-E M('1H90T*($-O;7!A;GD@8V]N2!O9B!N970@;W!E&ES=&5N8V4L(&5X<&ER871I;VX@;V8@=F%R:6]U2!R M96QA=&EV92!T;R!T:&4@36%R:V5T:6YG(&%N9`T*($QA8F5L;&EN9R!);G9E M#(P,4,[3F]T92`Q,"X@0V]M;6ET;65N M=',@86YD#0H@0V]N=&EN9V5N8VEE#(P,30[3&ET:6=A=&EO;B8C>#(P M,40[*2!O9B!T:&4@0V]M<&%N>2!A;F0@=&AE#0H@0V]M<&%N>28C>#(P,3D[ M28C>#(P,3D['!A;G-I;VX@:6YT;R!N97<@;6%R:V5T28C>#(P,3D["!A$$P.S,P+"`R,#$T+B!4 M:&4@0V]M<&%N>2!W:6QL(&-O;G1I;G5E('1O(&%S6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5. M5#H@-"4G/@T*($%S(&]F(%-E<'1E;6)E$$P.S,P+"`R,#$T+"!T:&4@ M0V]M<&%N>2!H87,@86-C=6UU;&%T960@80T*(&QO;F`T*(&%S2!H M87,@;F5T(&QO;F"!B87-I2`R,#$T+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z M(#0E)SX-"B!4:&4@0V]M<&%N>2!I"!O9B!M=6QT M:7!L92!S=&%T92!A;F0@9F]R96EG;B!J=7)I0T*(&AA65A`T*(&-R961I="!C87)R>69O2!B92!U=&EL:7IE M9"!I;B!F=71U65A2!A;'-O(&)E('-U8FIE8W0@=&\@69O M3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D M.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O M'0O:'1M M;#L@8VAA6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4 M.B`T)2<^#0H@26X@2G5L>2`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E&ES=&EN9R!S<&%C92!I;B!!86-H96XL($=E28C>#(P,3D[#(P04,[("AE M=7)O*2`H87!P2!5+E,N("0T-"PP,#`@870-"B!397!T96UB M97(F(WA!,#LS,"P@,C`Q-"!E>&-H86YG92!R871E2`R,#$T+"!T:&4@ M0V]M<&%N>2!E;G1E&ES=&EN9R!S<&%C92!I;B!$86YV97)S M+"!-87-S86-H=7-E='1S#0H@=&AR;W5G:"!&96)R=6%R>28C>$$P.S(X+"`R M,#(Q+B!-;VYT:&QY(')E;G0@:7,@87,@9F]L;&]W6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\ M='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$=&]P('=I9'1H/3-$,R4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X- M"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y4:&4@8F%S92!R96YT(&9O M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X- M"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$=&]P('=I9'1H/3-$,R4@86QI9VX],T1L969T/B8C>#(P,C([/"]T M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y4:&4@8F%S92!R96YT M(&9O6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$ M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$=&]P('=I9'1H/3-$,R4@86QI9VX],T1L969T/B8C>#(P,C([ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y4:&4@8F%S92!R M96YT(&9O2`R,#$X('=I M;&P@8F4@)#6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T* M(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#,E(&%L:6=N/3-$;&5F M=#XF(W@R,#(R.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^ M5&AE(&)A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB M/CQI/DQI8V5N2!E M;G1E&5C=71I;VX@;V8@=&AE(&%G6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G M/@T*(#QB/CQI/DQI=&EG871I;VX\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*($9R;VT@=&EM92!T;R!T:6UE+"!T:&4@0V]M<&%N M>2!I2!E0T*(&5S M=&EM871E$$P.S(V+"`R,#$R+"!T:&4@0V]M<&%N>2!W87,@ M:6YF;W)M960@=&AA="!T:&4-"B!$97!A0T*(&-O;7!L:65D('=I M=&@@=&AE('-U8G!O96YA(&%N9"!H87,@$$P.S$S+"`R,#$S M+"!T:&4@0V]M<&%N>2!E;G1E28C>#(P,3D[2!A9W)E960@=&\@=&]L;"!T:&4@87!P;&EC86)L92!S=&%T=71E M2!H87,@8F5E;B!I;F-U2!H87,-"B!I;F-U'!E;G-E'!E8W1S('1O(&-O;G1I;G5E('1O(&EN8W5R(&%D M9&ET:6]N86P@97AP96YS97,@:6X@=&AE(&9U='5R92X\+W`^#0H@/'`@28C>$$P.S@L(#(P,3,L M('1H92!#;VUP86YY#0H@9FEL960@82!M;W1I;VX@=&\@9&ES;6ES28C>#(P,3D[2!F:6QE9"!T:&5I M28C>$$P.S@L(#(P,34N/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*($]N($9E8G)U87)Y)B-X03`[-"P@,C`Q M,RP@86X@86QL96=E9"!S=&]C:VAO;&1E0T*(&9I M;&5D(&$@9&5R:79A=&EV92!A8W1I;VX@=VET:"!T:&4@1&ES=')I8W0@0V]U M28C>#(P,3D[2!A;F0@ M:71S('-T;V-K:&]L9&5R28C>#(P,3D[6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`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`T*('1H92!A;&QO8V%T:6]N(&]F(')E28C>#(P,3D[2`V-B4@86YD(#28C M>#(P,3D[$$P.S,P+"`R M,#$T#0H@86YD($UA2X@ M5&AE(')E;6%I;FEN9R!A2!A;F0@:6YC;'5D92!G;V]D=VEL;"!A;F0@:6XM<')O8V5S M2P-"B!A M$$P.S,Q+"`R,#$T+B!);G1E'10 M87)T7S$T,3@T.#@W7V(X.61?-&0X8E\Y-F5A7S=B83$S960Q.68S-PT*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q-#$X-#@X-U]B.#ED7S1D.&)? M.39E85\W8F$Q,V5D,3EF,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#$X M<'0[($Q%5%1%4BU34$%#24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`P<'@[ M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&(^/&D^26XM M4')O8V5S#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE M=R!2;VUA;B<[($U!4D=)3BU43U`Z(#9P=#L@3$545$52+5-004-)3D'0M#(P,40[*0T*(&%S2!A<'!R;W9A;"!A;F0@:7,@86)L M92!T;R!C;VUM97)C:6%L:7IE('!R;V1U8W1S#0H@87-S;V-I871E9"!W:71H M('1H92!)4%(F86UP.T0@87-S971S+"!T:&5S92!A&-E6EN9R!V86QU92!O9B!T:&4@25!2)F%M<#M$(&%S'0^)SQD:78^#0H@/'`@ M'0M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5TA) M5$4M4U!!0T4Z(&YO2!C;VUP86YY+`T*(&]R M($5#4"P@9F]R("0Q,RXP(&UI;&QI;VX@:6X@8V%S:"P@=VET:"!A9&1I=&EO M;F%L('!O=&5N=&EA;`T*('!A>6UE;G1S('5P('1O(&$@;6%X:6UU;2!O9B`D M,34N,"!M:6QL:6]N(&)A6UE;G1S(&UA>2!B92!M M861E+"!A="!T:&4@0V]M<&%N>28C>#(P,3D[#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$P<'0@)U1I;65S M($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#$R<'0[($Q%5%1%4BU34$%#24Y' M.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`T)3L@+7=E8FMI="UT97AT+7-TFEN9R!S:6=N:69I8V%N=`T*('5N;V)S97)V86)L92!I;G!U=',@:6YC M;'5D:6YG('1H92!P2!O9B!A8VAI979I;F<@96%C:"!O9@T* M('1H92!P;W1E;G1I86P@;6EL97-T;VYE2X@5&AE(&9A:7(@ M=F%L=64@;V8@=&AE(&-O;G1I;F=E;G0-"B!C;VYS:61E28C M>#(P,3D[6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-E M;G0@06-C;W5N=&EN9R!06QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26X@36%Y(#(P,30L('1H92!&:6YA M;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A#(P,40[ M*2`R,#$T+3`Y+"`\:3Y2979E;G5E#0H@9G)O;2!#;VYT2!T;R!R96-O9VYI>F4-"B!R979E;G5E('=H96X@:70@=')A;G-F M97)S('!R;VUI&-H86YG92!F;W(@=&AO2!I;F-L=61E#0H@ M:61E;G1I9GEI;F<@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,@:6X@=&AE(&-O M;G1R86-T+"!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A"!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[ M,S`L(#(P,30@86YD(#(P,3,-"B!W97)E(&%S(&9O;&QO=W,@*&EN('1H;W5S M86YD$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.S,P M+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(L,3,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH-C8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=E:6=H=&5D(&%V97)A9V4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.2PR-C`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XT,"PR-38\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XS."PY-S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,#D\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP M+C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C`R/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E-I>"!-;VYT M:',@16YD960\8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(L,3,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M-C8T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%=E:6=H=&5D(&%V97)A9V4@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.2PR-C`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XT,"PR-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS."PY-S$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5F9F5C M="!O9B!D:6QU=&EV92!S96-U6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,#$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,BPP-CD\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS."PY-S$\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`S/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C`N,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@ M6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/&)R("\^#0H@06-Q=6ES M:71I;VX\8G(@+SX-"B!$871E($9A:7(\8G(@+SX-"B!686QU92`H:6X\8G(@ M+SX-"B!T:&]U6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(Q+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C<75I6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C4S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($QO;F6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($]T:&5R(&%S$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(R+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*(%1O=&%L(&QI86)I;&ET:65S(&%S6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0R-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\+V1I=CX\$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.S,P+#PO8CX\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L#(P,3D[$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L#(P,3D[$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E=F5N=64\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$P,"PW-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C@W+#`T,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0L-34W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C,R.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+#6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C0L,C$X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@T,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E M85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA M28C>#(P,3D[$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF5D/&)R("\^#0H@0V]S=#PO8CX\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF5D/&)R("\^#0H@1V%I;G,\+V(^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D=R;W-S/&)R("\^#0H@56YR M96%L:7IE9#QB$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUA6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%53(%1R96%S=7)Y('-E8W5R:71I97,\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ.2PT.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*(%-H;W)T+71E$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4X M+#0X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+#0Y.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CDT+#0V-3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XR,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CDT+#0U-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\ M=&0@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF5D/&)R("\^#0H@3&]S6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.S,Q+"`R,#$T.CPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C,Q+#0X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(T+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,2PW-SD\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XY-RPT-#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-RPT M,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@'0^)SQD M:78^#0H@/'`@28C>#(P,3D[$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,30@86QI9VX],T1C96YT97(^/&(^*&EN#0H@)#`P,"8C>#(P,3D[$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%T(%-E<'1E;6)E$$P M.S,P+"`R,#$T.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.2PT.#<\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-H;W)T+71E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C4L-SDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C4L-SDW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\ M=&0@8V]L6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.S,Q+"`R,#$T.CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT2!S96-U$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q+#0X-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(T+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(T+#$W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A M;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Q+##(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Q+#2!,979E;"`S($EN<'5T'0^)SQD:78^#0H@/'`@F5S('1H92!C:&%N9V4@ M:6X@9F%I$$P.S,P+"`R,#$T.CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XV+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(Q.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT2!T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-#(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XU+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0^)SQD:78^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D9A M:7(F(WA!,#M686QU928C>$$P.V%T/"]B/CQB$$P.S,P+"8C>$$P.S(P,30\+V(^/&)R("\^#0H@/&(^*"!I;B`D,#`P M)B-X,C`Q.3MS*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.TEN<'5T/"]B/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@$$P.T%V97)A9V4\8G(@+SX-"B`H6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`P<'0G/@T*(%!R;V)A8FEL:71Y('=E:6=H=&5D/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#%P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T* M(&EN8V]M92!A<'!R;V%C:#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L M:6=N/3-$8V5N=&5R/DUI;&5S=&]N92!D871E$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&-E;G1E3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF M,S<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y M9%\T9#AB7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)VUA M3I4:6UE$$P.SPO<#X-"B`\ M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ, M05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O M$$P.S,P+#QB$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V M(&%L:6=N/3-$8V5N=&5R/CQB/BAI;@T*("0P,#`F(W@R,#$Y.W,I/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!287<@;6%T97)I86QS(&%N9"!S=7!P M;&EE$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT M.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU+#$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XV+#(V,3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8W-3PO=&0^#0H@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(W,SPO=&0^#0H@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)V)O$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/"]T MF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4Z M.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$S+#0T-3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPY-#@\+W1D/@T* M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/"]TF4Z,7!X M.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B M.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%?-V)A,3-E9#$Y M9C,W+U=O'0O:'1M;#L@8VAA6EN9R!686QU92!O9B!' M;V]D=VEL;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78^ M#0H@/'`@"!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L M(#(P,30@:7,@87,@9F]L;&]W6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#DV-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT2!T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH,RPP.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,V+#@V-SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\+V1I=CX\6EN9R!V86QU92!O9B!T:&4@0V]M<&%N>28C>#(P,3D[$$P.S,P M+`T*(#(P,30@:7,@87,@9F]L;&]W6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-E<'1E;6)E$$P.S,P+#QB$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@Q+#,P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5N9&EN9R!B86QA;F-E M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)VUA3I4:6UE$$P.SPO<#X-"B`\=&%B;&4@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@86QI M9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB/E-E<'1E;6)E$$P M.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E M$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$ M)V)O$$P.SPO=&0^#0H@ M/"]TF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L#(P,3D[$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD M96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE M65E(&-O;7!E;G-A=&EO;CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XY+#`X,SPO=&0^#0H@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N M="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ+#$V,3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ+#4X-SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`P M,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0T-3PO M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-S4\ M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/=&AE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XX,#(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)V)O$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N M="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ,RPW-C(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M6QE/3-$9F]N="US M:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@ M28C>#(P,3D[$$P.S,P+"`R,#$T(&%N9"`R,#$S.CPO<#X-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%2 M1TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.TUO;G1H$$P.T5N9&5D/"]B/CQB$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L#(P,3D[$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L#(P M,3D[$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C,T-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4T,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M+#8R-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(X M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#$P,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$Q.3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XV+#,S,3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU+#`X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XT+#`R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#,Q-#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XV+#"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\$$P.S,P+"`R,#$T(&%N9"`R,#$S('=E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/E-I>"!-;VYT:',@16YD960\ M8G(@+SX-"B!397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L,38R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV+#$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-T;V-K(&]P=&EO;G,\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,C0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$L-#(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$L-3(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0L,#(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(L-SDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,S$T/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8L-S$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T2!O M9B!3=&]C:R!/<'1I;VX@06-T:79I='D\+W1D/@T*("`@("`@("`\=&0@8VQA M6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@ M5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!S=&]C:R!O<'1I M;VX@86-T:79I='D@9F]R('1H90T*('-I>"!M;VYT:',@96YD960@4V5P=&5M M8F5R)B-X03`[,S`L(#(P,30Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.RAY96%R$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/D%G9W)E9V%T93QB$$P.W1H;W5S86YD M$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]U='-T86YD:6YG(&%T M($%P$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C,L-#DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RXR-SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+CDR/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C,Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,BXR M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO&5R8VES960\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C(R/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ,2XT.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-3$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$T+C$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS."PR.#<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE&5R8VES86)L92!A="!397!T M96UB97(F(WA!,#LS,"P@,C`Q-#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XS+CDY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,U M+#DR.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($]P=&EO;G,@=F5S=&5D(&%N9"!E>'!E8W1E M9"!T;R!V97-T(&%T(%-E<'1E;6)E$$P.S,P+"`R,#$T/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XS+#4P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"XP M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N.3<\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E M;G1E$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$N-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$N,SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-C`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C`N.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'!E8W1E9"!O<'1I;VX@;&EF92`H>65A$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT+C(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N,3D\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0X M+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4P+C8\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0Y+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q M+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78^#0H@/'`@$$P.S,P+"`R,#$T.CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`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`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($=R86YT960\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV-C0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%9E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@T-C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(P+C0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3(Q/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR,RXQ,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($]U='-T86YD:6YG(&%T(%-E<'1E;6)E$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-#$X-#@X M-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%?-V)A,3-E M9#$Y9C,W+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO6]U=',@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`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`F7,@2D@;VYE+6AA;&8@;V8@=&AE('!R;V9I=',@96%R;F5D(&9R;VT@'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S('1O(&%C<75I'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`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`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#QS M<&%N/CPOF5D($QO'0^)SQS<&%N/CPOF5D($-O'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPOF5D($QO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!396-U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-#$X-#@X-U]B M.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%?-V)A,3-E9#$Y M9C,W+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO2!T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q-#$X M-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB7SDV96%?-V)A M,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA2`S,2P@,C`Q,SQB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA&EM=6T\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)S(P,C$\'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6%B;&5S(&%N9"!!8V-R=6%L'0^ M)SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ+#`P,#QS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A M;F1S+"!U;FQEF5D(%!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E M(%-E'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(%!E'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879AF5D M(%!E'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO65E(%-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(%!E M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(%!E'0^)SQS<&%N M/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2`H1&5T M86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD'0^)SQS<&%N/CPO&5R8VES960\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^ M)SQS<&%N/CPO&5R8VES86)L M92!A="!397!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R M8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,30\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)S0@>65A&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,30\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES86)L92!A="!397!T96UB97(@,S`L M(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA'!E8W1E9"!T;R!V97-T(&%T(%-E<'1E M;6)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Q-#$X-#@X-U]B.#ED7S1D.&)?.39E85\W8F$Q,V5D,3EF,S<-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,30Q.#0X.#=?8C@Y9%\T9#AB M7SDV96%?-V)A,3-E9#$Y9C,W+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2`S,2P@,C`Q-#QB6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES960@:6X@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D+"!&86ER(%9A;'5E($%S2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO7,\7,\7,\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2`H1&5T86EL*2`H4F5S=')I8W1E9"!3=&]C:R!A M;F0@4F5S=')I8W1E9"!3=&]C:R!5;FET'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO"!L:6%B:6QI='D\+W1D/@T* M("`@("`@("`\=&0@8VQAF%T:6]N('!E'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2`R,#$T M('1H2`R,#$X/&)R/E531"`H)"D\8G(^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB M#(P86,[*3QB'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@86=R965D(&%D9&ET:6]N86P@<&%Y;65N=',@ M=7!O;B!A8VAI979E;65N="!O9B!D979E;&]P;65N="!M:6QE'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6]U=',@<&%Y;65N=',\+W1D/@T*("`@("`@ M("`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htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

Payables and Accruals [Abstract]

Employee compensation $ 9,083 $ 11,967

Research and development 1,161 1,587

Professional, legal and accounting fees 1,021 1,304

Sales and income taxes 1,000 1,445

Warranty 775 794

Other 722 802

Accrued expenses $ 13,762 $ 17,899

X

- Definition

Accrued Research and Development Expense, Current

+ References

No definition available.

+ Details

Name: abmd_AccruedResearchAndDevelopmentExpenseCurrent

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_SalesAndExciseTaxPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability.

+ References

No definition available.

+ Details

Name: us-gaap_StandardProductWarrantyAccrualCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 27 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Acquisitions - Additional Information (Detail) (USD $)
0 Months Ended 3 Months Ended 6 Months Ended

Jul. 01, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 01, 2014

Business Acquisition [Line Items]

Payments to acquire businesses, cash paid $ 15,750,000

Expense for the change in fair value contingent consideration 219,000

Selling, general and administrative

Business Acquisition [Line Items]

Legal, consulting and other costs related to the acquisition included in consolidated statements of operations 1,100,000

ECP Entwicklungsgesellschaft mbH

Business Acquisition [Line Items]

Business acquisition, date of acquisition agreement Jul. 01, 2014

Payments to acquire businesses, cash paid 13,000,000

Potential payouts payments 15,000,000

Business combination, contingent consideration arrangements, descriptions With respect to such milestone payments, the share purchase agreement provides: • that, upon the earlier of (i) the Company’s receipt of European CE Marking approval relating to the sale of an expandable device based on certain patent rights acquired from ECP, or (ii) the Company bringing of a successful claim against a third party competitor (or reaching an economically equivalent settlement) for the infringement of certain patent rights acquired from ECP, it will pay Syscore an additional $7.0 million (provided that if such claim or settlement does not prohibit the third party competitor’s further marketing, production, sale, distribution, lease or use of any violating or infringing products, but only awards monetary damages to us or to Abiomed Europe, the amount payable to Syscore shall be limited to the lower of the amount of aggregate damages received and $7.0 million); and • that, upon the first to occur of (i) the Company’s successful commercialization of one or more rotatable and expandable devices based on certain patent rights acquired from ECP, where such devices achieve aggregate worldwide revenues of $125.0 million, including the revenues of third party licensees, or (ii) the Company’s sale of (A) ECP, (B) all or substantially all of ECP’s assets, or (C) certain of ECP’s patent rights, the Company will pay to Syscore the lesser of (y) one-half of the profits earned from such sale described in the foregoing item (ii), after accounting for the costs of acquiring and operating ECP, or (z) $15.0 million (less any previous milestone payment).

Expense due to infringement of certain patent rights acquired 7,000,000

Aggregate worldwide revenues, including revenues of third party licensees, targeted to be met for milestone payments 125,000,000

Revenues 0

Net loss 1,100,000

Expense for the change in fair value contingent consideration 200,000

AIS GmbH Aachen Innovative Solutions

Business Acquisition [Line Items]

Business acquisition, date of acquisition agreement Jun. 30, 2014

Payments to acquire businesses, cash paid $ 2,800,000

X

- Definition

Aggregate Contingent Milestone Payments to Be Paid

+ References

No definition available.

+ Details

Name: abmd_AggregateContingentMilestonePaymentsToBePaid

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Contingent Milestone Payments to Be Paid

+ References

No definition available.

+ Details

Name: abmd_ContingentMilestonePaymentsToBePaid

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Date when the business acquisition agreement was executed, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The net gains or losses recognized for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The revenues and gains recognized recorded for each transaction with the acquiree that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 28 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Income (Loss) Per Share - Additional Information (Detail)
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Stock Options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Shares excluded from the calculation of diluted weighted average shares outstanding 47,000 297,000 44,000 3,923,000

Restricted Stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Shares excluded from the calculation of diluted weighted average shares outstanding 465,000 354,000 465,000 1,198,000

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation Recognized (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation $ 4,024 $ 2,798 $ 8,314 $ 6,719

Cost of product revenue

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation 148 139 357 347

Research and development

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation 773 540 1,626 1,285

Selling, general and administrative

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation $ 3,103 $ 2,119 $ 6,331 $ 5,087

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 30 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of the Consideration Transferred (Detail) (USD $)
In Thousands, unless otherwise specified
0 Months Ended

Jul. 01, 2014

Business Acquisition [Line Items]

Cash consideration $ 15,750

Contingent consideration 6,000

Total consideration transferred $ 21,750

X

- Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 31 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Preliminary Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Jul. 01, 2014

Mar. 31, 2014

Acquired assets:

Cash and cash equivalents $ 53

Accounts receivable 25

Property and equipment 619

In-process research and development 18,500

Goodwill 36,867 1,964 37,990

Long-term deferred tax assets 813 874

Other assets acquired 141

Total assets acquired 22,176

Liabilities assumed:

Accounts payable 295

Accrued liabilities 131

Total liabilities assumed 426

Net assets acquired $ 21,750

X

- Definition

Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Accrued Liabilities

+ References

No definition available.

+ Details

Name: abmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of assets acquired at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities assumed at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of property, plant, and equipment recognized as of the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 32 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Income (Loss) Per Share
6 Months Ended

Sep. 30, 2014

Net Income (Loss) Per Share

Note 2. Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the Company’s employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company’s basic and diluted net income (loss) per share for the three and six months ended September 30, 2014 and 2013 were as follows (in thousands, except per share data):

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

Basic Net Income (Loss) Per Share


Net income (loss)
 $ 3,839 $ 1,059 $ 2,130 $ (664 )









Weighted average shares used in computing basic net income (loss) per share
 40,448 39,260 40,256 38,971









Net income (loss) per share - basic
 $ 0.09 $ 0.03 $ 0.05 $ (0.02 )









 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

Diluted Net Income (Loss) Per Share


Net income (loss)
 $ 3,839 $ 1,059 $ 2,130 $ (664 )









Weighted average shares used in computing basic net income (loss) per share
 40,448 39,260 40,256 38,971

Effect of dilutive securities
 1,791 2,077 1,813 —









Weighted average shares used in computing diluted net income (loss) per share
 42,239 41,337 42,069 38,971

Net income (loss) per share - diluted
 $ 0.09 $ 0.03 $ 0.05 $ (0.02 )









For the three months ended September 30, 2014, approximately 47,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 465,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share.

For the six months ended September 30, 2014, approximately 44,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 465,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share.

For the three months ended September 30, 2013, approximately 297,000 shares underlying stock options primarily related to out-of-the-money stock options and approximately 354,000 restricted shares primarily related to performance-based awards for which milestones have not been met, were not included in the computation of diluted earnings per share.

For the six months ended September 30, 2013, approximately 3,923,000 shares underlying stock options and approximately 1,198,000 restricted shares were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period.

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Pro Forma Consolidated Financial Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]

Revenue $ 51,938 $ 44,359 $ 100,761 $ 87,042

Income before income tax provision 4,557 329 2,770 (1,850)

Net income (loss) $ 4,218 $ (41) $ 2,260 $ (2,631)

X

- Definition

Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Income Taxes

+ References

No definition available.

+ Details

Name: abmd_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeIncomeTaxes

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 34 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

Goodwill Activity (Detail) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Sep. 30, 2014

Jul. 01, 2014

Goodwill [Line Items]

Beginning balance $ 37,990 $ 1,964

Additions 1,964

Foreign currency translation impact (3,087)

Ending balance $ 36,867 $ 1,964

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_GoodwillLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 35 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

Current assets:

Cash and cash equivalents $ 17,483 $ 20,916

Short-term marketable securities 77,981 55,663

Accounts receivable, net 23,072 24,357

Inventories 13,445 13,948

Prepaid expenses and other current assets 3,310 3,082

Total current assets 135,291 117,966

Long-term marketable securities 16,473 41,761

Property and equipment, net 7,351 6,889

Goodwill 36,867 37,990

In-Process Research and Development 17,198

Long-term deferred tax assets 813

Other assets 1,551 801

Total assets 215,544 205,407

Current liabilities:

Accounts payable 7,616 7,746

Accrued expenses 13,762 17,899

Deferred revenue 5,756 4,766

Total current liabilities 27,134 30,411

Other long-term liabilities 210 228

Contingent consideration 5,797

Long-term deferred tax liabilities 6,865 6,415

Total liabilities 40,006 37,054

Commitments and contingencies (Note 10)

Stockholders' equity:

Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none 0 0

Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 41,831,077 shares at September 30, 2014 and 41,122,695 shares at March 31, 2014; Outstanding - 40,577,134 shares at September 30, 2014 and 39,916,328 shares at March 31, 2014 417 411

Additional paid in capital 447,433 436,136

Accumulated deficit (248,780) (250,910)

Treasury stock at cost - 1,253,943 shares at September 30, 2014 and 1,206,367 shares at March 31, 2014 (17,567) (16,554)

Accumulated other comprehensive loss (5,965) (730)

Total stockholders' equity 175,538 168,353

Total liabilities and stockholders' equity $ 215,544 $ 205,407

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Available-for-Sale Securities

-URI http://asc.fasb.org/extlink&oid=6505594

+ Details

Name: us-gaap_AvailableForSaleSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 36 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8

Components of Stock-Based Compensation (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation $ 4,024 $ 2,798 $ 8,314 $ 6,719

Restricted stock units and awards

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation 3,334 2,162 6,754 5,098

Stock Options

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation 624 598 1,423 1,523

Employee Stock Purchase Plan

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation $ 66 $ 38 $ 137 $ 98

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 37 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Operating activities:

Net income (loss) $ 2,130 $ (664)

Adjustments required to reconcile net income (loss) to net cash provided by operating activities:

Depreciation and amortization 1,196 1,322

Bad debt expense 27 15

Stock-based compensation 8,314 6,719

Write-down of inventory 559 537

Deferred tax provision 450 453

Change in fair value of contingent consideration 219

Changes in assets and liabilities:

Accounts receivable 1,108 1,912

Inventories (653) (876)

Prepaid expenses and other assets (139) (762)

Accounts payable (581) (1,494)

Accrued expenses and other long-term liabilities (3,732) (1,978)

Deferred revenue 1,004 (62)

Net cash provided by operating activities 9,902 5,122

Investing activities:

Purchases of marketable securities (44,920) (33,849)

Proceeds from the sale and maturity of marketable securities 47,890 25,750

Acquisition of ECP and AIS, net of cash assumed (15,697)

Purchase of other investment (750) (750)

Purchases of property and equipment (1,496) (1,236)

Net cash used for investing activities (14,973) (10,085)

Financing activities:

Proceeds from the exercise of stock options 2,560 5,318

Payments in lieu of issuance of common stock for minimum payroll taxes (1,013) (426)

Proceeds from the issuance of stock under employee stock purchase plan 397 312

Net cash provided by financing activities 1,944 5,204

Effect of exchange rate changes on cash (306) 428

Net (decrease) increase in cash and cash equivalents (3,433) 669

Cash and cash equivalents at beginning of period 20,916 9,451

Cash and cash equivalents at end of period 17,483 10,120

Supplemental disclosure of cash flow information:

Cash paid for income taxes 299 870

Supplemental disclosure of non-cash investing and financing activities:

Contingent consideration related to acquisition of ECP 6,000

Fixed asset expenditures incurred, not yet paid $ 577 $ 92

X

- Definition

Noncash or Part Noncash Acquisition Acquisition Related Contingent Consideration

+ References

No definition available.

+ Details

Name: abmd_NoncashOrPartNoncashAcquisitionAcquisitionRelatedContingentConsideration

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Future cash outflow to pay for purchases of fixed assets that have occurred.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with other investments held by the entity for investment purposes not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireOtherInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) (Contingent Consideration, ECP Entwicklungsgesellschaft mbH, Level 3, USD $)
In Thousands, unless otherwise specified
6 Months Ended

Sep. 30, 2014

Contingent Consideration | ECP Entwicklungsgesellschaft mbH | Level 3

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Additions $ 6,000

Payments

Change in fair value 219

Foreign currency translation impact (422)

Ending balance $ 5,797

X

- Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) recognized in other comprehensive income (loss) for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories (Tables)
6 Months Ended

Sep. 30, 2014

Components of Inventories

The components of inventories are as follows:

 September 30,
2014 March 31,
2014

 (in $000’s)

Raw materials and supplies
 $ 6,052 $ 6,414

Work-in-progress
 5,718 6,261

Finished goods
 1,675 1,273





 $ 13,445 $ 13,948





X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities and Fair Value Measurements - Additional Information (Detail) (USD $)
6 Months Ended

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Other Investments

Mar. 31, 2014

Other Investments

May 31, 2013

Equity Securities

May 31, 2013

Equity Securities

Additional Investment commitment

Sep. 30, 2014

Equity Securities

Additional Investment payment

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Change in fair value of the contingent consideration $ 219,000

Cost method investment, fair value 800,000 700,000 700,000

Aggregate carrying amount of other investment $ 1,551,000 $ 801,000 $ 1,500,000 $ 800,000

X

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value portion of investments accounted under the cost method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=29638263&loc=d3e39828-111592

+ Details

Name: us-gaap_CostMethodInvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 41 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Tables)
6 Months Ended

Sep. 30, 2014

Accrued Expenses

Accrued expenses consist of the following:

 September 30, March 31,

 2014 2014

 (in $000’s)

Employee compensation
 $ 9,083 $ 11,967

Research and development
 1,161 1,587

Professional, legal and accounting fees
 1,021 1,304

Sales and income taxes
 1,000 1,445

Warranty
 775 794

Other
 722 802





 $ 13,762 $ 17,899





X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Basis of Preparation
6 Months Ended

Sep. 30, 2014

Nature of Business and Basis of Preparation

Note 1. Nature of Business and Basis of Preparation

Abiomed, Inc. (the “Company” or “Abiomed”), is a leading provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the Securities and Exchange Commission, or SEC.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year or any other subsequent period.

There have been no changes in the Company’s significant accounting policies for the three and six months ended September 30, 2014 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014 that has been filed with the SEC, except for as noted below.

In-Process Research and Development

In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that the Company acquires, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when the Company has regulatory approval and is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.

Contingent Consideration

As discussed in Note 3. “Acquisitions,” on July 1, 2014, the Company acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock.

Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the various milestones. The material factors that may impact the fair value of the contingent consideration, and therefore this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration, and the associated liability at each reporting date, will be updated by reflecting the changes in fair value reflected in the Company’s statement of operations.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

X

- Definition

The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Sep. 30, 2014

Mar. 31, 2014

Class B Preferred Stock, par value $ 0.01 $ 0.01

Class B Preferred Stock, Authorized 1,000,000 1,000,000

Class B Preferred Stock, Issued 0 0

Class B Preferred Stock, outstanding 0 0

Common stock, par value $ 0.01 $ 0.01

Common stock, Authorized 100,000,000 100,000,000

Common stock, Issued 41,831,077 41,122,695

Common stock, Outstanding 40,577,134 39,916,328

Treasury stock, shares 1,253,943 1,206,367

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 45 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Segment and Enterprise Wide Disclosures
6 Months Ended

Sep. 30, 2014

Segment and Enterprise Wide Disclosures

Note 11. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 66% and 74% of the Company’s total consolidated assets are located within the U.S. as of September 30, 2014 and March 31, 2014, respectively. The remaining assets are located primarily in Germany and include goodwill and in-process research and development of $54.1 million and $35.4 million at September 30, 2014 and March 31, 2014, respectively, associated with the Impella acquisition in May 2005 and ECP acquisition in July 2014. Total assets outside of the U.S. excluding goodwill and in-process research and development amounted to 9% of total consolidated assets as of September 30, 2014 and March 31, 2014. International sales (primarily in Europe) accounted for 11% of total revenue for each of the three and six months ended September 30, 2014 and 7% and 8% of total revenue for the three and six months ended September 30, 2013, respectively.

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Sep. 30, 2014

Oct. 31, 2014

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Trading Symbol ABMD

Entity Registrant Name ABIOMED INC

Entity Central Index Key 0000815094

Current Fiscal Year End Date --03-31

Entity Filer Category Large Accelerated Filer

Entity Common Stock, Shares Outstanding 40,894,675

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 47 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Basis of Preparation (Policies)
6 Months Ended

Sep. 30, 2014

In-Process Research and Development

In-Process Research and Development

In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that the Company acquires, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when the Company has regulatory approval and is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.

Contingent Consideration

Contingent Consideration

As discussed in Note 3. “Acquisitions,” on July 1, 2014, the Company acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock.

Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the various milestones. The material factors that may impact the fair value of the contingent consideration, and therefore this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration, and the associated liability at each reporting date, will be updated by reflecting the changes in fair value reflected in the Company’s statement of operations.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

X

- Definition

Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 05

-Paragraph 4

-Subparagraph (a)-(d)

-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457

+ Details

Name: us-gaap_BusinessCombinationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.15)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 15

-Article 5

+ Details

Name: us-gaap_InProcessResearchAndDevelopmentPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Revenue:

Product revenue $ 51,774 $ 44,288 $ 100,434 $ 86,897

Funded research and development 164 57 315 118

Total Revenue 51,938 44,345 100,749 87,015

Costs and expenses:

Cost of product revenue 9,612 9,027 19,301 17,750

Research and development 8,693 7,721 17,755 15,008

Selling, general and administrative 29,455 26,199 61,053 54,166

Costs and Expenses, Total 47,760 42,947 98,109 86,924

Income from operations 4,178 1,398 2,640 91

Other income (loss):

Investment income, net 36 25 80 41

Other (loss) income, net (39) 6 (28) (15)

Nonoperating Income (Expense), Total (3) 31 52 26

Income before income tax provision 4,175 1,429 2,692 117

Income tax provision 336 370 562 781

Net income (loss) $ 3,839 $ 1,059 $ 2,130 $ (664)

Basic net income (loss) per share $ 0.09 $ 0.03 $ 0.05 $ (0.02)

Basic weighted average shares outstanding 40,448 39,260 40,256 38,971

Diluted net income (loss) per share $ 0.09 $ 0.03 $ 0.05 $ (0.02)

Diluted weighted average shares outstanding 42,239 41,337 42,069 38,971

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(a),(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 49 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Goodwill and In-Process Research and Development
6 Months Ended

Sep. 30, 2014

Goodwill and In-Process Research and Development

Note 6. Goodwill and In-Process Research and Development

Goodwill

Goodwill has been recorded in connection with the Company’s acquisitions of Impella Cardiosystems AG, or Impella, in 2005 and ECP and AIS in July 2014, as discussed in Note 3. “Acquisitions.” The carrying value of goodwill and the change in the balance for the six months ended September 30, 2014 is as follows:

 September 30,

 2014

 (in $000’s)

Beginning balance
 $ 37,990

Additions
 1,964

Foreign currency translation impact
 (3,087 )



Ending balance
 $ 36,867



The Company has no accumulated impairment losses on goodwill.

In-Process Research and Development

As described in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP and AIS and recorded $18.5 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows from the expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses and taking into account the stage of development of the technology at the acquisition date, the time and resources needed to complete development. The Company used a discount rate of 22.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2014 is as follows:

 September 30,
2014

 (in $000’s)

Beginning balance
 $ —

Additions
 18,500

Foreign currency translation impact
 (1,302 )



Ending balance
 $ 17,198



X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories
6 Months Ended

Sep. 30, 2014

Inventories

Note 5. Inventories

The components of inventories are as follows:

 September 30,
2014 March 31,
2014

 (in $000’s)

Raw materials and supplies
 $ 6,052 $ 6,414

Work-in-progress
 5,718 6,261

Finished goods
 1,675 1,273





 $ 13,445 $ 13,948





The Company’s inventories relate to its circulatory care product lines, primarily the Impella and AB5000 product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During the six months ended September 30, 2014 and 2013, the Company recorded $0.6 million and $0.5 million, respectively, in write-downs of inventory.

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Goodwill and In-Process Research and Development (Tables)
6 Months Ended

Sep. 30, 2014

Carrying Value of Goodwill

The carrying value of goodwill and the change in the balance for the six months ended September 30, 2014 is as follows:

 September 30,

 2014

 (in $000’s)

Beginning balance
 $ 37,990

Additions
 1,964

Foreign currency translation impact
 (3,087 )



Ending balance
 $ 36,867



Carrying value of In-Process Research and Development

The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2014 is as follows:

 September 30,
2014

 (in $000’s)

Beginning balance
 $ —

Additions
 18,500

Foreign currency translation impact
 (1,302 )



Ending balance
 $ 17,198



X

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b),(d)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Income (Loss) Per Share (Tables)
6 Months Ended

Sep. 30, 2014

Computation of Basic and Diluted Net Income (Loss) Per Share

The Company’s basic and diluted net income (loss) per share for the three and six months ended September 30, 2014 and 2013 were as follows (in thousands, except per share data):

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

Basic Net Income (Loss) Per Share


Net income (loss)
 $ 3,839 $ 1,059 $ 2,130 $ (664 )









Weighted average shares used in computing basic net income (loss) per share
 40,448 39,260 40,256 38,971









Net income (loss) per share - basic
 $ 0.09 $ 0.03 $ 0.05 $ (0.02 )









 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

Diluted Net Income (Loss) Per Share


Net income (loss)
 $ 3,839 $ 1,059 $ 2,130 $ (664 )









Weighted average shares used in computing basic net income (loss) per share
 40,448 39,260 40,256 38,971

Effect of dilutive securities
 1,791 2,077 1,813 —









Weighted average shares used in computing diluted net income (loss) per share
 42,239 41,337 42,069 38,971

Net income (loss) per share - diluted
 $ 0.09 $ 0.03 $ 0.05 $ (0.02 )









X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes
6 Months Ended

Sep. 30, 2014

Income Taxes

Note 9. Income Taxes

Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each fiscal year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized.

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses incurred for most of its existence, expiration of various federal and state attributes, the uncertainty relative to the Marketing and Labelling Investigation and the FCA Investigation (each as defined below in “Note 10. Commitments and Contingencies—Litigation”) of the Company and the Company’s Pre-Market Approval, or PMA, application with the U.S. Food and Drug Administration, or FDA, for its Impella products, the Company’s expansion into new markets, such as Japan, the government reimbursement environment for the Company’s products, the Company’s profitability for recent years and uncertainties around the Company’s future profitability. Based on the review of all available evidence, the Company determined that the objectively verifiable negative evidence outweighed the positive evidence and it recorded a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of September 30, 2014. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on its results of operations.

As of September 30, 2014, the Company has accumulated a long-term deferred tax liability of $6.9 million as the result of a difference in accounting for the Company’s goodwill associated with its Impella acquisition that was completed in May 2005, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net long-term deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period. As of September 30, 2014, the Company has net long-term deferred tax assets of $0.8 million relating to differences between the book and tax basis of assets and liabilities associated with the ECP acquisition completed in July 2014.

The Company is subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. Because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized.

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses
6 Months Ended

Sep. 30, 2014

Accrued Expenses

Note 7. Accrued Expenses

Accrued expenses consist of the following:

 September 30, March 31,

 2014 2014

 (in $000’s)

Employee compensation
 $ 9,083 $ 11,967

Research and development
 1,161 1,587

Professional, legal and accounting fees
 1,021 1,304

Sales and income taxes
 1,000 1,445

Warranty
 775 794

Other
 722 802





 $ 13,762 $ 17,899





Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at September 30, 2014 and March 31, 2014.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation
6 Months Ended

Sep. 30, 2014

Stock-Based Compensation

Note 8. Stock-Based Compensation

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three and six months ended September 30, 2014 and 2013:

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

 (in $000’s) (in $000’s)

Cost of product revenue
 $ 148 $ 139 $ 357 $ 347

Research and development
 773 540 1,626 1,285

Selling, general and administrative
 3,103 2,119 6,331 5,087









 $ 4,024 $ 2,798 $ 8,314 $ 6,719









The components of stock-based compensation for the three and six months ended September 30, 2014 and 2013 were as follows:

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

 (in $000’s) (in $000’s)

Restricted stock units and awards
 $ 3,334 $ 2,162 $ 6,754 $ 5,098

Stock options
 624 598 1,423 1,523

Employee stock purchase plan
 66 38 137 98









 $ 4,024 $ 2,798 $ 8,314 $ 6,719









Stock Options

The following table summarizes the stock option activity for the six months ended September 30, 2014:

 Shares
Underlying
Options
(in thousands) Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Term (years) Aggregate
Intrinsic
Value
(in thousands)

Outstanding at April 1, 2014
 3,492 $ 13.27 4.92

Granted
 313 22.26

Exercised
 (222 ) 11.49

Cancelled and expired
 (5 ) 15.66





Outstanding at September 30, 2014
 3,578 $ 14.16 5.04 $ 38,287





Exercisable at September 30, 2014
 2,787 $ 11.94 3.99 $ 35,928





Options vested and expected to vest at September 30, 2014
 3,502 $ 14.00 4.97 $ 38,013





The aggregate intrinsic value of options exercised was $3.0 million for the six months ended September 30, 2014. The total fair value of options vested during the six months ended September 30, 2014 was $1.7 million.

The remaining unrecognized stock-based compensation expense for unvested stock option awards at September 30, 2014 was approximately $5.7 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.5 years.

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The weighted average grant-date fair value for options granted during the six months ended September 30, 2014 and 2013 was $9.05 and $9.67 per share, respectively.

The fair value of options granted during the three and six months ended September 30, 2014 and 2013 were calculated using the following weighted average assumptions:

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

Risk-free interest rate
 1.75 % 1.39 % 1.60 % 0.85 %

Expected option life (years)
 4.19 4.23 4.19 4.26

Expected volatility
 48.7 % 50.6 % 49.3 % 51.9 %

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock and adjustments for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise experience and estimates of future exercises of unexercised options. An expected dividend yield of zero is used in the option valuation model because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future. The Company estimates forfeitures based on an analysis of actual historical forfeitures, adjusted to reflect that historical forfeitures may not be indicative of forfeitures in the future.

Restricted Stock and Restricted Stock Units

In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the six months ended September 30, 2014:

 Number of
Shares
(in thousands) Weighted
Average
Grant Date
Fair Value
(per share)

Outstanding at April 1, 2014
 1,174 $ 21.37

Granted
 664 21.88

Vested
 (465 ) 20.48

Forfeited
 (121 ) 23.10



Outstanding at September 30, 2014
 1,252 $ 21.80



The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of September 30, 2014 was $17.0 million and the weighted-average period over which this cost will be recognized is 2.0 years.

The weighted average grant-date fair value for restricted stock and restricted stock units granted during the six months ended September 30, 2014 and 2013 was $21.88 and $23.18 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the six months ended September 30, 2014 and 2013 was $9.5 million and $6.0 million, respectively.

Performance Based Awards

Included in the restricted stock and restricted stock units activity discussed above are certain awards that vest subject to certain performance-based criteria.

In May 2014, performance-based awards of restricted stock units for the potential issuance of 379,752 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company is recognizing compensation expense based on the probable outcome related to the prescribed performance milestones on the outstanding awards.

In May 2013, performance-based awards of restricted stock units for the potential issuance of 268,988 shares of common stock were issued to certain executive officers and employees, all of which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed performance milestones for these awards such that 154,991 shares of common stock will vest subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.

In May 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees of the Company, all of which will vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed performance milestones for these awards. These awards are still subject to service requirements for vesting for these employees and the compensation expense is being recognized accordingly.

In May 2011 and June 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, which vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of September 30, 2014, the Company has met the prescribed milestones for 234,000 shares underlying these awards and recorded all related stock compensation expense. In March 2014, the Company modified the performance condition on the remaining 50,000 restricted stock units. As of September 30, 2014, the Company believes that it is probable that the prescribed performance milestones will be met on these restricted stock units and the compensation expense is being recognized accordingly.

During the three and six months ended September 30, 2014, the Company has recorded $2.1 million and $3.7 million, respectively, in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at September 30, 2014 is $8.0 million based on the Company’s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 1.8 years.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
6 Months Ended

Sep. 30, 2014

Commitments and Contingencies

Note 10. Commitments and Contingencies

Commitments

In July 2013, the Company entered into a lease agreement to continue renting its existing space in Aachen, Germany through July 31, 2023. The building serves as the Company’s European headquarters and houses most of the manufacturing operations for its Impella product line. The lease payments are approximately 34,500€ (euro) (approximately U.S. $44,000 at September 30, 2014 exchange rates) per month.

In February 2014, the Company entered into a lease agreement to continue renting its existing space in Danvers, Massachusetts through February 28, 2021. Monthly rent is as follows:

• The base rent for March 2014 through April 2014 was $66,000 per month; and

• The base rent for May 2014 through February 2016 is $74,050 per month; and

• The base rent for March 2016 through February 2018 will be $70,750 per month; and

• The base rent for March 2018 through February 2021 will be $72,750 per month.

License Agreement

In April 2014, the Company entered into an exclusive license agreement with Opsens, Inc. for the rights to certain optical sensor technologies in the field of cardio-circulatory assist devices. The Company made a $1.5 million upfront payment upon execution of the agreement and agreed to make additional payments of up to $4.5 million upon the achievement of certain development milestones.

Contingent Consideration

As discussed in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP using a combination of cash and potential post-acquisition milestone payments. These milestone payments may be payable at some time over the next 20 years, depending on the achievement of certain technical, regulatory and commercial milestones. The maximum amount of the aggregate milestone payments could be $15.0 million. As of September 30, 2014, the fair value of the contingent consideration was $5.8 million.

Litigation

From time to time, the Company is involved in legal and administrative proceedings and claims of various types. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.

On October 26, 2012, the Company was informed that the Department of Justice, United States Attorney’s Office for the District of Columbia was conducting an investigation (the “Marketing and Labelling Investigation”) focused on the Company’s marketing and labeling of the Impella 2.5. On October 31, 2012, the Company accepted service of a subpoena related to this investigation seeking documents related to the Impella 2.5. The Company believes that is has substantially complied with the subpoena and has submitted the requested documents to the United States Attorney’s Office. On September 13, 2013, the Company entered into a tolling agreement with the United States Attorney’s Office, pursuant to which the Company and the United States Attorney’s Office mutually agreed to toll the applicable statutes of limitations for all criminal, civil and administrative offenses and violations that could be charged or claimed against the Company as of that date until June 2, 2014. On May 27, 2014, the Company executed an extension of the tolling agreement through February 2, 2015. The investigation is ongoing, however, and the Company is unable to predict the ultimate outcome or determine whether a liability has been incurred or make an estimate of the reasonably possible liability, if any, that could result from any unfavorable outcome associated with this investigation. The Company has incurred significant expenses related to this investigation and expects to continue to incur additional expenses in the future.

On November 16 and 19, 2012, two purported class action complaints were filed against the Company and certain of its officers in the U.S. District Court for the District of Massachusetts, or the District Court, by alleged purchasers of its common stock, on behalf of themselves and persons or entities that purchased or acquired common stock of the Company between August 5, 2011 and October 31, 2012. The complaints alleged that the defendants violated the federal securities laws in connection with disclosures related to the Company’s marketing and labeling of the Impella 2.5 product and seek damages in an unspecified amount. The District Court consolidated these complaints and a consolidated amended complaint was filed by the plaintiffs on May 20, 2013. On July 8, 2013, the Company filed a motion to dismiss the consolidated class action. Oral arguments on the Company’s motion to dismiss were conducted before the District Court on September 18, 2013. On April 10, 2014, the District Court entered an order granting the Company’s motion and dismissed the consolidated and amended complaint. On May 9, 2014, the plaintiffs filed a notice of appeal, and subsequently filed their appellate brief with the U.S. Court of Appeals for the First Circuit, or the First Circuit, on July 16, 2014. The appeal process remains ongoing with oral arguments scheduled for January 8, 2015.

On February 4, 2013, an alleged stockholder of the Company filed a derivative action with the District Court on the Company’s behalf against each of the Company’s directors. The complaint alleged that the directors breached their fiduciary duties to the Company and its stockholders in connection with disclosures related to the Company’s marketing and labeling of its Impella 2.5 product and sought damages in an unspecified amount. On March 22, 2013, the Company filed a motion to dismiss the derivative action. On June 21, 2013, the District Court granted the Company’s motion to dismiss. The plaintiff appealed the dismissal to the First Circuit. The First Circuit affirmed the District Court’s Order of Dismissal in a written opinion issued on June 10, 2014.

On April 25, 2014, the Company received a subpoena from the Boston regional office of the United States Department of Health and Human Services, or HHS, Office of Inspector General requesting materials relevant to the Company’s reimbursement of expenses and remuneration to healthcare providers for a six month period from July 2012 through December 2012 in connection with a civil investigation under the False Claims Act (the “FCA Investigation” and, together with the Marketing and Labelling Investigation, the “DOJ Investigations”). The Company submitted the requested documents to HHS and believes that it substantially complied with the subpoena. On November 6, 2014, the Company received notice from the Department of Justice, United States Attorney’s Office for the District of Massachusetts in the form of a Civil Investigative Demand (“CID”) requesting additional document production relating to this matter for the time period of January 1, 2012 through December 31, 2013. The Company intends to respond to the CID and cooperate with the U.S. Attorney’s Office in connection with the FCA investigation.

The Company is unable to estimate a potential liability with respect to the DOJ Investigations and the appeal of the dismissal of the purported class action claim. There are numerous factors that make it difficult to meaningfully estimate possible loss or range of loss at this stage of these investigations and lawsuits, including that: the proceedings are in relatively early stages, there are significant factual and legal issues to be resolved and information obtained or rulings made during any lawsuits or investigations could affect the methodology for calculation. In addition, with respect to claims for which damages are the requested relief, no amount of loss or damages has been specified. Therefore, the Company is unable at this time to estimate its possible losses and accordingly, no adjustment has been made to the financial statements to reflect the outcome of these uncertainties.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Financial Instruments Recorded at Fair Value (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration $ 5,797

US Treasury Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 19,487 31,487

US Government-sponsored Enterprises Debt Securities | Short-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 58,494 24,176

US Government-sponsored Enterprises Debt Securities | Long-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 16,473 41,761

Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 94,454 97,424

Level 2 | US Treasury Securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 19,487 31,487

Level 2 | US Government-sponsored Enterprises Debt Securities | Short-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 58,494 24,176

Level 2 | US Government-sponsored Enterprises Debt Securities | Long-term Investments

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Available-for-sale securities, fair value disclosure 16,473 41,761

Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration $ 5,797

X

- Definition

Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28360136&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies - Additional Information (Detail)
0 Months Ended 1 Months Ended

Sep. 30, 2014

USD ($)

Apr. 30, 2014

USD ($)

Sep. 30, 2014

For March 2014 through April 2014

USD ($)

Sep. 30, 2014

For May 2014 through February 2016

USD ($)

Sep. 30, 2014

For March 2016 through February 2018

USD ($)

Sep. 30, 2014

For March 2018 through February 2021

USD ($)

Jul. 01, 2014

ECP Entwicklungsgesellschaft mbH

Sep. 30, 2014

ECP Entwicklungsgesellschaft mbH

USD ($)

Jul. 01, 2014

ECP Entwicklungsgesellschaft mbH

USD ($)

Jul. 31, 2013

Europe

Lease Agreements

Sep. 30, 2014

Europe

Lease Agreements

USD ($)

Sep. 30, 2014

Europe

Lease Agreements

EUR (€)

Commitments and Contingencies [Line Items]

Facilities leases, base rent per month $ 66,000 $ 74,050 $ 70,750 $ 72,750 $ 44,000 € 34,500

Lease, expiration date Jul. 31, 2023

License agreement, upfront payment 1,500,000

License agreement, maximum agreed additional payments upon achievement of development milestones 4,500,000

Potential payouts payments 15,000,000

Period of milestone payment 20 years

Fair value of contingent consideration $ 5,797,000 $ 5,800,000

X

- Definition

Achievement of Certain Performance Milestones Period

+ References

No definition available.

+ Details

Name: abmd_AchievementOfCertainPerformanceMilestonesPeriod

Namespace Prefix: abmd_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional License Fees, Upon Achievement of Certain Milestones

+ References

No definition available.

+ Details

Name: abmd_AdditionalLicenseFeesUponAchievementOfCertainMilestones

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: abmd_CommitmentsAndContingenciesLineItems

Namespace Prefix: abmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Lease Agreement Monthly payment

+ References

No definition available.

+ Details

Name: abmd_LeaseAgreementMonthlyPayment

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Up Front Licensing Fee Paid

+ References

No definition available.

+ Details

Name: abmd_UpFrontLicensingFeePaid

Namespace Prefix: abmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Date which lease or group of leases is set to expire, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

XML 59 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities and Fair Value Measurements (Tables)
6 Months Ended

Sep. 30, 2014

Marketable Securities

The Company’s marketable securities at September 30, 2014 and March 31, 2014 are invested in the following:

 Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Market
Value

 (in $000’s)

At September 30, 2014:


US Treasury securities
 $ 19,487 $ — $ — $ 19,487

Short-term government-backed securities
 58,480 17 (3 ) 58,494

Long-term government-backed securities
 16,498 3 (28 ) 16,473







 $ 94,465 $ 20 $ (31 ) $ 94,454







 Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Market
Value

 (in $000’s)

At March 31, 2014:


US Treasury securities
 $ 31,487 $ — $ — $ 31,487

Short-term government-backed securities
 24,174 6 (4 ) 24,176

Long-term government-backed securities
 41,779 8 (26 ) 41,761







 $ 97,440 $ 14 $ (30 ) $ 97,424







Financial Instruments Recorded at Fair Value

The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:

 Level 1 Level 2 Level 3 Fair Value

 (in $000’s)

At September 30, 2014:


Assets


U.S. Treasury securities
 $ — $ 19,487 $ — $ 19,487

Short-term government-backed securities
 — 58,494 — 58,494

Long-term government-backed securities
 — 16,473 — 16,473

Liabilities


Contingent consideration
 — — 5,797 5,797

 Level 1 Level 2 Level 3 Fair Value

 (in $000’s)

At March 31, 2014:


U.S. Treasury securities
 $ — $ 31,487 $ — $ 31,487

Short-term government-backed securities
 — 24,176 — 24,176

Long-term government-backed securities
 — 41,761 — 41,761

Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs

The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended September 30, 2014:

 September 30,

 2014

 (in $000’s)

Beginning balance
 $ —

Additions
 6,000

Payments
 —

Change in fair value
 219

Foreign currency translation impact
 (422 )



Ending balance
 $ 5,797



Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2014:

 Fair Value at
September 30, 2014
( in $000’s)
Significant Unobservable Input
 Weighted Average
(range, if
applicable)

Contingent consideration
 $ 5,797
Probability weighted

income approach
 Milestone dates 2018 to 2021

 Discount rate Probability of occurrence 8% to 12%
0% to 100%

X

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Basis of Preparation - Additional Information (Detail) (USD $)
0 Months Ended

Jul. 01, 2014

Business And Basis Of Presentation [Line Items]

Payments to acquire businesses, cash paid $ 15,750,000

ECP Entwicklungsgesellschaft mbH

Business And Basis Of Presentation [Line Items]

Payments to acquire businesses, cash paid 13,000,000

ECP Entwicklungsgesellschaft mbH | Maximum

Business And Basis Of Presentation [Line Items]

Potential payouts payments $ 15,000,000

X

- Details

Name: abmd_BusinessAndBasisOfPresentationLineItems

Namespace Prefix: abmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 61 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Restricted Stock and Restricted Stock Units Activity (Detail) (Restricted Stock and Restricted Stock Units, USD $)
6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Restricted Stock and Restricted Stock Units

Number of Shares

Beginning Balance 1,174,000

Granted 664,000

Vested (465,000)

Forfeited (121,000)

Ending Balance 1,252,000

Weighted Average Grant Date Fair Value

Beginning Balance $ 21.37

Granted $ 21.88 $ 23.18

Vested $ 20.48

Forfeited $ 23.10

Ending Balance $ 21.80

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 62 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

Goodwill and In-Process Research and Development - Additional Information (Detail) (USD $)
1 Months Ended

Jul. 31, 2014

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Line Items]

Accumulated impairment loss, goodwill $ 0

In-Process Research and Development $ 18,500,000 $ 17,198,000

Fair value inputs, discount rate 22.50%

X

- Details

Name: abmd_GoodwillAndIntangibleAssetsDisclosureLineItems

Namespace Prefix: abmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a,h)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 63 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Net income (loss) $ 3,839 $ 1,059 $ 2,130 $ (664)

Other comprehensive (loss) income:

Foreign currency translation (losses) gains (4,804) 1,795 (5,240) 2,321

Net unrealized (losses) gains on marketable securities (22) 31 5 10

Other comprehensive (loss) income (4,826) 1,826 (5,235) 2,331

Comprehensive (loss) income $ (987) $ 2,885 $ (3,105) $ 1,667

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Marketable Securities and Fair Value Measurements
6 Months Ended

Sep. 30, 2014

Marketable Securities and Fair Value Measurements

Note 4. Marketable Securities and Fair Value Measurements

Marketable Securities

The Company’s marketable securities are classified as available-for-sale securities and, accordingly, are recorded at fair value. The difference between amortized cost and fair value is included in stockholders’ equity.

The Company’s marketable securities at September 30, 2014 and March 31, 2014 are invested in the following:

 Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Market
Value

 (in $000’s)

At September 30, 2014:


US Treasury securities
 $ 19,487 $ — $ — $ 19,487

Short-term government-backed securities
 58,480 17 (3 ) 58,494

Long-term government-backed securities
 16,498 3 (28 ) 16,473







 $ 94,465 $ 20 $ (31 ) $ 94,454







 Amortized
Cost Gross
Unrealized
Gains Gross
Unrealized
Losses Fair Market
Value

 (in $000’s)

At March 31, 2014:


US Treasury securities
 $ 31,487 $ — $ — $ 31,487

Short-term government-backed securities
 24,174 6 (4 ) 24,176

Long-term government-backed securities
 41,779 8 (26 ) 41,761







 $ 97,440 $ 14 $ (30 ) $ 97,424







Fair Value Hierarchy

Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows, or similar techniques, and at least one significant model assumption or input is unobservable.

The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above:

 Level 1 Level 2 Level 3 Fair Value

 (in $000’s)

At September 30, 2014:


Assets


U.S. Treasury securities
 $ — $ 19,487 $ — $ 19,487

Short-term government-backed securities
 — 58,494 — 58,494

Long-term government-backed securities
 — 16,473 — 16,473

Liabilities


Contingent consideration
 — — 5,797 5,797

 Level 1 Level 2 Level 3 Fair Value

 (in $000’s)

At March 31, 2014:


U.S. Treasury securities
 $ — $ 31,487 $ — $ 31,487

Short-term government-backed securities
 — 24,176 — 24,176

Long-term government-backed securities
 — 41,761 — 41,761

The Company has determined that the estimated fair value of its investments in U.S. Treasury securities, short-term government-backed securities and long-term government-backed securities are reported as Level 2 as they are not exchange-traded instruments.

The Company’s financial liabilities consisted of contingent consideration potentially payable to former ECP shareholders related to the acquisition of ECP in July 2014. This liability is reported as Level 3 as estimated fair value of the contingent consideration related to the acquisition of the ECP requires significant management judgment or estimation and is calculated using the income approach, using various revenue and cost assumptions and applying a probability to each outcome.

The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended September 30, 2014:

 September 30,

 2014

 (in $000’s)

Beginning balance
 $ —

Additions
 6,000

Payments
 —

Change in fair value
 219

Foreign currency translation impact
 (422 )



Ending balance
 $ 5,797



The change in fair value of the contingent consideration of $0.2 million for the six months ended September 30, 2014 was primarily due to an increase in fair value due to the effect of the passage of time on the fair value measurement and the impact of foreign currency exchange rates. Adjustments associated with the change in fair value of contingent consideration are included in research and development expenses on the Company’s condensed consolidated statements of operations.

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2014:

 Fair Value at
September 30, 2014
( in $000’s)
Significant Unobservable Input
 Weighted Average
(range, if
applicable)

Contingent consideration
 $ 5,797
Probability weighted

income approach
 Milestone dates 2018 to 2021

 Discount rate Probability of occurrence 8% to 12%
0% to 100%

Other Investment

In May 2013, the Company invested $0.8 million in preferred stock of a private technology company. In addition, the Company committed to invest an additional $0.7 million if the private technology company achieves certain milestones or receives shareholder approval requesting the additional funding. In September 2014, the private technology company requested this additional funding and the Company paid the additional $0.7 million. There are no additional outstanding funding commitments associated with this investment.

This other investment is accounted for using the cost method and is measured at fair value on a nonrecurring basis only if there are identified events or change in circumstances that may have a significant adverse effect on the fair value of these investments. The aggregate carrying amount of this other investment was $1.5 million and $0.8 million at September 30, 2014 and March 31, 2014, respectively, and is classified within other assets in the unaudited condensed consolidated balance sheets.

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Basic Net Income (Loss) Per Share

Net income (loss) $ 3,839 $ 1,059 $ 2,130 $ (664)

Weighted average shares used in computing basic net income (loss) per share 40,448 39,260 40,256 38,971

Net income (loss) per share - basic $ 0.09 $ 0.03 $ 0.05 $ (0.02)

Diluted Net Income (Loss) Per Share

Net income (loss) $ 3,839 $ 1,059 $ 2,130 $ (664)

Weighted average shares used in computing basic net income (loss) per share 40,448 39,260 40,256 38,971

Effect of dilutive securities 1,791 2,077 1,813

Weighted average shares used in computing diluted net income (loss) per share 42,239 41,337 42,069 38,971

Net income (loss) per share - diluted $ 0.09 $ 0.03 $ 0.05 $ (0.02)

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 108 233 1 false 35 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.abiomed.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.abiomed.com/taxonomy/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.abiomed.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.abiomed.com/taxonomy/role/StatementOfIncomeAlternative CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Sheet http://www.abiomed.com/taxonomy/role/StatementOfOtherComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME false false R6.htm 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.abiomed.com/taxonomy/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 108 - Disclosure - Nature of Business and Basis of Preparation Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock Nature of Business and Basis of Preparation false false R8.htm 109 - Disclosure - Net Income (Loss) Per Share Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Income (Loss) Per Share false false R9.htm 110 - Disclosure - Acquisitions Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisitions false false R10.htm 111 - Disclosure - Marketable Securities and Fair Value Measurements Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Marketable Securities and Fair Value Measurements false false R11.htm 112 - Disclosure - Inventories Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories false false R12.htm 113 - Disclosure - Goodwill and In-Process Research and Development Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Goodwill and In-Process Research and Development false false R13.htm 114 - Disclosure - Accrued Expenses Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R14.htm 115 - Disclosure - Stock-Based Compensation Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R16.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R17.htm 118 - Disclosure - Segment and Enterprise Wide Disclosures Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment and Enterprise Wide Disclosures false false R18.htm 119 - Disclosure - Nature of Business and Basis of Preparation (Policies) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlockPolicies Nature of Business and Basis of Preparation (Policies) false false R19.htm 120 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Income (Loss) Per Share (Tables) false false R20.htm 121 - Disclosure - Acquisitions (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Acquisitions (Tables) false false R21.htm 122 - Disclosure - Marketable Securities and Fair Value Measurements (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Marketable Securities and Fair Value Measurements (Tables) false false R22.htm 123 - Disclosure - Inventories (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) false false R23.htm 124 - Disclosure - Goodwill and In-Process Research and Development (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill and In-Process Research and Development (Tables) false false R24.htm 125 - Disclosure - Accrued Expenses (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R25.htm 126 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R26.htm 127 - Disclosure - Nature of Business and Basis of Preparation - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPreparationAdditionalInformation Nature of Business and Basis of Preparation - Additional Information (Detail) false false R27.htm 128 - Disclosure - Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureComputationOfBasicAndDilutedNetIncomeLossPerShare Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) false false R28.htm 129 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformation Net Income (Loss) Per Share - Additional Information (Detail) false false R29.htm 130 - Disclosure - Acquisitions - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureAcquisitionsAdditionalInformation Acquisitions - Additional Information (Detail) false false R30.htm 131 - Disclosure - Fair Value of the Consideration Transferred (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureFairValueOfTheConsiderationTransferred Fair Value of the Consideration Transferred (Detail) false false R31.htm 132 - Disclosure - Preliminary Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosurePreliminaryEstimatedFairValuesOfTheAssetsAcquiredAndLiabilitiesAssumed Preliminary Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Detail) false false R32.htm 133 - Disclosure - Pro Forma Consolidated Financial Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureProFormaConsolidatedFinancialInformation Pro Forma Consolidated Financial Information (Detail) false false R33.htm 134 - Disclosure - Investable Marketable Securities (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureInvestableMarketableSecurities Investable Marketable Securities (Detail) false false R34.htm 135 - Disclosure - Financial Instruments Recorded at Fair Value (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureFinancialInstrumentsRecordedAtFairValue Financial Instruments Recorded at Fair Value (Detail) false false R35.htm 136 - Disclosure - Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureChangeInFairValueOfContingentConsiderationAsDeterminedByLevel3Inputs Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) false false R36.htm 137 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureMarketableSecuritiesAndFairValueMeasurementsAdditionalInformation Marketable Securities and Fair Value Measurements - Additional Information (Detail) false false R37.htm 138 - Disclosure - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureQuantitativeInformationAboutInputsAndValuationMethodologiesUsedForFairValueMeasurementsClassifiedInLevel3 Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) false false R38.htm 139 - Disclosure - Components of Inventories (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureComponentsOfInventories Components of Inventories (Detail) false false R39.htm 140 - Disclosure - Inventories - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureInventoriesAdditionalInformation Inventories - Additional Information (Detail) false false R40.htm 141 - Disclosure - Goodwill Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureGoodwillActivity Goodwill Activity (Detail) false false R41.htm 142 - Disclosure - Goodwill and In-Process Research and Development - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureGoodwillAndInProcessResearchAndDevelopmentAdditionalInformation Goodwill and In-Process Research and Development - Additional Information (Detail) false false R42.htm 143 - Disclosure - In-Process Research and Development Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureInProcessResearchAndDevelopmentActivity In-Process Research and Development Activity (Detail) false false R43.htm 144 - Disclosure - Accrued Expenses (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses (Detail) false false R44.htm 145 - Disclosure - Stock-Based Compensation Recognized (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureStockBasedCompensationRecognized Stock-Based Compensation Recognized (Detail) false false R45.htm 146 - Disclosure - Components of Stock-Based Compensation (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureComponentsOfStockBasedCompensation Components of Stock-Based Compensation (Detail) false false R46.htm 147 - Disclosure - Summary of Stock Option Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureSummaryOfStockOptionActivity Summary of Stock Option Activity (Detail) false false R47.htm 148 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R48.htm 149 - Disclosure - Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureWeightedAverageAssumptionsUsedToCalculateFairValueOfOptionsGranted Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail) false false R49.htm 150 - Disclosure - Summary of Restricted Stock and Restricted Stock Units Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureSummaryOfRestrictedStockAndRestrictedStockUnitsActivity Summary of Restricted Stock and Restricted Stock Units Activity (Detail) false false R50.htm 151 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R51.htm 152 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R52.htm 153 - Disclosure - Segment and Enterprise Wide Disclosures - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureSegmentAndEnterpriseWideDisclosuresAdditionalInformation Segment and Enterprise Wide Disclosures - Additional Information (Detail) false false All Reports Book All Reports Element abmd_FairValueInputsProbabilityOfOccurrence had a mix of decimals attribute values: 0 2. Element us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 had a mix of decimals attribute values: -5 -3. Element us-gaap_BusinessCombinationContingentConsiderationLiability had a mix of decimals attribute values: -5 -3. Element us-gaap_FairValueInputsDiscountRate had a mix of decimals attribute values: 2 3. Element us-gaap_Goodwill had a mix of decimals attribute values: -5 -3. Element us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill had a mix of decimals attribute values: -5 -3. Element us-gaap_OtherAssetsNoncurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_PaymentsToAcquireBusinessesGross had a mix of decimals attribute values: -5 -3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '127 - Disclosure - Nature of Business and Basis of Preparation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '130 - Disclosure - Acquisitions - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '137 - Disclosure - Marketable Securities and Fair Value Measurements - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '148 - Disclosure - Stock-Based Compensation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Shares' elements on report '150 - Disclosure - Summary of Restricted Stock and Restricted Stock Units Activity (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jul. 31, 2014' Process Flow-Through: Removing column 'Jul. 01, 2014' Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Process Flow-Through: 107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS abmd-20140930.xml abmd-20140930.xsd abmd-20140930_cal.xml abmd-20140930_def.xml abmd-20140930_lab.xml abmd-20140930_pre.xml true true XML 67 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

Components of Inventories (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

Inventory [Line Items]

Raw materials and supplies $ 6,052 $ 6,414

Work-in-progress 5,718 6,261

Finished goods 1,675 1,273

Inventories $ 13,445 $ 13,948

X

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4),(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 68 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Acquisitions (Tables)
6 Months Ended

Sep. 30, 2014

Fair Value of the Consideration Transferred

The acquisition-date fair value of the consideration transferred is as follows:

 Total
Acquisition
Date Fair
Value (in
thousands)

Cash consideration
 $ 15,750

Contingent consideration
 6,000



Total consideration transferred
 $ 21,750



Preliminary Estimated Fair Values of the Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on July 1, 2014, the date of acquisition (in thousands):

Acquired assets:


Cash and cash equivalents
 $ 53

Accounts receivable
 25

Property and equipment
 619

In-process research and development
 18,500

Goodwill
 1,964

Long-term deferred tax assets
 874

Other assets acquired
 141



Total assets acquired
 22,176

Liabilities assumed:


Accounts payable
 295

Accrued liabilities
 131



Total liabilities assumed
 426



Net assets acquired
 $ 21,750



Pro Forma Consolidated Financial Information

 Three Months Ended
September 30, Six Months Ended
September 30,

 2014 2013 2014 2013

 (in $000’s) (in $000’s)

Revenue
 $ 51,938 $ 44,359 $ 100,761 $ 87,042

Income before income tax provision
 4,557 329 2,770 (1,850 )

Net income (loss)
 4,218 (41 ) 2,260 (2,631 )

X

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Summary of Stock Option Activity (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Options
Outstanding at April 1, 2014	3,492
Granted	313
Exercised	(222)
Cancelled and expired	(5)
Outstanding at September 30, 2014	3,578	3,492
Exercisable at September 30, 2014	2,787
Options vested and expected to vest at end of year	3,502
Weighted-Average Exercise Price
Outstanding at April 1, 2014	$ 13.27
Granted	$ 22.26
Exercised	$ 11.49
Cancelled and expired	$ 15.66
Outstanding at September 30, 2014	$ 14.16	$ 13.27
Exercisable at September 30, 2014	$ 11.94
Options vested and expected to vest at September 30, 2014	$ 14.00
Weighted-Average Remaining Contractual Term (years)
Outstanding	5 years 15 days	4 years 11 months 1 day
Exercisable at September 30, 2014	3 years 11 months 27 days
Options vested and expected to vest at September 30, 2014	4 years 11 months 19 days
Aggregate Intrinsic Value
Outstanding at September 30, 2014	$ 38,287
Exercisable at September 30, 2014	35,928
Options vested and expected to vest at September 30, 2014	$ 38,013

Investable Marketable Securities (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
US Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Market Value	$ 19,487	$ 31,487
US Government-sponsored Enterprises Debt Securities \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Market Value	58,494	24,176
US Government-sponsored Enterprises Debt Securities \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Market Value	16,473	41,761
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	94,465	97,440
Gross Unrealized Gains	20	14
Gross Unrealized Losses	(31)	(30)
Fair Market Value	94,454	97,424
Level 2 \| US Treasury Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	19,487	31,487
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Market Value	19,487	31,487
Level 2 \| US Government-sponsored Enterprises Debt Securities \| Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	58,480	24,174
Gross Unrealized Gains	17	6
Gross Unrealized Losses	(3)	(4)
Fair Market Value	58,494	24,176
Level 2 \| US Government-sponsored Enterprises Debt Securities \| Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	16,498	41,779
Gross Unrealized Gains	3	8
Gross Unrealized Losses	(28)	(26)
Fair Market Value	$ 16,473	$ 41,761

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Jul. 01, 2014	Mar. 31, 2014
Income Taxes [Line Items]
Long-term deferred tax liability	$ 6,865		$ 6,415
Amortization period of deferred tax liability (years)	15 years
Long-term deferred tax assets	$ 813	$ 874

In-Process Research and Development Activity (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Jul. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Beginning balance		$ 18,500
Additions	18,500
Foreign currency translation impact	(1,302)
Ending balance	$ 17,198	$ 18,500

Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended					6 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2014 Level 3	Sep. 30, 2014 ECP Entwicklungsgesellschaft mbH	Sep. 30, 2014 ECP Entwicklungsgesellschaft mbH Level 3 Probability weighted income approach	Sep. 30, 2014 ECP Entwicklungsgesellschaft mbH Level 3 Probability weighted income approach Contingent Consideration Minimum	Sep. 30, 2014 ECP Entwicklungsgesellschaft mbH Level 3 Probability weighted income approach Contingent Consideration Maximum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		$ 5,797	$ 5,797	$ 5,800	$ 5,797
Milestone date						2018	2021
Discount rate	22.50%					8.00%	12.00%
Probability of occurrence						0.00%	100.00%

Segment and Enterprise Wide Disclosures - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended								3 Months Ended		6 Months Ended
	Sep. 30, 2014 Segment	Jul. 01, 2014	Mar. 31, 2014	Sep. 30, 2014 United States	Mar. 31, 2014 United States	Sep. 30, 2014 Europe	Jun. 30, 2014 Europe	Mar. 31, 2014 Europe	Sep. 30, 2014 International	Sep. 30, 2013 International	Sep. 30, 2014 International	Sep. 30, 2013 International
Segment Reporting Information [Line Items]
Number of business segments	1
Percentage of total consolidated assets				66.00%	74.00%
Goodwill	$ 36,867	$ 1,964	$ 37,990				$ 54,100	$ 35,400
Percentage of total consolidated assets, excluding goodwill						9.00%		9.00%
Percentage of total product revenue									11.00%	7.00%	11.00%	8.00%

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Payables and Accruals [Abstract]
Employee compensation	$ 9,083	$ 11,967
Research and development	1,161	1,587
Professional, legal and accounting fees	1,021	1,304
Sales and income taxes	1,000	1,445
Warranty	775	794
Other	722	802
Accrued expenses	$ 13,762	$ 17,899

Acquisitions - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended
Acquisitions - Additional Information (Detail) (USD $)	Jul. 01, 2014	Sep. 30, 2014	Sep. 30, 2014	Jul. 01, 2014
Business Acquisition [Line Items]
Payments to acquire businesses, cash paid	$ 15,750,000
Expense for the change in fair value contingent consideration			219,000
Selling, general and administrative
Business Acquisition [Line Items]
Legal, consulting and other costs related to the acquisition included in consolidated statements of operations		1,100,000
ECP Entwicklungsgesellschaft mbH
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement			Jul. 01, 2014
Payments to acquire businesses, cash paid	13,000,000
Potential payouts payments				15,000,000
Business combination, contingent consideration arrangements, descriptions	With respect to such milestone payments, the share purchase agreement provides: • that, upon the earlier of (i) the Company’s receipt of European CE Marking approval relating to the sale of an expandable device based on certain patent rights acquired from ECP, or (ii) the Company bringing of a successful claim against a third party competitor (or reaching an economically equivalent settlement) for the infringement of certain patent rights acquired from ECP, it will pay Syscore an additional $7.0 million (provided that if such claim or settlement does not prohibit the third party competitor’s further marketing, production, sale, distribution, lease or use of any violating or infringing products, but only awards monetary damages to us or to Abiomed Europe, the amount payable to Syscore shall be limited to the lower of the amount of aggregate damages received and $7.0 million); and • that, upon the first to occur of (i) the Company’s successful commercialization of one or more rotatable and expandable devices based on certain patent rights acquired from ECP, where such devices achieve aggregate worldwide revenues of $125.0 million, including the revenues of third party licensees, or (ii) the Company’s sale of (A) ECP, (B) all or substantially all of ECP’s assets, or (C) certain of ECP’s patent rights, the Company will pay to Syscore the lesser of (y) one-half of the profits earned from such sale described in the foregoing item (ii), after accounting for the costs of acquiring and operating ECP, or (z) $15.0 million (less any previous milestone payment).
Expense due to infringement of certain patent rights acquired				7,000,000
Aggregate worldwide revenues, including revenues of third party licensees, targeted to be met for milestone payments				125,000,000
Revenues		0
Net loss		1,100,000
Expense for the change in fair value contingent consideration		200,000
AIS GmbH Aachen Innovative Solutions
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Jun. 30, 2014
Payments to acquire businesses, cash paid	$ 2,800,000

Preliminary Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Jul. 01, 2014	Mar. 31, 2014
Acquired assets:
Cash and cash equivalents		$ 53
Accounts receivable		25
Property and equipment		619
In-process research and development		18,500
Goodwill	36,867	1,964	37,990
Long-term deferred tax assets	813	874
Other assets acquired		141
Total assets acquired		22,176
Liabilities assumed:
Accounts payable		295
Accrued liabilities		131
Total liabilities assumed		426
Net assets acquired		$ 21,750

Goodwill Activity (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Jul. 01, 2014
Goodwill [Line Items]
Beginning balance	$ 37,990	$ 1,964
Additions	1,964
Foreign currency translation impact	(3,087)
Ending balance	$ 36,867	$ 1,964

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Current assets:
Cash and cash equivalents	$ 17,483	$ 20,916
Short-term marketable securities	77,981	55,663
Accounts receivable, net	23,072	24,357
Inventories	13,445	13,948
Prepaid expenses and other current assets	3,310	3,082
Total current assets	135,291	117,966
Long-term marketable securities	16,473	41,761
Property and equipment, net	7,351	6,889
Goodwill	36,867	37,990
In-Process Research and Development	17,198
Long-term deferred tax assets	813
Other assets	1,551	801
Total assets	215,544	205,407
Current liabilities:
Accounts payable	7,616	7,746
Accrued expenses	13,762	17,899
Deferred revenue	5,756	4,766
Total current liabilities	27,134	30,411
Other long-term liabilities	210	228
Contingent consideration	5,797
Long-term deferred tax liabilities	6,865	6,415
Total liabilities	40,006	37,054
Commitments and contingencies (Note 10)
Stockholders' equity:
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none	0	0
Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 41,831,077 shares at September 30, 2014 and 41,122,695 shares at March 31, 2014; Outstanding - 40,577,134 shares at September 30, 2014 and 39,916,328 shares at March 31, 2014	417	411
Additional paid in capital	447,433	436,136
Accumulated deficit	(248,780)	(250,910)
Treasury stock at cost - 1,253,943 shares at September 30, 2014 and 1,206,367 shares at March 31, 2014	(17,567)	(16,554)
Accumulated other comprehensive loss	(5,965)	(730)
Total stockholders' equity	175,538	168,353
Total liabilities and stockholders' equity	$ 215,544	$ 205,407

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities:
Net income (loss)	$ 2,130	$ (664)
Adjustments required to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,196	1,322
Bad debt expense	27	15
Stock-based compensation	8,314	6,719
Write-down of inventory	559	537
Deferred tax provision	450	453
Change in fair value of contingent consideration	219
Changes in assets and liabilities:
Accounts receivable	1,108	1,912
Inventories	(653)	(876)
Prepaid expenses and other assets	(139)	(762)
Accounts payable	(581)	(1,494)
Accrued expenses and other long-term liabilities	(3,732)	(1,978)
Deferred revenue	1,004	(62)
Net cash provided by operating activities	9,902	5,122
Investing activities:
Purchases of marketable securities	(44,920)	(33,849)
Proceeds from the sale and maturity of marketable securities	47,890	25,750
Acquisition of ECP and AIS, net of cash assumed	(15,697)
Purchase of other investment	(750)	(750)
Purchases of property and equipment	(1,496)	(1,236)
Net cash used for investing activities	(14,973)	(10,085)
Financing activities:
Proceeds from the exercise of stock options	2,560	5,318
Payments in lieu of issuance of common stock for minimum payroll taxes	(1,013)	(426)
Proceeds from the issuance of stock under employee stock purchase plan	397	312
Net cash provided by financing activities	1,944	5,204
Effect of exchange rate changes on cash	(306)	428
Net (decrease) increase in cash and cash equivalents	(3,433)	669
Cash and cash equivalents at beginning of period	20,916	9,451
Cash and cash equivalents at end of period	17,483	10,120
Supplemental disclosure of cash flow information:
Cash paid for income taxes	299	870
Supplemental disclosure of non-cash investing and financing activities:
Contingent consideration related to acquisition of ECP	6,000
Fixed asset expenditures incurred, not yet paid	$ 577	$ 92

Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) (Contingent Consideration, ECP Entwicklungsgesellschaft mbH, Level 3, USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014
Contingent Consideration \| ECP Entwicklungsgesellschaft mbH \| Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Additions	$ 6,000
Payments
Change in fair value	219
Foreign currency translation impact	(422)
Ending balance	$ 5,797

Marketable Securities and Fair Value Measurements - Additional Information (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014 Other Investments	Mar. 31, 2014 Other Investments	May 31, 2013 Equity Securities	May 31, 2013 Equity Securities Additional Investment commitment	Sep. 30, 2014 Equity Securities Additional Investment payment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of the contingent consideration	$ 219,000
Cost method investment, fair value					800,000	700,000	700,000
Aggregate carrying amount of other investment	$ 1,551,000	$ 801,000	$ 1,500,000	$ 800,000

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Class B Preferred Stock, par value	$ 0.01	$ 0.01
Class B Preferred Stock, Authorized	1,000,000	1,000,000
Class B Preferred Stock, Issued	0	0
Class B Preferred Stock, outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, Authorized	100,000,000	100,000,000
Common stock, Issued	41,831,077	41,122,695
Common stock, Outstanding	40,577,134	39,916,328
Treasury stock, shares	1,253,943	1,206,367

Document and Entity Information	6 Months Ended
Document and Entity Information	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Trading Symbol	ABMD
Entity Registrant Name	ABIOMED INC
Entity Central Index Key	0000815094
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		40,894,675

Nature of Business and Basis of Preparation (Policies)	6 Months Ended
Nature of Business and Basis of Preparation (Policies)	Sep. 30, 2014
In-Process Research and Development	*In-Process Research and Development* In-process research and development (“IPR&D”) assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D represents the fair value assigned to technologies that the Company acquires, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs when the Company has regulatory approval and is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.
Contingent Consideration	*Contingent Consideration* As discussed in Note 3. “Acquisitions,” on July 1, 2014, the Company acquired all of the issued shares of ECP Entwicklungsgesellschaft GmbH, a German limited liability company, or ECP, for $13.0 million in cash, with additional potential payments up to a maximum of $15.0 million based on the achievement of certain technical, regulatory and commercial milestones. These milestone payments may be made, at the Company’s option, by a combination of cash or Abiomed common stock. Contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the various milestones. The material factors that may impact the fair value of the contingent consideration, and therefore this liability, are the probabilities of achieving the related milestones and the discount rate. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration, and the associated liability at each reporting date, will be updated by reflecting the changes in fair value reflected in the Company’s statement of operations.
Recent Accounting Pronouncements	*Recent Accounting Pronouncements* In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers to provide updated guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies may need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company in the first quarter of fiscal 2017. Early adoption is not permitted. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

Commitments and Contingencies - Additional Information (Detail)							0 Months Ended			1 Months Ended
	Sep. 30, 2014 USD ($)	Apr. 30, 2014 USD ($)	Sep. 30, 2014 For March 2014 through April 2014 USD ($)	Sep. 30, 2014 For May 2014 through February 2016 USD ($)	Sep. 30, 2014 For March 2016 through February 2018 USD ($)	Sep. 30, 2014 For March 2018 through February 2021 USD ($)	Jul. 01, 2014 ECP Entwicklungsgesellschaft mbH	Sep. 30, 2014 ECP Entwicklungsgesellschaft mbH USD ($)	Jul. 01, 2014 ECP Entwicklungsgesellschaft mbH USD ($)	Jul. 31, 2013 Europe Lease Agreements	Sep. 30, 2014 Europe Lease Agreements USD ($)	Sep. 30, 2014 Europe Lease Agreements EUR (€)
Commitments and Contingencies [Line Items]
Facilities leases, base rent per month			$ 66,000	$ 74,050	$ 70,750	$ 72,750					$ 44,000	€ 34,500
Lease, expiration date										Jul. 31, 2023
License agreement, upfront payment		1,500,000
License agreement, maximum agreed additional payments upon achievement of development milestones		4,500,000
Potential payouts payments									15,000,000
Period of milestone payment							20 years
Fair value of contingent consideration	$ 5,797,000							$ 5,800,000

Nature of Business and Basis of Preparation - Additional Information (Detail) (USD $)	0 Months Ended
	Jul. 01, 2014
Business And Basis Of Presentation [Line Items]
Payments to acquire businesses, cash paid	$ 15,750,000
ECP Entwicklungsgesellschaft mbH
Business And Basis Of Presentation [Line Items]
Payments to acquire businesses, cash paid	13,000,000
ECP Entwicklungsgesellschaft mbH \| Maximum
Business And Basis Of Presentation [Line Items]
Potential payouts payments	$ 15,000,000

Summary of Restricted Stock and Restricted Stock Units Activity (Detail) (Restricted Stock and Restricted Stock Units, USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Restricted Stock and Restricted Stock Units
Number of Shares
Beginning Balance	1,174,000
Granted	664,000
Vested	(465,000)
Forfeited	(121,000)
Ending Balance	1,252,000
Weighted Average Grant Date Fair Value
Beginning Balance	$ 21.37
Granted	$ 21.88	$ 23.18
Vested	$ 20.48
Forfeited	$ 23.10
Ending Balance	$ 21.80

Goodwill and In-Process Research and Development - Additional Information (Detail) (USD $)	1 Months Ended
	Jul. 31, 2014	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Line Items]
Accumulated impairment loss, goodwill		$ 0
In-Process Research and Development	$ 18,500,000	$ 17,198,000
Fair value inputs, discount rate	22.50%

Components of Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Inventory [Line Items]
Raw materials and supplies	$ 6,052	$ 6,414
Work-in-progress	5,718	6,261
Finished goods	1,675	1,273
Inventories	$ 13,445	$ 13,948